EAACI 2025

13-16 JUNE
GLASGOW
UNITED KINGDOM

Breaking boundaries in Allergy, Asthma and Clinical Immunology:
Integrating Planetary Health for a Sustainable Future

www.eaaci.org
#EAACIcongress



Final Programme

EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

Breaking boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future

Welcome to the EAACI Annual Congress 2025!

We are delighted to welcome you to this prestigious event, where the global allergy and clinical immunology community comes together to share groundbreaking research, clinical insights, and best practices. Following the resounding success of last year's Congress in Valencia, we are committed to making this year's gathering in Glasgow even more memorable—because at EAACI, each year is an opportunity to raise the bar.

As you explore the eProgramme, you'll discover a rich and diverse selection of sessions, including keynote lectures, symposia, oral abstract presentations, and interactive workshops. These will cover a comprehensive range of topics—such as allergic rhinitis, asthma, food allergies, drug hypersensitivity, immunotherapy, and more—reflecting the breadth and depth of our field.

Our esteemed speakers and presenters will share their expertise, latest findings, and thought-provoking perspectives, setting the stage for meaningful discussions and new collaborations. The Annual Congress is the culmination of a year's worth of scientific dedication, planning, and community effort—designed to inspire, inform, and ignite progress in allergy and clinical immunology.

We hope you enjoy every moment of your journey with us at EAACI Annual Congress 2025, and we thank you for being part of this exceptional experience.

In order to match this format, we have split our Scientific Programme into 3 parts:

Live Scientific Programme	A selection of the most exceptional sessions, to be delivered to you from 13 to 16 June 2025. You will find the details of this programme from pages 34 to 193.
Industry Programme	All the valuable content brought to you by our sponsors and exhibitors.
On Demand Scientific Programme	The sessions streamed live will be available to all congress delegates in the on-demand section, to be fully replayed. Sessions will be available around an hour after the live session has ended.

A selection of the content will be available for 6 months after the Congress depending on author consent.

Contents

Welcome messages 4
EAACI Committees 6
General information 8
EAACI Congress 2025 App 14
Ceremonies 15
EAACI Fellows 18
EAACI Awards 2025 16
Description of Session Types 24
EAACI Activity Challenge 26
Sessions Guide 29
Programme Description • Friday, 13 June 34
Programme Description • Saturday, 14 June 91
Programme Description • Sunday, 15 June 136
Programme Description • Monday, 16 June 184
National Society Village 194
Sponsorship & Exhibition 196
Founder Sponsors 198
Company Sponsored Symposia 200
Exhibition Floor Plan 226
List of Exhibitors & Sponsors 227
NAS Village Floor Plan 228
Industry Profiles 230

Contacts

EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Tel: +41 44 205 55 33
email: info@eaaci.org
website: www.eaaci.org

Congress Venue
Scottish Event Campus
Exhibition Way
Glasgow
G3 8YW
website: https://www.sec.co.uk/

Congress Registration
registration@eaaci.org

Abstract Handling
abstract@eaaci.org

Press & Media Contact Information
communications@eaaci.org
Tel: +41 44 205 55 33

The EAACI Media and Embargo Policy is available HERE.

EAACI Technical Support
support@eaaci.org

Exhibition and Sponsorship
sponsors@eaaci.org

EAACI Hybrid Congress 2022 Online Platform
https://virtual.eaaci.org/

General Enquiries
congress@eaaci.org

Hotels Requests
hotels@eaaci.org

Welcome messages

Dear Distinguished Colleagues,

I'm absolutely delighted to invite you to the EAACI Annual Congress 2025, taking place in the vibrant city of Glasgow, United Kingdom, from June 13 to 16, 2025. This year's congress is set to be a truly landmark event as we come together under the inspiring theme, "Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future."

We are at a defining moment in our field, and this congress is not just an opportunity to learn—it's a call to action. We've curated a program that will ignite your curiosity and fuel your passion, from groundbreaking research and clinical advancements to innovative approaches to global health challenges. Expect to engage in dynamic sessions that explore cutting-edge diagnostic tools, emerging therapies, and transformative global trends that are reshaping allergy care as we know it.

But the EAACI Congress is more than just scientific sessions—it's where our community thrives. It's about forging connections, sparking collaborations, and sharing ideas that will drive real progress. Glasgow, with its rich history and welcoming spirit, provides the ideal setting for this exciting journey. Whether you're a seasoned expert or just starting out in the field, there will be countless opportunities to connect with peers, exchange insights, and contribute to shaping the future of allergy and immunology.

Mark your calendars and get ready for an unforgettable experience. Together, we'll push the boundaries of what's possible and elevate the standard of allergy care worldwide.

I look forward to seeing you in Glasgow!

Yours sincerely,



María Torres
EAACI President
European Academy of Allergy
and Clinical Immunology

Welcome messages

Dear Esteemed Colleagues,

It is my great pleasure to welcome you to the EAACI Annual Congress 2025, hosted in the historic city of Glasgow, United Kingdom, from June 13 to 16, 2025. As we unite under the forward-thinking theme, “Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future,” we are not just preparing for a congress—we are embarking on a journey of innovation, inspiration, and transformation.

Our scientific program is designed to spark curiosity and challenge conventional thinking, offering a dynamic mix of the latest discoveries and real-world applications. Whether it’s exploring cutting-edge advancements in allergen immunotherapy, unraveling the intricate links between environmental health and allergic diseases, or diving into the most recent clinical breakthroughs, you’ll find a wealth of thought-provoking sessions that push the boundaries of our field.

But beyond the exceptional content, what truly sets this congress apart is you—the vibrant community of professionals, researchers, and clinicians who are dedicated to advancing allergy and clinical immunology. Glasgow’s Scottish Event Campus (SEC) will serve as the perfect backdrop for collaboration, networking, and forging meaningful connections that will shape the future of our field.

Join us for an unforgettable experience where your professional journey takes center stage. Let’s come together to create a congress that not only informs but also inspires us all to take allergy care to new heights.

Welcome to Glasgow!

Warm regards,



André Moreira
EAACI Vice President of Congresses
European Academy of Allergy and Clinical Immunology

EAACI Committees

EAACI Executive Committee

EAACI Board of Officers

María Torres, *President*
Mohamed Shamji, *Secretary General*
Patrizia Bonadonna, *Treasurer*
André Moreira, *VP Congresses*
Jolanta Walusiak-Skorupa, *VP Education & Specialty*
Oliver Pfaar, *VP Communications*
Oscar Palomares, *VP Science*
Stefano Del Giacco, *Past President*

EAACI Section Chairpersons

Ian Adcock, *Asthma Section Chair*
Annick Barbaud, *Dermatology Section Chair*
Adam Chaker, *ENT Section Chair*
Alexandra Santos, *Basic & Clinical Immunology Section Chair*
Sophia Tsabouri, *Pediatrics Section Chair*
Cevdet Ozdemir, *Allied Health and Primary Care Section Chair*
Aspasia Karavelia, *JM Assembly Chair*

EAACI Interest and Working Group Representatives

Constantinos Pitsios
Arantza Vega Castro

Members at Large

Milena Sokolowska
Carmen Panaitescu
Ingrid Terreehorst
Isabella Annesi-Maesano
Gülfem Elif Çelik
María Escribese

EAACI Committees

Scientific Programme Committee (SPC)

Maria Jose Torres, *EAACI President*
Mohamed Shamji, *EAACI Secretary General*
André Moreira, *EAACI Vice-President Congresses*
Oscar Palomares, *EAACI Vice-President Science*
Jolanta Walusiak-Skorupa, *EAACI Vice-President Education*
Oliver Pfaar, *EAACI Vice-President Communication*
Stefano Del Giacco, *EAACI Past President*
Mübeccel Akdis, *Scientific Programme Committee Co-Chair*
Ibon Eguiluz, *Scientific Programme Committee Co-Chair*

Section Secretaries 2024-2026

Jasper Kappen, *Section Secretary Asthma*
Emilia Vassilopoulou, *Section Secretary Allied Health and Primary Care*
Teresa Caballero, *Section Secretary Dermatology*
Sietze Reitsma, *Section Secretary ENT*
Andrzej Eljaszewicz, *Section Secretary Basic & Clinical Immunology*
Wojciech Feleszko, *Section Secretary Pediatrics*
Rubén Fernández-Santamaría, *JM Assembly Secretary*

Interest Group Chairs 2024-2026

Carmen Milagros Rondon, *IG Chair Allergen Immunotherapy*
Alma Villasenor Solis, *IG Chair Allergy Diagnosis & Systems Medicine*
Lene Heise Garvey, *IG Chair Drug Allergy*
Isabel Skypala, *IG Chair Food Allergy*
Paola Mason, *IG Chair Environmental and Occupational Allergy*

Working Group Chairs 2024-2026

Célia Antunes, *WG Chair Aerobiology & Air Pollution*
Ines Paciencia, *WG Chair One Health*
Oliver Price, *WG Chair Allergy, Asthma & Sport*
Carina Venter, *WG Chair Immunomodulation & Nutrition*
Sophia Karagiannis, *WG Chair AllergoOncology*
Alessandra Vultaggio, *WG Chair Biological*
Arzu Bakirtas, *WG Chair Eosinophilic Eosophagitis*
Thulja Trikamjee, *WG Chair Epidemiology*
Cagatay Karaaslan, *WG Chair Genomics & Proteomics*
Joana Vitte, *WG Chair Infections*
Elisa Boni, *WG Chair Insect Venom Hypersensitivity*
Diana Silva, *WG Chair Ocular Allergy*
Ismail Ogulur, *WG Chair Epithelial Cell Biology*
Francesco Cinetto, *WG Chair Immunodeficiencies*

Patients Organisations Committee

Ozlem Ceylan, *Committee Chair*

General information A - W

A

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 13'000 members from 125 countries, as well as over 75 National Allergy Societies.

➜ Visit *http://www.eaaci.org* for more information.

Abstracts

Abstracts will be displayed on the congress platform as of Friday 13th June 2025. Presented abstract texts will be published in the official EAACI Allergy Journal after the Congress and on EAACI content platforms (subject to consent).

B

Badges

Your badge will be available in the myEAACI portal from 2 June. A confirmation email will be sent to you.

To beat the queues, print your badge in colour ahead of the event. Badge holders can be collected from the registration area.

Please note:

- Digital versions on mobile phones, tablets, and other devices will not be accepted.
- Badges are personal, individual, and non-transferable. If printed in duplicate and shared or used in breach of any of these rules, the badge will be deemed invalid and entrance to the Congress denied. Entry may be refused without a valid Photo ID (Passport / ID Card/ Driving Licence).

The congress badge should be worn at all times in order to gain access to the session rooms and other events. Please note that access to the congress areas will only be permitted with an official congress badge. If you have lost your badge, a new one can be printed (with proof of your original registration) at the Registration desk for a fee. Your badge will be scanned at the entrance to session rooms for CME accreditation and internal EAACI statistical purposes.

Bank / ATM Machines

There are two ATMs inside the congress centre in front of the Exhibition door 4A.

C

Certificate of Attendance

A Certificate of Attendance can be downloaded from the myEAACI portal after completing the delegate survey.

Cloakroom

A cloakroom will be located in the Registration area. It is free of charge for congress attendees.

Cloakroom opening hours:

Friday, 13 June 2025	07:00 – 23:00
Saturday, 14 June 2025	06:30 – 19:15
Sunday, 15 June 2025	07:00 – 19:15
Monday, 16 June 2025	08:30 – 15:00

Important Notice: Due to the tight security measures applied at the SEC, it is strongly advised to leave suitcases at hotels as all bags will be subject to inspection by venue security.

Currency

The local currency is Pound Sterling (GBP). Onsite registration payments must be made using cashless methods.

SEC venues operate a cashless system. They will only accept contactless or card payments at food & drink outlets, merchandise sales points and the cloakroom.

CME Credits

We are very pleased to communicate that the EAACI Congress 2025, Glasgow, UK 13/06/2025 – 16/06/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 29.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that they spent in the educational activity.

Please find below the breakdown of ECMEC®s per day:

13 June 2025 ➜ **8.0**
14 June 2025 ➜ **8.0**
15 June 2025 ➜ **8.0**
16 June 2025 ➜ **5.0**

Congress Scholarship

EAACI Congress 2025 allocated 125 scholarships to EAACI Junior Members. The application was made in connection with the abstract submission and had to be applied for by the presenting author of an abstract. EAACI Congress Scholarship includes complimentary registration to the congress and a scholarship of EUR 500 to be issued two weeks after the congress.

D

Disclaimer

EAACI will not be held liable for personal injuries or for loss of or damage to property incurred by participants at the EAACI Congress 2025. Participants are encouraged to purchase insurance to cover loss incurred in the event of cancellation,

medical expenses, or damage to or loss of personal effects when travelling outside of their own countries. EAACI cannot be held liable for any hindrance or disruption of the EAACI Congress 2025 proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control (force majeure). Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

E

EAACI Campus

EAACI Campus is located within the registration area. Information about EAACI activities such as membership, publications, EAACI Knowledge Hub and future events is available under one roof.

Opening hours of the EAACI Campus:

Friday, 13 June 2025	08:30 – 18:00
Saturday, 14 June 2025	08:30 – 18:00
Sunday, 15 June 2025	08:30 – 18:00

EAACI Events app and Digital Congress Platform

The new EAACI Events app will allow you to explore the EAACI Congress 2025 programme and exhibition:
Browse, search, and personalise the entire event programme.
Search and locate exhibitors in the Exhibition Hall.
Access useful information about the Congress.
Access Congress abstracts (available from 13 June 2025).
Access recordings of presented abstracts (OAS and FT); available 24 hours after the presentation.
Provide your feedback by evaluating speakers and sessions.
Vote in sessions that have polls.
Create and synchronise events with your calendar.
A portion of the EAACI Congress 2025 Scientific Programme will be live streamed on the Digital Congress Platform and in the EAACI Events app.

Exhibition

The exhibition area is the ideal place to meet key industry leaders and learn about the latest developments in allergy products and therapies.

Delegates will be able to navigate through the various stands in the vibrant exhibition area and conduct enriching face to face interactions with industry partners by taking part in their stand activities.

EAACI Congress 2025 Exhibition is open on 13-15 June 2025 from 09:00 – 17:30.

Exhibition access restrictions:
Advertising of medicinal products is governed by the Laws and regulations of both local British and EU authorities.

F

Food and Beverage

Catering services are located in the exhibition area. Coffee and lunch are not included in the registration fee. Water fountains are available throughout the venue.

G

General Assembly

EAACI's General Assembly will take place from 7:45-08:45 on Sunday, 15 June 2025. Access is restricted to EAACI members.
EAACI membership fees for 2025 must be paid before access to the General Assembly is permitted. EAACI staff will be available at the entrance should you wish to purchase membership. Only online card payments are accepted.
Your membership number and status is printed on your badge. If you do not have the number on your badge and you are a member of EAACI, please contact the Registration desk in the registration area to have a new badge issued.

L

Language

The official language of EAACI Congress 2025 is English.

M

Membership

Visit the EAACI Campus to sign-up, renew, or simply learn more about EAACI membership.

Mobile Phone Policy

Please respect other delegates and switch mobile phones to silent in all meeting rooms.

N

National Society Village

The National Society Village is located in the exhibition area. It is open from Friday, 13 June 2025 to Sunday, 15 June 2025 from 09:00 – 17:30. We encourage you to visit this area to learn more about other allergy, asthma and immunology societies.

P

Personal wheeled Vehicles

Hoverboards, skateboards, segways, scooters, rollerblades, and bicycles are not permitted for use within the venue or the Boulevard.

Photography, filming and video recording

Taking photographs or making any other form of electronic recording during the sessions in the meeting rooms is strictly forbidden. An official photographer will be present for the entire event. Photos will be available for download on the congress website after the meeting. Please note, by registering to attend the EAACI Congress 2025, you acknowledge and agree that official photographs taken during the congress may be used for future meeting promotional purposes.

R

Registration

Registration is located at the main congress entrance - Hall 5.

Badge printing kiosks are available in the registration area.

Registration fee for delegates includes:

Admission to the congress and the exhibition

Pocket Programme

Opening Ceremony and Welcome Reception

Closing Ceremony and Closing Reception

The opening hours are:

Friday, 13 June 2025	07:00 – 18:00
Saturday, 14 June 2025	07:30 – 18:00
Sunday, 15 June 2025	07:00 – 19:00
Monday, 16 June 2025	08:00 – 15:00

S

Safety, welfare and behaviour

Glasgow is a generally very safe city. Yet, like most other major cities, there is petty crime. Therefore, please be aware of thieves and pick-pockets at all times. Please pay special attention to your personal belongings, especially when walking in the city centre or using the public transportation system, but also inside the congress venue. Do not wear your badge outside the congress venue, and do not give it to anybody, even if you are leaving the congress. Any security problems or concerns within the congress venue should be reported to a member of EAACI. Security staff will handle any emergency situation and everyone is required to follow instructions announced via the public information system. Emergency exits are marked with green exit signs.

In respect of British and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EAACI Congress shall be limited solely to participants who are 18 years of age or older. Registration by anyone who is under 18 is unauthorised and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification must be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time. This also applies to children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. Badges are required to be worn at all times in the congress venue.

EAACI holds a very firm position against any form of discrimination and aims for a respectful, safe and productive environment for all participants including service providers and others associated with EAACI Congresses and Events. This position applies to all EAACI events and/or events organised in the name of EAACI. EAACI does not tolerate any disruptive behaviour, sexual harassment, bullying, racism, physical or verbal abuse or any other form of unacceptable behaviour by participants and/or staff at our meetings. All delegates and staff shall adhere to dignity and mutual respect. EAACI expects fair and appropriate behaviour at all times.

EAACI reserves the right to take any action deemed necessary and appropriate, including immediate removal from the meeting without warning or refund, in response to any incident of unacceptable behaviour. EAACI reserves the right to prohibit attendance at any future EAACI Meetings. For internal purpose, all reports about incidents of unacceptable and/or disruptive behaviour will be referred to as complaints and stored according to GDPR Rules and Regulations.

In case of support, please do not hesitate to contact the EAACI Congress and Events Manager by sending an email to Noureddine M'ghari.

Session Attendance

Sessions may fill up quickly. Please arrive in good time for the start of a session. Due to health and safety regulations, hosts and hostesses are instructed to restrict access once the maximum capacity of the room is reached. Please refer to hostesses for overflow options.

General information A - W

Smoking Policy

SEC Glasgow operates a no smoking policy throughout the venue. E-cigarettes and vaping are not permitted within the venue.

Smoking is permitted outside the venue in the dedicated smoking zones.

Speaker Service Centre

The Speaker Service Centre is located in the Registration area. The opening hours are:

Thursday, 12 June	15:00 – 18:30
Friday to Sunday	07:00 – 18:30
Monday, 16 June	07:30 – 15:00

Shop

A shop is available inside the venue.

T

Telephone

The international access code for the United Kingdom is +44.
In case of emergency call 112

V

Venue

Scottish Event Campus (SEC)

Previously known as the Scottish Exhibition & Conference



Centre (SECC), the Scottish Event Campus is the UK's largest integrated conference and exhibition centre. Situated in the heart of Glasgow, SEC offers the perfect combination of advanced technical facilities, professional service, proven experience and an unbeatable location.

The SEC has established an enviable reputation for hosting international conferences of all sizes, from 10-10,000 delegates with some specialist events at 25,000. The purpose-built SEC Armadillo, designed by award winning architects Foster and Partners, can accommodate 3000 delegates and is supported by 16 break-out rooms seating 30-300, with a second auditorium providing tiered and floor level seating for up to 624 delegates.

Technical facilities throughout the complex are of the highest standard. Sound, light and audio-visual systems are all computer-managed using fibre optic technology for professional and stress-free presentations. Data lines plus cabling for video conferencing and satellite links are in-built for minimum intrusion.

All of these facilities are directly linked to 22,355 mÇ of exhibition space in the five halls, providing flexible space for concurrent exhibitions, banquets, concerts, large-scale events or additional meeting halls

➜ For more information click or scan the Qr code

Visa, ETA & visiting the United Kingdom

Participants are advised to make their own arrangements with respect to entering the United Kingdom.
If you need a letter of invitation to support a visa application, access your EAACI Congress 2025 registration in the myEAACI portal, and submit your details using the "Generate Visa Letter" button. Please apply for a visa within a reasonable time prior to making your bookings.
Visitors to the UK who do not need a visa for short stays will require permission to travel through an electronic travel authorisation (ETA). To check if you require an ETA, visit Apply for an electronic travel authorisation (ETA).

W

WiFi Access

Complimentary Wi-Fi is available throughout the congress building.

BECOME AN EAACI MEMBER

Over 17,300 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.



Benefits applied to all categories

- ✓ **Free access to online Allergy, PAI and CTA journals**
- ✓ **Full voting rights & eligibility for election**
- ✓ **Possibility to join Task Forces**
- ✓ **50% Discount EAACI Knowledge Exam**

Full Membership

50% DISCOUNT DURING EAACI CONGRESS 2025

150€*

- ✓ EAACI Annual Congress Up to 25% discount
- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount

** For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€.*

Junior Membership
(under 41 years old)

Complimentary

- ✓ EAACI Annual Congress Up to 55% discount
- ✓ EAACI Focused Meetings Up to 70% discount
- ✓ EAACI Schools & Master Classes Up to 50% discount
- ✓ Elegibility for EAACI fellowships & Scholarships
- ✓ Elegibility for EAACI events travel grants

EAACI / NAS Dual Membership

30€

- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount
- ✓ EAACI Annual Congress member rate discount

*This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at **www.eaaci.org/membership***

Discover our full membership offer at **EAACI.org/membership** or send an email to **member@eaaci.org**



KNOW THE SIGNS, TAKE ACTION.

EAACI

Anaphylaxis Awareness Day

SAVE THE DATE! 21 NOVEMBER 2025

EAACI.org

EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

Download the Official EAACI 2025 Mobile App

All information at your fingertips during the Congress

- Access to the full scientific programme and available abstracts
- Overview of the industry exhibition and programme
- Real time updates on the programmes
- Connect to the **congress Wi-Fi** to download the EAACI Events app



Free Wi-Fi
Network: **SSID: eaaci-congress**

ANDROID DEVICES
GET IT ON Google play

iOS DEVICES
Download on the App Store

Welcome Ceremony

As we open the EAACI 2025 Congress, we invite you to join the Welcome Ceremony, featuring inspiring remarks by the EAACI President and the VP Congresses. Be among the first to celebrate this year's recipients of the prestigious EAACI Awards. This kick-off event offers a glimpse into the rich scientific programme that awaits you over the next three days—an exciting journey through the latest innovations and collaborations in allergy and clinical immunology.
Closing Ceremony

Closing Ceremony

At the conclusion of the Congress, we gather once more for the Closing Ceremony, where the EAACI President and the VP Congresses will express their gratitude to all participants and reflect on the Congress' most memorable moments and achievements. Join us as we celebrate our collective success and look forward to the future of our community.

Fellowship Winners

EAACI CLINICAL FELLOWSHIP 2025

Ahmed Elmazaly
Alejandra Jover Walsh
Berta Mascaró-Hereza
Halime Yağmur
Hazal Kayıkçı
Irene Sanchidrián
Maria Luisa Quinones
Marta Planas Vinós
Milica Terzić
Serena Traversi
Sofia Carreras Kàtcheff

EAACI RESEARCH FELLOWSHIP 2025

Angel Maldonado Fuentes
Behnaz Shafie
Elif Öztemiz Topcu
Felicia Anggraini
Giulia Gualtiero
Guozhen Fan
Julián Montoto-Louzao
Margherita Perlato
Mirjana Radomirovic
Nuria Contreras Gómez
Patricia Diez-Echave
Sim Ray Yue

EAACI UKRAINE FELLOWSHIP 2025

Mariia Pylypko

EAACI Awards 2025

Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2025 will be presented during the Opening Ceremony.



Ludger Klimek
Clemens von Pirquet Award 2025

Head of the Center for Rhinology and Allergology in Wiesbaden; board-certified in otolaryngology, allergology, environmental medicine, and head/neck plastic surgery.

Renowned expert in chronic rhinosinusitis, nasal polyposis, and airway immunology; author of over 600 peer-reviewed publications and multiple influential textbooks in allergology.

Vice President of EAACI (2022–2024), Chair of the EAACI CRS Guideline Project, and President of multiple German Allergy Congresses; past president of AeDA and VP of the German Academy of Allergology.



Antti Lauerma
Daniel Bovet Award 2025

Professor at the University of Helsinki and Director of the Inflammation Center at Helsinki University Hospital, specializing in dermatology, allergology, immunology, and the skin microbiome.

Over 13,000 citations; editor of The Skin Microbiome Manual; contributor to major studies like “Burden of Skin Diseases” and advocate for tolerance-building approaches to allergy prevention.

Led Finland’s national allergy program (2008–2018); chaired the EAACI Congress 2017 and was a key speaker at EAACI 2024; recipient of the Pro Congress Award and Finnish Dermatological Society Medal.

EAACI Awards 2025

Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2025 will be presented during the Opening Ceremony.



Marianne van Hage
Paul Ehrlich Award 2025

Professor at Karolinska Institutet and Senior Consultant at Karolinska University Hospital; renowned for her groundbreaking work on molecular allergy diagnostics and alpha-Gal syndrome.

Author of over 400 publications with an h-index of 94; has advanced understanding of allergen risk prediction, tick-induced food allergy, and AGS mechanisms.

Member of Academia Europae; Board Member and Editor for multiple scientific journals and foundations; recipient of several prestigious awards and lectureships.



Tomas Chivato Pérez
Charles Blackley Award 2025

Dean of Medicine at Universidad CEU San Pablo since 2011; Vice President of Education & Specialty at EAACI; Member of Spain's Royal National Academy of Medicine. Held academic roles at Harvard, Zurich, and Imperial College; over 258 publications, 20 patents, h-index 56.

Expert in allergy, anaphylaxis, and respiratory disease; over 90 publications and key co-author of the GALAXIA 2022 anaphylaxis guideline and a 2024 review on AI in asthma and COPD.

Active in bioethics and medical education reform; co-editor of a book on addiction treatment and a public voice on ethical concerns around euthanasia.

EAACI Fellows 2025

EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.



Montserrat Fernandez-Rivas
EAACI Clinical Fellow Award 2025

Head of the Allergy Department at Hospital Clí nico San Carlos and Associate Professor at Universidad Complutense, with a focus on food allergy education and care.

Over 20 years leading Spanish and EU-funded projects on diagnostics, immunotherapy, and severity of food allergy; co-developed the Food Allergy Severity Score (FASS) and co-leads the BIOGRIAL biomarker project.

Long-standing EAACI member; chaired the 2018 guideline on food allergen immunotherapy and co-chairs the Co-FAITH Task Force; 264 publications, h-index 67, and nearly 19,000 citations.



Carsten Schmidt-Weber
EAACI Clinical Fellow Award 2025

Director of ZAUM Munich since 2010; co-founder of the Institute of Allergy Research and German Centre of Lung Research (DZL).

Held academic roles at Harvard, Zurich, and Imperial College; over 258 publications, 20 patents, h-index 56.

Long-time member; Immunology Section Chair, Vice President (2017–2019), and 2018 Congress President.



Marta Ferrer Puga
EAACI Clinical Fellow Award 2025

Dean of the School of Medicine at Universidad de Navarra; trained and conducted research in Spain and the U.S., including SUNY Stony Brook and MUSC.

Leads studies on chronic spontaneous urticaria, angioedema, and peanut immunotherapy using nanoparticles; coordinates national research projects and databases.

Recipient of the 2023 EAACI Clemens von Pirquet Award; Chair of the EAACI Tailored Education Committee and Harvard Macy scholar.

EAACI Fellows 2025

EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.



Jürgen Schwarze
EAACI Clinical Fellow Award 2025

Internationally recognized for research on immune mechanisms linking RSV bronchiolitis to allergic airway disease, with a focus on mucosal immune priming.

Holds the Edward Clark Chair at the University of Edinburgh; former Clinical Lead of CYANS and Wellcome Trust Senior Clinical Fellow.

Held multiple leadership positions in EAACI, including Secretary General (2019–2022), and currently Vice President for Science and Research at the BSACI.



Hugh A Sampson
EAACI Clinical Fellow Award 2025

Over 40 years of NIH-funded research with 600+ publications; led breakthroughs in food allergy diagnostics, immunotherapy, and understanding of eosinophilic esophagitis and atopic dermatitis.

Chaired major working groups setting global standards for diagnosing anaphylaxis and conducting food challenge protocols.

Mentor to 50+ fellows; past AAAAI president; recognized by Clarivate and Scholar GPS as a top global expert in food allergy.



Peter Schmidt- Grendelmeier
EAACI Clinical Fellow Award 2025

Former Head of the Allergy Unit at University Hospital Zurich; now consultant at Medicine Campus Davos; over 320 publications in dermatology and allergy.

EAACI Vice President for Education (2015–2019), Chair of Dermatology Section and Exam Committee; dedicated educator with 100+ trainees, online platforms, and international lectures.

Leads major atopic dermatitis research (ProRaD), with studies across Europe and Africa; works with WHO and Swiss Tropical Institute to improve allergy care in sub-Saharan Africa.

EAACI Fellows 2025

EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.



Markus Ollert
EAACI Research Fellow Award 2025

Director of the Department of Infection and Immunity at LIH and Professor in Denmark, Prof. Ollert has led major allergy and immunology programs in Germany, Luxembourg, and Denmark, with over 300 publications and recognized impact in allergy diagnostics and COVID-19 management.

Long-time EAACI leader (Vice-President Science 2022–2024, former IGAD Chair), senior author of the first Molecular Allergology Users' Guide, and inaugural Editor-in-Chief of EAACI's Research & Innovation Hub (2025).

Pioneer in immune tolerance research and multi-omics diagnostics; co-founder of two biotech companies (PLS-Design and Tolerogenics) focused on allergy diagnostics and therapies, with a mission to prevent and cure allergic diseases.



Philippe Gevaert
EAACI Research Fellow Award 2025

Professor in Rhinology and Allergy at Ghent University, internationally recognized for pioneering work on chronic rhinosinusitis with nasal polyps (CRSwNP) and development of biologic treatments.

First to demonstrate clinical efficacy of biologics (anti-IL-5, anti-IgE, IL-4R antagonists) in CRSwNP; authored 277 peer-reviewed publications, h-index 69, and named Highly Cited Researcher by Clarivate in 2023 and 2024.

Led multiple EAACI roles (Junior Members, ENT Section, Infection & Allergy IG); directs the Upper Airways Research Lab and Clinical Trial Centre at Ghent University since 2022.

EAACI Fellows 2025

EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.



Heimo Breiteneder
EAACI Research Fellow Award 2025

Cloned the first plant allergen (Bet v 1); led groundbreaking work on recombinant allergens, isoallergens, and allergen classification by protein families.

Professor and Head of Medical Biotechnology at the Medical University of Vienna; expert in plant and animal food allergens, including fish allergy and latex.

200 publications, h-index 71, and 18,000 citations; contributed to allergy research and melanoma studies, with a focus on epithelial interactions with allergens.



Sophia Karagiannis
EAACI Research Fellow Award 2025

First to develop anti-cancer IgE antibodies for clinical use; founder of Epsilogen Ltd and author of multiple patents in antibody technology.

Bridges allergy and oncology through groundbreaking work on IgE, IgG4, and B cell immunity in solid tumors, shaping the emerging field of AllergoOncology.

Founding member and current Chair of the AllergoOncology Working Group; co-led major EAACI initiatives and position papers in this field.

EAACI Awards 2025

Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2025 will be presented during the Opening Ceremony.



Eugenio De Corso
Cezmi Akdis Prize 2025

Medical Director at Fondazione Policlinico Gemelli IRCCS and Adjunct Professor at the Catholic University of the Sacred Heart, specializing in CRSwNP and type 2 inflammation.

Leads studies on biologic therapies (e.g., dupilumab, benralizumab) for severe airway diseases; co-developed the DAMADECO score for integrated CRSwNP and asthma management.

MAuthor of 140+ publications; Associate Editor of Acta Otorhinolaryngologica Italica; active member of EUFOREA, Italian Academy of Rhinology, EPOS Steering Group, and national biologics commission.



Jessy Elst
EAACI Allergopharma Award 2025

Senior Postdoc at UAntwerp, specializing in mast cells, basophils, and drug-induced hypersensitivity, with a focus on the MRGPRX2 receptor and anaphylaxis.

Leads development of advanced diagnostic tools like the Mast Cell Activation Test (MAT) and Basophil Activation Test (BAT), including single-cell transcriptomic profiling.

Author of 90+ publications with 1,200+ citations; recipient of the EAACI 2025 Research Award for her work on mast cell-based drug allergy diagnostics.



Janice Layhadi
EAACI Early Career Research Award 2025

Research Associate at Imperial College London, specializing in allergen immunotherapy (AIT) and immune tolerance mechanisms, including IL-10-producing lymphoid cells.

Known for identifying novel biomarkers – such as basophil diamine oxidase (DAO) – to monitor AIT efficacy using flow cytometry and immune profiling techniques.

EAACI–Allergopharma Research Award winner (2022); co-author of 50+ papers with nearly 2,000 citations on basophils, mast cells, and regulatory immune pathways in allergy.

EAACI POC
PATIENT ORGANISATIONS COMMITTEE

Building Healthier Communities: Patients and Professionals in Partnership

A dynamic platform where patient advocacy meets professional expertise. We are dedicated to fostering collaboration between patients and healthcare professionals to enhance the quality of care and support for individuals affected by allergy, asthma and immunological conditions.

At the EAACI POC, we believe in the power of partnership. Our committee serves as a bridge, connecting patients, caregivers, and healthcare professionals in a shared journey towards better health and well-being.

Join us in our mission to create a more inclusive and compassionate healthcare system.



Patients Organisations Committee
SINCE 2011

EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

www.eaaci.org
#EAACIcongress

For more information **about the POC**

Description of Session Types

E

EAACI Journals Highlights (JH)

Organised with Allergy, Pediatric Allergy and Clinical Immunology, and Clinical and Translational Allergy Journals of EAACI, the traditional "Best of EAACI Journals" session provides the audience with an opportunity to review the best papers published throughout the year.

F

Flash Talks (FT)

Moderators will lead a discussion of around 15 related posters in the session, asking the audience and the presenters to set the work in context and draw out important themes and conclusions. These sessions will be in an electronic format and will take place in four designated PDS Zones in the Exhibition Hall. Moreover, in each e-Poster area there is a Poster Help Desk.
Presented only on-site and not live streamed. Recording will be availble on EAACI Congress Digital Platform after the congress.

I

Interactive Workshops (IWS)

Interactive Workshops are sessions in which speakers share and discuss evidence and experience gathered – clinical, translational and/or basic – in a certain field. In agreement with the current pandemic situation this year IWS will occur in a hybrid format (mixed personal/online). The session room will be set up in a more informal way to allow interactive discussions with the participants. Live interaction with the audience is encouraged, either in person or remote via the live webcasting.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

J

JMA Sessions (JMA)

A programme designed by and for the JMA with the support of internationally renowned experts throughout all topics. Get accredited knowledge and valuable education exploring the latest technologies and approaches and solutions for your future professional pathway.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

M

Meet the Expert (MET)

Pre-registration is required. A separate registration fee applies. Meet the Expert allow delegates to meet in a small group with outstanding researchers and clinicians. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new insights. No presentations will be given, instead the participants will have ample time for interaction with the faculty member and their peers.
For onsite participants only.

O

Oral Sessions (OAS)

The most exciting work from abstracts submitted to the congress will be honoured with a place in these sessions, which start with a brief introductory talk from one of the chairs. Each presenter highlights their work and answers questions from attendees.
Presented only on-site and not live streamed. Recording will be availble on EAACI Congress Digital Platform after the congress.

P

Plenary Symposia (PL)

Plenary Symposia are the core of the congress activities. These are exhaustive reviews of a major subject of the specialty, addressed to all congress participants. Plenary Symposia are scheduled at "prime times" in the programme, with no crossover with other activities to enable maximum attendance. Two parallel symposia will be held, one primarily clinical and the other focused on basic science. Leading international speakers have been invited to conduct these symposia. Given the large nature, Plenary Symposia do not have allocated time for questions or discussions.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

Pro & Con Sessions (P&C)

The Pro & Con Sessions allow speakers to debate controversial topics in an attractive format which provides "food for thought". These lunch time sessions take place in the exhibition hall.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

Description of Session Types

S

Satellite Symposia (SAT)
Satellite Symposia commence once the main programme has concluded for the day. These symposia are organised independently by the sponsoring companies who also select the topics and speakers which are approved by the Scientific Programme Committee.

Sister Society Symposia (SSS)
EAACI has collaborated with a number of sister societies to develop symposia that represent regional or scientific areas common to EAACI and the sister society. This is a chance to expand your knowledge beyond the traditional boundaries.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congres.

Symposia (SYM)
Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congres.

T

Thematic Symposia (TS)
The Thematic Symposia are theme-based, cutting-edge and educational sessions in which the speakers critically highlight novel breakthroughs specific to the theme. The target audience consists of delegates who are interested in the topic and wish to update their knowledge in the area.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

Thematic Poster Session (TPS)
Abstracts are grouped thematically into blocks of 15-20 posters and displayed for a whole day. At lunchtime, presenters are available to discuss their work and answer questions from delegates and moderators alongside their posters.
For onsite participants only.

E-Thematic Poster Session (E-TPS)
Abstracts in this category will be available on the digital platform only.

G

Ground Breaking Discoveries (GBD)
The GBD are high-level sessions developed based on the current projects of EAACI's Research and Outreach Committee on current topics in allergy, asthma and clinical immunology intended to promote innovative research and the knowledge exchange network,
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

Y

Year in Review (YIR)
The Year in Review Sessions are complete and authoritative, focused on the highlights published during the previous year on a specific topic.
Onsite, live streamed on EAACI Congress Digital Platform and available On-Demand after the congress.

14 June 2025
Glasgow, United Kingdom

EAACI Congress 2025

Beat Allergy Walk&Run

The Beat Allergy Walk & Run has been a beloved tradition at the EAACI Annual Congresses for years, and you've enjoyed being a part of it. It is our pleasure to announce that the EAACI Congress 2025 will feature the EAACI Beat Allergy Walk & Run on Saturday, 14 June 2025 at 7:00.

You can participate in the run by choosing to cover a distance of either 2.5 km, 5 km or 10 km, by walking or running. This event provides a fun opportunity for all of us to gather together and enjoy the sport amidst the beautiful surroundings. It's a great chance to have some fun, meet new people, and make some wonderful memories of the congress and the hosting city.

Each year, the Beat Allergy Walk & Run proudly donates all its proceeds to a charitable cause. This year, our chosen beneficiary is Glasgow Children's Hospital Charity.

Glasgow Children's Hospital Charity aims to be there for every child treated in hospital in the West of Scotland. They raise funds to help those who tirelessly care for and nurture young lives at their most vulnerable; to invest in equipment, research and the continued improvement of facilities and services for children and families in hospital.

We encourage everyone to participate in the Beat Allergy Walk & Run, whether you are a seasoned runner or simply want to take a leisurely stroll. It is a great way to get some exercise, meet new people, and get to know Valencia's atmosphere and environment. You can also bring your friends and family along, as this event is open to all ages.

- **Jun 14, 2025**
- **7:00 AM to 8:30 AM**
- **2.5k - 10k**

➜ Registration information is available online, please scan or click on the QR code.



Hatha Yoga Class

Due to overwhelming demand for our Saturday class we have made this activity available on first congress day as well!

Find your balance with a grounding Hatha Flow yoga session led by an SEC professional instructor on Friday, 13 June. This energising practice is open to all levels and offers a mindful start to your day - with zero carbon footprint and maximum inner peace.

This energising session is the perfect way to start your Congress day with movement, mindfulness, and community. Whether you're a seasoned yogi or a complete beginner, this class is open to all levels.

- Friday, 13 June
- 7:00 - 7:45 am
- Congress Venue
- Mats provided

35 spots only per class

- Friday, 13 June
- 9:00 - 9:45 am
- Congress Venue
- Mats provided

35 spots only per class

For more information, please scan or click on the QR code.

Vinyasa Flow Yoga Class

Find your balance with a grounding Vinyasa Flow yoga session led by Dr. Rosan Meyer on Saturday, 14 June. This energising practice is open to all levels and offers a mindful start to your day - with zero carbon footprint and maximum inner peace.

This energising session is the perfect way to start your Congress day with movement, mindfulness, and community. Whether you're a seasoned yogi or a complete beginner, this class is open to all levels. Spaces are limited to 25 participants, so we encourage you to register early to secure your spot.

- Saturday, 14 June
- 7:00 - 8:00 am
- Congress Venue
- Mats provided | 25 spots only per class

Saturday class booked out!

For more information, please scan or click on the QR code.

PAAM 2025

PEDIATRIC ALLERGY & ASTHMA MEETING

23-25 OCTOBER

PALMA DE MALLORCA, SPAIN

PAAM



#PAAM2025

eaaci.org

EAACI

EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

SCIENTIFIC PROGRAMME

- Symposia (SY)
- Interactive Workshops (IWS)
- Innovation Hub (IH)
- Meet the Expert (MTE)
- Ground Breaking Discoveries (GBD)
- EAACI Enlightening Talk (ET)
- EAACI Special Session (ESS)
- POC (POC)
- Sponsored Sessions (SAT)
- Thematic Symposium (TSY)
- Sister Society Symposia (SSS)
- Flash Talks (FT)
- JMA Sessions (JMA)
- Oral Abstract Sessions (OAS)
- Plenary Symposia (PL)
- Pro & Con Sessions (P&C)
- Thematic Poster Sessions (TPS)
- Year in Review Sessions (YIR)
- Oral Abstract Sessions on Clinical Trials (OAS-CT)
- Pitch Session (PiS)
- e-Thematic Poster Session (E-TPS)

INDUSTRY

- Satellite Symposia (SAT)
- Mini Satellite Symposia (MSAT)

EAACI

ANTIBIOTIC ALLERGY AWARENESS CAMPAIGN

"CORRECT LABELS, BETTER LIVES"



#CorrectLabelsBetterLives

#AntibioticAllergyAwareness

EAACI.org

ISAF-RHINA 2025

INTERNATIONAL SEVERE ASTHMA FORUM
& EUROPEAN RHINALLERGY MEETING

20-22 NOVEMBER
PORTO, PORTUGAL

INTERNATIONAL SEVERE ASTHMA FORUM
isaf

RHINA
European Rhinallergy Meeting



#ISAFRHINA2025

EAACI.org

EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY


EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

EAACI Allergy School 2025

Biologicals, type 2 inflammation and eosinophil-associated diseases

4 - 6 September

Florence, Italy



eaaci.org

DHM 2026

DRUG HYPERSENSITIVITY MEETING

9–11 APRIL • ANTWERP, BELGIUM

DHM
Drug Hypersensitivity Meeting



#DHM2026

eaaci.org

EAACI
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

000079 **Analysis of patients undergoing metronidazole challenge testing: a real-life data**
Kurtulus Aksu (Türkiye)

000103 **Characterization of Allergenic Proteins in Pine Nut: A Clinical Case Study**
Azahara Lopez-Raigada (Spain)

000140 **Effectiveness of Tezepelumab in uncontrolled severe asthma. ADVANCAT (Advancing severe asthma care with Tezepelumab in Catalonia)**
Olga Luengo (Spain)

000167 **Omega 5 Gliadin positive presentation clinical profile**
Muntajibuddin Ahmed (India)

000197 **Studies on the effects of various tobacco and nicotine use methods on the course and control of asthma**
Natalya Nenasheva (Moscow)

000239 **Staggered oral peanut challenge with regular consumption at home**
Laura Dalton (Ireland)

000274 **Prophylaxis with androgens can cause liver cancer in patients with Hereditary Angioedema**
Raffaele Brancaccio (Italy)

000312 **Hand dermatitis in a painter, who is to blame?**
Mercedes Wanabilá Bosepa Toraó (Spain)

000332 **Increased eosinophil-derived neurotoxin levels in serum of chronic spontaneous urticaria patients**
Eun-Mi Yang (Korea, Republic of)

000339 **Successful Case Series of Desensitization Shortening for Chemotherapy-Induced Hypersensitivity**
Sun Young Paik (Korea, Republic of)

000372 **A Case Report of Late-Onset Immunodeficiency: Good's Syndrome**
Öykü Ünsal (Türkiye)

000389 **Use of Dupilumab as Adjuvant Treatment in Oral Food Desensitization: A Case Report**
Azahara Lopez-Raigada (Spain)

000431 **Machine Learning-Based Analysis of Clinical and Laboratory Features Predicting Malassezia- specific IgE Elevation in Dermatological Disorders**
Jemin Kim (Korea, Republic of)

000451 **Breaking the Reaction Cycle: Tailored Solutions for Contrast Media Hypersensitivity**
Beatriz Sáez Salas (Spain)

000453 **Managing Platinum Salt Hypersensitivity: Insights from a Year of Clinical Experience**
Beatriz Sáez Salas (Spain)

000454 **Impact of Omalizumab on Serum IgE Levels: An Observational Cohort Study**
Beatriz Sáez Salas (Spain)

000486 **Objective and Subjective Sleep Assessments in Patients With Atopic Dermatitis Treated With Dupilumab: Results From DUPISTAD, a Phase 4 Randomized Placebo-Controlled Study**
Anastasia Petrova (United Kingdom)

000531 **Autoimmune progesterone dermatitis in two sisters**
Young-Hee Nam (Korea, Republic of)

000565 **Omalizumab for oral desensitization in children with cow's milk allergy**
Javier Martínez Olmos (Spain)

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

000594 **The Role of Asthma and COVID-19 in Shaping the Severity of Pediatric Mycoplasma pneumoniae Infections: A Regional Perspective from the United States**
Divya Reddy Voladri (United States of America)

000672 **Benralizumab as treatment in a patient with Near-Fatal Asthma exacerbation**
Adelaida Cabrera Nuñez (Spain)

000680 **The Fundamental Role of Education in Achieving Control in a Child with Severe Uncontrolled Asthma**
LUIS MOREJON (Spain)

000710 **SDRIFE-like skin rash due to paracetamol**
Carl Capellen (Switzerland)

000734 **A Systematic Review of Multidimensional Predictors for Refractory Chronic Rhinosinusitis**
Di Wu (China)

000762 **Transition: the future starts earlier**
Rosa Buonagura (Italy)

000766 **Clonal mast cell disorders, allergy to hymenoptera venom and venom immunotherapy – our experience**
Daniela Kapustová (Slovakia)

000773 **Stratification Value of Nasal Brushing Arachidonate 15-Lipoxygenase in Stapokibart (CM310) Treatment for Patients with Seasonal Allergic Rhinitis: Results from MERAK**
Bing Yan (China)

000788 **Efficacy of Omalizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps and Association with Local Immunoglobulin E**
Shen Shen (China)

000812 **Comparison between allergy tests result**
Vira Semianchuk (Ukraine)

000854 **Allergen and Panallergen Sensitization Profile in Pediatric Eosinophilic Esophagitis Patients: a single centre experience**
Cristina Ferrigno (Italy)

000865 **Molecular spreading of allergy in patients with sensitisation to ragweed and wormwood allergens**
Olga Kolesnikova (Ukraine)

000868 **Prevalence of ltp syndrome among patients in Ukraine with respiratory allergy caused by sensitisation to wormwood ltp protein (Art v 3)**
Olga Kolesnikova (Ukraine)

000943 **Efficacy of Benralizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) in a Real-World Setting: Experience at La Paz University Hospital**
Leticia de las Vecillas Sanchez (Spain)

000995 **An unusual cause of recurrent facial oedema**
Xin Luo (China)

001015 **A shifted paradigm, from the monobiotic to the holobiotic, holds profound implications for the ideas of infection and immunity**
Richard Doehring (New Zealand)

001042 **Searching for an Alternative Contrast Agent in a Patient with Allergy to Multiple Macrocyclic Gadolinium-Based Contrast Agents**
Azahara Lopez-Raigada (Spain)

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

001066 **The Impact of Bee Sting Experiences on Quality of Life and Perceived Health Threat in Korean Beekeepers with Bee Venom Allergy**
Jeong Min Park (Korea, Republic of)

001129 **From Symptoms to MBPT: A Machine Learning Approach to Asthma Diagnosis**
Jin-Young Lee (Korea, Republic of)

001168 **Intradermal testing beyond allergy diagnosis: Insights into Gardner-Diamond Syndrome**
Brenda Aissé Coronel González (Spain)

001310 **The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases**
He Zhang (China)

001403 **Impact on IgE of therapy using auto serum injections for cold allergy and insect allergy**
Lawrence DuBuske (United States of America)

001413 **Approach to penicillin allergy**
Merve Taş (Türkiye)

001422 **IgG3 antibodies specific for alpha-gal as a part of the cardiac risk profile of alpha-gal antibodies in patients living in an area with heavy tick infestation**
Thomas Platts-Mills (United States of America)

001476 **Hypersensitivity to endogenous progesterone manifested as fixed drug eruption: a case report**
Maria Angelica Collado Arocha (Spain)

001493 **Allergic contact dermatitis due to acrylates contained in catheter fixation devices catheters**
Estela Menéndez-Rivero (Spain)

001537 **Effectiveness of a Provincial Policy to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study**
Joseph Najem (Canada)

001556 **Cofactor-induced LTP anaphylaxis**
Nithya Rajendran (United Kingdom)

001566 **Anaphylaxis to diethyltoluamide (DEET) containing insect repellent**
Vicente Albéndiz Gutiérrez (Spain)

001581 **Inflammatory Responses to Ole e 7 and Pru p 3 in Pollen-Food Syndrome: Insights from ex vivo Blood Culture Models**
Lucía De Dulanto García (Spain)

001589 **Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)**
Fiorella Adrianzen Alvarez (Spain)

001600 **Allergic contact dermatitis caused by acrylates: two different perspectives on the same issue**
Vicente Albéndiz Gutiérrez (Spain)

001638 **A patient with aggressive Systemic Mastocytosis: a Case Report**
Julian Londoño (Colombia)

001643 **Clinical-laboratory evaluation of children with chronic urticaria**
Juliana Goncalves Primon (Brazil)

001672 **Etoricoxib-Induced DRESS Syndrome**
María Nerea Otero-Fernández (Spain)

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

001683 **When Pruritus is Beyond Allergy: Waldenström Macroglobulinemia (WM) Presenting as Allergic Itch in the Community**
Jason Ohayon (Canada)

001685 **An unusual reaction to cosmetic**
Annalisa Santucci (Italy)

001699 **Occupational contact dermatitis to non latex gloves**
Vicente Albéndiz Gutiérrez (Spain)

001503 **Urticaria exacerbations in children with chronic urticaria receiving COVID-19 vaccination**
Maria Savva (Greece)

100006 **A real-world study of tezepelumab in severe asthmatics of a French cohort**
Sarah BOUNETTA BELMOKHTAR (France)

100020 **Health Quality and Treatment Satisfaction in IEI Patients; Not only IgRT but Comorbidities**
Elif Karakoç Aydiner (Türkiye)

100057 **Specific IgE molecular sensitization pattern of House dust mite allergen-components by Component Resolved Diagnosis [CRD] in 318 patients of allergic diseases [Respiratory allergy [168], Food allergy [80], Atopic dermatitis [70]**
Pooran Kathuria (India)

100085 **Code Anaphylaxis: enhancing the management of Hymenoptera venom anaphylaxis**
Denisse Monserrate Tello Montúfar (Spain)

100086 **High Prevalence of Atopy in a General Population**
Irene Fernández Franco (Spain)

100093 **Arcoxia - cause of erythema fixed drug**
Corina Porr (Romania)

100094 **A Mycoplasma pneumoniae infection in an alergic preschool-aged child. Case report**
Corina Porr (Romania)

100106 **Update in the diagnosis of fixed drug eruption**
Paula Ollo (Spain)

100109 **Codeine as a Cause of Hepatotoxicity: A Case with Clinical Confirmation**
Mariana Muñoz Ramirez (Spain)

100147 **Flare up by diethylthiurea/dibutylthiourea**
Ángel Luis Villalón García (Spain)

100155 **Protein study and clinical relevance in a patient allergic to sweet potato with tolerance to potato**
Ángel Luis Villalón García (Spain)

100166 **Contact urticaria with phenoxyethanol**
Virginia Martinez Alcaina (Spain)

100205 **Air Quality and Asthma: The Role of Particulate Matter in Almaty's Public Health Crisis**
Aray Batyrbaeva (Kazakhstan)

100209 **Reliability of UCT and DLQI Questionnaires for Urticaria in the Republic of Kazakhstan**
Aray Batyrbaeva (Kazakhstan)

000330 **Association between changes in blood eosinophil levels and alterations in olfactory function in asthma**
Y.-H. Nam (Korea Republic of)

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

100219 **Investigating Autoimmunity in Chronic Spontaneous Urticaria : The astonishing association**
Mona Sharma (India)

100259 **Rapid drug desensitization with chemotherapy: When should omalizumab be considered?**
Zeynep Yegin Katran (Türkiye)

100261 **Cross-reactivity among different proton pump inhibitors in a patient with recurrent anaphylaxis to pantoprazole and esomeprazole**
Hanna Lindemann (Switzerland)

100334 **Chryseobacterium indologenes: An emerging bacteria with antiviral properties**
Hossam M. Ashour (United States of America)

100448 **Aspects related to anaphylaxis in oral food challenge for cow's milk in a tertiary pediatric hospital**
Heloísa Gouveia Machado (Brazil)

100455 **Ocrelizumab-associated secondary hypogammaglobulinemia and sever pneumonia: Case Report**
Metin Keren (Türkiye)

100457 **Use of subcutaneous human immunoglobulin in patients with hypogammaglobulinemia secondary to nephrotic syndrome in a tertiary pediatric hospital**
Heloísa Gouveia Machado (Brazil)

100478 **Cross-sectional study of vitamin D levels in the adult population of Kazakhstan**
Khan Viktoriya (Kazakhstan)

100509 **The cause of perioperative hypersensitivity in adults and consequences of subsequent anesthesia**
Zeynep Yegin Katran (Türkiye)

100514 **Chronic urticaria and eradication of helicobacter pillory-evaluation of treatment results**
Lali Bugadze (Georgia)

100516 **Systemic reaction with dry powder device in patient allergic to milk**
Virginia Martinez Alcaina (Spain)

100536 **Late onset immunodeficiency in children**
FELLA LAMRANI (Algeria)

100541 **Systematic evaluation of ChatGPT`s performance on 40 dermatological allergology questions with clinical error impact assessment for erroneous AI-guided chatbot-advice**
Sonja Mathes (Germany)

100606 **Cofactor-mediated spice anaphylaxis: a case report**
Anabel Peláez Vargas (Spain)

100607 **Eating Under Observation**
Vyanka Redenbaugh (United Kingdom)

100629 **Asthma outcomes in young adults completed sublingual immunotherapy in adolescence**
Andrey Kamaev (Sankt-Peterburg)

100631 **Long-term post treatment benefits of house dust mites sublingual immunotherapy in polysensitized children**
Andrey Kamaev (Sankt-Peterburg)

100632 **The Uniqueness of Patch Testing in Delayed Clindamycin Allergy**
Ana Melissa Yanes Bonilla (Spain)

100645 **The role of Helminthes in the development of cough with unknown etiology**
Sopio Gamkrelidze (Georgia)

E-TPS Display Only

07:45 - 07:45 E-TPS Display Only Digital section *(e-Thematic Poster Session)*

100648 **The Impact of Radon Baths and Speleotherapy in Tskaltubo on the Immune System**
Manana Chikhladze (Georgia)

100480 **The Association Between Selective IgA Deficiency and Bronchial Asthma in Children Aged 4– 18 Years: A Systematic Review**
Maria Tsaroucha (Greece)

000878 **Kounis Syndrome induced by anaphylaxis after consuming hake**
Estela Menéndez-Rivero (Spain)

000098 **A peri-Anesthetic Reaction in a Pediatric Patient with Anaplastic Astrocytoma of the Body's Corpus Callosum**
Viviana Mendoza (Spain)

000111 **Allergy to Isobornyl Acrylate (IBOA) present in Sensors and Insulin Infusion Systems in Pediatric Population**
Viviana Mendoza (Spain)

000587 **Generalized Acute Eosinophilic Folliculitis Induced by Drugs in an Oncology Patient**
Viviana Mendoza (Spain)

000248 **Evaluation of the tolerability of the administration of subcutaneous immunotherapy in a cluster schedule, in patients with rhinoconjunctivitis and/or asthma with sensitization to Olea europaea with or without sensitization to grasses**
Manuel Alcántara Villar (Spain)

D1.396 **Identifying Allergies, Prematurities, and GERD as Risk Factors for Recurrent Respiratory Infections in Children: A Case-Control Study**
Audi Yudhasmara (Indonesia)

07:45 - 08:30 MTE1 - Clinical studies on allergen immunotherapy with inhaled allergens: Optimization and standardization of methodological approaches

(Carron 1, Meet the Expert)

*Chair: **Oliver Pfaar (Germany)***

Please note that this session is limited to 30 participants and pre-registration is required to secure your spot

07:45 **Clinical studies on Allergen Immunotherapy with inhaled allergens: optimization and standardization of methodological approaches**

07:45 - 08:30 MTE2 - Tips and tricks for biological treatment of CRSwNP: setting the indication, choosing the right biological, managing side effects, switching, tapering

(Carron 2, Meet the Expert)

*Chair: **Marie Lundberg (Finland)***

Please note that this session is limited to 30 participants and pre-registration is required to secure your spot.

07:45 **Tips and tricks for biological treatment of CRSwNP: setting the indication, choosing the right biological, managing side effects, switching, tapering**

08:30 - 10:00 IH1 - AI in allergy and lung health: predicting the future, transforming diagnosis
(Innovation Hub, Innovation Hub)

Chairs: ***Fabio S. Ryser (Switzerland), Stephanie Dramburg (Germany)***

08:30 **Decoding lung function trajectories: AI insights from childhood to adulthood**
Adnan Custovic (United Kingdom)

09:00 **Predictors of response to oral immunotherapy**
Michelle Huffaker (United States of America)

09:30 **AI as a game-changer: predicting biomarkers to transform allergy immunotherapy**
Mohamed Shamji (United Kingdom)

08:30 - 10:00 IWS1 - Managing venom allergy: what's new
(Hall 1, Interactive Workshop)

Chairs: ***Beatrice Maria Bilò (Italy), Arantza Vega Castro (Spain)***

08:30 **Risk factors and cofactors in insect allergy: do we know them?**
Margitta Worm (Germany)

09:00 **Component resolved diagnosis in serum and in basophil activation test**
Peter Kopac (Slovenia)

09:30 **Protocols for venom immunotherapy in the era of depot formulations**
Gunter Sturm (Austria)

08:30 - 10:00 IWS2 - Management of delayed drug hypersensitivity reactions
(Meeting Academy M1, Interactive Workshop)

Chairs: ***Elizabeth Phillips (United States of America), Marina Atanaskovic-Markovic (Serbia)***

08:30 **Treating through in maculopapular exanthema**
Kathrin Scherer Hofmeier (Switzerland)

09:00 **Re-introduction of drugs in drug reaction with eosinophilia and systemic symptoms**
Lukas Joerg (Switzerland)

09:30 **Evaluation of fixed drug eruption – skin test or drug provocation test?**
Angele Soria (France)

08:30 - 10:00 IWS3 - Omics
(Forth, Interactive Workshop)

Chairs: ***Maria Escribese (Spain), Cagatay Karaaslan (Türkiye)***

08:30 **Landscape of the omics in allergy reasearch.**
Markus Ollert (Luxembourg)

09:00 **Viral infections and asthma exacerbations.**
Urszula Radzikowska (Switzerland)

09:30 **Interaction of infant gut microbiome and their maternal lineage.**
Alma Villasenor Solis (Spain)

08:30 - 10:00 JMA 1 - Inborn errors of immunity: Increasing awareness in clinical practice
(AIsh, JMA)

Chairs: ***Philippe Eigenmann (Switzerland), Mattia Giovannini (Italy)***

08:30 **Tregopathies**
Riccardo Castagnoli (Italy)

09:00 **Interferonophaties**
Petter Brodin (United Kingdom)

09:30 **Inborn errors and treatment modalities**
Ayca Kiykim (Türkiye)

08:30 - 10:00 SY1 - Clinical impact of Immune mechanisms driving asthma
(Clyde Auditorium, Symposium)

Chairs: ***Jasper Kappen (Netherlands), Brian Lipworth (United Kingdom)***

08:30 **How can we unravel the type 2 low mechanism**
Ian Adcock (United Kingdom)

09:00 **Immune skewing and the impact on treatment response in adult asthma**
Celeste Porsbjerg (Denmark)

09:30 **Immune Skewing in pediatric asthma – clinical consequences**
Adnan Custovic (United Kingdom)

08:30 - 10:00 SY2 - Cofactor-dependent food-induced anaphylaxis
(Lomond Auditorium, Symposium)

Chairs: ***Riccardo Asero (Italy), Constantinos Pitsios (Cyprus)***

08:30 **Wheat-Dependent Exercise-induced anaphylaxis**
Knut Brockow (Germany)

09:00 **Alpha-Gal syndrome**
Tilo Biedermann (Germany)

09:30 **LTP-Syndrome**
Rosa Muñoz-Cano (Spain)

09:00 - 10:00 EAACI-BSACI Session 1 - Inequalities in Access to Care: Three conditions - One Problem
(EAACI Global Stage EAACI Special Session)

Chair: ***A. Fox (United Kingdom)***

08:30 **Food allergy**
Nicola Jay (United Kingdom)

09:15 **Immunotherapy**
Michel Erlewyn-Lajeunesse (United Kingdom)

09:30 **Asthma**
R. Gore (United Kingdom)

09:45 **Q & A**

09:00 - 10:00 L-FT01 - Allergen Immunotherapy
(Dochart 1, Flash Talks)

Chairs: ***Umit Murat Sahiner (Türkiye), Marco Caminati (Italy)***

09:00 100067 **Differential IgG and IgA induction by rArt v 1-based SCIT and SLIT in murine asthma**
Kaissar Tabynov (Kazakhstan)

09:07 100068 **Efficacy of 300IR house dust mite sublingual immunotherapy tablet on steroid sparing in patients with house dust mite allergic rhinitis: an in-depth analysis**
Giorgio W Canonica (Italy)

09:14 100101 **House dust mite sublingual immunotherapy is effective in generating functional blocking antibodies IgA1 and IgA2: RDBPC Phase II/III studies of Japanese and European Cohorts**
Nichell Samson (United Kingdom)

09:21 100175 **Threshold Oral Food Challenge Outcomes in the ADAPT Peanut Oral Immunotherapy Program**
Tim Brettig (Australia)

09:28 100216 **Ara h 1-2 complexes: key molecules for the activation of Ara h 2-specific B cells in the absence of Ara h 2-specific T cells?**
Charlotte Castenmiller (Netherlands)

09:35 100352 **Effects of oral immunotherapy on the immunological profile of peanut-allergic young children: insights from transcriptomic and epigenetic analyses**
Isabella Badolati (Sweden)

09:42 100398 **Real life effectiveness and safety of sublingual immunotherapy with aeroallergens. A retrospective study**
Inmaculada Buendía Jiménez (Spain)

09:49 100528 **Modulation of innate and adaptive immune compartments by plant-derived Fel d 1 bioparticles at the single cell molecular level**
Sean Keane (United Kingdom)

09:00 - 10:00 L-FT02 - Food Allergy
(Dochart 2, Flash Talks)

Chairs: ***Simona Barni (Italy), Natalia Isabel Perez Sanchez (Spain)***

09:00 100180 **Immunomodulatory Inflection Point in Peanut Allergy: Evidence from Placebo-Treated Participants**
George du Toit (United Kingdom)

09:07 100257 **Milk FPIES: Not Your Average Dairy Tale. Characteristics and prognosis of milk FPIES in children**
Patricia Quijada-Morales (Spain)

09:14 100282 **Prevalence and timing of cow's milk allergy formula prescriptions in infants: a UK CPRD analysis**
Nikita Punjabi (United Kingdom)

09:21 100369 **Sensory Processing Difficulties in Children with Eosinophilic Esophagitis**
Arzu Bakirtas (Türkiye)

09:28 100400 **The Safety and Effectiveness of Using the 6-Step iMAP Milk Ladder in Children with IgE- Mediated Cow's Milk Protein Allergy**
Caoimhe Cronin (Ireland)

09:35 100408 **The patterns and prevalence of food allergy in UK adults population**
Clare Mills (United Kingdom)

09:42 100410 **Risk Assessment of Anaphylactic Reactions to Peanut Traces in Peanut-Allergic Individuals in Germany**
Agata Weronika Szubert (Germany)

09:49 100443 **Metabolomic study of allergic reaction to walnut**
Antonio Jesús García-Cívico (Spain)

09:56 100444 **The frequency and severity of 192 foods causing a food allergy in adults**
Emily Kallen (Netherlands)

09:00 - 10:00 L-OAS01 - Aerobiology and Pollution
(Carron 1, Oral Abstract Sessions)

*Chairs: **Célia Antunes (Portugal), Stefanie Gilles (Germany)***

09:00 100327 **Impact of wildfires on emergency department admissions for respiratory diseases in a tertiary hospital in Portugal**
Margarida Alves (Portugal)

09:12 100414 **Multimodal Deep Learning Model Improves Real-Time Allergenic Pollen Classification**
Reto Abt (Switzerland)

09:24 100507 **Mapping plant-derived panallergen sensitization from the open source Allergen Chip national French database**
Caroline Klingebiel (France)

09:36 100644 **Enhancing pollen forecasting for allergy management: a data-driven ensemble modeling approach**
Maria P. Plaza (Germany)

09:00 - 10:00 L-OAS02 - Dermatology
(Carron 2, Oral Abstract Sessions)

*Chairs: **Maria Bova (Italy), Peter Schmid-Grendelmeier (Switzerland)***

09:00 100064 **Skin microbiome and eczema**
Qing Chong (Australia)

09:12 100227 **Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria**
Ana Maria Giménez-Arnau (Spain)

09:24 100249 **Rocatinlimab Significantly Improves Clinical Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis by Specifically Reducing OX40R+ T-Cell Population Without Signs of Immunosuppression**
Jonathan Bernstein (United States of America)

09:36 100550 **Atopic Dermatitis severity correlation with Staphylococcus aureus as function of demographic and environmental factors**
Avidan U. Neumann (Germany)

09:00 - 10:00 SSS 1 - EAACI & JSA Joint Symposium: New Insights into the Mechanism and Treatment Strategies for Unified Airway Disease
(Boisdale, Sister Society Symposium) *Organisateur: JSA*

Chairs: ***Motohiro Ebisawa (Japan), Maria Jose Torres (Spain)***

09:00 **Clinical Remission in Asthma and its Correlation with Nasal Comorbidities**
Keiji Oishi (Japan)

09:20 **Concepts and Pathology of Eosinophilic Rhinosinusitis**
Tetsuji Takabayashi (Japan)

09:40 **Phenotypes and inflammatory molecular endotypes of chronic rhinosinusitis and its implication for asthma**
Tsuguhisa Nakayama (Japan)

09:45 **Q & A**

10:15 - 11:45 PL2 - Infections and the Development of Allergy: Unraveling the Connections
(Lomond Auditorium, Plenary Lectures)

Chairs: ***Mohamed Shamji (United Kingdom), Milena Sokolowska (Switzerland)***

10:15 **Asthma and ABPA: Similarities and Differences**
Marco Caminati (Italy)

10:45 **RSV Infection: A Catalyst for Allergy and Asthma Development**
Wendy Fonseca (United States of America)

11:15 **Human Milk Antibodies: Protective Roles Against Allergy Development**
Kirsi Jarvinen-Seppo (United States of America)

10:15 - 11:45 PL3 - EAACI Highlight Plenary session Focus on Angioedema and Mast Cell Diseases
(Hall 1, Plenary Lectures)

Chairs: ***Patrizia Bonadonna (Italy), Cevdet Ozdemir (Türkiye)***

10:15 **The Clinical Faces of Mastocytosis**
Cem Akin (United States of America)

10:37 **Emerging Therapeutic Options for Mastocytosis**
Vito Sabato (Belgium)

10:59 **The Clinical Faces of Hereditary Angioedema**
Teresa Caballero (Spain)

11:21 **Advances in Histaminergic Angioedema**
Marta Ferrer (Spain)

10:15 - 12:00 PL1 - Innovations and Emerging Therapies in Food Allergy: Bridging Research and Clinical Practice

(Clyde Auditorium, Plenary Lectures)

Chairs: ***Maria Jose Torres (Spain), Alexandra Santos (United Kingdom)***

10:15 **Novel Biomarkers and Diagnostic Tools in Food Allergy**
Hugh Sampson (United States of America)

10:45 **Pathways to tolerance in food allergy**
Jonathan Hourihane (Ireland)

11:15 **Addressing myths in food allergy: why it matters**
Paul J. Turner (United Kingdom)

11:45 **Our journey from tragedy to transforming allergic lives**
Nadim Ednan-Laperouse (United Kingdom)

12:00 - 13:00 FT01 - Mastocytosis and mast cells diseases

(Dochart 2, Flash Talks)

Chairs: ***Sigurd Broesby-Olsen (Denmark), Vito Sabato (Belgium)***

12:00 000374 **Retrospective Evaluation of Patients Diagnosed with Childhood (Cutaneous) Mastocytosis: Türkiye Childhood Mastocytosis Study Group Multicenter Study**
Öner Özdemir (Türkiye)

12:07 000488 **The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights From the PRISM Survey**
Jessica Hobart (United Kingdom)

12:14 000616 **Prevalence, Risk and Protective Factors of Anaphylactic Reactions in Patients with Mastocytosis: A Single-Center Analysis**
Andrea Sangalli (Italy)

12:21 000621 **Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study**
Hanneke Oude Elberink (Netherlands)

12:28 001149 **Basal serum tryptase: sex- and age-specific reference intervals in the pediatric and adult population**
Yannick Chantran (France)

12:35 001204 **Besides HαT, β-duplications and tryptase gene deletions are frequent and also modify circulating tryptase levels in a birth cohort**
Yannick Chantran (France)

12:42 001637 **Unveiling clinical patterns in hereditary alpha tryptasemia among anaphylaxis patients**
Luis Carrasco Gómez (Spain)

12:49 100459 **Hereditary Alpha Tryptasemia in a Swiss Cohort: Are Symptoms Possibly Linked to Menopause?**
Fiona Schmid (Switzerland)

12:56 100300 **Bruton's Tyrosine Kinase Inhibitor Attenuates Mast Cell Activation via Both FceRI- and MRGPRX2-Mediated Pathways**
Zhao Wang (China)

12:00 - 13:00 L-FT03 - Asthma
(Dochart 1, Flash Talks)

Chair: ***Paola Mason (Italy)***

12:00 100082 **Whole blood gene expression signatures of children with asthma and allergic sensitisation**
Ellen Kong (United Kingdom)

12:07 100159 **A promising alternative to monoclonal antibody therapy for the treatment of severe Asthma – a Capsid virus-like particle-based vaccine displaying AI-generated TSLP antigens**
Louise Goksøyr (Denmark)

12:14 100208 **The Perfect Storm: Temporal analysis of air during the world's most deadly epidemic thunderstorm asthma event**
Cenk Suphioglu (Australia)

12:21 100330 **Mepolizumab's Safety and Efficacy in Children and Adolescents with Severe Eosinophilic Asthma: A Real-World Perspective**
Gaye Kocatepe (Türkiye)

12:28 100389 **Impulse Oscillometry in Children: GAMLSS-Derived Predictive Equations and Post- Bronchodilation Variability**
Carla Martins (Portugal)

12:35 100501 **Comparison of Serum Periostin and IL-13 Levels in Positive and Negative Wheezing Children According to the Asthma Predictive Index and Healthy Controls**
HATİCE Eke-Gungor (Türkiye)

12:42 100532 **Baseline Type 2 Biomarkers and Mucus Plug Response in Patients With Uncontrolled Moderate-to-Severe Asthma Treated With Dupilumab in the VESTIGE Study**
Arnaud Bourdin (France)

12:49 100650 **The association of childhood lung function trajectories with asthma: Results from the Portuguese population-based birth cohort**
Francisca Mendes (Portugal)

12:00 - 13:00 L-OAS03 - Clinical Immunology
(Carron 1, Oral Abstract Sessions)

Chairs: ***Hideaki Morita (Japan), Thomas Eiwegger (Austria)***

12:00 100030 **Primary and Safety Outcomes of a Phase 3, Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Paediatric Patients Aged 4–11 Years With Activated PI3Kδ Syndrome (APDS)**
Michaela Semeraro (France)

12:12 100395 **AllergoOncology: Non-allergic urticarial skin reactions associated with MOv18 IgE, a first-in- class IgE antibody recognizing Folate Receptor alpha (FRl>)**
Jitesh Chauhan (United Kingdom)

12:24 100424 **AllergoOncology and Glioblastoma: NR1D2 Activation Reprograms Tumor-Associated Macrophages and Limits Immunosuppression**
Aurélie Poli (Luxembourg)

12:36 100449 **Duodenal T cell Profiling in Patients with Primary Antibody Deficiencies: Associations with Enteropathy**
Semra Demir (Türkiye)

12:48 100044 **Long-Term Immunological Changes After Corrective Cardiac Surgery**
Sevgi Bilgic Eltan (Türkiye)

12:00 - 13:00 L-OAS04 - Allergy Diagnosis
(Carron 2, Oral Abstract Sessions)

Chairs: ***Adriana Ariza (Spain), Tomás Chivato (Spain)***

12:00 100182 **The basophil activation test is the most accurate test in predicting allergic reactions during oral food challenges to baked and fresh cow's milk**
Irene Bartha (United Kingdom)

12:12 100289 **Serum Albumin Sensitization in Children with Cow's Milk Allergy: Clinical Implications for Beef Allergy**
Cansu Özdemiral (Türkiye)

12:24 100426 **New sesame components can improve the diagnosis of sesame allergy**
Constance Den Hartog Jager (Netherlands)

12:36 100452 **Development of a streamlined, miniaturized and multi-allergen basophil activation test (SMMABAT) and early evaluation in the clinical research settings**
Jean Marc Busnel (France)

12:00 - 13:00 POC - Codex Alimentarius & Precautionary Allergen Labelling (PAL): A New Era for Food Safety and Patient Information
(EAACI Global Stage, POC)

Chairs: ***Sabine Schnadt (Germany), Benjamin C. Remington (Netherlands)***

12:00 **Codex Alimentarius & Precautionary Allergen Labelling (PAL): A New Era for Food Safety and Patient Information**
Paul J. Turner (United Kingdom), Benjamin C. Remington (Netherlands), Beatrice Povolo (Canada)

12:00 - 13:00 SSS 2 - EAACI & APAPARI Joint Symposium: Emerging concepts in the management of food allergies
(Meeting Academy M1, Sister Society Symposium)

Chairs: ***Motohiro Ebisawa (Japan), Gary Wong (China)***

12:00 **Epidemiology and natural history of food allergy**
Sakura Sato (Japan)

12:15 **Should we standardize global guidelines for AD and Food Allergy prevention?**
Elizabeth Huiwen Tham (Singapore)

12:35 **Shaping the Future of Food Allergy Prevention with the use of Biomarkers**
Jihyun Kim (Korea, Republic of)

12:00 - 13:00 TPS08 - Allergen immunotherapy 01
(Poster Zone, Thematic Poster Session)

Chairs: ***Carmen Panaitescu (Romania), Cristina Quecchia (Italy)***

D1.134 **Mapping the Patient's Journey Prior to Allergen Immunotherapy**
Gabriela Aray Moran (Spain)

D1.135 **"Bee Pollen" as a Potential Trigger for Anaphylaxis: A Case Study**
Anna Ventosa (Spain)

D1.136 **Allergen awareness of patients in allergology consultations at the pneumophthisiology department of the Ignace Deen University Hospital**
IBRAHIMA THIERNO Diallo (Guinea)

D1.137 **Characterization of Pana g 1, a novel allergen from Korean ginseng, Panax ginseng triggering Pollen-Food Allergy Syndrome**
Haeun Kim (Korea, Republic of)

D1.138 **IgE cross-reactivity between grass species in the presence of Japanese cedar pollen sensitization**
Takeru Sugawara (Japan)

D1.139 **Staphylococcus aureus (carriage and sensitization) - is it a significant factor in allergic rhinitis?**
Iryna Kalikina (Ukraine)

D1.140 **Molecular Profiling of Olive Pollen in a Peruvian Population**
Oscar Calderón (Peru)

D1.144 **Global variations of IgE cross-reactivity in Cupressus allergy**
Hiroki Matsuhara (Japan)

D1.145 **A Clinical Decision Support System (CDSS) based on Machine Learning for the diagnosis of Seasonal Allergenic Rhinitis (SAR) and patient-tailored AIT prescription**
Francesco Monnati (Italy)

D1.148 **Heterogeneity of sensitization profiles between Central and Southern European allergic patients**
Cristina Cacheiro-Llaguno (Spain)

12:00 - 13:00 TPS09 - Allergen immunotherapy 02
(Poster Zone, Thematic Poster Session)

Chairs: ***Martha Jimenez Freites (Spain), Montserrat Alvaro Lozano (Spain)***

D1.149 **Murine IgG1 increased γ subcutaneous immunotherapy suppressed development of allergic asthma**
Masaya Matsuda (Japan)

D1.150 **Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)**
Jun Bai (China)

D1.152 **Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units**
Teresa Garriga-Baraut (Spain)

D1.153 **Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites**
Andrzej Bożek (Poland)

D1.154 **Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix**
ANA MARIA PUENTES ORTIZ (Spain)

D1.155 **Alterations in B cell memory induced by house dust mite allergen immunotherapy**
Ellen ketelaere (Belgium)

D1.156 **Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients**
Doo Hee Han (Korea, Republic of)

D1.157 **Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis**
Hang Du (Switzerland)

D1.159 **The successful resolve of nasal polyps in patient with dupilumab treatment**
Vladyslav Tsaryk (Ukraine)

D1.162 **Selecting the right immunotherapy for Vespa velutina nigrithorax anaphylaxis: does one treatment fits all?**
Carolina Macedo (Portugal)

D1.163 **IgE High-Affinity Receptor Expression as a Predictive Biomarker for Oral Immunotherapy Outcomes in Severe Egg and Milk Allergies**
Laura Vinas (Spain)

12:00 - 13:00 TPS01 - Allergy diagnosis 01

(Poster Zone, Thematic Poster Session)

Chairs: ***María Isabel Montañez (Spain), Markus Ollert (Luxembourg)***

D1.02 **Prevalence of allergic respiratory disorders in urban V/s rural Indian population**
Muntajibuddin Ahmed (India)

D1.03 **Sustainable and gluten free bread: Are legumes a hidden risk for occupational IgE-mediated respiratory allergy?**
Sabine Kespohl (Germany)

D1.04 **Diagnostic approach for respiratory symptoms linked to microbial contamination in metalworking fluids**
Sabine Kespohl (Germany)

D1.05 **Bet v 6 as a Marker of Pollen Cross-Reactivity in Southern Europe: Insights from a Birch-Free Region**
Monica Stephani Archila Ramirez (Spain)

D1.07 **Profile of sensitization to inhalant allergens in Valencia: Analysis of 1.898 skin prick tests over one year**
Laura Frattini Llorens (Spain)

D1.09 **Dynamics of pollen allergy in Ukraine during the full-scale invasion shows demand for diagnostics increased with changed sensitization patterns seen**
Victoria Rodinkova (Ukraine)

D1.10 **Tree pollen allergy profile in Ukraine assessed by large-scale molecular component analysis**
Victoria Rodinkova (Ukraine)

D1.11 **Age and Gender Patterns in Fungal Allergen Sensitization: A Study from Central Ukraine**
Victoria Rodinkova (Ukraine)

D1.12 **Optimal Conventional Diagnostic Approach for Wheat Allergy in Chinese Children**
Ting Fan Leung (Hong Kong)

D1.13 **EHealth tools suitability and technologic innovation use in an Environmental Exposure Chamber**
Dario Antolin-Amerigo (Spain)

D1.14 **Molecular Allergy Profiling of Pollen Sensitization in Cluj-Napoca**
Teodora Balaneanu (Romania)

D1.15 **Relationship between sensitization to peanuts and tree nuts in children with allergic diseases in a population of the Russian Federation**
Oxana Ussenova (Kazakhstan)

12:00 - 13:00 TPS02 - Allergy diagnosis 02
(Poster Zone, Thematic Poster Session)

Chairs: ***Martin Bachmann (Switzerland), Gonçalo Silva (Portugal)***

D1.16 **Molecular sensitization profiles in house dust mite allergic patients from Valencian Community**
Luis ÁNgel Navarro (Spain)

D1.17 **Acute generalized exanthematous pustulosis with overlay of serum sickness, triggered by a spider bite: Case report**
Elida Berenice Nuñez (Mexico)

D1.18 **Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results**
Pauline Janssen (Belgium)

D1.19 **Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals**
Manuel Alberto Figueiras Rincón (Spain)

D1.20 **Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach**
Mª Dolores Ladrón De Guevara De Las Heras (Spain)

D1.22 **Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children**
Büşra Koçali (Türkiye)

D1.23 **Unrestricted Potential: The Role of AMS in Tackling Allergy Labels**
Melwin Solis (Ireland)

D1.24 **Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results**
Christian Lupinek (Austria)

D1.25 **Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency**
Eralda Lekli (Albania)

12:00 - 13:00 TPS03 - Allergy diagnosis 03
(Poster Zone, Thematic Poster Session)

Chairs: ***Rubén Fernández-Santamaría (Spain), Thulja Trikamjee (South Africa)***

D1.28 **Anaphylaxis after appendectomy: A case of allergy to sugammadex**
Caoimhe Cronin (Ireland)

D1.29 **Class III Chitinases as Potential Allergens in Raspberry-Induced Anaphylaxis**
CARLOS MORENO LOPEZ (Spain)

D1.30 **An exotic anaphylaxis in the mediterranean: due to a clinical case**
MARIA JESUS GIMENEZ REVILLA (Spain)

D1.31 **Quality Of Life In Alexithymic Patients With Anaphylaxis**
Roberta Zunno (Italy)

D1.32 **The effect of chelation on carmine allergy induced by epicutaneous sensitization to carmine in cosmetics**
Maiko Yamaura (Japan)

D1.33 **Oat Allergy in a Young Adult: Allergenic Protein Profiling and Clinical Implications**
CRISTINA HIGUERA BENÍTEZ (Spain)

D1.34 **Hypersensitivity Reactions to Iodinated and Gadolinium-Based Contrast Media: Clinical and Epidemiological Insights**
Sofia Carreras-Kàtcheff (Spain)

D1.35 **Lipid transfer protein and Profilin-associated food-dependent exercise-induced anaphylaxis: A case series**
Ceren Üstün (Türkiye)

D1.36 **Prevalence of thaumatin and Alternaria co-sensitization**
Teresa Martínez Piélago (Spain)

D1.37 **Sometimes it is not what it seems**
Maria Jose Calvo Delgado (Spain)

D1.38 **Anaphylactic reaction to chia seeds: A case report**
Paula Padin Sobral (Spain)

D1.39 **Differential Diagnosis of Perioperative Anaphylaxis: The Hidden Role of Chlorhexidine**
Maria Victoria Sousa Pérez (Spain)

D1.42 **Case Report of Allergy to Mint and Basil**
Amina Mustafa (United Kingdom)

D1.43 **Performance Evaluation of a Semi-Quantitative Rapid Test Kit for Dust Mites: For Home Self-Monitoring and Control Effectiveness Assessment**
He Zhang (China)

12:00 - 13:00 TPS04 - Allergy diagnosis 04

(Poster Zone, Thematic Poster Session)

*Chairs: **Leyla Pur Ozyigit (United Kingdom), Alma Villasenor Solis (Spain)***

D1.44 **A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine**
MELGAR ACEBU (Philippines)

D1.45 **Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report**
Angela Klain (Italy)

D1.46 **Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach**
Areej Alkahtani (Saudi Arabia)

D1.48 **Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation**
Rachel McDermott (Ireland)

D1.49 **Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions**
Sofía Gómez De La Cruz Pérez (Spain)

D1.50 **Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy**
Eralda Lekli (Albania)

D1.52 **An exotic anaphylaxis in the mediterranean: due to a clinical case**
MARIA JESUS GIMENEZ REVILLA (Spain)

D1.53 **Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis**
Vania Livia Cantafio Duo' (Italy)

D1.54 **Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests**
Elena Petkova (Bulgaria)

D1.55 **Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis's box?**
Elena Petkova (Bulgaria)

12:00 - 13:00 TPS05 - Allergy diagnosis 05

(Poster Zone, Thematic Poster Session)

Chairs: ***Stephanie Dramburg (Germany), Christiane Hilger (Luxembourg)***

D1.57 **Antigen-specific IgE antibody levels as negative predictors of oral food challenge with cow's milk in children with cow's milk allergy**
Jun Mochida (Japan)

D1.58 **Pilocarpine in the management of allergic rhinosinusitis; a prospective, placebo-controlled study for a novel use of a cholinergic agent**
Lydia Theodoropoulou (United States of America)

D1.59 **Asymptomatic sensitisation to food allergens is common in adults -findings from the PAFA study**
Hannah Wardman (United Kingdom)

D1.60 **Impact of real-world confounders on the accuracy of an AI model to support the read out of skin prick automated test results**
Sven Seys (Belgium)

D1.62 **Improved In-vitro Allergy Diagnostics using a Molecular Composite of Purified Peanut Allergens**
Sabina Wuenschmann (United States of America)

D1.63 **Descriptive Study on the Evolution of Patients Treated with Oral Immunotherapy (OIT) Using Pasteurized Egg White at the Fundación Alcorcón University Hospital**
Maria de los Angeles Gonzalez-Labrador (Spain)

D1.64 **Severe Food Protein-Induced Enterocolitis Syndrome: A French Multicenter Study of Children Admitted to Critical Care**
Chloé JOSSERAND (France)

D1.65 **Pollen Food Allergy Syndrome in Patients with Quercus ilex Sensitization in the Population of Madrid**
Gabriela Acuña Vila (Spain)

D1.66 **Reactivity, severity and tolerance development in 50 wheat-allergic children across two oral food challenges**
Friederike Bluhme (Germany)

D1.67 **Development and validation of Skin Prick Test solutions for assessing sensitization patterns to edible insects among children sensitized to house dust mite**
Lara Meixner (Germany)

D1.68 **Rice allergy: a case report**
Harriet Roberts (United Kingdom)

D1.69 **Safety in the peach juice food challenge in LTP allergic patients**
Nadine Blanco Toledano (Spain)

D1.70 **No more restrictive diets for LTP allergic patients. The importance of oral food challenge**
Nadine Blanco Toledano (Spain)

D1.71 **Risk Factors for Anaphylaxis in Food-Allergic Children During Oral Food Challenge Tests**
Tadej Pungertnik (Slovenia)

D1.72 **Comparison of the allergenic composition of available SPTs for the diagnosis of sensitization to D. pteronyssinus**
Rosa Gallego (Spain)

12:00 - 13:00 TPS13 - Anaphylaxis 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Daniela Carvalho (Portugal), Deniz İlgün Gürel (Türkiye)***

D1.262 **Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom**
Hirokuni Hirata (Japan)

D1.264 **Assessment by general practitioners of a therapeutic patient education guide for allergic patients**
Catharina Chatain (France)

D1.265 **Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan**
Masao Tamura (Japan)

D1.266 **Investigation of anaphylaxis in mastocytosis mouse models**
Laetitia Clauss (Switzerland)

D1.267 **Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort**
Luc De Chaisemartin (France)

D1.268 **The endothelial glycocalyx as a therapeutic target in anaphylaxis**
Sergio Fernandez-Bravo (Spain)

D1.269 **Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells**
Sergio Fernandez-Bravo (Spain)

D1.270 **Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences**
Fionnuala Cox (Ireland)

D1.271 **Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications**
Radka Galanska (Czech Republic)

D1.272 **Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom**
Xiang Gao (China)

D1.273 **Anaphylactic Reaction Following Sulphur Hexafluoride Administration**
Natalia Katrachoura (Greece)

12:00 - 13:00 TPS14 - Anaphylaxis 02

(Poster Zone, Thematic Poster Session)

Chairs: ***Mattia Giovannini (Italy), Andrea Macías-Camero (Spain)***

D1.274 **Anaphylaxis Risks in Beekeeping: The Importance of Developing a Health Education Program**
Tea Močnik (Slovenia)

D1.275 **Wheat-free diet restore the normal intestinal microbiome structure in patients with wheatdependent exercise-induced anaphylaxis**
Zhirong Du (China)

D1.276 **Social #anaphylaxis: how social media reveals shifting trends in public health concerns**
Sofía Proaño Mosquera (Spain)

D1.278 **Chlorhexidine allergy in perioperative anaphylaxis: undeclared and overlooked**
Elias Marquart (Austria)

D1.279 **Vit v 5: A Chitinase Implicated in Grape-Induced Anaphylaxis**
Laura Berzal Plaza (Spain)

D1.282 **Identification of Thaumatin-like protein (Ole E 13) as a potential allergen in green olives, a case report**
María Luisa Quiñones (Spain)

D1.283 **Idiopathic anaphylaxis in a child, Alpha-gal syndrome. Is it an entity in children?**
Sira García-Iturri Gallego (Spain)

D1.284 **Trends in Recurrent Anaphylaxis Triggered by Food, Drug, and Insect Allergies from 2015 to 2021: A Population-Based Retrospective Cohort Study Using the National Insurance Claims Database of Japan**
Sakura Sato (Japan)

D1.285 **Analysis of systemic food reactions in patients sensitized to Bet v1 in Madrid (Spain)**
Dinara Korshunova (Spain)

D1.286 **Nebulized inhaled epinephrine versus epinephrine autoinjector for the treatment of foodinduced anaphylaxis in young children – a randomized controlled clinical trial**
Benjamin Marcus (Germany)

D1.287 **Lipid profiling of Co-factor Induced Anaphylaxis: The Impact of Exercise and Aspirin on metabolism**
Blanca Raposo-Martínez (Spain)

D1.289 **Severe allergy to albumin after cesarean section**
Johanna Mandelin (Finland)

12:00 - 13:00 TPS06 - Asthma 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Jordon Jaggers (United States of America), Lucía Cremades-Jimeno (Spain)***

D1.88 **Mepolizumab and intestinal parasitic infection: A case report**
Kurtulus Aksu (France)

D1.90 **Remission of asthma on biological therapy: one center experience**
Anna Bobcakova (Slovakia)

D1.91 **Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)**
Francisco Ramos-Lima (Spain)

D1.92 **Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe**
Gabriele Brembilla (Italy)

D1.93 **ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up**
Filippo Moletta (Italy)

D1.94 **Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients**
Mona Al-Ahmad (Kuwait)

D1.95 **Dupilumab-induced eosinophilia: a transient effect**
Sofia Ferreira (Portugal)

D1.96 **Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)**
Sofia Ferreira (Portugal)

D1.98 **MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties**
Isabel Peñalver (Spain)

D1.99 **Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP**
Martina Bullita (Italy)

D1.102 **Md**
Elena Petkova (Bulgaria)

12:00 - 13:00 TPS07 - Asthma 02

(Poster Zone, Thematic Poster Session)

Chair: ***Hasan Bayram (Türkiye)***

D1.103 **Two cases of discrepancy between fractional exhaled nitric oxide and airway eosinophils in asthma**
Young-Il Koh (Korea, Republic of)

D1.104 **Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia**
Bashayr Hijazi (Saudi Arabia)

D1.105 **Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy**
Eugenija Basioli Kasap (Croatia)

D1.106 **Grape polyphenols reduce the concentration of LPS in patients with asthma**
Lawrence DuBuske (United States of America)

D1.107 **Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19**
Lawrence DuBuske (United States of America)

D1.108 **Grape polyphenols increase the concentration of BPI in asthma patients who have had SARSCoV-2**
Lawrence DuBuske (United States of America)

D1.109 **Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy**
Stefan Frent (Romania)

D1.110 **Analysis of clinical and anamnestic risk factors of bronchial asthma in children**
Tahira Panahova (Azerbaijan)

D1.111 **Improving severe asthma through psychological management of traumatic life events**
Sarah BOUNETTA BELMOKHTAR (France)

D1.112 **Managing patients with Type 2 inflammation in a joint interdisciplinary "United Airways Clinic" at Lund University Hospital, Sweden**
Jens Richter (Sweden)

D1.113 **Severe Asthma and Depression: the Overlooked Burden**
Margarida Nunes (Portugal)

D1.114 **The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden**
Margarida Nunes (Portugal)

D1.115 **Post-emergency asthma management**
Angéline Rancy (France)

12:00 - 13:00 TPS17 - Basic immunology 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Usmaan Ahmed (United Kingdom), José Antonio Cañas (Spain)***

D1.342 **Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model**
Chun Yi Lee (Taiwan)

D1.343 **Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis**
Nikolaos Biris (United States of America)

D1.344 **Role of nodular lymphoid hyperplasia as immunologic precursor of IBD development in patients with IBS-like symptoms: an observational, ambispectic, muliticenter study "The NILO study"**
Laura Bruno (Italy)

D1.345 **Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study**
Martina Ceraudo (Italy)

D1.346 **Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine**
Ilaria Baglivo (Italy)

D1.347 **Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms**
David Longhino (Italy)

D1.349 **Age-related fungal molecular clusters revealed by allergen chip assay in Eastern France**
Amir Guemari (France)

D1.350 **A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes**
Adam Chaker (Germany)

D1.351 **The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility**
Lawrence DuBuske (United States of America)

D1.352 **Assessment of the Efficacy of Mepolizumab in Modulating Disease Activity in Eosinophilic Granulomatosis with Polyangiitis: A 12-Month Analysis Evaluating the Birmingham Vasculitis Activity Score**
Richard Borrelli (Italy)

D1.353 **When eosinophils surpass the limits without a known cause**
Leonor Gonçalves (Portugal)

D1.355 **Impact of mesothelin in women with endometriosis**
Lawrence DuBuske (United States of America)

12:00 - 13:00 TPS18 - Biologicals 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Friederike Bärhold (Germany), Alessandra Vultaggio (Italy)***

D1.362 **Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab**
Jae-Hyuk Jang (Korea, Republic of)

D1.363 **Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis**
Isabel Dotor Ruiz (Spain)

D1.364 **Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic**
William H. Yang (Canada)

D1.365 **ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates**
Linda Liu (United States of America)

D1.366 **Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab**
Giselle Mosnaim (United States of America)

D1.367 **Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results**
Eyal Ben Dori (Israel)

D1.368 **Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years**
Teet Pullerits (Sweden)

D1.369 **Characteristics of patients with severe asthma undergoing biological treatment at a reference center**
Albertina Capelo (Brazil)

D1.370 **Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab**
Leyla Namazova-Baranova (Moscow)

D1.371 **Dupilumab for the treatment of refractory severe chronic spontaneous urticaria**
PAZ SUAREZ (Spain)

12:00 - 13:00 TPS15 - Dermatology 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Annick Barbaud (France), Laurence Bouillet (France)***

D1.291 **Hypertryptasemia and TPSAB1 allele β tryptase duplication, a case report**
Jean-Marc Gilardoni (France)

D1.292 **Assessing Quality of Life in Chronic Spontaneous Urticaria: Insights from DLQI Scores**
Abhishek De (India)

D1.293 **Urinary Levels of Environmental Pollutants Are Associated with the Severity and Persistence of Atopic Dermatitis in Young Children**
Sanghee Shin (Korea, Republic of)

D1.294 **Does food allergy test-guided dietary advice improve eczema control in children? Protocol for Trial of food allergy IgE tests for Eczema Relief (TIGER) study**
Matthew Ridd (United Kingdom)

D1.295 **Clinical, Laboratory and Prognostic Evaluation of Antinuclear Antibody Positive and Negative Children with Chronic Urticaria**
Gizem Kabadayı (Türkiye)

D1.296 **Paediatric AD vs Food Allergy Management in the South of Ireland**
Adina Elena Zagoneanu (Ireland)

D1.297 **The Effects of Virtual Reality on AD**
I-Jen Wang (Taiwan)

D1.298 **Topical gluconolactone induces immune tolerance in cutaneous lupus erythematosus in human and mice**
Kolios Antonios (Switzerland)

D1.299 **The prevalence and management features of adolescents with atopic dermatitis under humanitarian crisis**
Olena Sharikadze (Ukraine)

D1.300 **Alopecia areata associated with atopy has a distinct cytokine, chemokine and IgE profile**
Lawrence DuBuske (United States of America)

D1.302 **The Fecal Microbiome: Geographical Location and Associated Dietary Habits Matter More Than Atopic Dermatitis**
Danielle Fehr (Switzerland)

D1.303 **Preschooler with Toxic Epidermal Necrolysis Associated with Adenovirus Respiratory Infection**
Ricardo Martinez Tenopala (Mexico)

D1.304 **Occupational allergic contact dermatitis (Chronic hand eczema) to lily of the Incas and houseleek in a florist**
Isabel Gonzalez Martin (Spain)

D1.305 **Management of Contact Dermatitis in Pediatric Type 1 Diabetes: A Therapeutic Protocol with Topical Pimecrolimus**
Amelia Licari (Italy)

D1.306 **Is there a role of Genetics in Acute and Chronic Urticaria? A Systematic Review and Metaanalysis**
George Konstantinou (Greece)

12:00 - 13:00 TPS11 - Drug allergy 01
(Poster Zone, Thematic Poster Session)

Chairs: ***Ana Maria Copaescu (Canada), Gabriele Cortellini (Italy)***

D1.216 **From Acetaminophen to sauerkraut**
Martine Morisset (France)

D1.217 **Rapid drug desensitization in children: case report**
MAI PHAN (Vietnam)

D1.219 **Impact of a Penicillin Allergy Delabeling Program on Antibiotic Selection and Perioperative Outcomes: A Prospective Comparative Cohort Study**
Eisa Saleh (Canada)

D1.222 **Comparative analysis and evaluation of clinical and stewardship implications of parent reported antibiotic allergy labels within paediatric care**
Michaela Lucas (Australia)

D1.223 **Evaluation of Immediate-Type Allergic Reactions to Amide Group Local Anesthetics In Children: A Single-Center**
Sinem Aslan (Türkiye)

D1.224 **Clinical performance of IgE Quaternary Ammoniums, Atracurium, Rocuronium and Suxamethonium for the diagnosis of an allergy to curares**
Marie Lagreula (France)

D1.225 **Direct single dose mass delabelling of antibiotic allergy in paediatrics**
Sheena Coyne (Ireland)

D1.226 **Increased incidence of suspected clindamycin hypersensitivity reactions in pediatric patients due to its expanded use in clinical practice**
Leonardo Tomei (Italy)

D1.227 **Risk stratification of drug allergy in children with immediate or delayed urticaria during antibiotic treatment**
Leonardo Tomei (Italy)

D1.228 **Patch testing and HLA genotyping as diagnostic tools for DRESS related to concomitant multidrug exposure**
Derya Unal (Türkiye)

D1.229 **Limited interest of suxamethonium, rocuronium and atracurium specific IgE reagents for the diagnosis of NMBA allergy sensitization**
Pol Andre Apoil (France)

D1.230 **Acute Localized Exanthemathous pustulosis induced by Pertuzumab and Trastuzumab with positive Lymphocyte Transformation test**
Nicola Giangrande (Spain)

D1.231 **When Antihistamines Paradoxically Worsen Chronic Spontaneous Urticaria: Trust Your Patient**
Cassim Akhoon (United Kingdom)

12:00 - 13:00 TPS12 - Drug allergy 02
(Poster Zone, Thematic Poster Session)

Chairs: ***Patrizia Bonadonna (Italy), Lukas Joerg (Switzerland)***

D1.233 **Pembrolizumab IgE mediated drug hypersensitivity reaction and successful desensitisation**
Maria Zande (Greece)

D1.234 **The Importance of Differential Diagnosis in DRESS Syndrome: Review of 2 Cases**
Ana Marino Fernandez (Spain)

D1.235 **Clorhexidine allergy in northern area of Seville**
Andres Muro Noa (Spain)

D1.236 **Clinical Outcomes of Neuromuscular Blocking Agent Rechallenge Based on Skin Prick Test in Patients with Intraoperative Anaphylaxis**
Byung-Jae Lee (Korea, Republic of)

D1.237 **What Do Drug Skin Tests Tell Us About Quinolone Allergy? Adult Allergy Reference Center Experience**
Ceyda Tunakan Dalgıc (Türkiye)

D1.238 **Urgent desensitization to amiodarone**
BEATRIZ IBORRA RONCO (Spain)

D1.239 **Nonsteroidal anti-inflammatory drug cross-hypersensitivity phenotypes show high carbonyl levels**
Isabel María Jiménez-Sánchez (Spain)

D1.243 **L-asparaginase desensitization in children**
Gaye Kocatepe (Türkiye)

D1.244 **Retrospective Analysis of Adverse Reactions to Iodinated Contrast Media: Experience in 165 Patients**
Erika Garcia Prado (Spain)

D1.245 **Platinum salt hypersensitivity: Experience of our Center**
Sofia Luisa Tocci (Italy)

D1.246 **Cephalosporin Allergy in Children**
Michaela Lucas (Australia)

D1.247 **Tolerance to intravenous sodium heparin despite a positive subcutaneous challenge test: A case report**
Laura Rodríguez Calderón (Spain)

12:00 - 13:00 TPS10 - Food allergy 01

(Poster Zone, Thematic Poster Session)

Chairs: ***Berber Vlieg-Boerstra (Netherlands), Cecilia Berin (United States of America)***

D1.165 **Impact of Food Allergy on the Quality of Life in Singapore Children and Their Families**
Elizabeth Huiwen Tham (Singapore)

D1.166 **The link between Food Allergy and Eosinophilic Esophagitis**
Erica Chericoni (Italy)

D1.167 **Food allergy prevalence and trends in Singaporean children from 2009 to 2022: Results of the GUSTO and S-PRESTO cohort studies**
Clare Cheng (Singapore)

D1.169 **Prevalence and clinical picture of wheat allergy in German children**
Birgit Kalb (Germany)

D1.170 **The Critical Role of School Nurses in Managing Food Allergies: A Comprehensive Review**
Rita Nocerino (Italy)

D1.171 **Preventive Effects of Lactococcus lactis on Ovalbumin-Induced Food Allergy in Mice**
Eun-Ae Yang (Korea, Republic of)

D1.172 **Proteomic Profiling Identifies PRG2 as a Potential Biomarker for Childhood Food Allergy**
Sumin Lee (Korea, Republic of)

D1.173 **Prevalence of Food Allergy and Anaphylaxis in Korean School-aged Children: A Populationbased Study**
You Hoon Jeon (Korea, Republic of)

D1.174 **Does Wheat-Dependent Exercise-Induced Anaphylaxis Exist in Childhood? - Development and Application of a Diagnostic Protocol**
Birte Scholz (Germany)

D1.175 **Impact of dog ownership on allergen exposure and tolerance development: Analysis of Can f 1 levels in house dust samples**
Dorothea Böhm (Germany)

D1.176 **Validation of the Korean versions of the Child- and Parent-Rated Scale of Food Allergy Anxiety (K-SOFAA-C and K-SOFAA-P)**
Sehun Jang (Korea, Republic of)

D1.177 **FPIES in fish in children: Study of the natural history of the disease**
KONSTANTINOS MILIORDOS (Greece)

D1.178 **FIRE Starters: Investigating Food Induced Immediate Esophageal Response in Eosinophilic Esophagitis**
Maria-Catalina Cernat (Romania)

D1.179 **Cruciferous Vegetables and Food Allergy: A Case Study on Steamed Broccoli-Induced Urticaria**
Fernando Pineda de la Losa (Spain)

D1.168 **Are Asymptomatic and Symptomatic Eosinophilic Esophagitis Different Phenotypes in Children?**
Handan Duman Senol (Türkiye)

D1.180 **Mandarin-Induced Allergic Reactions: A Case Study Investigating Germin-Like Proteins and Cross-Reactivity**
Fernando Pineda de la Losa (Spain)

12:00 - 13:00 TPS23 - Genomics and proteomics + Ocular Allergy

(Poster Zone, Thematic Poster Session)

*Chairs: **Urszula Radzikowska (Switzerland), Carlos Aranda Clemente (Spain)***

D1.435 **Eosinophilic diseases: from nasal polyposis, eosinophilic asthma to EGPA (Eosinophilic Vasculitis with PolyAngioitis), evaluation of possible biomarkers of disease evolution**
Chiara Laface (Italy)

D1.437 **Frequency of SNPs associated with pharmacogenetic phenotypes in Asthma in two Colombian populations**
Beatriz Martinez (Colombia)

D1.439 **Is allergic conjunctivitis tip of the allergic iceberg ?**
Arti Shah (India)

D1.440 **Single cell pipeline to improve immune cell annotation through comparison of multiple bioinformatic methods**
William Fulton (United Kingdom)

12:00 - 13:00 TPS16 - Immune deficiencies and autoimmunity 01

(Poster Zone, Thematic Poster Session)

*Chair: **Luis F Santamaria-Babi (Spain)***

D1.308 **Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)**
Jan Baros (Czech Republic)

D1.309 **Association of Antenatal Corticosteroids with Risk of Autoimmune Diseases in Children: a Nationwide Cohort Study**
Hui-Ju Tsai (Taiwan)

D1.310 **Phenotypes of patients with Hereditary Angioedema (HAE): a case series**
Foteini Kapsouli (Greece)

D1.311 **Treatment Dilemmas in CARMIL2 Deficiency**
Adeeb Nasser Eldin (Israel)

D1.312 **Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series**
Kamil Romdhani (Canada)

D1.313 **Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center**
Nour Aljefri (Saudi Arabia)

D1.315 **Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)**
Alejandro Luis Ferri (Italy)

D1.316 **Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease**
Edgardo Adrián Puerto Díaz (Mexico)

D1.318 **Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data**
Markus Magerl (Germany)

D1.319 **The Silent Threat of Hereditary Angioedema in Children: Single Center Experience**
Gül ÜNLÜ KILAVUZ (Türkiye)

D1.322 **A Prescription for Lower Immunity: The Hidden Cost of Certain Psychiatric Medications**
Cláudia M. Marques (Portugal)

D1.323 **Concurrence of essential mixed cryoglobulinemia and cold agglutinin disease: a matter of shared light chains. Case series and literature review**
Nicola Monaco (Italy)

D1.324 **Evaluation of the Potential for Sebetralstat to Cause Pseudo-allergic Reactions**
Sally Hampton (United Kingdom)

D1.325 **Autoantibodies to interferon-gamma: clinical features, treatment outcomes, and in-vitro monitoring of disease**
Valerie Chiang (Hong Kong)

12:00 - 13:00 TPS19 - Infections

(Poster Zone, Thematic Poster Session)

Chair: ***Nida Öztop (Türkiye)***

D1.397 **Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management**
Kacper Packi (Poland)

D1.398 **Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases**
Enrique Javier Soto Hurtado (Spain)

D1.402 **Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection**
Svitlana Zubchenko (Ukraine)

D1.403 **Use of ketotifen as treatment for post viral infection cough in children**
Todor Popov (Bulgaria)

D1.404 **Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections**
Irving López-Fletcher (Guatemala)

D1.405 **Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts**
Ekaterina Potapova (Germany)

D1.406 **The microbiota of the urogenital canal related to papillomavirus infection**
Marta Lomikovska (Ukraine)

12:00 - 13:00 TPS22 - Microbiome
(Poster Zone, Thematic Poster Session)

*Chair: **Vanesa Esteban (Spain)***

D1.428 **Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation**
Young Yoo (Korea, Republic of)

D1.430 **Urban Forest Fungal Microbiome Diversity and Its Impact on Asthma and Allergic Inflammation**
WONSUCK YOON (Korea, Republic of)

D1.431 **Associations of the composition of intestinal microbiota with the initial manifestations of IgEmediated food allergy in children 6-12 months old**
Anastasia Lamasova (Moscow)

D1.433 **The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children**
Lucie Zahradníčková (Czech Republic)

12:00 - 13:00 TPS20 - Pediatrics
(Poster Zone, Thematic Poster Session)

*Chair: **Camelia Berghea (Romania)***

D1.408 **Relationship between excessive screen use and allergic diseases**
Marilyn Urrutia Pereira (Brazil)

D1.409 **Unmasking the Hidden Link: Malnutrition and Allergies in Pediatric Patients**
Serena Coppola (Italy)

D1.410 **Diet-induced obesity in children population**
Lasha Tchelidze (Georgia)

D1.411 **The importance of breathing exercises in the rehabilitation of allergic asthma in children**
Silvije Segulja (Croatia)

D1.412 **Educational Interventions for Allergic Children in School Settings: A Systematic Literature Review**
Amelia Licari (Italy)

D1.413 **Profiles of Heart Rate Variability in Asthmatic Children with Acute Exacerbation**
Wei-Yu Chen (Taiwan)

D1.414 **Parents' hesitancy towards vaccination: a Cross-sectional study in Saudi Arabia**
Amer Khojah (Saudi Arabia)

D1.416 **Pediatric Mast Cell Activation Syndrome: A Case Series Highlighting Varied Clinical Responses to Treatment and natural history**
Anat Cohen - Engler (Israel)

D1.417 **A review of healthcare transition of young people aged 16-18 years old seen in a tertiary paediatric allergy service**
Nikita Punjabi (United Kingdom)

D1.418 **A complex case of recurrent spontaneous angioedema in a young teenager, 'The Devil is in the details'**
Yousif Bakheet (United Kingdom)

D1.419 **Setbacks in the management of multiple nuts allergy in atopic children**
Madalina Coman-Stanemir (Romania)

12:00 - 13:00 TPS21 - COVID19
(Poster Zone, Thematic Poster Session)

*Chair: **Janice A Layhadi (United Kingdom)***

D1.422 **A service review of the complex COVID-19 vaccination service**
Sukriti Ray (United Kingdom)

D1.423 **Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic**
Murat Türk (Türkiye)

D1.424 **Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic**
Solange Oliveira Rodrigues Valle (Brazil)

D1.425 **Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report**
Salem Alsuhaymi (Saudi Arabia)

D1.426 **Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome**
Lawrence DuBuske (United States of America)

12:00 - 13:00 L-TPS07 - Biologicals 04
(Poster Zone, Thematic Poster Session)

D1.372 **Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria**
Otilia Petrovicova (Slovakia)

D1.374 **"The Role of Atopy Biomarkers in Predicting Dupilumab Response in Moderate to Severe Atopic Dermatitis: A Single Center Retrospective Study"**
Edoardo Cataudella (Italy)

D1.376 **Emerging inmunomodulatory agents for atopic dermatitis**
Stephanie Steixner Zevallos (Spain)

D1.377 **Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report**
Joao Marcelino (Germany)

D1.378 **Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis**
Shauni De Vriese (Belgium)

D1.379 **AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)**
Pola Kalek (Austria)

D1.380 **Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow**
Nina Mól (Poland)

D1.383 **Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report**
Margarita Soledad Giraldo-Tugores (Spain)

D1.384 **Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective "Real-Life" Analysis**
Edoardo Cataudella (Italy)

D1.385 **Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity**
Abdulrahman Aljaber (Saudi Arabia)

D1.386 **Impact of dupilumab on allergen specific immunoglobulin E production**
Lawrence DuBuske (United States of America)

12:00 - 13:00 L-TPS08 - Allied health and primary care 02
(Poster Zone, Thematic Poster Session)

Chairs: ***Gavriela Feketea (Greece), Farah Hannachi (Luxembourg)***

D1.388 **Frequency of Allergic Diseases in Various Age Groups**
Seda Altiner (Türkiye)

D1.389 **How Youth Understand and Manage Risks Associated with Their Food Allergy in Everyday Life**
Britt Egmose (Denmark)

D1.390 **Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR**
William H. Yang (Canada)

D1.391 **Comparing Dietary Advancement Therapy for IgE-Mediated Egg Allergy in Primary and Tertiary Care: A Retrospective Review**
Aoife Gallagher (Ireland)

D1.392 **Allergic Rhinitis Patients Appear to be at Risk of Lower Quality of Life and Higher Probability of Moderate or Severe Anxiety: Results of an Online Survey in Lithuania**
Gediminas Gumbis (Lithuania)

D1.393 **Building Local Capacity and Improving Access to Specialist Allergist Care for Indigenous Patients in Northern Quebec, Canada**
Michael Aw (Canada)

D1.394 **Characteristics, healthcare provision and expectations of patients with atopic dermatitis as part of the ADCompanion study to evaluate a digital form of care**
Josephine Telschow (Germany)

12:00 - 13:00 L-TPS01 - Allergy diagnosis 14
(Poster Zone, Thematic Poster Session)

Chairs: ***Pedro Alves (Portugal), Aray Batyrbaeva (Kazakhstan)***

D1.73 **A Case of Severe Cutaneous Form of Bacillus Anthracis: Edema Malignant Causing Laryngeal Edema**
ÖZGE ATİK (Türkiye)

D1.74 **Molecular IgE sensitization profiling in a patient with Asteraceae weed pollen allergy and anaphylaxis to honey**
Cristian-Tudor Radu (Romania)

D1.75 **Anaphylaxis during Picc Line replacement**
Caroline Klingebiel (France)

D1.76 **The Hot Chocolate Drink Dilemma**
Xi Ying Soo (United Kingdom)

D1.77 **Perioperative Hypersensitivity Outcomes: A retrospective review of 112 patients seen between 2019 and 2024 at two allergy centres**
Natalya Ellis (United Kingdom)

D1.78 **Analytical Verification of Omega-5 gliadin (Tri a 19) Allergen Assay on the IMMULITE 2000 XPi System***
Nicholas Ready (United Kingdom)

D1.79 **Cardiovascular symptoms during anaphylaxis: An analysis from the European Anaphylaxis Registry**
Aikaterina Alexiou (Germany)

D1.82 **Diagnostic challenges in amoxicillin-clavulanate anaphylaxis: an inconclusive in vitro study - Case Report**
Duarte Nuno Silva (Portugal)

D1.83 **Asthma and multi-food allergy were risk factors for Oral Food Challenge failure**
Urszula Jedynak-Wąsowicz (Poland)

D1.84 **IgE-mediated allergy to chlorhexidine: case report**
Radovan Mijanovic (Serbia)

D1.85 **Basophil activation test in β-Lactam Anaphylaxis: A Case Series from a Tertiary Hospital**
Duarte Nuno Silva (Portugal)

D1.86 **Hypersensitivity Reaction to Lugol's Solution: A Case Report**
Alice Botta (Italy)

12:00 - 13:00 L-TPS02 - Asthma 09

(Poster Zone, Thematic Poster Session)

Chairs: ***Ozge Can Bostan (Türkiye), Alina Gherasim (France)***

D1.116 **Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis**
Carmen Arrieta-Pey (Spain)

D1.117 **Combing dual biologics therapy for severe asthma : a series of ten cases**
Maria Julia Rendon Salazar (Mexico)

D1.118 **The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience**
Ricardo Martinez Tenopala (Mexico)

D1.119 **Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model**
Jinho Yu (Korea, Republic of)

D1.122 **Hydrogen peroxide in exhaled breath condensate as a marker for monitoring biologic treatment response in severe asthmatic patients**
Claudia Gagliani (Italy)

D1.123 **Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment**
Oliver Massey (Australia)

D1.124 **Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab**
Piotr Damiański (Poland)

D1.125 **Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos**
Andreina Mugno (Spain)

D1.126 **Deciphering Genetic Causal Relationships and Molecular Mechanisms Linking Multiple Allergic Diseases and Schizophrenia**
Shitao RAO (Hong Kong)

D1.127 **Distinct roles of Natural killer T Cells and Innate Lymphoid Cells in Type I and II airway Inflammation Induced by Viral Infection**
Yoon-Seok Chang (Korea, Republic of)

D1.128 **Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency**
Daniele Giovanni Ghiglioni (Italy)

D1.129 **Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD**
Zhenping Zhu (United States of America)

D1.130 **Associations between Serum Clara Cell Protein 16 (CC16) and Asthma Severity in Children**
Tetiana Umanets (Ukraine)

D1.131 **TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)**
Jasper Kappen (Netherlands)

12:00 - 13:00 L-TPS03 - Food allergy 06

(Poster Zone, Thematic Poster Session)

Chair: ***Bianca Olivieri (Italy)***

D1.182 **Investigation of risk factors for the development of food-induced enterocolitis syndrome in children with a history of allergic proctocolitis caused by milk**
Tikfleslis Theodoros (Greece)

D1.184 **Evaluation of recombinant GAPDH for validation as a new apple allergen in the Mexican pediatric population**
ANGELICA TORRES ARROYO (Mexico)

D1.185 **One-day oral challenge test in low risk nut allergic children**
María Luisa Quiñones (Spain)

D1.186 **Reggsolving the eggnigma. Characteristics and prognosis of egg FPIES in children**
Patricia Quijada-Morales (Spain)

D1.187 **The role of gut microbiota in non-specific lipid transfer protein (nsLTP) allergies: insights from 16S rRNA gene sequencing**
Elisa Zubeldia Varela (Spain)

D1.188 **Diet Diversity in Early Childhood, and Prevalence of Food Allergies in Children with Autism Spectrum Disorder**
Zoe Palmer (Ireland)

D1.189 **An Analysis of Adrenaline Auto-Injector distribution in the Republic of Ireland between 2019 to 2023**
Shama Jawed (Ireland)

D1.190 **The Impact of Heat-Processing in Egg and Milk FPIES: A Multi-Center Study in the Southwest United States**
Anna Cheng (United States of America)

D1.191 **Global Survey on Healthcare Provider Practices in the Primary Prevention of Food Allergy: Implementation and Regional Gaps**
Agnes Sze Yin Leung (China)

D1.192 **Natural Course and Predictors of Cow's Milk Allergy Resolution in an Asian Pediatric Cohort: Data from a Tertiary Care Center**
Apichaya Kriengwatanasiri (Thailand)

D1.193 **Pumpkin Seed Allergy in Children**
Bilge Acikalin (Türkiye)

D1.194 **Phylogenetic relationships across allergenic foods to guide the risk assessment of novel food proteins**
Federica Orsenigo (United Kingdom)

D1.195 **Immunoproteomic study of pear (Pyrus communis) in mexican population**
ANGELICA TORRES ARROYO (Mexico)

D1.196 **Characterizing the detectable milk protein allergens in milk ladder foods**
Carina Venter (United States of America)

D1.197 **Casual consumption of small amounts of peanut in children with IgE-mediated allergy is associated with outgrowing IgE-mediated peanut allergy: results of a retrospective observational study**
Elinor Simons (Canada)

12:00 - 13:00 L-TPS04 - Food allergy 07

(Poster Zone, Thematic Poster Session)

Chairs: ***A. Kuehn (Luxembourg), C. Aranda Clemente (Spain)***

D1.202 **Small-Spotted Catshark Parvalbumin Sensitization in Fish-Allergic Patients**
Christine Hafner (Austria)

D1.203 **Pine Nut Allergy in a Pediatric Patient with Multiple Sensitizations to Tree Nuts and Storage Proteins**
Cristina Rivas Juesas (Spain)

D1.204 **Pea-ling Back the Layers: A Systematic Review of Pea Allergies**
RISPAH NG'ANG'A (United Kingdom)

D1.205 **Characterization of a cohort of fish allergic portuguese patients**
Pedro Samuel Figueiredo (Portugal)

D1.206 **A 50-year history of IgE-mediated hypersensitivity reactions to Saccharomyces cerevisiae presenting with respiratory symptoms**
Pratap Harbham (United Kingdom)

D1.207 **"Do nut know what: What is the current role of the prick test and serum IgE in the diagnosis of walnut allergy?**
Daniele Giovanni Ghiglioni (Italy)

D1.208 **Clinical relevance of food allergen families**
Federica Orsenigo (United Kingdom)

D1.209 **Pollen and Food Non-Specific Lipid Transfer Proteins: Clinical Presentations and Sensitization Profiles in a Mediterranean Population**
Diana D´elia Torrence (Spain)

D1.210 **Effects of Omalizumab on Human Basophils in Children with Cow's Milk Protein Allergy**
Mehmet Tarik Cilingiroglu (Türkiye)

D1.211 **Blinded Safety Outcomes Of The COMBINE Study**
Kari Nadeau (United States of America)

D1.212 **IgE mediated allergic reaction to rice**
Carole Guillet (Switzerland)

D1.213 **Exercise-Induced Anaphylaxis in a 18-Year-Old Woman with Egg Allergy and Potential Bird-Egg Syndrome**
Carole Guillet (Switzerland)

D1.214 **Food Allergy: Even in doubt, Challenge Test**
Leticia Herrero Lifona (Spain)

12:00 - 13:00 L-TPS05 - Drug allergy 06
(Poster Zone, Thematic Poster Session)

Chair: ***Marina Atanaskovic-Markovic (Serbia)***

D1.248 **Perioperative hypersensitivity reaction (POH) with tranexamic acid: study of 2 cases**
Jose Julio Laguna Martinez (Spain)

D1.249 **Improving inpatient antimicrobial stewardship through single dose oral amoxicillin challenge among penicillin allergic veterans**
Debendra Pattanaik (United States of America)

D1.250 **Beyond the Label: A Multidisciplinary Effort to De-label Penicillin Allergy**
Saray Sity Harel (Israel)

D1.251 **Documentation of drug allergy in the Electronic Health Record (EHR) at a Tertiary paediatric allergy service in the UK**
Aysenur Kaya (United Kingdom)

D1.252 **A model based economic evaluation to assess impact of Penicillin Allergy in COPD patients**
Lavanya Diwakar (United Kingdom)

D1.253 **Comparison of Immune-Related Adverse Events in Patients Treated with Atezolizumab and Durvalumab: A Critical Concern for Clinical Management**
Yilei Cui (United States of America)

D1.254 **Assessing the Accuracy of Penicillin Allergy Labels in Paediatric Care: Focusing on Educational Gaps in Both Families and Healthcare Workers**
Morgan Keogh (United Kingdom)

D1.255 **Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q): A Cross-Cultural Adaptation and Reliability Study**
Leyla Pur Ozyigit (United Kingdom)

D1.256 **Development of multiple drug hypersensitivity after DRESS syndrome induced by piperacillin/tazobactam**
Sibylla Chantraine (Switzerland)

D1.257 **Extensive allergological workup in the management of immediate adverse drug reactions to chemotherapy- a single centre experience**
Margherita Perlato (Italy)

D1.258 **Comparison of the Negative Predictive Values of One-Day and Five-Day Drug Provocation Tests in Late-Mild and Cutaneous Beta-Lactam Allergies in Children**
GULAY IREM PARLAK OZEL (Türkiye)

D1.259 **Healthcare interoperability: the promises and pitfalls relating to penicillin allergy delabelling**
Pillai Prathap (United Kingdom)

D1.260 **Hypersensitivity to Iodinated Contrast Media: Diagnostic Evaluation and Re-exposure Outcomes**
Ana Cristina Coelho (Portugal)

12:00 - 13:00 L-TPS06 - Immune deficiencies and autoimmunity 04
(Poster Zone, Thematic Poster Session)

Chair: ***Deniz Eyice Karabacak (Türkiye)***

D1.326 **Six Cases of Adult-Onset PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Cervical Adenopathy) Syndrome**
Seda Altiner (Türkiye)

D1.327 **A Rare Primary Immunodeficency Hidden in Autoimmunity: Heterozygote CD3G variant in a 49-year-old Female Patient**
Seda Altiner (Türkiye)

D1.329 **Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan**
Aray Batyrbaeva (Kazakhstan)

D1.332 **Hereditary Angioedema in Ukraine**
Anastasiia Bondarenko (Ukraine)

D1.333 **A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach**
Shiri Curelaru (Israel)

D1.334 **A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia**
GULAY IREM PARLAK OZEL (Türkiye)

D1.335 **TeloNet is born; why immunologists should know about telomere disorders**
Hilary Longhurst (New Zealand)

D1.336 **Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)**
Soraya Regina Abu Jamra (Brazil)

D1.337 **Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024**
Soraya Regina Abu Jamra (Brazil)

12:00 - 18:00 EAACI-COURSE - EAACI Course on immunology update: selected topics in basic and translational immunology

(Meeting Academy M2, EAACI Course)

LIMITED CAPACITY: ***MAX 100 PAX***

This course will provide a review of select basic immunology topics, with an emphasis on recent advances and issues that are relevant to the pathogenesis and treatment of immune-mediated diseases.
The course is designed for practicing clinicians, trainees, and individuals in biotechnology and pharmaceutical companies who are involved in the development of therapies for immunological diseases.
The goals of the course are to:

- *Understand the major advances in basic immunology that are most relevant to human diseases, and the unresolved issues and future challenges.*
- *Discuss the fundamental mechanisms underlying immunologic diseases including autoimmune and allergic disorders.*
- *Identify the basic principles underlying therapeutic modulation of the immune system, and the mechanisms of action of the major classes of immune modulators*

12:00 **Introduction to the immune system**
Abul Abbas (United States of America)

12:30 **Innate immunity**
Abul Abbas (United States of America)

13:30 **Coffee break**

13:45 **Antigen presentation, T cell activation**
Abul Abbas (United States of America)

14:45 **CD4 T cell subsets**
Abul Abbas (United States of America)

15:45 **Coffee break**

16:15 **B cells and antibodies**
Abul Abbas (United States of America)

17:00 **Immune tolerance and regulation**
Abul Abbas (United States of America)

13:15 - 14:00 P & C 1 - Is premedication useful to prevent non-IgE mediated immediate drug hypersensitivity reactions

(EAACI Global Stage, Pro Con)

*Chair: **Lene Heise Garvey (Denmark)***

13:15 **PRO**
Ana Maria Copaescu (Canada)

13:38 **CON**
Knut Brockow (Germany)

13:15 - 14:15 ET 1 - EAACI Enlightening Talks-1

(Innovation Hub, EAACI Enlightening Talk)

*Chair: **Lene Heise Garvey (Denmark)***

13:15 **Translating Science into Clinical Impact: The Journey of Allergy Research**
Giorgio W Canonica (Italy)

13:45 **Conquering allergies: A lifelong quest to turn tolerance into therapy**
Stephen R. Durham (United Kingdom)

13:15 - 14:45 EAACI Special Session 1 - NAIS Forum 2025: Updates in Anaphylaxis

(Hall 1, EAACI Special Session)

*Chair: **Mohamed Shamji (United Kingdom), Asli Akkor (Türkiye)***

13:30 **What is new in guideline based clinical practice in anaphylaxis?**
Cem Akin (United States of America)

13:55 **Emerging allergens: which ones are pivotal in anaphylaxis?**
Amandine Divaret-Chauveau (France)

14:20 **News on molecular events of the vascular system in anaphylaxis**
Vanesa Esteban (Spain)

13:15 - 14:45 FT02 - Anaphylaxis, new perspectives and treatments

(Dochart 1, Flash Talks)

*Chairs: **Margitta Worm (Germany), Rosa Muñoz-Cano (Spain)***

13:15 001319 **Risk of Anaphylaxis in Patients with Large Local Reactions to Hymenoptera Stings: Retrospective and Prospective study**
Gonçalo Martins (Portugal)

13:22 001196 **Pharmacokinetics and Pharmacodynamics following repeat dosing of ARS-1 (adrenaline nasal spray) versus intramuscular injection during induced allergic rhinitis: sub-analysis**
Anne Ellis (Canada)

13:29 001519 **The Cross-Canada Registry for Anaphylaxis Fatalities (CRAFT): Demographics, Triggers, Co- factors and Management**
Alexandre Ton That (Canada)

13:36 001340 **Development of a Validated, Updated North American Anaphylaxis Management Plan**
Aikaterini Anagnostou (United States of America)

13:43 000922	**Cold-Induced Anaphylaxis: New Perspectives on Clinical and Genetic Characteristics** Mojca Bizjak (Slovenia)
13:50 001428	**Prescription rates of adrenaline autoinjectors in Austria – a population-based study** Stefan Woehrl (Austria)
13:57 001423	**Pharmacokinetics by Adrenaline Products from Various Studies** Matthew Greenhawt (United States of America)
14:04 001135	**Adrenaline-use during the acute treatment of anaphylaxis – data from the European Anaphylaxis Registry** Veronika Höfer (Germany)
14:11 000953	**Pollen induces pseudo-allergy via MRGPRX2/Mrgprb2 on mast cells** Liu Yun (China)
14:18 000513	**Circulating mastocyte-derived prostaglandins in perioperative anaphylaxis** Audrey Kamga (France)
14:25 001333	**Risk factors for severe food anaphylaxis; data from the Allergy-Vigilance Network** Guillaume Pouessel (France)

13:15 - 14:45 FT03 - Urticaria and Angioedema

(Dochart 2, Flash Talks)

Chairs: ***Polina Pyatilova (Germany), Annalisa Santucci (Italy)***

13:15 000830	**Sleep disturbance is a significant mediator between active disease and impaired work productivity in patients with chronic urticaria: Findings from a causal mediation analysis** Hugo Wai Fung Mak (Hong Kong)
13:22 001349	**Hidden parasitic causes in chronic spontaneous urticaria** Can Tuzer (Türkiye)
13:29 000880	**IgE anti-TPO; from acute to chronic urticaria** Jorge Sanchez (Colombia)
13:36 001225	**The characteristics of Chronic Inducible Urticaria in Cape Town, South Africa** Cascia Day (South Africa)
13:43 001209	**Impaired vascular autonomic control in HAE patients** Francesca Perego (Italy)
13:50 000949	**Clinical Validation of a Novel Kinin Biomarker Assay for Characterisation of Bradykinin- Mediated Pathologies in US Subjects with Hereditary Angioedema** Evangelia Pardali (Netherlands)
13:57 001667	**Demographic and diagnostic features of hereditary angioedema patients due to C1 inhibitor deficiency: a large cohort from the Italian network for hereditary and acquired angioedema (ITACA) Registry** Riccardo Senter (Italy)
14:04 000399	**Characterization of pathomechanisms of acute and chronic spontaneous urticaria** Thomas Buttgereit (Germany)
14:11 000624	**Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Subanalysis of the Phase 3 OASIS-HAE Study** Danny M. Cohn (Netherlands)
14:18 001686	**Real-World Evaluation of Omalizumab in Chronic Spontaneous and Inducible Urticaria: A Longitudinal Analysis during 15 years from a Lisbon UCARE** Gonçalo Martins (Portugal)

13:15 - 14:45 JMA 2 - Nano- and new technologies in diagnosing and treating allergies
(Boisdale, JMA)

Chair: ***Fabio S. Ryser (Switzerland)***

13:15 **Nanostructures in allergy diagnosis**
María Isabel Montañez (Spain)

13:45 **Virus-like particles (VLP)- vaccines against allergies**
Martin Bachmann (Switzerland)

14:15 **Adjuvant allergen fusion proteins for the treatment of allergies**
Stefan Schülke (Germany)

13:15 - 14:45 OAS01 - Occupational Allergy: back to the future
(Carron 1, Oral Abstract Sessions)

Chairs: ***Hille Suojalehto (Finland), Virginie Doyen (Belgium)***

13:15 000692 **Determinants of fractional exhaled nitric oxide (FeNO) among workers at risk of developing occupational asthma in high-risk occupational settings**
Mohamed Fareed Jeebhay (South Africa)

13:27 000987 **Clinical and Inflammatory Characteristics of Occupational Asthma Caused by Persulfate Salts in Hairdressers: A Multicenter Cohort Study**
Virginie Doyen (Belgium)

13:39 000945 **Allergic sensitization and respiratory symptoms among Norwegian salmon processing workers**
Inga Elda (Norway)

13:51 001122 **The Norwegian SHInE Project: Joint forces to prevent work-related salmon allergy**
Berit Bang (Norway)

14:03 000675 **Skin prick test extracts from different salmon tissues**
Miriam Grgic (Norway)

14:15 100391 **Standard Series Patch Testing: 5-Year Single-Center Study of 504 Patients**
Joana Guimarães (Portugal)

14:27 100419 **Five Years of Supplemental Batteries Patch Testing In a Portuguese Center**
Joana Guimarães (Portugal)

13:15 - 14:45 OAS02 - Biologics in the combined airway
(Carron 2, Oral Abstract Sessions)

Chairs: ***Ludger Klimek (Germany), Jasper Kappen (Netherlands)***

13:15 000025 **Efficacy of two years of treatment with anti-IL-5/R therapy for reduction in use of oral glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis**
Florence Roufosse (Belgium)

13:27 001109 **Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study**
David Jackson (United Kingdom)

13:39 000608 **Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)**
Lavina Davidescu (Romania)

13:51 001255 **Impact of Immunogenicity on Clinical Outcomes in Patients from a Severe Asthma Unit Treated with Mepolizumab**
Margarida Gomes (Portugal)

14:03 000559 **Dupilumab Effectiveness Through Two Years in Patients with CRSwNP Treated in Real-World Practice: Results from the Global AROMA Registry**
Martin Wagenmann (Germany)

14:15 001234 **Improved Quality of Life, Early Symptom Control and Reduced Surgery with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Results from the SYNAPSE Study**
Martin Wagenmann (Germany)

14:27 001397 **REALITI-N: First Ambidirectional Cohort Study Evaluating Real-World Mepolizumab Use in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)**
Eugenio De Corso (Italy)

13:15 - 14:45 SY3 - Beyond the future - perspectives in the diagnosis and treatment of allergy and asthma
(Clyde Auditorium, Symposium)

Chairs: ***Marcin Moniuszko (Poland), Celeste Porsbjerg (Denmark)***

13:15 **New horizons in biologic therapy: Identifying targets in allergy**
Parameswaran Nair (Canada)

13:45 **Exploring stem cells for allergy and asthma treatment: Potential without certification**
Andrzej Eljaszewicz (Poland)

14:15 **Genetic determinants of mucosal host defense in pediatric asthma: implications for therapy**
Carsten Schmidt-Weber (Germany)

13:15 - 14:45 SY4 - Management of severe food allergy in children
(Lomond Auditorium, Symposium)

Chairs: ***Thomas Eiwegger (Austria), Stefania Arasi (Italy)***

13:15 **New paradigm in the management of food allergy - DEFASE validation steps**
Alessandro Fiocchi (Italy)

13:45 **Slow oral immunotherapy for food allergy - what evidence do we have?**
Anna Asarnoj (Sweden)

14:15 **Management of Eosinophilic Esophagitis as a side effect of food oral immunotherapy**
Antonella Cianferoni (United States of America)

13:30 - 14:30 GBD 1 - Ground breaking discoveries 1
(Forth, Ground Breaking Discoveries)

Chairs: ***Liam O'Mahony (Ireland), Cecilia Berin (United States of America)***

13:30 **Thresholds for microbiome-dependent oral tolerance**
Talal Chatila (United States of America)

13:50 **Options for multiple food allergies - food avoidance or pharmacologic treatment?**
Gary Wong (China)

14:10 **Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy**
Sarita Patil (United States of America)

14:15 - 15:00 P & C 2 - Timing in oral immunotherapy: Early vs Late introduction
(EAACI Global Stage, Pro Con)

*Chair: **Paul J. Turner (United Kingdom)***

14:15 **PRO: Benefits of Early Introduction**
Carmen Riggioni-Viquez (Canada)

14:38 **CON: Advantages of Later Introduction**
Marta Vazquez-Ortiz (United Kingdom)

15:00 - 16:30 FT04 - Epidemiology and clinical management of drug allergy
(Dochart 1, Flash Talks)

*Chairs: **Lene Heise Garvey (Denmark), Marina Labella Alvarez (Spain)***

15:00 000521 **Disinfectant-induced anaphylaxis: analysis of the Allergy Vigilance Network database**
Elleni-Sofia Vaia (France)

15:07 000754 **Features of Perioperative Hypersensitivity Reactions Manifestations in Children with Bronchial Asthma**
Olena Sharikadze (Ukraine)

15:14 001473 **Descriptive bias in the clinical history of adverse drug reactions in children**
Giacomo Gagliardi (Italy)

15:21 001000 **Characterization of pediatric population with suspected beta-lactam allergy followed in a Portuguese Immunoallergology Department**
Ana Bernardino (Portugal)

15:28 001508 **Evaluation of Pediatric Patients with Suspicion of Beta-Lactam Allergy: 5-Year Clinical Experience of Erciyes University Pediatric Allergy Unit**
Burcu Erdoğan (Türkiye)

15:35 001484 **How Useful Are Major and Minor Determinants of Penicillin in Evaluating Non-Immediate Hypersensitivity Reactions?**
Irene Rosmaninho (Portugal)

15:42 000471 **Evaluating the PEN-FAST Tool for Penicillin Allergy Delabeling in an Asian Cohort**
Xin Rong Lim (Singapore)

15:49 001071 **Safe Strategy for NSAID Reintroduction in moderate to severe asthmatics with COX-1 NSAID hypersensitivity**
Sarah BOUNETTA BELMOKHTAR (France)

15:56 001332 **Intranasal Aspirin Challenge for Diagnosis of Aspirin-Exacerbated Respiratory Disease: Symptom Score Criteria and Optimal Dosage**
Juan Meng (China)

16:03 001549 **Multidisciplinary approach in the management of hypersensitivity reactions to biological agents and successful rapid drug desensitization**
Ceyda Tunakan Dalgıc (Türkiye)

16:10 000623 **Drug Induced Anaphylaxis Maybe The Only Manifestation of Systemic Mastocytosis**
Emine Nihal Mete Gokmen (Türkiye)

16:17 001455 **New frontiers in the diagnosis of betalactam allergy**
Alejandra Jover Walsh (Spain)

15:00 - 16:30 FT05 - Immunotherapy from patient and epidemiological study perspective
(Dochart 2, Flash Talks)

Chairs: ***Cristina Quecchia (Italy), Marcin Moniuszko (Poland)***

15:00 000066
Impact of allergic rhinitis activity on the effect of 300IR house dust mite sublingual immunotherapy tablet in adolescent patients
Eric Fromentin (France)

15:07 001569
Correlation between subjective and objective parameters in house dust mite nasal allergen challenge
Kunnathummal Rohil (India)

15:14 000096
Profile of patients treated with the 300IR liquid sublingual immunotherapy for cat allergy and perception of treatment effect: Results from a French survey
Myriam Zakariya (France)

15:21 001242
Disease burden of allergic rhinitis in children : results of the ORACLE survey among paediatricians
Guillaume Lezmi (France)

15:28 001157
Allergen-Specific Ige Assessment Across China: A Nationwide Cross-Sectional Study
Xiaoqun Luo (China)

15:35 000279
Safety and compliance of sublingual immunotherapy with house dust mite extract in patients with atopic dermatitis for 1 year
Dong-Ho Nahm (Korea, Republic of)

15:42 000450
Patient-reported outcomes after 5 years of oral immunotherapy for peanut allergy: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
Tal Oryan (United Kingdom)

15:49 100070
Steroid sparing effect of liquid sublingual immunotherapy in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study
Julien Cottet (France)

15:56 100090
The Efficacy and Safety of Ultra-Rush Subcutaneous Immunotherapy for Allergic Rhinitis
Jing Ye (China)

16:03 100183
A multi center retrospective study of the incidence of systemic reactions, spontaneous abortions and pre-term birth in pregnant women who undergo specific immunotherapy for Hymenoptera venom because of severe allergic reactions to Hymenoptera venom
Giovanna Sfriso (Italy)

16:10 000590
Positive impact on quality of life with a depigmented-polymerized house dust mite extract immunotherapy
Lourdes Gonzalez (Spain)

16:17 100339
Characterisation of patients with significant treatment effect of intralymphatic immunotherapy
Hans Jürgen Hoffmann (Denmark)

15:00 - 16:30 IWS4 - Assessment of control in chronic rhinitis and CRS
(Forth Interactive, Workshop)

Chairs: ***Laura Van Gerven (Belgium), Jan Hagemann (Germany)***

15:00 **Lessons from asthma questionnaires**
Jasper Kappen (Netherlands)

15:30 **The concept of control in CRS**
Ludger Klimek (Germany)

16:00 **Control in allergic rhinitis**
Aspasia Karavelia (Greece)

15:00 - 16:30 JMA3 - JMA IWS: Mastering the art of research: Writing, publishing, and building your research team

(Meeting Academy M1, JMA)

Chairs: ***Rubén Fernández-Santamaría (Spain), Bianca Olivieri (Italy)***

15:00 **How to write a successful project: From idea to submission**
J. Upton (Canada)

15:30 **How to write high-impact research paper: From idea to submission**
Doris Kollmann (Germany)

16:00 **Building and leading a successful research team**
Stefan Schülke (Germany)

15:00 - 16:30 OAS-CT1 - Clinical Trials on Airways Diseases

(Innovation Hub, Oral Abstract Session on Clinical Trials)

Chairs: ***Santiago Quirce (Spain), Jordon Jaggers (United States of America)***

15:00 001678 **Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma**
Rekha Chaudhuri (United Kingdom)

15:12 001088 **Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma Experience Early and Sustained Benefit with Depemokimab in the Randomised, Double-Blind, Parallel-Group, Replicate ANCHOR-1/2 Studies**
Joaquim Mullol (Spain)

15:24 000642 **Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps overall and in patients with and without co-morbid asthma: results from the phase 3 WAYPOINT study**
Brian Lipworth (United Kingdom)

15:36 000778 **Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial**
Shen Shen (China)

15:48 001671 **Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma**
Rekha Chaudhuri (United Kingdom)

16:00 000682 **PQ Grass induces tolerogenic humoral and cellular immune responses: biomarker results from a pivotal Phase III trial**
Janice A Layhadi (United Kingdom)

15:00 - 16:30 OAS03 - Allergic diseases in the perspective of innate immune responses

(Carron 1, Oral Abstract Sessions)

Chairs: ***Jitesh Chauhan (United Kingdom), Andrzej Eljaszewicz (Poland)***

15:00 000530 **Microglia–Neuron Interactions Promote Chronic Itch via the NLRP3-IL-1β-GRPR Axis**
Xueting Liu (China)

15:12 000994 **Surfactants in oral care products may exacerbate Eosinophilic Esophagitis by disrupting epithelial barriers and triggering pro-inflammatory responses**
Özge Ardicli (Switzerland)

15:24 001488 **Cannabinoid WIN55,212-2: Unlocking New Therapeutic Potential for Atopic Dermatitis by Restoring Skin Homeostasis**
Natalia Cuervo López (Spain)

15:36 001341	**Macrophages mediated impairment of inflammation resolution in nasal polyps** Zhaofeng Xu (China)
15:48 000751	**Nasal polyp CD62Llow eosinophils as a prognostic biomarker of chronic rhinosinusitis with nasal polyp severity and predictive biomarker of mepolizumab and dupilumab response** Matteo Accinno (Italy)
16:00 001101	**NSAIDs administration promotes allergic sensitization by altering the production of lipid mediators** Toa Okawara (Japan)
16:12 000972	**Isolated Basophils Maintain Functionality and Specificity: A Promising Prospect for Future Drug Allergy Studies** Silvia Calvo-Serrano (Spain)

15:00 - 16:30 OAS04 - Drug Allergy: from bench to bedside

(Carron 2, Oral Abstract Sessions)

Chairs: ***Lukas Joerg (Switzerland), Sevim Bavbek (Türkiye)***

15:00 000500	**Evaluation of MRGPRX2-mediated mast cell activation in immediate hypersensitivity reactions to neuromuscular blocking agents** Deniz Eyice Karabacak (Türkiye)
15:12 000535	**Unlocking the Potential of Cytokines for Endotyping Immediate Hypersensitivity Reactions Induced by Chemotherapeutic and Biological Agents** Kimberly Yasmin Solis (Spain)
15:24 001370	**Efficacy and Safety of Chemotherapeutic Drug Desensitization in Children** Büşra Koçali (Türkiye)
15:36 000375	**The value of skin testing with TNF-inhibitors in patients with local and systemic hypersensitivity reactions** Nilay Orak Akbay (Türkiye)
15:48 001069	**Meloxicam as a Safe Bet: Rethinking the Approach to NSAID Hypersensitivity Alternative Drugs** Catarina Dourado (Portugal)
16:00 000407	**Efficacy of aspirin therapy after desensitization on CRSwNP patients with N-ERD - a RDBCT study** Alma Helevä (Finland)
16:12 000528	**Low-dose acetylsalicylic acid therapy after desensitization is safe for pregnant women with NSAID-induced urticaria/angioedema and NASID-exacerbated cutaneous disease** Sen Hee Tay (Singapore)

15:00 - 16:30 SY5 - Climate change effects on allergic patients: Emerging environmental threats

(Clyde Auditorium, Symposium)

Chairs: ***Mubeccel Akdis (Switzerland), Elaine Fuertes (United Kingdom)***

15:00	**From allergen exposure to multi-bioexposome: Lessons from respiratory infections and allergic diseases** Stefanie Gilles (Germany)
15:30	**Molecular techniques to assess for atopic sensitization in the era of climate change. What is new?** Stephanie Dramburg (Germany)
16:00	**Novel pollutants in the face of climate change: from indoor pollution to outdoor microplastics** Cezmi Akdis (Switzerland)

15:00 - 16:30 SY6 - Utility of molecular allergology in diagnosis and management of complex sensitization profiles

(Lomond Auditorium, Symposium)

Chairs: ***Claudia Traidl-Hoffmann (Germany), Ronald van Ree (Netherlands)***

15:00	**Cyclophillins – a neglected family of panallergen** Paolo Matricardi (Germany)
15:30	**The complex picture of meat allergy** Christiane Hilger (Luxembourg)
16:00	**Allergy risk of plant-based protein alternatives** Amandine Divaret-Chauveau (France)

15:00 - 16:30 TSY1 - Bi-directional neuro-immune communications controlling allergy

(Hall 1, Thematic Symposium)

Chairs: ***Oscar Palomares (Spain), Milena Sokolowska (Switzerland)***

15:00	**FceRI regulation on nociceptors and their impact on allergic lung inflammation** Sebastien Talbot (Canada)
15:30	**Mast cell-nociceptor communication in allergic skin inflammation** Lilian Basso (France)
16:00	**Nociceptors and Innate lymphoid cells in barrier integrity** Christoph Klose (Germany)

15:30 - 16:30 EAACI-BSACI Session 2 - EAACI-BSACI Session 2 - Allergy Prevention

(EAACI Global Stage, EAACI Special Session)

Chair: ***Sophia Tsabouri (Greece)***

15:30	**Oral tolerance induction for preventing food allergy** G. Lack (United Kingdom)
15:45	**Infant skincare interventions for preventing atopic dermatitis** R. J. Boyle (United Kingdom)
16:00	**Oral tolerance induction for preventing asthma** H. Arshad (United Kingdom)
16:15	**Q & A**

16:30 - 18:00 JMA Poster session 01 - JMA Poster Session 1: Allergen Immunotherapy / Biologicals / Allergoncology

(Poster Zone, JMA)

Chairs: ***Martha Jimenez Freites (Spain), Mattia Giovannini (Italy)***

D1.282	**AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies** Xinyi Chen (United Kingdom)
D1.283	**Murine IgG1 increased by subcutaneous immunotherapy suppressed development of allergic asthma** Masaya Matsuda (Japan)

D1.284 **A Clinical Decision Support System (CDSS) based on Machine Learning for the diagnosis of Seasonal Allergenic Rhinitis (SAR) and patient-tailored AIT prescription**
Francesco Monnati (Italy)

D1.285 **Effect of Metformin on allergen specific immunotherapy**
Yu-mi Park (Korea, Republic of)

D1.286 **Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis**
Nathalie Khünl-Brady (Austria)

D1.287 **Alterations in B cell memory induced by house dust mite allergen immunotherapy**
Ellen ketelaere (Belgium)

D1.288 **Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis**
Hang Du (Switzerland)

D1.289 **Effectiveness and safety of Venom ImmunoTherapy (VIT) with "Rapid Cluster" induction protocol**
Emanuele Acampora (Italy)

D1.290 **Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study**
Dominika Ochab-Krupnik (Poland)

D1.291 **Comparison of Completion Rates and Factors Influencing Discontinuation in Paediatric Allergen Immunotherapy: A Five-Year Single-Center Experience**
Elvira Efstathiou (United Kingdom)

D1.292 **Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts**
Abid Hussain (Denmark)

D1.293 **Blood morphology in health & cancer: comparative, preliminary study on 783 patients**
Alicja Majos (Poland)

D1.294 **A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase**
Jose Carlos Hernandez Walias (Spain)

D1.295 **When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus**
Carlota Dias (Portugal)

D1.296 **Consistent long term benefit of allergen immunotherapy in patients with allergic rhinitis**
Plamena Novakova (Bulgaria)

D1.297 **Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus- Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy**
Christine Yee Yan Wai (Hong Kong)

D1.298 **Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience**
Nour Aljefri (Saudi Arabia)

D1.299 **Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment**
Àlvar Piracés Buitrago (Spain)

16:30 - 18:00 JMA Poster session 02 - JMA Poster Session 2: Basic Immunology / Biomarkers / Infections / Immunodeficiencies

(Poster Zone, JMA)

Chairs: ***Rubén Fernández-Santamaría (Spain), Andrzej Eljaszewicz (Poland)***

D1.302 **Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine**
Ilaria Baglivo (Italy)

D1.303 **Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts**
Ekaterina Potapova (Germany)

D1.304 **MiRNA-29a is downregulated in food anaphylaxis and involved in the endothelial glycocalyx stability**
Antonio Muñoz-Callejas (Spain)

D1.305 **Monocytic myeloid-derived suppressor cells (M-MDSCs) increase the expression of TIGIT on γδ T cells**
Michał Zarobkiewicz (Poland)

D1.306 **Childhood exhaled nitric oxide levels predict new-onset allergic rhinitis in adolescence and young adulthood**
Chin-Hung Wang (Taiwan)

D1.307 **Involvement of periostin-dependent and -independent pathways in the formation of skin inflammation and itch in a mouse model of atopic dermatitis**
Yukako Tanaka (Japan)

D1.308 **Antibiotic Cocktail-Induced Gut Microbiota Dysbiosis Modulates Gut and Airway Immunity, Attenuating Allergic Airway Inflammation**
Choi Doo Young (Korea, Republic of)

D1.309 **Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study**
Martina Ceraudo (Italy)

D1.310 **Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center**
Nour Aljefri (Saudi Arabia)

D1.311 **SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps**
Yong Seok Jo (Korea, Republic of)

D1.312 **The bacterial lysate OM-85 mitigates HDM-induced allergic inflammation through the airway epithelial cell- macrophage crosstalk**
Athanasios Kouklas (Switzerland)

D1.313 **Allergen sensitization as a One Health approach: computational IgE clustering in a large cohort of dogs to resolve exposure profiles across Europe**
Theresa-Maria Boehm (Luxembourg)

D1.314 **Classification, early determinants and long-term impact on asthma of the IgG responses to rhinovirus VP1 (RV-VP1): a longitudinal study in two birth cohorts**
Ekaterina Potapova (Germany)

D1.315 **CVID: the crossroad between immune dysregulation, autoimmunity and cancer**
Marianna Franco (Italy)

D1.316 **Prediction of walnut allergy in sensitized children with atopic diseases**
Franziska Sattler (Germany)

D1.317 **Transcriptome kinetics of esophageal epithelial cells in response to interleukin 13**
Mirelle Kleuskens (Netherlands)

16:30 - 18:00 JMA Poster session 03 - JMA Poster Session 3: Dermatology / Mastocytosis / Mast cells

(Poster Zone, JMA)

Chair: ***Polina Pyatilova (Germany)***

D1.322 **Sodium dodecyl sulfate impairs the skin epithelial barrier by inducing oxidative stress in human skin**
Manru Li (Switzerland)

D1.323 **Urinary Levels of Environmental Pollutants Are Associated with the Severity and Persistence of Atopic Dermatitis in Young Children**
Sanghee Shin (Korea, Republic of)

D1.324 **Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters**
Ji-Su Shim (Korea, Republic of)

D1.325 **A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway**
Basak Ezgi Sarac (Türkiye)

D1.327 **Transepidermal Water Loss in Atopic Diseases**
Maria Savva (Greece)

D1.328 **Diagnostic characterization of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): Case series from a tertiary care hospital and literature review**
Luis Carrasco Gómez (Spain)

D1.329 **Evaluation of ChatGPT Responses to Frequently Asked Questions by Parents of Children with Atopic Dermatitis**
Maria Savva (Greece)

D1.330 **Triggers and prodromal indicators of angioedema attacks in hereditary angioedema patients**
Lucía Ruiz Del Barrio (Spain)

D1.331 **Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol**
Elena Mazoteras-Martínez (Spain)

D1.332 **Clinical, Laboratory and Prognostic Evaluation of Antinuclear Antibody Positive and Negative Children with Chronic Urticaria**
Gizem Kabadayı (Türkiye)

D1.333 **The Fecal Microbiome: Geographical Location and Associated Dietary Habits Matter More Than Atopic Dermatitis**
Danielle Fehr (Switzerland)

D1.334 **Quality of life of families with children suffering from chronic urticaria**
Maria Savva (Greece)

D1.335 **Contact Dermatitis and Rhinoconjunctivitis due to Palisander Wood Exposure in a Cabinetmaker**
Ana Melissa Yanes Bonilla (Spain)

D1.336 **IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas**
Kinga Fabiańczyk (Poland)

16:30 - 18:00 JMA Poster session 04 - JMA Poster Session 4: Drug Allergy
(Poster Zone, JMA)

Chairs: ***Marina Labella Alvarez (Spain), Jose Julio Laguna Martinez (Spain)***

D1.342 **Impact of a Penicillin Allergy Delabeling Program on Antibiotic Selection and Perioperative Outcomes: A Prospective Comparative Cohort Study**
Eisa Saleh (Canada)

D1.343 **The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital**
CRISTINA HIGUERA BENÍTEZ (Spain)

D1.344 **Penicillin-allergic labelled patients with a PEN-FAST score of 0 could safely be de-labelled by non-allergists**
Nina Frelih (Slovenia)

D1.345 **Nonsteroidal anti-inflammatory drug cross-hypersensitivity phenotypes show high carbonyl levels**
Isabel María Jiménez-Sánchez (Spain)

D1.346 **Platinum salt hypersensitivity: Experience of our Center**
Sofia Luisa Tocci (Italy)

D1.347 **Synthetic folic acid allergy**
Vyanka Redenbaugh (United Kingdom)

D1.348 **Direct single dose mass delabelling of antibiotic allergy in paediatrics**
Sheena Coyne (Ireland)

D1.349 **Iodinated Contrast Media During Acute DRESS: A Hidden Risk for Future Drug Hypersensitivity?**
Irene Rosmaninho (Portugal)

D1.350 **SDRIFE related to generalized corticosteroids' hypersensitivity: A case report**
Ana Filipa Vassalo (Portugal)

D1.351 **Association of chemokine levels with types of reactions after alcohol consumption in patients with nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD)**
Karolina Frachowicz-Guerreiro (Poland)

D1.352 **Hypersensitivity reactions during therapy with platinum compounds and taxanes – who can benefit from consulting an allergist?**
Olga Plackowska (Poland)

D1.353 **Sarcoid-like reaction induced by aspirin therapy after aspirin desensitization in a patient with aspirin-exacerbated respiratory disease**
Gabriela Trąd (Poland)

D1.354 **Insights from Drug Provocation Testing in Quinolone Allergy**
Anna Ventosa (Spain)

16:30 - 18:00 JMA Poster session 05 - JMA Poster Session 5: Epidemiology / Allergy diagnosis / Allied Health and Primary care

(Poster Zone, JMA)

Chair: ***Riccardo Castagnoli (Italy)***

D1.362 **A confidence score for basophil activation test: improving interpretation around diagnostic cutoffs**
Leonard Bezinge (Switzerland)

D1.363 **Characteristics, healthcare provision and expectations of patients with atopic dermatitis as part of the ADCompanion study to evaluate a digital form of care**
Josephine Telschow (Germany)

D1.364 **Prevalence of thaumatin and Alternaria co-sensitization**
Teresa Martínez Piélago (Spain)

D1.365 **Differential Diagnosis of Perioperative Anaphylaxis: The Hidden Role of Chlorhexidine**
Maria Victoria Sousa Pérez (Spain)

D1.366 **Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists**
Xin Rong Lim (Singapore)

D1.367 **Research transparency, reproducibility and accessibility in Allergy, 2003 – 2023: Preliminary results of the TRACES study**
Hugo Wai Fung Mak (Hong Kong)

D1.368 **Class III Chitinases as Potential Allergens in Raspberry-Induced Anaphylaxis**
CARLOS MORENO LOPEZ (Spain)

D1.369 **Analysis of Sensitization Profiles and Cross-Reactivity of Lipocalin Allergens in Czech Allergy Patients**
Jana Bojcukova (Czech Republic)

D1.370 **No more restrictive diets for LTP allergic patients. The importance of oral food challenge**
Nadine Blanco Toledano (Spain)

D1.371 **Review of skin testing for delay hypersensitivity drug reactions, possible covariates involved in the results**
Julia Rodriguez De Guzman (Spain)

D1.372 **Algorithmic methods for quantifying spontaneous activation in basophil activation tests: toward scalable data analysis**
Adrian Leathers (Switzerland)

D1.373 **A long-term freezing protocol to help democratize a streamlined approach to the basophil activation test**
Marie-Elise Castaing-Lasvignottes (France)

D1.374 **Comparing Dietary Advancement Therapy for IgE-Mediated Egg Allergy in Primary and Tertiary Care: A Retrospective Review**
Aoife Gallagher (Ireland)

D1.375 **An EAACI Task Force Initiative for Visualizing Historical Pollen and Spore Calendars in Europe**
Jose Oteros (Spain)

D1.376 **Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)**
Alejandro Luis Ferri (Italy)

D1.377 **Cross-disciplinary working in adult food allergy: experience from the UK**
Hannah Hunter (United Kingdom)

16:30 - 18:00 JMA Poster session 06 - JMA Poster Session 6: Anaphylaxis / Food Allergy / Insect Venom Hypersensitivities

(Poster Zone, JMA)

Chairs: ***Bianca Olivieri (Italy), Pedro Alves (Portugal)***

D1.382 **Long-term efficacy and re-sting outcomes following venom immunotherapy discontinuation: A 978-patient analysis**
Lidija Bojanić (Slovenia)

D1.383 **Anaphylaxis Risks in Beekeeping: The Importance of Developing a Health Education Program**
Tea Močnik (Slovenia)

D1.384 **Validation of the Korean versions of the Child- and Parent-Rated Scale of Food Allergy Anxiety (K-SOFAA-C and K-SOFAA-P)**
Sehun Jang (Korea, Republic of)

D1.385 **A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system**
Andrea Escolar-Peña (Spain)

D1.386 **Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells**
Sergio Fernandez-Bravo (Spain)

D1.387 **Legumes Sensitization in Tree nut- vs. Peanut-Allergic Children: What Makes the Difference?**
Isabela Assugeni (Luxembourg)

D1.388 **Investigation of risk factors for the development of food-induced enterocolitis syndrome in children with a history of allergic proctocolitis caused by milk**
Tikfleslis Theodoros (Greece)

D1.389 **Social #anaphylaxis: how social media reveals shifting trends in public health concerns**
Sofía Proaño Mosquera (Spain)

D1.390 **Changes in temperature during allergic reactions to food in human volunteers**
Sara Albarracín (Spain)

D1.391 **Pumpkin Seed Allergy in Children**
Bilge Acikalin (Türkiye)

D1.392 **Clinical relevance of food allergen families**
Federica Orsenigo (United Kingdom)

D1.393 **Unveiling Pitaya Pollen Allergenicity: A Case Study in Occupational Allergy**
Manuel Sobrino García de Zúñiga (Spain)

D1.394 **Acute generalized exanthematous pustulosis with overlay of serum sickness, triggered by a spider bite: Case report**
Elida Berenice Nuñez (Mexico)

D1.395 **'When I became older, I started having to manage that more myself' – experiences of adolescents with food allergies: a qualitative study**
Juan Enrique Trujillo Wurttele (Ireland)

D1.396 **Vit v 5: A Chitinase Implicated in Grape-Induced Anaphylaxis**
Laura Berzal Plaza (Spain)

D1.397 **Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production**
Aidan Maloney (United States of America)

16:30 - 18:00 JMA Poster session 07 - JMA Poster Session 7: Pediatrics
(Poster Zone, JMA)

Chairs: ***Wojciech Feleszko (Poland), Nihat Sapan (Türkiye)***

D1.402 **Development and validation of Skin Prick Test solutions for assessing sensitization patterns to edible insects among children sensitized to house dust mite**
Lara Meixner (Germany)

D1.403 **Descriptive Study on the Evolution of Patients Treated with Oral Immunotherapy (OIT) Using Pasteurized Egg White at the Fundación Alcorcón University Hospital**
Maria de los Angeles Gonzalez-Labrador (Spain)

D1.404 **Profiles of Heart Rate Variability in Asthmatic Children with Acute Exacerbation**
Wei-Yu Chen (Taiwan)

D1.405 **Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study**
Tamara Hernandez Hernandez (Mexico)

D1.406 **Reactivity, severity and tolerance development in 50 wheat-allergic children across two oral food challenges**
Friederike Bluhme (Germany)

D1.407 **Does severe asthma exist in preschool children?**
Francisco de Asís Palazón Rico (Spain)

D1.408 **Basophil Activation Test for Chronic Spontaneous Urticaria: the experience of a paediatric allergy centre**
Chiara Ferrecchi (Italy)

D1.409 **Prevalence of Sleep-Disordered Breathing and Its Impact on Quality of Life in Children with Allergic Diseases in Makkah, Saudi Arabia**
Amer Khojah (Saudi Arabia)

D1.410 **Risk Factors for Anaphylaxis in Food-Allergic Children During Oral Food Challenge Tests**
Tadej Pungertnik (Slovenia)

D1.411 **Selective IgA Deficiency in the Pediatric Population: A Gateway to Allergies and Autoimmunity**
Rocio del Pilar Garcia Brito (Spain)

D1.412 **A review of healthcare transition of young people aged 16-18 years old seen in a tertiary paediatric allergy service**
Nikita Punjabi (United Kingdom)

D1.413 **The Silent Threat of Hereditary Angioedema in Children: Single Center Experience**
Gül ÜNLÜ KILAVUZ (Türkiye)

D1.414 **Eat the fruit, do not swallow the seed: A rare case of Cucurbitaceae allergy causing anaphylaxis**
Halime YAĞMUR (Türkiye)

D1.415 **Clinical relevance of sensitizations to pneumoallergens detected in southern Spain**
María Dolores Rodríguez Bote (Spain)

D1.416 **Immediate Hypersensitivity to Chlorhexidine: A Case Series**
Francisco de Asís Palazón Rico (Spain)

16:30 - 18:00 JMA Poster session 08 - JMA Poster Session 8: ENT / Asthma / Environmental Allergy / Ocupational Allergy

(Poster Zone, JMA)

Chairs: ***Fabio S. Ryser (Switzerland), Jasper Kappen (Netherlands)***

D2.422 **The Role of Inflammatory Parameters in Predicting Allergy in Childhood Asthma**
Halil Alkaya (Türkiye)

D2.423 **What are our children breathing? Tracking exposure to air pollution during a school day**
Gonçalo Silva (Portugal)

D2.424 **Nasal transcriptomics as a biomarker for ICS/LABA treatment in paediatric asthma in the PUFFIN study**
Yidan Sun (Netherlands)

D2.425 **Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma**
Efthymia Theofani (Greece)

D2.426 **IgE cross-reactivity between grass species in the presence of Japanese cedar pollen sensitization**
Takeru Sugawara (Japan)

D2.427 **ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up**
Filippo Moletta (Italy)

D2.428 **The Impact of Obesity in Asthma and Small Airway Dysfunction: Prevalence, Clinical characteristics, and Predictors**
Nicolò Valli (Italy)

D2.429 **Balancing Green Initiatives with Public Health: A Framework for Allergy-Friendly Urban Planning**
Katarina Stevanovic (Germany)

D2.430 **Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting**
Robert Greig (United Kingdom)

D2.431 **Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment**
Oliver Massey (Australia)

D2.432 **Characterization of Juniperus oxycedrus pollen extract and identification of putative allergens**
Sandra Sivill (Spain)

D2.433 **5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification**
Joana Guimarães (Portugal)

D2.434 **Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata**
Clara Padró (Spain)

D2.435 **Exploring association between lung function, asthma and epigenetic predisposition to obesity**
Tsen-Hsin Tai (Taiwan)

D2.436 **Systemic characteristic of 15-LOX and 5-LOX oxo-metabolites in older patients with aspirin exacerbated respiratory disease**
Piotr Szatkowski (Poland)

D2.437 **Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab**
Robert Greig (United Kingdom)

16:45 - 17:45 EAACI-BSACI Session 3 - EAACI-BSACI Session 3 - Transforming UK Allergy Frameworks

(EAACI Global Stage, EAACI Special Session)

Chairs: ***Maria Jose Torres (Spain), A. Semic-Jusufagic (United Kingdom)***

16:45 **UK National Allergy Strategy**
Adam Fox (United Kingdom)

17:05 **Transforming transitional allergy care: The EAACI-BSACI experience**
C. Gore (United Kingdom)

17:25 **Q & A**

16:45 - 18:15 FT06 - Mechanisms and applications in allergy and asthma research

(Dochart 1, Flash Talks)

Chairs: ***Alexandra Santos (United Kingdom), Cagatay Karaaslan (Türkiye)***

16:45 001296 **Applying Standards for the Validation and Accreditation of Basophil Activation Test**
Silvia Calvo-Serrano (Spain)

16:52 001202 **Detection of blocking antibodies using a basophil activation test in sera from allergic patients treated with investigational birch pollen allergy vaccine DM-101PX**
Janneke Ruinemans- Koerts (Netherlands)

16:59 001250 **Mast cells as innate sensors of the disease microenvironment: deconvoluting plasticity using minimal cytokine-activated gene signatures**
Chiara Tontini (United Kingdom)

17:06 000978 **Optimizing immunogenicity of virus-like particles (VLPs) displaying HDM allergens: effects of heterologous priming with mRNA vaccines**
Alain Jacquet (Thailand)

17:13 001307 **Molecular recognition and cross-reactivity of the major yellow jacket venom allergen Ves v 5 by a highly specific nanobody**
Bjarke Krogstrup Jensen (Denmark)

17:20 000128 **The role of differential expression of HR1 and HR2 on B cells and their functions**
Minglin Yang (Switzerland)

17:27 000505 **Analyses of epitopes associated with the IgE antibody repertoire to Fel d 1 for design of immunotherapeutic molecules**
Anna Pomés (United States of America)

17:34 000270 **Marginal Zone B Cells: Key Players In Radiation-Induced Hyposplenism**
Sevval Kaplan Kilic (Türkiye)

17:41 001652 **Characterization of the clinical phenotype of patients with CSU treated with cyclosporin alone or combined with omalizumab**
Beatrice Lauro (Italy)

17:48 001557 **Omalizumab as a diagnostic and therapeutic trial for recurrent isolated angioedema: a retrospective observational study**
Valeria Motisi (Italy)

17:55 100506 **Innate lymphoid cells shape immune responses underlying food allergy and tolerance**
Janarthanan Ragavan Ilangovan (United Kingdom)

16:45 - 18:15 FT07 - Biologicals, biomarkers and microbiome
(Dochart 2, Flash Talks)

Chairs: ***Urszula Radzikowska (Switzerland), Ismail Ogulur (Switzerland)***

16:45 000603
Dupilumab Improves Type 2 Inflammatory Biomarkers Over Time in Patients With Chronic Obstructive Pulmonary Disease
Jigna Heble (United States of America)

16:52 000473
Reduction in Oral Corticosteroid Burden in Patients With Moderate-to-Severe Asthma Initiating Dupilumab in the Real-World: The RAPID Registry
Enrico Heffler (Italy)

16:59 000866
A Novel Treatment for Drug-Induced Acute Interstitial Nephritis: Benralizumab
Aviv Talmon (Israel)

17:06 001362
Omalizumab in CSU: analysis of potential markers of response
Maria Clara Ruffi (Italy)

17:13 000209
Chronic spontaneous urticaria with wheals, angioedema, or both: Differences in clinical characteristics, biomarkers and treatment response
Gülseren Tuncay (Germany)

17:20 000388
Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis
Paul K Keith (Canada)

17:27 001165
The distinct effects of IL-4, IL-13, and IL-22 in epithelial barrier dysfunction and human skin inflammation
Paolo D'Avino (Switzerland)

17:34 000667
Dysbiosis promotes the IgE sensitization accompanied with higher PGD2 production in the intestine
Naoaki Sakamoto (Japan)

17:41 000133
Microbiome variation during Dermatophagoides pteronyssinus cultures used in allergen extracts
David Calzada (Spain)

17:48 001177
Food emulsifier polysorbate 80 causes gut barrier distruption and inflammation
Can Zeyneloglu (Switzerland)

16:45 - 18:15 IH2 - AI and Education: shaping the future of allergy and respiratory health
(Innovation Hub, Innovation Hub)

Chairs: ***Janice A Layhadi (United Kingdom), I-Jen Wang (Taiwan)***

16:45
Innovating allergy and asthma education: building a resilient future for global health
Paul V. Williams (United States of America)

17:15
Development of person-centred, digitally-enabled, artificial intelligence-assisted care in rhinitis
Bernardo Sousa-Pinto (Portugal)

17:45
Applying artificial intelligence to investigate epigenetic mechanisms in allergy and autoimmunity
Christopher Chang (United States of America)

16:45 - 18:15 IWS5 - Exploring the clinical management of Eosinophilic Esophagitis
(Forth Interactive, Workshop)

Chairs: ***Willem Van De Veen (Switzerland), Antonella Cianferoni (United States of America)***

16:45 **Eosinophilic Esophagitis beyond eosinophils**
Thomas Greuter (Switzerland)

17:15 **Challenges in diagnosis and monitoring**
Alfredo Lucendo (Spain)

17:45 **Treatment insights and potential differences**
Arzu Bakirtas (Türkiye)

16:45 - 18:15 OAS05 - Hereditary Angioedema
(Carron 1, Oral Abstract Sessions)

Chairs: ***Teresa Caballero (Spain), Maria Bova (Italy)***

16:45 000481 **HAE with normal C1Inh (HAE-n C1INH) and spontaneous mast cell AE (AE-MC): clinical similarities and differences**
Alexis Bocquet (France)

16:57 000619 **Improvements in Quality of Life in Patients With Hereditary Angioedema Receiving Donidalorsen: Post Hoc Analysis From the OASIS-HAE Study and Results From the OASISplus Open-Label Extension**
Marc A. Riedl (United States of America)

17:09 000394 **Bradykinin induces endothelial barrier dysfunction through the modulation of VE-cadherin localization**
Robin Lochbaum (Germany)

17:21 001237 **The invisible part of Hereditary Angioedema: don't forget the elderly. An analysis of patients from the ITACA Register**
Francesca Perego (Italy)

17:33 001607 **Real-world evidence study on the effectiveness and safety of lanadelumab in France: the SERENITI study**
Laurence Bouillet (France)

17:45 001425 **Genetic variant spectrum of SERPING1 gene in 46 families residents of Southern Spain with hereditary angioedema with C1-INH deficiency (HAE-C1-INH). Identification of 11 novel variants**
Krasimira Baynova (Spain)

16:45 - 18:15 OAS06 - From Basic Immunology to translational applications
(Carron 2, Oral Abstract Sessions)

Chairs: ***Christoph Bergmann (Germany), Cristobalina Mayorga (Spain)***

16:45 000092 **T cell receptor signaling is required for maintenance of allergen-specific epidermal-resident memory CD8+ T cells**
Anders Funch (Denmark)

16:57 001184 **Dysregulations in L-phenylalanine metabolism facilitate pro-inflammatory Th2 phenotype in severe allergy**
Abhijeet Kulkarni (Switzerland)

17:09 000463 **The role of IgE in Crohn's disease by impairing the capacity of plasmacytoid dendritic cells to generate FOXP3+ Tregs**
Cristina Benito Villalvilla (Spain)

17:21 000716 **The role of IgD in the development of natural and induced tolerance to allergens**
Juan-Felipe Lopez (Switzerland)

17:33 001128 **Ovalbumin-loaded nanoparticles for allergen specific immunotherapy**
Ana M. Pérez-Moreno (Spain)

17:45 000630 **Successful translation of the ex vivo immunomodulatory pharmacodynamic profile of VLP Peanut to the clinic**
Mohamed Shamji (United Kingdom)

16:45 - 18:15 SY7 - Treating chronic inflammation in the upper airways
(Lomond Auditorium, Symposium)

Chairs: ***Philippe Gevaert (Belgium), Ludger Klimek (Germany)***

16:45 **Non-Allergic Rhinitis – surgical options or medical treatment?**
Laura Van Gerven (Belgium)

17:15 **Systemic steroids in chronic rhinosinusitis: no risk no fun?**
Valérie Hox (Belgium)

17:45 **NERD treatment options: from past to future**
Sanna Toppila-Salmi (Finland)

16:45 - 18:15 SY8 - Diet and Allergy
(Hall 1, Symposium)

Chairs: ***Cevdet Ozdemir (Türkiye), Carina Venter (United States of America)***

16:45 **Overview of dietary management and advice to adults with food allergy**
Isabel Skypala (United Kingdom)

17:15 **Meeting requirements and providing elimination advice in children with food allergy**
Rosan Meyer (France)

17:45 **Beyond elimination: Total diet approach for prevention and treatment of allergic disease**
Berber Vlieg-Boerstra (Netherlands)

16:45 - 18:15 TSY2 - Aril-hydrocarbon receptor (AhR): regulation and impact on human health
(Meeting Academy M1, Thematic Symposium)

Chairs: ***Claudia Mauri (United Kingdom), Inge Kortekaas Krohn (Belgium)***

16:45 **AhR signalling & environmentally-induced skin damage**
Thomas Haarmann-Stemmann (Germany)

17:15 **AhR activation via Immunonutrition to improve health**
Franziska Roth-Walter (Austria)

17:45 **AhR ligands in the treatment of atopic dermatitis**
Jos Smits (Netherlands)

18:30 - 19:45 Opening Ceremony
(Clyde Auditorium, Ceremony)

07:45 - 08:30 MTE5 - Allergen immunotherapy for allergic disease: Indications and contraindications
(Carron 1, Meet the Expert)

*Chair: **Montserrat Alvaro Lozano (Spain)***

07:45 **Allergen immunotherapy for allergic disease: Indications and contraindications**

07:45 - 08:30 MTE6 - Pathogenic mechanisms in the evolution of food allergy
(Carron 2, Meet the Expert)

*Chair: **Talal Chatila (United States of America)***

07:45 **Pathogenic mechanisms in the evolution of food allergy**

07:45 - 08:30 MTE7 - Diversity of regulatory B cells: Markers and functions
(Dochart 1, Meet the Expert)

*Chair: **Claudia Mauri (United Kingdom)***

07:45 **Diversity of regulatory B cells: Markers and functions**

07:45 - 08:30 MTE8 - Clinical Pathway on direct drug provocation testing
(Dochart 2, Meet the Expert)

*Chair: **Philip Li (Hong Kong)***

07:45 **Pathogenic mechanisms in the evolution of food allergy**

08:30 - 10:00 EAACI Special Session 2 - Presidential Symposium : To combat antimicrobial resistance: EAACI perspective through the lens of planetary health
(Lomond Auditorium, Lomond Auditorium)

*Chair: **Lene Heise Garvey (Denmark)***

08:30 **President welcome address**
Maria Jose Torres (Spain)

08:35 **Antibiotic allergy as a variable for estimating antibiotic resistance**
Vito Sabato (Belgium)

08:55 **Panel Discussion**
Frank S Virant (United States of America), Mário Morais-Almeida (Portugal), Gailen Marshall (United States of America)

09:20 **EAACI approach to precise diagnosis of antibiotic allergy**
Maria Jose Torres (Spain)

09:40 **Panel Discussion**
Frank S Virant (United States of America), Mário Morais-Almeida (Portugal), Gailen Marshall (United States of America)

08:30 - 10:00 IH3 - Nanotechnology in allergy: From diagnostics to precision therapies
(Innovation Hub, Innovation Hub)

Chairs: ***María Isabel Montañez (Spain), Martin Bachmann (Switzerland)***

08:30 **Transepidermal water loss: a novel predictor for food challenge outcomes**
Charles Schuler (United States of America)

09:00 **Pharmacogenetics of drug allergy**
Jean-Lous Gueant (France)

09:30 **Engineering nanostructures for SLIT: a step towards food allergen precision therapy**
Juan L Paris (Spain)

08:30 - 10:00 IWS6 - Innovations in Betalactam allergy diagnosis
(Meeting Academy M1, Interactive Workshop)

Chairs: ***Jean-Christoph Caubet (Switzerland), Ricardo Madrigal-Burgaleta (United Kingdom)***

08:30 **Practical aspects of BAT and LTT**
Rubén Fernández-Santamaría (Spain)

09:00 **Harmonising betalactam cross reactivity and identifying**
Ingrid Terreehorst (Netherlands)

09:30 **Risk for resensitizations in allergy to beta-lactams**
Gulfem Celik (Türkiye)

08:30 - 10:00 JMA 4 - Year in review
(Alsh, JMA)

Chairs: ***Aspasia Karavelia (Greece), Martha Jimenez Freites (Spain)***

08:30 **Immunomodulation**
Jitesh Chauhan (United Kingdom)

09:00 **Food allergy**
Bianca Olivieri (Italy)

09:30 **Airway allergy**
Ozge Can Bostan (Türkiye)

08:30 - 10:00 SY10 - Chronic spontaneous urticaria: latest clinical developments
(Hall 1, Symposium)

Chairs: ***Charlotte Mortz (Denmark), Pavel Kolkhir (Germany)***

08:30 **Updates in urticaria guidelines**
Emek Kocaturk Goncu (Türkiye)

09:00 **Management chronic urticaria in children**
Sophia Tsabouri (Greece)

09:30 **Urticaria therapy: the past and the future**
Allen Kaplan (United States of America)

08:30 - 10:00 SY9 - Impact of natural disasters on respiratory and immune health
(Clyde Auditorium, Symposium)

Chairs: ***Nikos Papadopoulos (Greece), Jouni Jaakkola (Finland)***

08:30 **Impact of earthquakes on respiratory health and immune function**
Hasan Bayram (Türkiye)

09:00 **Impact of flooding on respiratory health?**
Gennaro D'Amato (Italy)

09:30 **Wildfires and allergic airway diseases**
Sayantani Sindher (United States of America)

09:00 - 09:15 France - NAIS: French Society of Allergology
(EAACI Global Stage, NAIS Session)

09:00 **Shared medical decision-making in the scope of oral immunotherapy**
Amandine Divaret-Chauveau (France)

09:00 - 10:00 L-FT04 - Food Allergy from Diagnosis to Management
(Dochart 1, Flash Talks)

Chairs: ***Pablo Rodríguez del Río (Spain), Heimo Breiteneder (Austria)***

09:00 100059 **Identification of a dominant IgE epitope on Mal d 1 relevant for apple allergy**
Hilal Demir (Austria)

09:07 100190 **A double-blind randomized controlled trial of Abatacept vs placebo as adjuvant to peanut oral immunotherapy to induce immunologic changes in severe persistent peanut allergy (ATARI)**
Philippe Bégin (Canada)

09:14 100198 **The Natural History of Tree Nut (TN) Allergy in Children and Adolescents in Greece**
Sofia Lydia Papathanasiou (Greece)

09:21 100243 **Optimization of the administration of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: The SPEED study, a "Real Life" study**
Julien Cottet (France)

09:28 100324 **TARC levels in patients with atopic dermatitis: a marker for clinical improvement following sublingual immunotherapy?**
Maria Eduarda Trocoli Zanetti (Brazil)

09:35 100471 **Burden of Treatment of Home Introduction of Peanuts in Children with Peanut Allergies**
Molly Cremin (Ireland)

09:42 100500 **Food Oral Immunotherapy for Egg Allergy: Experience from the Croatian Referral Centre for Paediatric Allergy**
Milan Juric (Croatia)

09:49 100503 **A Comparative Analysis of Egg Allergy Management and Diagnostic Practices in Canada and Ireland: A Survey Study**
Aoife Gallagher (Ireland)

09:56 100654 **Late reactions to wheat, butter, and vegetable margarins favour asthma, non-allergic rhinitis and Obstructive Sleep Apnea (OSA) underpinning difficulties to increase the dose of SLIT. Eviction diet ameliorates OSA and helps increasing the SLIT dose**
Kalomoira Kefala (France)

09:00 - 10:00 L-FT05 - Allergy Diagnosis
(Dochart 2, Flash Talks)

*Chairs: **Thulja Trikamjee (South Africa), Diana Silva (Portugal)***

09:00 100008
Date Fruit Allergy in the Context of Emerging Diets
Sarai Colmenares (Spain)

09:07 100024
Cold Urticaria in Adult patients: A single centre Turkey Case Series
ÖZGE ATİK (Türkiye)

09:14 100096
Comparison of Transepidermal Water Loss and Electrical Impedance Spectroscopy for Assessing Skin Barrier Function Modeled by Stripping with Different Tapes
Charlotte Kiani (Germany)

09:21 100151
Anaphylaxis to Amoxicillin After a Well-Tolerated Provocation Test
Benoit STERLING (France)

09:28 100201
A validated algorithm for classifying infant food allergy
Alexsandria Odoi (Australia)

09:35 100237
Multiple detection of IgE-mediated allergic reactions using Microarray technology
Nadine Offermann (Germany)

09:42 100274
Feasibility of using a streamlined, miniaturized and multi-allergen basophil activation test (SMMABAT) for population-based studies
Jean Marc Busnel (France)

09:49 100301
In-Vivo Diagnosis of Acute Generalized Exanthematous Pustulosis: Insights from a Single- Center Experience
Ana Luísa Pinhal (Portugal)

09:00 - 10:00 L-OAS05 - Asthma: from bench to bedside
(Carron 1, Oral Abstract Sessions)

*Chairs: **Dilşad Mungan (Türkiye), Christer Janson (Sweden)***

09:00 100056
Pollution particles and their role on asthma exacerbations of adult patients who visited emergency departments in 2 university hospitals of Madrid city: A 2 year comparison using Big-Data Analysis
María Daniela Escalante-Carrero (Spain)

09:12 100061
Differential regulation of collagen deposition, proteinases, and their tissue inhibitors in low-T2 and non-T2 inflammatory phenotypes in experimental asthma models
Marlena Tynecka (Poland)

09:24 100272
Comparison of three treatment strategies in mild asthma: A carbon-utility analysis
Rafael José Vieira (Portugal)

09:36 100348
AI-Guided Design and Development of HXN-1011: A Potent Anti-TSLP Biparatopic Antibody
Zhenping Zhu (United States of America)

09:48 100570
Consumption of ultra-processsed foods at 4.5 years and physician-diagnosed asthma at 12 years in a population-based birth cohort
Daniil Lisik (Sweden)

09:00 - 10:00 L-OAS06 - Basic Immunology
(Carron 2, Oral Abstract Sessions)

Chairs: ***Inge Kortekaas Krohn (Belgium), Duygu Yazici (Switzerland)***

09:00 100397 **Bruton's Tyrosine Kinase Inhibitor Attenuates Skin Lesions in an Atopic Dermatitis Mouse Model by Suppressing Th2 Inflammation and Mast Cell Activation**
Zhao Wang (China)

09:12 100111 **Hereditary Angioedema disease-specific iPSC model from two HAE patients**
Luong Long (Japan)

09:24 100256 **Ascaris lumbricoides-derived cystatin modulating human monocytes: RNA sequencing reveals suppression of CD14 and inflammatory pathways**
Josefina Zakzuk (Colombia)

09:36 100394 **Exploring platelet content and their oxylipin pathway involvement in physiological conditions via multi-omics analysis**
Elena Izquierdo (Spain)

09:48 100420 **IgE plasmablasts and immature plasma cells orchestrate the secondary allergic response**
Mohammed Zghaebi (Austria)

09:15 - 09:30 UK - NAIS: British Society for Allergy & Clinical Immunology (BSACI)
(EAACI Global Stage, NAIS Session)

09:15 **UK National Allergy Strategy**
Adam Fox (United Kingdom)

09:30 - 09:45 Spain - NAIS: Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
(EAACI Global Stage, NAIS Session)

09:30 **SEAIC: Anaphylaxis committee initiatives**
Victoria Cardona (Spain)

09:45 - 10:00 Spain - Spanish Pediatric Society of Clinical Immunology, Allergy and Asthma (SEICAP)
(EAACI Global Stage, NAIS Session)

09:45 **SEICAP, and an overview of its scientific activity**

10:15 - 11:45 PL4 - Drug Allergy: Advances in Diagnosis, Management, and Prevention
(Clyde Auditorium, Plenary Lectures)

Chairs: ***Ingrid Terreehorst (Netherlands), Lene Heise Garvey (Denmark)***

10:15 **In Vivo Tests for Diagnosis: Challenges and Advances**
Annick Barbaud (France)

10:45 **Advancing Drug Allergy Diagnosis: The Role of In Vitro Tests and Biomarkers in Clinical Practice**
Cristobalina Mayorga (Spain)

11:15 **Pharmacogenomics and Precision Medicine in Drug Allergy: From Research to Clinical Application**
Elizabeth Phillips (United States of America)

10:15 - 11:45 PL5 - Microbiota and Immune Regulation: Insights from Gut to Lungs Across the Lifespan
(Lomond Auditorium, Plenary Lectures)

Chairs: ***Mubeccel Akdis (Switzerland), Oscar Palomares (Spain)***

10:15 **Airway microbiota and respiratory health across human life span**
Debby Bogaert (United Kingdom)

10:45 **A high-resolution view of immune modulation by the gut microbiome**
Kazuki Nagashima (United States of America)

11:15 **Type 2 responses in the lungs: mechanisms and implications**
Padraic Fallon (Ireland)

10:15 - 11:45 PL6 - Highlights of EAACI Guidelines: Latest Developments and Clinical Applications
(Hall 1, Plenary Lectures)

Chairs: ***Ibon Eguiluz (Spain), Carmen Panaitescu (Romania)***

10:15 **Drug Allergy: Implementing the Latest EAACI Guidelines in Clinical Practice**
Maria Jose Torres (Spain)

10:45 **Immunonutrition: Bridging Nutrition and Immune Health in Allergy Management**
Liam O'Mahony (Ireland)

11:15 **Food Allergy: New Guidelines for Diagnosis and Management**
Carmen Riggioni-Viquez (Canada)

12:00 - 13:00 L-FT06 - Clinical Immunology
(Dochart 1, Flash Talks)

Chairs: ***Elif Karakoç Aydiner (Türkiye), Federica Pulvirenti (Italy)***

12:00 100023 **Evaluation of Genetic Results of Patients with Ataxia-Telangiectasia: a single center experience**
Deniz Cagdas (Türkiye)

12:07 100113 **Monogenic atopic disorders as a novel category of innate errors of immunity: mutation affecting immune check-point molecule B7-H3/CD276 as a potential cause of severe atopic dermatitis**
Anna Sediva (Czech Republic)

12:14 100128 **Investigating the Role of Serum-and-Glucocorticoid-Inducible-Kinase-1 (SGK1) in the Pathogenesis of Behcet's Disease**
Seda Altiner (Türkiye)

12:21 100129 **The Impact of Anti-Ro52 Antibodies on Lung Function and Progressive Pulmonary Fibrosis in Antisynthetase Syndrome**
Marco Del Carria (Italy)

12:28 100228 **Pulmonary Involvement in Patients with Primary Antibody Deficiency – the results from multicentric cross-sectional study**
Tomas Milota (Czech Republic)

12:35 100595 **A one year, single centre, prospective study on EGPA patients treated with Mepolizumab**
Luisa Ricciardi (Italy)

12:42 100600 **From Stem Cells to Synergy: A High-Throughput Platform for Inborn Errors of Immunity – STAT1-GoF as Proof-of-Concept"**
Philip Li (Hong Kong)

12:49 100616 **Inborn Errors of Immunity in Children Diagnosed with Tuberculosis: A Single-Centre Experience in Southern Turkey**
Mahir Serbes (Türkiye)

12:00 - 13:00 L-FT07 - ENT
(Dochart 2, Flash Talks)

*Chairs: **Valérie Hox (Belgium), Michele Schiappoli (Italy)***

12:00 100013 **An overview of allergic rhinitis medications in the last ten years in Türkiye**
Fatma Esra Gunaydin (United Kingdom)

12:07 100026 **Amphiregulin mediates epithelial cell-eosinophil interactions and amplifies inflammation in CRSwNP**
Feng Lan (China)

12:14 100097 **Vocal Cord Dysfunction / Inducible Laryngeal Obstruction as a mimic for Anaphylaxis: A Retrospective Cross-Sectional Study**
Paul Satouris (Australia)

12:21 100179 **Role of PAF/PAFr system and PAF antagonists on proinflammatory mediator secretion in cultured human Upper Airway epithelial cells**
Joaquim Mullol (Spain)

12:28 100254 **Postoperative Recurrence in Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Expert Consensus**
Ruperto González Pérez (Spain)

12:35 100567 **Early detection of lower adherence to long-term e-Diary recording: a checkpoint to target early educational intervention in chronic diseases?**
Camilo Jose Hernandez Toro (Germany)

12:00 - 13:00 L-OAS07 - Oral immunotherapy for Food Allergy
(Carron 1, Oral Abstract Sessions)

*Chairs: **Sayantani Sindher (United States of America), Montserrat Alvaro Lozano (Spain)***

12:00 100291 **Retrospective cohort study to assess sustained unresponsiveness in children undergoing nut oral immunotherapy**
Simona Barni (Italy)

12:12 100355 **Investigation of allergen specific B cells**
Stephan Schneider (Switzerland)

12:24 100440 **Peanut SLIT-tablet is well-tolerated and safe: early results from ALLIANCE, a phase I/II trial**
Thomas Eiwegger (Austria)

12:36 100080 **Preliminary clinical proof of concept of VLP Peanut in peanut allergic patients**
Wayne G. Shreffler (United States of America)

12:48 100461 **B Cell Mechanisms in Peanut Oral Immunotherapy**
Ramona Hoh (United States of America)

12:00 - 13:00 L-OAS08 - Pediatrics
(Carron 2, Oral Abstract Sessions)

Chairs: ***Camelia Berghea (Romania), Gavriela Feketea (Greece)***

12:00 100009 **Role of infant formula manufactured from extensively hydrolysed protein in the development of allergic manifestations and sensitisation against cow´s milk protein. The Prevention of Allergic Diseases in Infants (PADI) study, a randomised, controlled trial**
Alessandro Fiocchi (Italy)

12:12 100204 **Allergy in children to illicit drugs, tobacco and alcohol**
Ignacio Gonzalez-Rodriguez (Spain)

12:24 100463 **Identification of predictive biomarkers associated to allergic diseases in newborns (BIOPAL)**
Marina Pérez-Gordo (Spain)

12:36 100609 **Developmental profiles of eczema, wheeze, and rhinitis from infancy to early adulthood**
Anhar Ullah (United Kingdom)

12:48 100612 **Cytokine responses to Haemophilus influenzae and development of asthma during childhood**
Eteri Regis (United Kingdom)

12:00 - 13:00 TPS - Poster Session
(Poster Area, Poster Walk)

12:00 - 13:00 SSS 3 - EAACI & SLAAI Joint Symposium : Air pollution In Latin America
(Hall 1, Sister Society Symposium)

Chair: ***Marilyn Urrutia Pereira (Brazil)***

12:00 **Effect of air pollution on respiratory allergic diseases**
Ignacio J Ansotegui (Spain)

12:20 **Pesticides and other pollutants in LATAM**
Herberto José Chong-Neto (Brazil)

12:40 **Pollution on Allergic Skin Diseases**
Isabel Rojo (Mexico)

12:00 - 13:00 TPS43 - ENT
(Poster Zone, Thematic Poster Session)

Chairs: ***Aspasia Karavelia (Greece), Allison J. Burbank (United States of America)***

D2.366 **The establishment of a Japanese cypress pollen environmental exposure chamber protocol**
Syuji Yonekura (Japan)

D2.367 **Omalizumab Efficacy in Relapse of Nasal Polyposis**
Hossein Esmaeilzadeh (Iran, Islamic Republic of)

D2.368 **Lack of anaerobic gut bacteria in patients with aspirin intolerance and allergy**
Guido Muehlmeier (Germany)

D2.369 **Impaired Retinoic Acid Metabolism and Eotaxin Overexpression in Eosinophilic Chronic Rhinosinusitis: Insights into Pathophysiology and Therapeutic Potential of CRABP1 Targeting**
IL-HO PARK (Korea, Republic of)

D2.370 **Trends in Sensitization to Pet Allergens and Correlation between Symptoms and Asthma in Allergic Rhinitis from 2017 to 2023 in China**
Menglin Wang (China)

D2.371 **Clinical Implication of Neutrophil Phenotypes in Chronic Rhinosinusitis With Nasal Polyps**
Dae Woo Kim (Korea, Republic of)

D2.372 **Evaluating ChatGPT's Performance in Answering Questions About Allergic Rhinitis and Chronic Rhinosinusitis**
He Zhang (China)

D2.373 **Diurnal variation in Japanese cedar pollinosis symptoms**
Tomokazu Matsuoka (Japan)

D2.374 **Smoking increases mortality risk of chronic inflammatory airway diseases: a real-world hospital cohort study**
Sanna Toppila-Salmi (Finland)

D2.375 **Concomitant allergic and ENT pathology in children with chronic inflammatory diseases**
Anastasia Lamasova (Moscow)

D2.376 **The role of endoscopic sinus surgery in chronic rhinosinusitis with minimally affected computed tomography**
HYEKYU MIN (Korea, Republic of)

D2.378 **Exploring the Connection Between Allergic Rhinitis and Sinusitis in Children**
Felicia Manole (Romania)

12:00 - 13:00 TPS45 - Aerobiology and pollution

(Poster Zone, Thematic Poster Session)

Chairs: ***Célia Antunes (Portugal), Hille Suojalehto (Finland)***

D2.398 **Is Cynodon dactylon an important cause of pollinosis in Madrid?**
Javier Subiza (Spain)

D2.399 **Antihistamine Residues in Wastewater may allow to estimate the burden by Airborne Pollen Concentrations**
Peter Schmid-Grendelmeier (Switzerland)

D2.402 **Main Pollen Types Identified in Aerobiological Stations of the Latin American Aerobiology Network (Red Latinoamericana de Aerobiología, RLA)**
Oscar Calderón (Peru)

D2.403 **Controlled exposure to grass and ragweed pollen in an Allergen Exposure Chamber**
Laura Haya (Canada)

D2.404 **Asthma, pollen and air pollution : using big data of south Korean health-care records**
GWANG CHEON JANG (Korea, Republic of)

D2.405 **Correlation between Emergency visits and Olea pollen levels**
Ignacio Garcia-Nunez (Spain)

D2.406 **Correlation between Emergency visits and Olea pollen levels in a child population**
Ignacio Garcia-Nunez (Spain)

D2.407 **A novel ambient air sampling device for detection of airborne microbes**
Emily Heath (United Kingdom)

D2.408 **Comparison of machine learning methods in characterizing and forecasting of the birch and grasses pollen seasons**
Małgorzata Bulanda (Poland)

D2.409 **Identification of novel immunological markers for assessing inflammatory-allergic processes in the lung exposed to HOCl acid mist in an animal model**
Anna Gil (Poland)

D2.410 **Evaluating the Impact of Air Cleaning Devices on Novel Allergens: Silkworm Allergen - Bombyx Mori (Bom m 1)**
Oliver Dsa (Ireland)

D2.411 **Identifying bioaerosol diversity in the atmosphere of Vilnius, Lithuania, by molecular methods: hints to clarify human bio-exposome**
Célia Antunes (Portugal)

12:00 - 13:00 TPS32 - Allergen immunotherapy 03

(Poster Zone, Thematic Poster Session)

Chairs: ***Usmaan Ahmed (United Kingdom), Susanne Vijverberg (Netherlands)***

D2.149 **Effectiveness and safety of specific sublingual immunotherapy with Pru p3 extract in patients with LTP allergy**
Francisco de Asís Palazón Rico (Spain)

D2.150 **Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom**
Lisa Arzt-Gradwohl (Austria)

D2.151 **Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)**
Pingping Zhang (China)

D2.152 **Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)**
Lishen Shan (China)

D2.153 **Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus- Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy**
Christine Yee Yan Wai (Hong Kong)

D2.154 **Real-life observational study on the effectiveness of a broad-spectrum allergen product in unresponsive pediatric patients**
Cristina Rivas Juesas (Spain)

D2.155 **Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy**
Jung Yeon Shim (Korea, Republic of)

D2.156 **Study on the Effect of the Mucosal Vaccine MV130 on Innate Immunity Factors in School-Age Children**
Mariia Shevchenko (Ukraine)

D2.157 **Peanut allergen-loaded microneedle array patch modulates the immune response to peanut allergy in Balb/c and C3H/HeJ mouse model**
Hyeon Ho Kim (Korea, Republic of)

D2.158 **Epitope Analysis and Mutation Design in Jug r 1 for Hypoallergenic Walnut Immunotherapy**
Jeongmin Lee (Korea, Republic of)

D2.159 **Real-World Protective Effects of Epicutaneous Immunotherapy in Peanut-allergic Toddlers**
Jay A. Lieberman (United States of America)

D2.162 **Low dose oral immunotherapy for children with severe cow's milk allergy**
Ryohei Suzuki (Japan)

D2.163 **Effectiveness and safety of Venom ImmunoTherapy (VIT) with "Rapid Cluster" induction protocol**
Emanuele Acampora (Italy)

D2.164 **Pediatric bee venom allergy: family background matters**
Ana Luísa Pinhal (Portugal)

D2.165 **Safety Profile and Clinical Outcome of Sublingual Immunotherapy (SLIT) with Pru p 3 in Patients with LTP Allergy Undergoing Food Reintroduction**
Patricia Letón-Cabanillas (Spain)

D2.166 **Randomized Controlled Trial of Sublingual Immunotherapy for Egg Allergy**
Nagatoshi Sagara (Japan)

12:00 - 13:00 TPS33 - Allergen immunotherapy 04

(Poster Zone, Thematic Poster Session)

Chairs: ***Mattia Giovannini (Italy), Willem Van De Veen (Switzerland)***

D2.167 **Effect of Metformin on allergen specific immunotherapy**
Yu-mi Park (Korea, Republic of)

D2.168 **Systemic reactions to subcutaneous immunotherapy in children**
Yoram Faitelson (Israel)

D2.169 **Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children**
Hui-Fang Kao (Taiwan)

D2.170 **The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season**
Esther Raskopf (Germany)

D2.171 **The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment**
Esther Raskopf (Germany)

D2.172 **Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions**
Ralph Mösges (Germany)

D2.173 **Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis**
Nathalie Khünl-Brady (Austria)

D2.174 **Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT**
Oliver Pfaar (Germany)

D2.175 **TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS**
Ralph Mösges (Germany)

D2.176 **Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients**
Lawrence DuBuske (United States of America)

D2.177 **The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis**
Yang Park (Korea, Republic of)

D2.178 **Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis**
Jeong-Hee Choi (Korea, Republic of)

D2.179 **Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study**
Cornelia Barnowski (Germany)

D2.180 **Immunological evaluation of cat allergic individuals living with or without a cat**
Amanda Atanasio (United States of America)

12:00 - 13:00 TPS48 - AllergoOncology
(Poster Zone, Thematic Poster Session)

D2.430 **Two cases of acquired angioedema: one with splenic lymphoma and the other with Waldenström's macroglobulinemia**
William H. Yang (Canada)

D2.431 **Association of serum IgE levels and atopic status with cancer in the general population**
Yoon Ho Joo (Korea, Republic of)

D2.432 **Blood morphology in health & cancer: comparative, preliminary study on 783 patients**
Alicja Majos (Poland)

D2.433 **AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies**
Xinyi Chen (United Kingdom)

D2.434 **AllergoOncology: Novel crusade for Basophil Activation Test**
Mariona Pascal-Capdevila (Spain)

12:00 - 13:00 TPS25 - Allergy diagnosis 06
(Poster Zone, Thematic Poster Session)

*Chair: **Thulja Trikamjee (South Africa)***

D2.03 **A Rare Case of Thyme Allergy in a Pediatric Patient: First Report and Clinical Insights**
Areej Alkahtani (Saudi Arabia)

D2.04 **Sensitization to common food allergens in a population of portuguese children**
Fernando Carvalho (Portugal)

D2.05 **A Retrospective Study Characterising the Types of Presentation of Soy Allergy in Adults**
Ky Lyn Tan (United Kingdom)

D2.06 **Peanut allergy diagnosis. Our experience**
Marta Isabel Rodriguez Cabreros (Spain)

D2.08 **Post-Traumatic Stress Disorder Associated with Anaphylaxis**
Raquel Baptista Pestana (Portugal)

D2.09 **Correlation Patterns Among House Dust Mite Allergens in Allergic Rhinitis: A Molecular Sensitization Study in Mallorca**
Daniel Hervas (Spain)

D2.10 **Can specific IgE components for egg allergy - predict egg ladder success?**
Juan Enrique Trujillo Wurttele (Ireland)

D2.11 **A confidence score for basophil activation test: improving interpretation around diagnostic cutoffs**
Leonard Bezinge (Switzerland)

D2.12 **Indirect Basophil Activation Test: development of a user-friendly protocol for plasma and allergen testing**
Federica Richina (Switzerland)

D2.13 **Structural Homology of Alt a 1 and Phl p 2 Suggests an explanation for coincidence of Grass and Alternaria Allergies**
Victoria Rodinkova (Ukraine)

D2.15 **The etiology and risk factors of food allergies in children in Albania**
Ergena Neziri (Albania)

D2.16 **Clinical evaluation of the efficacy of profilin isolated from Acanthamoeba as an allergen**
Hye-Kyung Park (Korea, Republic of)

12:00 - 13:00 TPS26 - Allergy diagnosis 07

(Poster Zone, Thematic Poster Session)

Chairs: ***Christiane Hilger (Luxembourg), Paola Mason (Italy)***

D2.17 **Prostate-Specific Protein Can f 5 as an Allergen in Seminal Fluid Hypersensitivity: A Case Study**
María José Martínez (Spain)

D2.18 **Identification of Potential Allergens in Lobularia maritima: A Case Study**
Gustavo Perdomo Gutierrez (Spain)

D2.19 **Atopic Dermatitis and Allergic Contact Dermatitis: Investigating the Role of Patch Testing**
Mona Sharma (India)

D2.20 **Chronic Idiopathic Urticaria with the presence of Helicobacter pylori infection-clinical and laboratory data correlation**
Lali Bugadze (Georgia)

D2.22 **Evaluating the Role of Telemedicine in Allergy Care: Patient Preferences and Experiences**
Hanna Lindemann (Switzerland)

D2.23 **The Natural Course Of Allergic Rhinitis In Cat Owners With Cat Allergy**
Çise Tüccar (Türkiye)

D2.24 **Vicilins – an overlooked group of storage protein allergens in walnut and hazelnut**
Jonas Lidholm (Sweden)

D2.25 **The spectrum of sensitization in atopic dermatitis in patients living in the Far East of Russia**
Aliya Barmenova (Kazakhstan)

D2.26 **Analysis of Sensitization Profiles and Cross-Reactivity of Lipocalin Allergens in Czech Allergy Patients**
Jana Bojcukova (Czech Republic)

D2.27 **Interregional differences in molecular profiles of sensitization to respiratory allergens in the Russian population**
Oxana Ussenova (Kazakhstan)

D2.28 **Interregional differences in the prevalence of sensitization to food allergens in different regions of Russia**
Oxana Ussenova (Kazakhstan)

D2.29 **Assessing Individual Pollen Allergies Using Self-reported Real-World Allergy Burden Data**
Jens Emil Vang Petersen (Denmark)

D2.30 **Combined sensitization among patients with allergic rhinitis and bronchial asthma: changes during the war in Ukraine**
Yevgeniya Dytyatkovska (Ukraine)

D2.31 **An Unexpected Easter Surprise: Anaphylaxis Triggered by Colored Candy Eggs**
Hanna Wassmer (Switzerland)

D2.32 **Assessment of local nasal IgE in patients with suspected dual allergic rhinitis before and after nasal allergen provocation – presentation of 6 cases**
Marcin Kurowski (Poland)

12:00 - 13:00 TPS27 - Allergy diagnosis 08
(Poster Zone, Thematic Poster Session)

Chairs: ***Carmen Riggioni-Viquez (Canada), Carlos Aranda Clemente (Spain)***

D2.33 **Correlation of chronic rhinosinusitis and lung function in allergy patients with chronic cough**
Lali Bugadze (Georgia)

D2.34 **Generalized allergic contact dermatitis: a case report**
Mane Manukyan (Armenia)

D2.35 **Prevalence of the sensitivity to aeroallergens among patients with asthma and allergic rhinitis (AR), based on skin prick test (SPT) and its seasonal variation**
Arti Shah (India)

D2.36 **Clinical Outcomes Of Dental Procedures In Patients With Hereditary Angioedema**
Çise Tüccar (Türkiye)

D2.37 **Prevalence of food cross-sensitization due to PR-10 proteins among patients of different age groups**
Mariana Lykova (Ukraine)

D2.38 **Clinical Evaluation of Alternaria alternata Extract Used for Skin Prick Test in Diagnosis of Alternaria alternata Allergy**
Xin Li (China)

D2.39 **Diagnostic performance of IgE sensitization with Blomia tropicalis for prediction of positive nasal challenge test**
Laura Osorio (Colombia)

D2.43 **Implementation of the New Italian Health Care Price List: Impact on Allergy Diagnostics**
Amelia Licari (Italy)

D2.44 **Kiwi Allergy in Singaporean Children**
Sansy Mathews (France)

D2.45 **Specific IgE for inhalant allergens: A cutoff of 0.35 kUA/L is too low**
Anette Flugt (Denmark)

D2.46 **Prevalence and prognosis of food allergies after liver transplantation in children**
Yoon Hee Kim (Korea, Republic of)

12:00 - 13:00 TPS28 - Allergy diagnosis 09
(Poster Zone, Thematic Poster Session)

Chairs: ***Vanesa Esteban (Spain), Aray Batyrbaeva (Kazakhstan)***

D2.47 **Application of magnetic particle chemiluminescence technology to detect sensitization in patients in Guangzhou, China: a study base on real-world medical data**
Baoqing Sun (China)

D2.48 **Evolving Trends in Pediatric Allergy Referrals Over the Past Decade**
Ana Raquel Pinto (Portugal)

D2.49 **Impact of Age and Allergen Type on Sensitization Changes in Chronic Rhinitis Children**
Wiparat Manuyakorn (Thailand)

D2.50 **Hereditary angioedema; single center experience**
Öner Özdemir (Türkiye)

D2.51 **'Allergy Testing'- but why do we need it? A conceptual misunderstanding leading to diagnostic delay and wastage of health care resources in children referred for 'allergy testing' with poorly controlled eczema**
Tushar Kanti Banerjee (United Kingdom)

D2.52 **Prevalence of sensitization to aeroallergens among atopic children in Ukraine**
Mariia Kryvopustova (Ukraine)

D2.53 **Prevalence of angioedema in the emergency department at Sant Joan De Déu (Manresa)**
Laura De los ríos ospina (Spain)

D2.54 **Basophil Activation Test for Chronic Spontaneous Urticaria: the experience of a paediatric allergy centre**
Chiara Ferrecchi (Italy)

D2.55 **Food-Dependent Exercise-Induced Anaphylaxis: Prevalence of Wheat as an Allergen Compared to Other Foods**
Ludger Albert Moser (Denmark)

D2.56 **Diagnostic value of the lymphocyte transformation test for the investigation of drug-induced enterocolitis syndrome (DIES)**
Ava de Brugerolle (France)

D2.57 **Recurrent pleural effusion in patient with hereditary angioedema: a case report**
Anna Valerieva (Bulgaria)

D2.58 **Relationship between the severity of atopic dermatitis and quality of life in children and adults attending an allergy clinic in Colombia between 2018-2020: A marginal mean weighting through stratification analysis (MMWS)**
Freddy Rivera (Colombia)

D2.59 **Assessment of quality of life in a population of children with allergic rhinitis**
Lasha Tchelidze (Georgia)

D2.60 **Stevens-Johnsons syndrome: the contemporary immunopathology and case study**
Lasha Tchelidze (Georgia)

D2.62 **Peak Flow Monitoring in Asthma Control**
I-Jen Wang (Taiwan)

D2.63 **Immediate Hypersensitivity to Chlorhexidine: A Case Series**
Francisco de Asís Palazón Rico (Spain)

D2.64 **Incidence and trends of Carboplatin Allergy in Gynecological Malignancy Patients at a single tertiary hospital in Hong Kong**
James Hooi (Hong Kong)

12:00 - 13:00 TPS37 - Anaphylaxis 03

(Poster Zone, Thematic Poster Session)

Chairs: ***Sergio Fernandez-Bravo (Spain), Nihat Sapan (Türkiye)***

D2.262 **Measurement of tryptasemia in a university hospital: prescribing reality versus recommendations**
Alexis Bocquet (France)

D2.263 **Anaphylaxis induced by goat's and sheep's milk: an allergen that we should keep under surveillance**
Guillaume Pouessel (France)

D2.264 **Food-induced Anaphylaxis: Characterization and Trends of a Four-year Single-center Survey**
Cláudia M. Marques (Portugal)

D2.265 **Allergy to peas and lentils: data from the Allergy-Vigilance Network**
Amandine Divaret-Chauveau (France)

D2.266 **Four-Year Analysis of the Incidence and Clinical Features of Perioperative Hypersensitivity Reactions in the Allergy-Anaesthesia Unit, Universitary Hospital Cruz Roja**
Jose Julio Laguna Martinez (Spain)

D2.267 **MiRNA-29a is downregulated in food anaphylaxis and involved in the endothelial glycocalyx stability**
Antonio Muñoz-Callejas (Spain)

D2.269 **Diagnostic challenges in evaluating diagnosis of mast cell disorder in a patient with severe allergy to hymenoptera venom**
Polliana Leru (Romania)

D2.270 **Roadmap of anaphylaxis registries across the world**
Guillaume Pouessel (France)

D2.271 **The non-mandatory food allergens that we should not sweep under the rug: data from the Allergy-Vigilance Network**
Amandine Divaret-Chauveau (France)

D2.272 **Anaphylaxis caused by Psyllium**
Begoña Astrain (Spain)

D2.273 **Kratom-induced anaphylaxis revealed Monoclonal Mast Cells of Clinical Significance**
Roberta Massaro (Italy)

D2.274 **Incidence of Perioperative Hypersensitivity Reactions in Spanish hospitals group. Three years of study 2022 to 2024**
Jose Julio Laguna Martinez (Spain)

D2.275 **Pine nuts, an emerging food allergen: data from the Allergy-Vigilance Network**
Amandine Divaret-Chauveau (France)

D2.276 **Buckwheat, an emerging allergen: data from the French Allergy-Vigilance Network**
Anays Piotin (France)

D2.277 **First described case of bean-dependent exercise-induced anaphylaxis (AIEDA) associated with eosinophilic esophagitis (EE): presentation of investigation protocol**
Albertina Capelo (Brazil)

12:00 - 13:00 TPS29 - Asthma 03

(Poster Zone, Thematic Poster Session)

Chairs: ***Ian Adcock (United Kingdom), I-Jen Wang (Taiwan)***

D2.82 **Association between additional corticosteroid usage and Uncontrolled Severe Asthma: A Retrospective Study Using the China Regional Database**
Kewu Huang (China)

D2.83 **Correct Inhaler Technique as a Key Element of Asthma Management: Post-Education Evaluation of Patients' Knowledge**
Maja Zrnić (Slovenia)

D2.84 **Heterogeneity of Elderly Asthma: a nationwide health and nutrition examination survey**
Jae-Woo Kwon (Korea, Republic of)

D2.85 **Living a Normal Life with Asthma: Development of a Conceptual Model**
Lucia De Prado Gomez (United Kingdom)

D2.86 **Characteristics of Severe type 2 Asthma Patients in China: A Retrospective Observational Study**
Kewu Huang (China)

D2.87 **Disease Burden of Severe Asthma Patients Treated with Medium and High Doses of ICS: A**
Regional Database Analysis from China

D2.88 **Regional Database Analysis from China**
Kewu Huang (China)

D2.89 **Investigation of Asthma Characteristics in Women with Generalized Periodontitis and Polycystic Ovary Syndrome**
Svitlana Zubchenko (Ukraine)

D2.90 **Decrease in New-Onset Asthma During the COVID-19 Pandemic**
Ji-Yong Moon (Korea, Republic of)

D2.91 **Distribution of Patients with Asthma According to the New Immune Response Classification**
Selma Yalçın (Türkiye)

D2.93 **Differential effects of dupilumab in women with severe uncontrolled asthma**
Krasimira Baynova (Spain)

D2.94 **Loss of lung function at 5 years in patients with asthma: DECLIVEMS study**
Krasimira Baynova (Spain)

D2.95 **Targeted CBT for persistent severe fatigue in a pulmonary rehabilitation setting: a case control study**
Karin Fieten (Switzerland)

D2.96 **Frequency of Herpes Zoster in Asthma and Associated Factors**
Selma Yalçın (Türkiye)

D2.92 **Comparison of responsiveness to bronchodilators using the 2021 or 2005 ATS/ERS guidelines: bicenter retrospective study**
Giovanni Costanzo (Italy)

D2.97 **"Can Do, Do Do" in patients with severe uncontrolled asthma referred for pulmonary rehabilitation in the alpine climate**
Karin Fieten (Switzerland)

D2.98 **Features of the course of the antenatal and neonatal period of children with bronchial asthma**
Tahira Panahova (Azerbaijan)

12:00 - 13:00 TPS30 - Asthma 04

(Poster Zone, Thematic Poster Session)

Chairs: ***Janice A Layhadi (United Kingdom), Nikos Papadopoulos (Greece)***

D2.99 **A mechanosensitive cytoskeleton protein talin2 involved in asthma pathogenesis**
An-Soo Jang (Korea, Republic of)

D2.100 **The usefulness of the forced oscillation technique in the diagnosis of bronchial asthma in seniors**
Martyna Miodonska (Poland)

D2.102 **Adult Gut Microbiota and Metabolomics in Different Phenotypes of Asthma**
Liu Yun (China)

D2.103 **Exploring association between lung function, asthma and epigenetic predisposition to obesity**
Tsen-Hsin Tai (Taiwan)

D2.104 **Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma**
Efthymia Theofani (Greece)

D2.105 **Clinical remission of severe asthma: 5-year follow-up**
Alexander Emelyanov (Saint-Petersburg)

D2.106 **Molecular Clustering Using microRNA Expression Profiles in Pediatric Asthma Reveals Differential Corticosteroid Responsiveness**
Min-Suk Yang (Korea, Republic of)

D2.107 **Effect of n-3 long-chain polyunsaturated fatty acid and vitamin D supplementation on human lung organoids**
Mina Ali (Denmark)

D2.108 **Real-life experience after 6 months with Tezepelumab in specialized asthma units across northern Spain**
Maria Victoria Garcia-Gallardo Sanz (Spain)

D2.109 **Interleukin-17A gene polymorphism contribute to the elderly asthma susceptibility: evidences from a case-control study**
Patcharaporn Punyashthira (Thailand)

D2.110 **MicroRNA Signatures of Pediatric Obesity-Associated Asthma: Identifying Molecular Links Between Obesity and Asthma in Children**
Harshita Shailesh (Qatar)

D2.111 **Wheeze phenotypes in infants whose mothers have asthma**
Bronwyn Brew (Australia)

D2.112 **The Impact of Obesity in Asthma and Small Airway Dysfunction: Prevalence, Clinical characteristics, and Predictors**
Nicolò Valli (Italy)

D2.114 **Insights from the BREATHE Study: Comorbidity Burden and Biomarker Trends in Severe Asthma Patients**
Ibon Eguiluz (Spain)

12:00 - 13:00 TPS31 - Asthma 05

(Poster Zone, Thematic Poster Session)

Chairs: ***Paul V. Williams (United States of America), Oliver Price (United Kingdom)***

D2.115 **Association of chemokine levels with types of reactions after alcohol consumption in patients with nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD)**
Karolina Frachowicz-Guerreiro (Poland)

D2.116 **Occupational asthma due to Chinese yeast, Yeast and Peptone**
María Luisa Quiñones (Spain)

D2.117 **The interaction of exposure to air pollutants and inflammatory markers on lung function and asthma symptoms in asthmatic patients**
Tsu-Nai Wang (Taiwan)

D2.118 **Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation**
Veronica Ravecca (Italy)

D2.119 **Real-life experience in eosinophilic granulomatosis with polyangiitis (EGPA) after 12 months with mepolizumab 300mg in specialized autoimmune and asthma units in an Universitary Hospital**
Maria Victoria Garcia-Gallardo Sanz (Spain)

D2.122 **Dupilumab-Induced Diffuse Eosinophilic Drug Rash with Hypereosinophilia in a Patient with Idiopathic Pulmonary Fibrosis and Severe Asthma Exacerbation: A First Case Report**
Ha-Kyeong Won (Korea, Republic of)

D2.123 **The impact of wartime environmental change on the frequency of asthma diagnoses**
Galyna Yeryomenko (Ukraine)

D2.124 **Clinical Characteristics and Predictors in Patients with Difficult-to-Treat Asthma**
Jou-Chun Chen (Taiwan)

D2.125 **Occupational asthma in hairdressers due to hair dyes containing para-amino compounds**
Robin Thirionet (Belgium)

D2.127 **The bacterial lysate OM-85 mitigates HDM-induced allergic inflammation through the airway epithelial cell-macrophage crosstalk**
Athanasios Kouklas (Switzerland)

D2.128 **Sarcoid-like reaction induced by aspirin therapy after aspirin desensitization in a patient with aspirin-exacerbated respiratory disease**
Gabriela Trąd (Poland)

D2.129 **Bacterial Species Cultured from Sputum of Asthmatic Patients with Bronchiectasis: Impact of Inhaled Corticosteroid Use**
Seung-Eun Lee (Korea, Republic of)

D2.130 **Genetic Associations of TSLP SNPs with Asthma Susceptibility and Severity**
Maral Ranjbar (Canada)

D2.131 **Classification, early determinants and long-term impact on asthma of the IgG responses to rhinovirus VP1 (RV-VP1): a longitudinal study in two birth cohorts**
Ekaterina Potapova (Germany)

D2.132 **Characteristics of Patients with Uncontrolled Severe Asthma Undergoing Biological Therapy Based on Spirometric Response: Our Experience**
Gabriela Aray Moran (Spain)

12:00 - 13:00 TPS41 - Basic immunology 02

(Poster Zone, Thematic Poster Session)

Chairs: ***Korneliusz Golebski (Netherlands), Duygu Yazici (Switzerland)***

D2.342 **Changes of MMP-9 and MMP-12 in response of acute viral infection in virtual model of macrophages**
Junehyuk Lee (Korea, Republic of)

D2.343 **Use of IDDA 2.1 score in Common Variable Immunodeficiency (CVID): a single center experience**
Bianca Sciacca (Italy)

D2.344 **Unraveling the Mysteries of Chronic Granulomatous Disease: A Case of detected Protein Deficiency Amidst Negative Genetic Screening**
Shajitha Melethil (United States of America)

D2.345 **Conformations of HVEM engaged in its Trans and Cis interactions are caused by two kinds of post-translational folding**
Lawrence DuBuske (United States of America)

D2.346 **Assessment of the safety of allogenic natural killer cells in the treatment of metastatic colon cancer**
Lawrence DuBuske (United States of America)

D2.247 **Allergen-Specific T Cells to House Dust Mite are absent on the circulation of local allergic rhinitis patients**
Carlos Aranda Clemente (Spain)

D2.348 **Clinical Course of Hereditary Angioedema Patients Transitioning off Androgens**
Ana Barbany Ventura (Spain)

D2.349 **Hereditary Angioedema in Bulgaria: an update on patient characteristics and treatment modalities**
Anna Valerieva (Bulgaria)

D2.350 **CVID: the crossroad between immune dysregulation, autoimmunity and cancer**
Marianna Franco (Italy)

12:00 - 13:00 TPS42 - Biologicals 02
(Poster Zone, Thematic Poster Session)

Chair: ***Alessandra Vultaggio (Italy)***

D2.351 **Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria**
Canan Caka (Türkiye)

D2.352 **Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria**
Çise Tüccar (Türkiye)

D2.353 **A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117**
Mang Yu (United States of America)

D2.354 **Questionnaire survey of new treatments for atopic dermatitis**
Hiromi Uehara (Japan)

D2.355 **Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria**
Jin Hyun Jung (Korea, Republic of)

D2.356 **Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria**
Nicolò Valli (Italy)

D2.357 **Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience**
Silvio Sartorio (Italy)

D2.358 **Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab**
Rocío Picos-Baliña (Spain)

D2.359 **Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age**
Carolina Macedo (Portugal)

D2.362 **Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis**
Maria Zande (Greece)

D2.363 **Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience**
Nour Aljefri (Saudi Arabia)

D2.364 **Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital**
Maria Kostara (Greece)

12:00 - 13:00 TPS38 - Dermatology 02
(Poster Zone, Thematic Poster Session)

Chairs: ***Claudia Traidl-Hoffmann (Germany), Manuel Pereira (Germany)***

D2.294 **Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023**
Maria Reverter Morales (Spain)

D2.295 **Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters**
Ji-Su Shim (Korea, Republic of)

D2.296 **Allergic contact dermatitis caused by a oxybutynin in a transdermal patch**
Iñaki Maiz (Spain)

D2.297 **SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria**
Annemarie Lekkerkerker (United States of America)

D2.299 **A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway**
Basak Ezgi Sarac (Türkiye)

D2.300 **Fixed Drug Eruption related to the use of NSAIDs**
Ruth Elizabeth Piña Yungasaca (Spain)

D2.302 **Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test**
Hana Cho Park (Spain)

D2.303 **Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy**
Alejandra Jover Walsh (Spain)

D2.304 **Transepidermal Water Loss in Atopic Diseases**
Maria Savva (Greece)

D2.305 **Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol**
Elena Mazoteras-Martínez (Spain)

D2.306 **Sodium dodecyl sulfate impairs the skin epithelial barrier by inducing oxidative stress in human skin**
Manru Li (Switzerland)

D2.307 **Diagnostic characterization of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): Case series from a tertiary care hospital and literature review**
Luis Carrasco Gómez (Spain)

D2.308 **Evaluation of ChatGPT Responses to Frequently Asked Questions by Parents of Children with Atopic Dermatitis**
Maria Savva (Greece)

12:00 - 13:00 TPS39 - Dermatology 03

(Poster Zone, Thematic Poster Session)

Chair: ***Lisa Beck (United States of America)***

D2.309 **Descriptive Study of Chronic Urticaria Under Treatment with Omalizumab: Our Experience**
Cristina Guerra Auyanet (Spain)

D2.310 **Dysregulation of barrier function and distribution of nerve cells in a mouse model of atopic dermatitis**
Yuko Honda (Japan)

D2.311 **Real World Web Survey on the Burden of Urticaria**
Karen Jui Lin Choo (Singapore)

D2.312 **Impact of metabolic disorders on immune dysregulation in psoriasis and atopic dermatitis**
Lawrence DuBuske (United States of America)

D2.313 **Importance of non-itchy erythema marginatum as a prodromal symptom of hereditary angioedema attacks**
Lawrence DuBuske (United States of America)

D2.314 **Late Presentation of Cutaneous Chronic Graft Versus Host Disease – A Case Report**
Charmaine Lim (Singapore)

D2.315 **Clinical features and Progress of Diagnosis and Therapy of Hereditary Angioedema in China: A Systemic Review of Published Cases**
Huiying Wang (China)

D2.316 **The role of Tumor necrosis factor ligand superfamily member 15 in Atopic dermatitis**
Chang Hyun Park (Korea, Republic of)

D2.317 **The role of sirtuin 2 (SIRT2) in atopic dermatitis**
Byung Chan Ko (Korea, Republic of)

D2.318 **Triggers and prodromal indicators of angioedema attacks in hereditary angioedema patients**
Lucía Ruiz Del Barrio (Spain)

D2.319 **Advancing Diagnosis and Management of Hereditary Angioedema in Brazil: Insights from the first 704 patients of a Multicenter Registry**
Luisa Karla Arruda (Brazil)

D2.322 **Quality of life of families with children suffering from chronic urticaria**
Maria Savva (Greece)

D2.323 **Higher neonatal urinary phthalate are associated with the development of infantile atopic dermatitis**
Kangmo Ahn (Korea, Republic of)

D2.324 **Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study**
Sorena Kiani (United Kingdom)

12:00 - 13:00 TPS36 - Drug allergy 03

(Poster Zone, Thematic Poster Session)

Chair: ***Gabriele Cortellini (Italy)***

D2.230 **Cross-Reactivity of Cephalosporins in Patients with IgE-Mediated Allergy to Penicillins: A Systematic Review**
Aiwen Wang (Singapore)

D2.231 **The experiences of ferric carboxymaltose desensitization and provocation**
Kurtulus Aksu (Türkiye)

D2.232 **SDRIFE related to generalized corticosteroids' hypersensitivity: A case report**
Ana Filipa Vassalo (Portugal)

D2.233 **Negative predictive value of skin tests with local anaesthetics**
Krzysztof Specjalski (Poland)

D2.235 **Is an allergy skin test with local anaesthetics necessary? Real life data with 124 patients**
Aytül Z. Sin (Türkiye)

D2.236 **Drug-induced angioedema by racecadotril in a patient treated with angiotensin-converting enzyme inhibitors**
Paloma Álvarez-Sala (Spain)

D2.237 **Corticosteroid allergy, hypertryptasemia and renal transplant**
Julia Ramirez-Cortes (Spain)

D2.238 **Successful Prevention of Subsequent L-Asparaginase Hypersensitivity in Children through Premedication: A Single-Center Experience**
Mongkol Lao-Araya (Thailand)

D2.239 **The First Successful Desensitization in Abemaciclib Hypersensitivity: A Case Report**
Merve Hormet Igde (Türkiye)

D2.242 **Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a Romanian University Hospital**
Brindusa Petrutescu (Romania)

D2.243 **From Risk to Solution: Effective Desensitization in a Confirmed Delayed Hypersensitivity Reaction to Albendazole**
María Gabriela Alcalá Rodríguez (Spain)

D2.245 **Long-Term Outcomes of Beta-Lactam Allergy De-Labelling: A Retrospective 10 year Analysis of Patient Confidence and Antibiotic Tolerance**
Nuzhat Abdurrachid (Portugal)

12:00 - 13:00 TPS44 - Environmental allergy and climate change + One health
(Poster Zone, Thematic Poster Session)

*Chairs: **Elaine Fuertes (United Kingdom), Isabella Annesi-Maesano (France)***

D2.382 **Clinical Manifestations of Dust Mite Allergy in Children Under 18 Years of Age**
Muntajibuddin Ahmed (India)

D2.383 **Nature Prescription: Another Alternative Therapy for Patients with Chronic Respiratory Disease – Pilot Study**
Marilyn Urrutia Pereira (Brazil)

D2.384 **Biostatistics in allergy and clinical immunology: reasons for concern and editorial recommendations**
Michal Ordak (Poland)

D2.385 **Association between long-term PM2.5 exposure and risk of Urticaria and Allergic rhinitis in children: A nationwide longitudinal cohort study**
Young A Park (Korea, Republic of)

D2.386 **Quantification of airborne allergens – Comparison between inhalable dust sampling and a new ambient air sampler**
Ingrid Sander (Germany)

D2.387 **Reducing the Carbon Footprint of Cetirizine Prescription: Exploring Patient Perspectives on Formulation Choice in an Allergy Clinic**
Emine Nebati (United Kingdom)

D2.388 **Greening office spaces: the impact of indoor plants on autonomic nervous system activity**
André Moreira (Portugal)

D2.389 **A Dynamic Interaction Between the Immune System, the Exposome, and Climate Change: The Shifting Sensitization Profile to Respiratory Allergens Across Life**
Mokhigul Ismatova (Uzbekistan)

D2.390 **Effects of Cigarette Smoke on Expression and Rhythmicity ofr Core Circadian Genes in Peripheral Blood Mononuclear Cells (PBMC) and Bronchial Epithelial Cells**
Hasan Bayram (Türkiye)

D2.391 **Changing Patterns of Aeroallergen Sensitization in Zagreb: Ragweed as the Predominant Allergen in a Sensitized Adult Population**
Marina Ikić Matijašević (Croatia)

D2.393 **Balancing Green Initiatives with Public Health: A Framework for Allergy-Friendly Urban Planning**
Katarina Stevanovic (Germany)

D2.394 **A class-variable immunoglobulin response to birch (B. pendula) pollen allergens**
Dorota Myszkowska (Poland)

D2.395 **Characterization of Juniperus oxycedrus pollen extract and identification of putative allergens**
Sandra Sivill (Spain)

D2.396 **Evaluating Advanced Fabric Care Technologies for Effective Dust Mite Eradication to Mitigate the Risk of Asthma**
Oliver Dsa (Ireland)

D2.397 **Air Pollution and Respiratory Health: A Regression Analysis of Asthma and Upper Respiratory Infections**
Ewelina Wawryk-Gawda (Poland)

12:00 - 13:00 TPS46 - Epidemiology
(Poster Zone, Thematic Poster Session)

Chairs: ***Joshua Lawson (Canada), Yagiz Pat (Türkiye)***

D2.413 **Association of sensitization to fur animal allergens and Bet v 1 in the Russian population**
Aliya Barmenova (Kazakhstan)

D2.414 **Trends in the prevalence of asthma in Korean children: a population-based study from 1995 to 2022**
Yang Hyeon-Jong (Korea, Republic of)

D2.415 **Application of magnetic particle chemiluminescence technology to detect sensitization in patients in Guangzhou, China: a study base on real-world medical data**
Peiyan Zheng (China)

D2.416 **Online Education Significantly Improves Physicians' Knowledge of Novel Long-Term Prophylaxis Therapies for Hereditary Angioedema**
Adriana Stan (United States of America)

D2.417 **Research transparency, reproducibility and accessibility in Allergy, 2003 – 2023: Preliminary results of the TRACES study**
Hugo Wai Fung Mak (Hong Kong)

D2.418 **Risk Factors for Severe Allergic Rhinitis and the Association with Serum sIgE Levels: A Study in Guangzhou, China**
Fengwen Shan (China)

D2.419 **Quality of life and measures of well-being of Canadian patients with HAE C1-INH based on data from the 2020 and 2024 national surveys**
Michelle Cooper (Canada)

D2.420 **Sensitization Profile of Lipocalins: sIgE Analysis in a Large Cohort of Patients with Suspected Allergies**
Emilia Majsiak (Poland)

12:00 - 13:00 TPS34 - Food allergy 02
(Poster Zone, Thematic Poster Session)

Chairs: ***George du Toit (United Kingdom), Caroline Roduit (Switzerland)***

D2.194 **Persisten severe cow's milk allergy with successful oral immunotherapy in adulthood**
Estela Menéndez-Rivero (Spain)

D2.195 **Clinical characteristics of eosinophilic esophagitis and gastroenteritis in Korean children: a single-center study**
Jihyun Kim (Korea, Republic of)

D2.196 **Utilization of Injectable Epinephrine Among Children with Parent-Reported Food Allergies**
Amer Khojah (Saudi Arabia)

D2.197 **Maternal Awareness of the Timing of Allergenic Food Introduction in Early Childhood: A Cross- Sectional Study**
Amer Khojah (Saudi Arabia)

D2.198 **Cross-reactivity between Fusarium venenatum and cooked mushrooms and Aspergillus fumigatus: A case study of food-induced allergy**
Ángel Luis Villalón García (Spain)

D2.199 **'When I became older, I started having to manage that more myself' – experiences of adolescents with food allergies: a qualitative study**
Juan Enrique Trujillo Wurttele (Ireland)

D2.202 **Threshold of Allergic Reactions to Cashew and Pistachio in a Large Israeli Population**
Liat Nachshon (Israel)

D2.203 **Awareness of and adherence to advice on early introduction of food allergens: is it preventing food allergy? Protocol for EarLY Food Allergens iNTroduction (ELYFANT) study**
Matthew Ridd (United Kingdom)

D2.204 **Research priorities for food allergy in children: A James Lind Alliance priority setting partnership**
Matthew Ridd (United Kingdom)

D2.205 **Validation of an Adapted Treatment Burden Questionnaire for Paediatric IgE-Mediated Milk and Egg Allergies: A Multicentre Study**
Aoife Gallagher (Ireland)

D2.206 **Evaluation of sustained unresponsiveness in children with IgE-Mediated Allergy to Cow's Milk Proteins Trough Oral Tolerance Induction Protocols**
Susana Rodríguez Cano (Spain)

D2.208 **Evaluating the Safety, Effectiveness, and Challenges of a Home-Based Egg Ladder Protocol in a Paediatric Allergy Clinic**
Deepnwita Patra (United Kingdom)

D2.209 **Does component-based diagnostics help us to clarify a sesame allergy in children?**
Ina Neugärtner (Germany)

D2.210 **Characterization of Allergenic Proteins in Ginger: A Clinical Case of Anaphylaxis**
Fernando Pineda de la Losa (Spain)

D2.211 **Fungal Contamination in Coffee Grounds: A Case of IgE-Mediated Allergy**
Fernando Pineda de la Losa (Spain)

D2.212 **Assessment of Adverse Reactions in Children with IgE-Mediated Food Allergy Following Desensitization Protocols**
Afroditi Kurkou (Greece)

12:00 - 13:00 TPS35 - Food allergy 03

(Poster Zone, Thematic Poster Session)

*Chairs: **Deniz İlgün Gürel (Türkiye), Elisa Zubeldia Varela (Spain)***

D2.213 **Unveiling Pitaya Pollen Allergenicity: A Case Study in Occupational Allergy**
Manuel Sobrino García de Zúñiga (Spain)

D2.214 **Alpha-Amylase Inhibitors as Allergens in Wheat Flour Sensitivity**
Fernando Pineda de la Losa (Spain)

D2.215 **Retrospective evaluation of the outcome of 106 oral food challenges performed in 2017 to 2024**
Martin Liska (Czech Republic)

D2.216 **Sensitization to legumes after an occupational allergy produced by guar gum**
Juan Mariano de la Borbolla (Spain)

D2.217 **A human monoclonal antibody displays promiscuous binding to multiple nsLTP allergens**
Geoffrey Mueller (United States of America)

D2.218 **Assessing the diagnostic value of specific igg4 in korean adult shrimp allergy based on symptom presence**
Hyun Kyung Oh (Korea, Republic of)

D2.219 **An "egg-bird syndrome" in a 12-year-old male child**
Marta Isabel Dias (Portugal)

D2.220 **NsLTPs as Allergens in Pitaya and Hemp Seeds: A Case Study**
Margarida Gomes (Portugal)

D2.222 **Histamine intolerance is uncommon among Chinese patients reporting allergic reactions to shrimp**
Ting Fan Leung (Hong Kong)

D2.223 **Implementing a liberated diet in food allergy management: Practical approaches and challenges from the TINA trial**
Jana Ruppel (Germany)

D2.224 **Cross-tolerance to cashew by prophylactic sublingual immunotherapy with different tree nuts in Brown Norway rats|Ana I. Sancho (Denmark)**

D2.225 **Fixed-Dose Oral Immunotherapy for High-Threshold Food Allergy: Efficacy and Safety in Real- World Practice**
Yael Koren (Israel)

D2.226 **Optimised recovery of specific food allergens from challenging food matrices**
Max Bermingham (United Kingdom)

D2.228 **Changes in temperature during allergic reactions to food in human volunteers**
Sara Albarracín (Spain)

D2.229 **Hypersensitivity reactions associated with the use of food supplements containing propolis. Analysis of observations reported to the French National Agency for Food, Environmental and Occupational Health Safety (Anses)**
Martine Morisset (France)

12:00 - 13:00 TPS40 - Immune deficiencies and autoimmunity 02

(Poster Zone, Thematic Poster Session)

Chairs: ***Pedro Alves (Portugal), Günnur Deniz (Türkiye)***

D2.325 **Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study**
Henriette Farkas (Hungary)

D2.326 **Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study**
Emel Aygören-Pürsün (Germany)

D2.327 **Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam**
Le Nguyen-Ngoc-Quynh (Vietnam)

D2.328 **Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes**
Sara Sebnem Kilic (Türkiye)

D2.329 **Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials**
Teresa Caballero (Spain)

D2.330 **Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile**
Antonio Gidaro (Italy)

D2.331 **Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study**
Yuxiang Zhi (China)

D2.332 **Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group**
Isabelle BOCCON-GIBOD (France)

D2.334 **Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia**
Mauricio Sarrazola Sanjuan (Colombia)

D2.336 **Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)**
Hanga Réka Horváth (Hungary)

D2.338 **The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients**
Fevzi Demirel (Türkiye)

D2.339 **Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health**
Ivan Cherrez-Ojeda (Ecuador)

D2.340 **A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden**
Linda Sundler Björkman (Sweden)

12:00 - 13:00 TPS49 - Immunomodulation and nutrition + System medicine
(Poster Zone, Thematic Poster Session)

Chairs: ***Hannah Hunter (United Kingdom), I-Jen Wang (Taiwan)***

D2.436 **Application Study on the prevention and treatment of spleen aminopeptide oral solution on seasonal allergic rhinitis**
Xueyan Wang (China)

D2.437 **Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema**
Danny M. Cohn (Netherlands)

D2.438 **Adipose-derived stem cells secretome attenuates eosinophilic inflammation in a chronic rhinosinusitis with nasal polyps mouse model**
KYU-SUP CHO (Korea, Republic of)

D2.439 **Low vitamin D levels in patients with allergic rhinitis and its supplementation**
Olga Naumova (Ukraine)

D2.440 **Burden of disease and patient preference in Hereditary Angioedema: findings from a mixed methods survey of carers and patients in the United Kingdom**
Alex Evans (United Kingdom)

12:00 - 13:00 TPS47 - Occupational allergy
(Poster Zone, Thematic Poster Session)

Chairs: ***Monika Raulf (Germany), Farah Hannachi (Luxembourg)***

D2.422 **Supporting second victims: linkages between patient safety and well-being of healthcare workers in allergy departments**
Dragan Mijakoski (North Macedonia)

D2.423 **Occupational sensitisation to Chrysonilia sitophila in an asthmatic patient with nasal polyposis**
Caroline Klingebiel (France)

D2.424 **Allergenic and inflammatory response of combined exposure of shrimp tropomyosin and microbial components in vitro**
Johanna Samulin-Erdem (Norway)

D2.425 **Prevalence of Latex Sensitization Among Nursing Staff in Intensive Care Units at the Hospital Universitario Austral: Comparative Analysis and Associated Factors**
Gustavo Marino (Argentina)

D2.426 **Occupational Asthma Due to Tenebrio Molitor in the Owner of a Mealworm Farm: A Case Report**
Dinara Korshunova (Spain)

D2.428 **Asthma severity and work exposure in 66 patient reffered to occupational and allergy unit**
Ilenia Folletti (Italy)

D2.429 **Biologic Therapy in Occupational Asthma: A Multicenter Retrospective Study on Treatment Outcomes and Occupational Impact**
Ilenia Folletti (Italy)

12:00 - 13:00 L-TPS13 - Anaphylaxis 05

(Poster Zone, Thematic Poster Session)

Chairs: ***Talal Chatila (United States of America), Andrea Macías-Camero (Spain)***

D2.278 **National Survey on Perioperative Hypersensitivity Reactions: Evaluating Practices and Challenges in Spanish Hospitals**
Jose Julio Laguna Martinez (Spain)

D2.279 **In an emergency, can YOU really give that adrenaline pen? – the need for structured, further and improved training in Ireland**
Juan Enrique Trujillo Wurttele (Ireland)

D2.282 **IgE-mediated anaphylaxis to quinine confirmed with a basophil activation test**
Carlos Morales Mateluna (Switzerland)

D2.283 **Beyond the skin. A rare case of contact angioedema due to Methylisothiazolinone**
Gabriele Cortellini (Italy)

D2.284 **Eat the fruit, do not swallow the seed: A rare case of Cucurbitaceae allergy causing anaphylaxis**
Halime YAĞMUR (Türkiye)

D2.286 **A case of prawn induced FDEIA**
Letizia Vacondio (Italy)

D2.287 **Evaluation of NSAID Hypersensitivity in Children: A Retrospective Analysis**
Gulay Irem Parlak Ozel (Türkiye)

D2.288 **Idursulfase Hypersensitivity Reactions: Unpacking Immunological Mechanisms Beyond Clinical Manifestations**
Lorena Hernández Pineda (Mexico)

D2.290 **Allergens involved in a case report of anaphylaxis to ginger (Zingiber officinale), a very rare but severe allergy**
Laetitia Pellicer-Garcia (France)

D2.289 **A Cardiovascular Enigma in the Emergency Room**
Leticia Domínguez-Cereijo (Spain)

D2.291 **The level of knowledge of adolescent and young adults about food allergies and anaphylaxis: Key information that can save lives - a pilot study**
Julia Majsiak (Poland)

D2.292 **Epinephrine Nasal Powder - a sustainable and reliable option for the treatment of anaphylaxis**
Robert Rönn (Sweden)

D2.293 **Assessment of the Efficacy of Specific Immunotherapy After a Long Break in Asthmatic Patients**
Besim Prnjavorac (Bosnia and Herzegovina)

12:00 - 13:00 L-TPS12 - Drug allergy 07
(Poster Zone, Thematic Poster Session)

Chairs: ***Cecilia Frecha (Spain), Francesca Mori (Italy)***

D2.246 **Anaphylaxis to sugammadex in a 15 year-old-girl**
Amruta Fulmali (United Kingdom)

D2.247 **Sensitization to Meloxicam, Celecoxib and Paracetamol in patients intolerant to non-steroidal antiinflamatory drugs (NSAIDS)**
Susana Rodríguez Cano (Spain)

D2.248 **Allergy to quinolones: a clinical case**
Paula Rodríguez Siverio (Spain)

D2.249 **Application of Desensitization Protocol with Rituximab in the Treatment of Corticosteroid- Dependent Nephrotic Syndrome in an Adolescent**
Afroditi Kurkou (Greece)

D2.250 **Can drug allergy develop in x-linked agammaglobulinemia (xla)? case report**
Nesrin Gulez (Türkiye)

D2.251 **Anaphylaxis due to Andrographis panniculata - an emerging problem**
Frank Schultheiss (Australia)

D2.252 **Confirmation of selectivity pattern to Non-Steroidal Anti-inflammatory Drugs: a retrospective study in a Central Hospital**
Catarina Guedes (Portugal)

D2.253 **Is it possible to treat DRESS without systemic corticosteroids?**
Diana Pérez-Alzate (Spain)

D2.254 **Can a medication leave its mark on the skin?**
Stephanie Steixner Zevallos (Spain)

D2.255 **NSAID Hypersensitivity Records: Assessing Documentation Practice, Challenges, and Areas for Improvement**
Leyla Pur Ozyigit (United Kingdom)

D2.256 **Cytokine release reaction after subcutaneous daratumumab**
Tamara Valls Ten (Spain)

D2.257 **Anaphylaxis with FOLFOX scheme: not everything is Oxaliplatin**
Luis Palacios Colom (Spain)

D2.258 **Fixed drug eruption caused by co-amoxiclav**
Marta Navratil (Croatia)

D2.259 **A Comprehensive Decision Algorithm for Hypersensitivity Reactions to Iodinated Contrast Media in a Tertiary Care Setting**
Ana Vitória Soares (Portugal)

12:00 - 13:00 L-TPS09 - Allergy diagnosis 15
(Poster Zone, Thematic Poster Session)

Chairs: ***Daniela Carvalho (Portugal), Teresa Alfaya Arias (Spain)***

D2.65 **Clinical relevance of sensitizations to pneumoallergens detected in southern Spain**
María Dolores Rodríguez Bote (Spain)

D2.66 **Deciphering The Molecular Profiles Between Asthma and Urticaria Using Transcriptomic Profiling**
Bassam Mahboub (United Arab Emirates)

D2.67 **Relation betwween IL-6 and asthma in children and adolescent**
Guillermo Salamanca Fernández (Spain)

D2.69 **Symptom Variability in Hypereosinophilic Syndrome: Observations From a Large Cohort Study**
Piotr Lacwik (Poland)

D2.70 **The Impact of Comorbidity of respiratory and atopic diseases on Mental Health and Wellbeing: a Community Survey in the US and Eastern Europe**
Victor Gascon Moreno (Austria)

D2.71 **Comprehensive approach to severe bronchial asthma: a case study and the role of biologic therapy**
Gulzada Abdushukurova (Kazakhstan)

D2.72 **Analysis of asthma prevalence and risk factors in infantile atopic dermatitis using data from the Korean national health insurance serice**
Minji Kim (Korea, Republic of)

D2.73 **Activation-induced marker (AIM) assay to study allergic skin reactions: a case study on p- phenylenediamine**
Marina Aparicio-Soto (Germany)

D2.74 **Analytical Verification of House Dust Mite Allergen Assays on the IMMULITE 2000 XPi System***
Nicholas Ready (United Kingdom)

D2.75 **Allergy to insects in children**
Lawrence DuBuske (United States of America)

D2.76 **When Eosinophilia Persists: Unmasking an Unexpected Diagnosis in a Dupilumab Treated Atopic Dermatitis Patient**
Válter Tavares (Portugal)

D2.77 **A Novel Neural Network for Quantifying Wheal and Erythema in Skin Prick Testing**
Ilya Tryakin (Germany)

D2.78 **Hypersensitivity Reactions to Biologics in Patients with Th1- and Th17-Driven Immune- Mediated Diseases: A Series of Three Cases**
Roberta Criado (Brazil)

12:00 - 13:00 L-TPS10 - Asthma 10

(Poster Zone, Thematic Poster Session)

Chairs: ***Lucía Cremades-Jimeno (Spain), Christer Janson (Sweden)***

D2.133 **Clinical and Direct Medical Burden of Hospitalized Children with Asthma Exacerbations**
Tamara Hernandez Hernandez (Mexico)

D2.134 **Transitioning adolescents and young adults with asthma: insights from a severe asthma series**
Rosa Buonagura (Italy)

D2.135 **What are our children breathing? Tracking exposure to air pollution during a school day**
Gonçalo Silva (Portugal)

D2.136 **Nasal transcriptomics as a biomarker for ICS/LABA treatment in paediatric asthma in the PUFFIN study**
Yidan Sun (Netherlands)

D2.137 **Long term, Persistent Eosinophilia in patients with Asthma and CRSwNP undergoing Dupilumab therapy: preliminar results of a 24-month follow up prospective study**
Aikaterini Detoraki (Italy)

D2.138 **The Effect of Human Milk Oligosaccharides 2'FL and 3FL on Macrophage polarization**
Vera Rijks (Netherlands)

D2.139 **Oxidative stress and tissue hypoxia are triggered through the increased respiratory effort during sleep and reflect the inflammation as a stress link in the gut-brain axis in children suffering asthma, allergic/non-allergic rhinitis, and/or eczema**
Kalomoira Kefala (France)

D2.140 **Allergic Sensitization Patterns in Western Romania: Impact of Airborne Allergens and Climate Factors**
Carmen Panaitescu (Romania)

D2.142 **Smoking cessation advice to parents in children with bronchial asthma- still it is a long way to go**
Tushar Kanti Banerjee (United Kingdom)

D2.144 **Occupational Asthma due to garlic powder: a case report**
Marco Biasioli (Italy)

D2.145 **The utility of blood eosinophils, IgE and skin prick testing in paediatric asthma diagnosis**
Clare Murray (United Kingdom)

D2.146 **Occupational Asthma due to Subtilisin: the power of specific inhalation challenge**
Marco Biasioli (Italy)

D2.147 **Comparison of clinical outcomes with Benralizumab in severe eosinophilic asthma: Switched and naïve patients**
Çise Tüccar (Türkiye)

12:00 - 13:00 L-TPS11 - Allergen immunotherapy 06

(Poster Zone, Thematic Poster Session)

*Chairs: **Todor Popov (Bulgaria), Tugba Kiratli Yolcu (Türkiye)***

D2.182 **Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children**
Naphisabet Wanniang (Luxembourg)

D2.183 **Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy**
Caroline Nilsson (Sweden)

D2.184 **Trends in aeroallergen immunotherapy prescription**
Andre Alberto (Portugal)

D2.185 **Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports**
Antica Mihaličeк (Croatia)

D2.186 **Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy**
Rosa Gallego (Spain)

D2.187 **Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?**
Carlota Dias (Portugal)

D2.188 **Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy**
Taiji Nakano (Japan)

D2.189 **Eosinophilic Esophagitis Induced by Sublingual Immunotherapy (SLIT): A Rare but Emerging Side Effect**
Gjustina Loloci (Albania)

D2.190 **Unmasking Autoimmunity: A Case of Thyroiditis Emerging After Allergy Immunotherapy**
Gjustina Loloci (Albania)

D2.191 **Autoimmune Disease Unmasked by Allergic Immunotherapy: A Case of Systemic Lupus Erythematosus (SLE) After SCIT**
Gjustina Loloci (Albania)

D2.192 **IgE-Mediated Immunotherapy-Induced Eosinophilic Granulomatosis with Polyangiitis (EGPA)**
Gjustina Loloci (Albania)

D2.193 **Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis**
Tariq Al Farsi (Oman)

13:15 - 14:00 P & C 3 - Is remission an adequate therapeutic goal for severe asthma
(EAACI Global Stage, Pro Con)

Chair: ***Amelia Licari (Italy)***

13:15 **PRO**
Stefano Del Giacco (Italy)

13:38 **CON**
Ian Adcock (United Kingdom)

12:00 - 13:00 SSS 4 - EAACI & ACAAI Joint Symposium : Unified Airway Disease
(Boisdale, Sister Society Symposium)

Chairs: ***Gailen Marshall (United States of America), Cherie Zachary (United States of America), Todd Mahr (United States of America)***

13:15 **Defining Asthma Remission: Challenges and Potentials**
Gailen Marshall (United States of America)

13:35 **Chronic Rhinosinusitis**
Cherie Zachary (United States of America)

13:55 **Q&A**
Todd Mahr (United States of America)

12:00 - 13:00 FT08 - Biological treatment in asthmatic diseases
(Dochart 1, Flash Talks)

Chairs: ***Mona Al-Ahmad (Kuwait), Cristiano Caruso (Italy)***

13:15 000203 **Hereditary α-Tryptasemia in Severe Allergic Asthma: Impaired Lung Function, Reduced Type 2 Biomarkers, and Suboptimal Omalizumab Response**
Peter Kopac (Slovenia)

13:22 000569 **Targeted Metabolomic Profiling as a Tool for Assessing Response to Biologicals: a case of Dupilumab in Severe Allergic Asthma**
Juan Carlos López-Rodríguez (Spain)

13:29 000478 **Asthma Severity and Patient-Reported Outcomes in Patients With Asthma and Allergic Rhinitis Initiating Dupilumab in RAPID**
Giselle Mosnaim (United States of America)

13:36 000474 **Treatment Patterns in Patients Who Initiated Dupilumab in a Real-World Clinical Setting: The RAPID Registry**
Giselle Mosnaim (United States of America)

13:43 000551	**Proteomic Modulation by Dupilumab in Severe Seasonal Asthma: Insights from a Short-Term Treatment Study in Ole e 7-Sensitized Patients** Nuria Contreras (Spain)
13:50 001621	**Dupilumab as a New Therapeutical Approach in Patients with Severe Seasonal Asthma Caused by Olive Pollen Sensitization** Sofía Gómez De La Cruz Pérez (Spain)
13:57 001156	**Decrease in Eosinophil-Derived-Neurotoxin upon mepolizumab is associated with asthma improvement** Luc De Chaisemartin (France)
14:04 000181	**Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients** Laura López-Duque (Spain)
14:11 001162	**Inflammatory markers in asthmatic patients receiving anti-interleukin-5 therapy** Merve Taş (Türkiye)
14:18 001052	**Evaluation of the concordance of definitions of Asthma Remission according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma** Andrea Giovanni Ledda (Italy)
14:25 001379	**Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma, Independent of Baseline IgE and FeNO in the Real World: 2-Year Results from REALITI-A** Jason Kihyuk Lee (Canada)
14:32 000050	**Prediction score for difficult-to-treat allergic bronchopulmonary aspergillosis** Koichiro Asano (Japan)

12:00 - 13:00 FT09 - Allergen immunotherapy in clinical studies

(Dochart 2, Flash Talks)

*Chairs: **Deniz Eyice Karabacak (Türkiye), Enza D'Auria (Italy)***

13:15 000071	**Relevant patient benefit in the short-term with a 300IR dosing pump-administered liquid sublingual immunotherapy: Results from the observational, prospective, longitudinal PRACTIS study** Julien Cottet (France)
13:22 001430	**Dietary outcomes following oral immunotherapy for cows milk allergy: Results from the SOCMA Study** Justine Dempsey (United Kingdom)
13:29 000898	**Randomized controlled trial of pancake oral immunotherapy for egg allergy** Wenyin Loh (Singapore)
13:36 001304	**Two-year Outcomes of Low-dose Oral Immunotherapy for Children with Severe Walnut Allergy** Yusuke Shimaoka (Japan)
13:43 000730	**Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics of IGNX001 in Peanut- Allergic (PA) Adults and Older Adolescents - Day 8 Safety Data for Cohort 1 of the ACCELERATE Peanut Study** Sara Barnes (France)
13:50 001621	**Positive effect of a 300IR dosing pump-administered liquid sublingual immunotherapy on allergic disease evolution: Results from the observational, prospective, longitudinal PRACTIS study** Eric Fromentin (France)
13:57 000557	**SQ tree SLIT-tablet is well tolerated in children with tree pollen allergic rhinitis and/or conjunctivitis in the TT-06 phase III trial** Rémi Gagnon (Canada)

14:04 000574	**Consistent efficacy of the SQ HDM SLIT-tablet in children (5–11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis across subgroups in the MT-12 phase III trial** Oliver Pfaar (Germany)
14:11 000207	**The safety of an optimal accelerated immunotherapy for allergic rhinitis in adolescent and adult patients in China (PERFECT study)** Shaobing Xie (China)
14:18 000615	**Safety of the SQ HDM SLIT-tablet in children (5–11 years) with house dust mite allergic rhinitis/ rhinoconjunctivitis in the MT-12 phase III trial** Oliver Pfaar (Germany)
14:25 100186	**The 300 IR house dust mite SLIT tablet improves allergic symptoms and reduces symptomatic medication use in adults and adolescents in a real-word data setting – results of a non- interventional studys** Oliver Pfaar (Germany)

13:15 - 14:45 OAS07 - Insights in pediatric allergy: from bench to bedside

(Carron 1, Oral Abstract Sessions)

*Chairs: **Roy Gerth van Wijk (Netherlands), Jean-Christoph Caubet (Switzerland)***

13:15 000322	**Neonatal alveolar macrophage imprinting assessed by maternal 12-HETE levels associate with childhood respiratory morbidity through airway microbiome and immune alterations and is modified by prenatal n-3 LCPUFA exposure** Liang Chen (Denmark)
13:27 001416	**Can Sensory Processing Disorder Be A Comorbidity Of Allergic Asthma In Children?** Berna Uzunoğlu (Türkiye)
13:39 000247	**Reduced Natural Moisturizing Factors and Caspase-14 Impaired Skin Barrier Function for Pediatric Atopic Dermatitis in Japan** Risa Fukuda (Japan)
13:51 001632	**The impact of Inflammatory Determinants on Fractional Exhaled Nitric Oxide (FeNO) Levels in School-Aged Children in Greece: Findings from the SynAir-G study** Paraskevi Xepapadaki (Greece)
14:03 000654	**Furan fatty acid metabolites in pregnant women and newborns are associated with risk of childhood asthma** Wang Tingting (Denmark)
14:15 001585	**Exploring the Relationship Between 25-Hydroxyvitamin D Levels and Allergic Rhinitis Severity** Cankat Genis (Türkiye)
14:27 000288	**PECU: A Multicenter Study on Pediatric Patients with Cold-Induced Urticaria** Hatice Betul Gemici Karaaslan (Türkiye)

13:15 - 14:45 OAS08 - Phenotypes and mechanisms in asthmatic diseases

(Carron 2, Oral Abstract Sessions)

*Chairs: **Adnan Custovic (United Kingdom), Hasan Bayram (Türkiye)***

13:15 000502	**Changes in small airway physiology measured by impulse oscillometry in subjects with allergic asthma following methacholine and inhaled allergen challenge** Khalid Abd-Elaziz (Netherlands)
13:27 001158	**Allergic airway inflammation impacts early differentiation processes of bronchial epithelial cell progenitors** Holger Garn (Germany)

13:39 001347 **Innate Immune Memory and Metabolic Reprogramming in the Lower Airway Epithelium of Patients with Allergic Asthma**
Inés Jardón Parages (Switzerland)

13:51 001082 **Novel Pollen Aerosolization System for Studying Inflammation in Differentiated Airway Epithelia from Patients with Allergic Rhinitis and Asthma**
Saeideh Hajighasemi (Australia)

14:03 001182 **Inflammatory phenotypes of severe asthma from sputum and plasma proteomic profiles**
Freda Yang (United Kingdom)

14:15 000524 **Characteristics of severe eosinophilic asthma in childhood-onset and adult-onset asthma in U- BIOPRED**
Freda Yang (United Kingdom)

14:27 001591 **The relationship between asthma duration and biomarker profiles in severe asthma**
Freda Yang (United Kingdom)

13:15 - 14:45 SY11 - T2 inflammation in the upper airways: from bench to bedside
(Clyde Auditorium, Symposium)

*Chairs: **Alla Nakonechna (United Kingdom), George du Toit (United Kingdom)***

13:15 **Allergic mechanisms contributing to mucosal T2 inflammation**
Ibon Eguiluz (Spain)

13:45 **The differential effect of anti-T2 biologicals in CRSwNP**
Philippe Gevaert (Belgium)

14:15 **Real-life use of biologicals in CRSwNP: prescription patterns, safety and prediction of response**
Marjolein Cornet (Netherlands)

13:15 - 14:45 SY12 - Food allergy: from prevention to prediction of therapeutic responses
(Lomond Auditorium, Symposium)

*Chairs: **Alla Nakonechna (United Kingdom), George du Toit (United Kingdom)***

13:15 **Biomarkers for food allergy**
Alexandra Santos (United Kingdom)

13:45 **Skin as the target for allergy prevention and treatment**
Helen Brough (United Kingdom)

14:15 **New mechanisms for the induction of tolerance by Oral Immunotherapy**
Mubeccel Akdis (Switzerland)

13:15 - 14:45 SY13 - Therapeutic options in indolent systemic mastocytosis: a roadmap
(Forth, Symposium)

*Chairs: **Sigurd Broesby-Olsen (Denmark), David González-de-Olano (Spain)***

13:15 **How can we target mast cells?**
Patrizia Bonadonna (Italy)

13:45 **Antimediator therapies in mastocytosis**
Theo Gülen (Sweden)

14:15 **Tyrosine kinase inhibitors in non-advanced mastocytosis**
Mariana Castells (United States of America)

13:15 - 14:45 TSY3 - Autoimmunity in allergic diseases: implications for treatment
(Hall 1, Thematic Symposium)

Chairs: ***Cristiana Stellato (Italy), Luis F Santamaria-Babi (Spain)***

13:15 **IgG and IgE autoantibodies in chronic spontaneous urticaria**
Pavel Kolkhir (Germany)

13:45 **IgG autoantiboides in asthma**
Manali Mukherjee (Canada)

14:15 **IgE autoantibodies in atopic dermatitis**
Inge Kortekaas Krohn (Belgium)

13:45 - 14:45 ET 2 - EAACI Enlightening Talks - 2
(Innovation Hub, EAACI Enlightening Talk)

13:45 **Nature's Role in Healing: Harnessing Biodiversity to Combat Asthma and Allergies**
Tari Haahtela (Finland)

14:15 **Climate Change, Air Pollution, and Allergy: Navigating Global Challenges for Planetary Health**
Isabella Annesi-Maesano (France)

14:15 - 15:00 P & C 4 - Should dupilumab be the standard first treatment choice for severe atopic dermatitis?
(EAACI Global Stage, Pro Con)

Chair: ***Lisa Beck (United States of America)***

14:15 **PRO**
Marie-Charlotte Brüggen (Switzerland)

14:38 **CON**
Martine Grosber (Belgium)

14:30 - 15:00 EAACI Special Session 3 - EAACI Meet and greet the EAACI Leadership
(Innovation Hub, EAACI Special Session)

14:30 **EAACI meet and greet the EAACI Leadership**
Maria Jose Torres (Spain), Patrizia Bonadonna (Italy), Jolanta Walusiak-Skorupa (Poland), Oscar Palomares (Spain), Stefano Del Giacco (Italy)

15:00 - 16:00 SSS 5 - EAACI & AAAAI Joint Symposium – Atopic Dermatitis 2025: Novel Pathophysiology & Treatment Insights
(Forth, Sister Society Symposium)

Chairs: ***Frank S Virant (United States of America), Carla M. Davis (United States of America)***

15:00 **Food Allergy and Atopic Dermatitis: A Complex Bidirectional Relationship**
Sharon R. Chinthrajah (United States of America)

15:20 **Future Atopic Dermatitis Treatment: Beyond IL-13 and JAK Inhibitors**
Mark Boguniewicz (United States of America)

15:40 **Approaching atopic dermatitis from a One Health Perspective**
Kari Nadeau (United States of America)

15:00 - 16:30 FT10 - Skin and allergy
(Dochart 1, Flash Talks)

Chairs: ***Jose Luis Garcia-Abujeta (Spain), Mar Guilarte (Spain)***

15:00 000242 **The PACI-ON Cohort Study: Modifying Eczema Control and Food Allergy by Early Intervention**
Kiwako Yamamoto-Hanada (Japan)

15:07 000229 **Serum Cytokine Profiles in Chronic Spontaneous Urticaria: Correlations with Disease Severity, Endotypes, and Autoreactivity**
Abhishek De (India)

15:14 000991 **Real-world use of topical treatments for children with atopic eczema: a systematic review**
Matthew Ridd (United Kingdom)

15:21 000643 **Analysis of Micro- and Macronutrient Levels in Children with Atopic Dermatitis Following BLW Complementary Feeding**
Olena Sharikadze (Ukraine)

15:28 000286 **Assessment of Transepidermal Water Loss in Children with Atopic Dermatitis and Healthy Controls Using a Novel Device**
Laura Carucci (Italy)

15:35 000364 **ROAD Study: Long-term Efficacy and Safety of Topical Therapy in Pediatric Moderate to Severe Atopic Dermatitis**
Tomoki Yaguchi (Japan)

15:42 001564 **Clinical Characteristics and Natural Course of Children with Dermographic Urticaria**
Nuran Ozciftci Ertugral (Türkiye)

15:49 001568 **The Psychological Burden of Atopic Dermatitis:Assessing Anxiety and Depression Prevalence with the HADS Scale in Argentina**
Maria Cecilia Cavallo (Argentina)

15:56 000373 **Temporal Trends and Relationships Among Nine Allergic Diseases Across All age groups in Korea (2002–2019)**
Ju Hee Kim (Korea, Republic of)

16:03 000604 **Development and Validation of the Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)**
Melba Muñoz (Germany)

16:10 000612 **The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States**
Marc A. Riedl (United States of America)

16:17 000492 **Impact on sexual health of clinical control in atopic dermatitis**
Ana Caraballo (Colombia)

15:00 - 16:30 FT11 - Biologics and airway disease in pediatric care
(Dochart 2, Flash Talks)

Chair: ***Ekaterina Khaleva (United Kingdom)***

15:00 000600 **Dupilumab Reduces Exacerbations and Improves Asthma Control in Children With Moderate- to-Severe Type 2 Asthma, Regardless of Asthma Duration**
Eckard Hamelmann (Germany)

15:07 000613 **Dupilumab Reduces Seasonal Exacerbation Rates in Children With Type 2 Asthma With or Without Evidence of Allergy**
Alessandro Fiocchi (Italy)

15:14 001674	**Study on the target level and influencing factors of dupilumab treatment in children with moderate to severe atopic dermatitis** Xiang Gao (China)
15:21 001350	**The effect of the community of residence on Wheeze/ asthma symptoms mediated through environmental risk factors and respiratory infection in children in southern Nigeria** Iso Oloyede (United Kingdom)
15:28 000822	**The Hints to Differentiate CAPs From Acute/Recurrent Acute Urticaria: A Multicenter Study** Deniz İlgün Gürel (Türkiye)
15:35 000186	**Is Chronic Rhinosinusitis Still an Underestimated Disease?** Vladimir Turuntas (Austria)
15:42 001642	**Evaluation of Asthma Course in Patients Hospitalized in Pediatric Intensive Care Unit Due to Severe Asthma Exacerbation** Cankat Genis (Türkiye)
15:49 000582	**How Food Allergen Sensitization Influences Asthma in Children with Atopic Dermatitis** Sayaka Hamaguchi (Japan)
15:56 000376	**Untargeted metabolomics reveals the metabolic profiles of children with allergic asthma in eastern and western China** Baoqing Sun (China)
16:03 000234	**Carboxylic Acid Metabolism and Key Biomarkers in Airway Allergic Diseases** Peiyan Zheng (China)

15:00 - 16:30 OAS-CT2 - Clinical Trials on Dermatology

(Innovation Hub, Oral Abstract Session on Clinical Trials)

Chairs: ***Anders Funch (Denmark), Torsten Zuberbier (Germany)***

15:00 000269	**Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H1-Antihistamine Treatment** Martin Metz (Germany)
15:12 000410	**Long-term efficacy of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis** Constance Katelaris (Australia)
15:24 001312	**Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Gene Expression and Protein Levels in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study** Bob Geng (United States of America)
15:36 001408	**Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S** Marc A. Riedl (United States of America)
15:48 000588	**Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment** Martin Metz (Germany)
16:00 000816	**Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies** Michihiro Hide (Japan)

16:12 001293 **Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies**
John Reed (United Kingdom)

15:00 - 16:30 OAS09 - Progress in understanding the mechanisms of airborne allergen immunotherapy
(Carron 1, Oral Abstract Sessions)

Chairs: ***Carmen Milagros Rondon (Spain), Martha Jimenez Freites (Spain)***

15:00 000324 **Subcutaneous AIT with a thermosensitive hydrogel formulation containing genetically engineered Bet v 1 is safe and induces a strong protective immune response in birch pollen allergic patients**
Anne Marie Salapatek (Canada)

15:12 000550 **Modulation of allergen-specific type 2 memory B cells over the course of 18 months sublingual immunotherapy for house dust mite allergy**
Menno van Zelm (Australia)

15:24 000745 **The Skin Sebum and Moisture Levels of Children with Allergic Diseases: How Predictive Are They for House Dust Mite Allergy?**
Seda Çevik (Türkiye)

15:36 001017 **Effectiveness of allergy immunotherapy on symptom-relieving medication use: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study**
Erik Melén (Sweden)

15:48 001164 **Effectiveness of allergy immunotherapy on asthma medication use and asthma exacerbations: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study**
Celeste Porsbjerg (Denmark)

16:00 001260 **Individual Differences in Response to Dust-Mite-Allergen Specific Immunotherapy in Allergic Rhinitis: A Meta-analysis of Randomized Controlled Trials**
Yuan Zhang (China)

16:12 001469 **Glutaraldehyde Cross-linking Stoichiometry: Impact on Structure, IgE Binding and Allergenic Activity of Betula verrucosa Pollen Extracts**
Jose Fernando Cantillo (Spain)

15:00 - 16:30 OAS10 - Understanding of mechanisms of food immunotherapy
(Carron 2, Oral Abstract Sessions)

Chairs: ***Thuy-My Le (Netherlands), Isabel Skypala (United Kingdom)***

15:00 000347 **Structural analysis of IgE epitopes of Ara h 2 reveals simultaneous binding of three copies of a human derived IgE Fab fragment to the major peanut allergen**
Juha Rouvinen (Finland)

15:12 000363 **Patterns of peanut ingestion in remission vs desensitized patients after completion of peanut oral immunotherapy at 3-years post-treatment**
Paxton Loke (Australia)

15:24 000790 **ROCI-OIT: Rapid Oral Continuous Infusion – Oral Immunotherapy; A Breakthrough methodology in the science of OIT**
Ghada E. Fouda (Egypt)

15:36 001131 **2-year outcome of low-dose oral immunotherapy for children with severe cashew allergy**
Motohiro Ebisawa (Japan)

15:48 001271 **Modified Peanut Allergen mRNA: A Novel Vaccine for Peanut Allergy**
Moshe Ben-David (Israel)

16:00 001285 **Sublingual immunotherapy with Pru p 3 induces DNA methylation changes towards tolerance in dendritic cells from patients with nsLTP allergy**
María del Carmen Martín-Astorga (Spain)

16:12 001509 **Cow Milk Oral Immunotherapy: A Single-Center Experience**
Fernando Carvalho (Portugal)

15:00 - 16:30 SY14 - Sustainable diets the gut microbiome and the immune
(Clyde Auditorium, Symposium)

*Chairs: **Ines Padua (Portugal), Emilia Vassilopoulou (Greece)***

15:00 **Sustainable diets the gut microbiome and the immune system**
Liam O'Mahony (Ireland)

15:30 **Healthy eating in the food allergy clinic, sustainable diets and avoidance of ultra processed foods**
Carina Venter (United States of America)

16:00 **The overall diet and environmental factors in oral immunotherapy**
Pete Smith (Australia)

15:00 - 16:30 SY15 - Airway immune metabolism in allergic diseasese
(Lomond Auditorium, Symposium)

*Chairs: **Andrzej Eljaszewicz (Poland), Domingo Barber (Spain)***

15:00 **Interleukin-2 and altered peptide ligands modulate allergen-specific T cell function and metabolism in vivo**
Winfried F. Pickl (Austria)

15:30 **Metabolism of T cells and immune homeostasis in allergic diseases**
Milena Sokolowska (Switzerland)

16:00 **Lipid metabolism and allergic asthma severity**
Maria Escribese (Spain)

15:15 - 16:15 TSY4 - Climate Change and Insect allergy
(Hall 1, Thematic Symposium)

*Chairs: **Gunter Sturm (Austria), Joana Vitte (France)***

15:00 **Worldwide changes in distribution of stinging insects**
Arantza Vega Castro (Spain)

15:30 **One Health approach applied to insect allergy**
Bernadette Eberlein (Germany)

16:00 **Diagnosis and treatment of allergies to emerging and locally relevant insects**
Elisa Boni (Italy)

15:15 - 16:15 EAJ - EAACI Journals
(Meeting Academy M1, EAJ)

Chairs: ***Philippe Eigenmann (Switzerland), Oliver Pfaar (Germany)***

15:15 **Molecular mechanisms of allergic inflammation**
C. Akdis (Switzerland)

15:35 **Redefining allergy trajectories, what we have learned from birth cohorts**
Philippe Eigenmann (Switzerland)

15:55 **Allergen Immunotherapy (AIT): citations and published evidence**
Oliver Pfaar (Germany)

15:30 - 15:45 Turkey - NAIS: Turkish National Society of Allergy and Clinical Immunology *(TNSACI)*
(EAACI Global Stage, NAIS Session)

15:30 **Food Allergies: A spectrum of reactions and challenges**
Özge Soyer (Türkiye)

15:45 - 16:00 Romania - NAIS: Romanian Society of Allergology and Clinical Immunology (RSACI)
(EAACI Global Stage, NAIS Session)

15:45 **35 Years of RSACI: Looking to the Future**
Carmen Panaitescu (Romania)

16:00 - 16:15 Greece - NAIS: Greek pediatric allergy society (GPAS)
(EAACI Global Stage, NAIS Session)

16:00 **"It is not just atopy:Primary Atopic Disorders (PADs)"**
Paraskevi Maggina (Greece)

16:15 - 16:30 Czech Republic - Czech Society of Allergology and Clinical Immunology (CSACI)
(EAACI Global Stage, NAIS Session)

16:15 **Monogenic atopy**
Anna Sediva (Czech Republic)

16:45 - 18:15 FT12 - Early-life influences on allergy and immune development
(Dochart 1, Flash Talks)

Chairs: ***George du Toit (United Kingdom), Antonella Cianferoni (United States of America)***

16:45 001571 **Formula Choice Influences Immune Tolerance Acquisition in Children with IgE-Mediated Cow's Milk Allergy: Preliminary Results from the EPICMA Study**
Rita Nocerino (Italy)

16:52 000258 **Differential alterations in DNA methylation profile between infants with IgE-mediated and non- IgE-mediated cow's milk allergy**
José Antonio Cañas (Spain)

16:59 001698 **First diagnostic confirmation through Lymphocyte Transformation Test of steroid-mediated type IV hypersensitivity**
Hana Cho Park (Spain)

17:06	000605	**Prediction of allergic disease trajectories up to adolescence** Miriam Leskien (Germany)
17:13	001094	**The integral precision model for personalized genotype-associated predictive diagnostics of atopic dermatitis in children** Volodymyr Dytiatkovskyi (Ukraine)
17:20	000543	**Novel JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease** Satoshi Fujita (Japan)
17:27	000838	**Co-existence of celiac disease and IgE mediated wheat allergy** Amna Al Kuwaiti (Ireland)
17:34	001654	**The Impact of Obesity on Pulmonary Function in School-Aged Children in Attica: Findings from the SynAir-G Study in Greece** Maria Kritikou (Greece)
17:41	001306	**Maternal Diet Index and childhood asthma and food allergy - a replication study from Sweden** Stina Bodén (Sweden)
17:48	000299	**Should Omalizumab Therapy Be Discontinued?** Ezgi Akkus (Türkiye)
17:55	000182	**Association between telomere length and atopic dermatitis among school-age children** Hsin-Yi Huang (Taiwan)

16:45 - 18:15 FT13 - Basic research in food allergy

(Dochart 2, Flash Talks)

*Chairs: **Cristobalina Mayorga (Spain), Bianca Olivieri (Italy)***

16:45	001563	**Host miRNA signatures to differentiate FPIES reaction from sepsis and acute gastroenteritis in children** Julián Montoto-Louzao (Spain)
16:52	001467	**A novel mouse model for the study of alpha-gal syndrome** Amanda Atanasio (United States of America)
16:59	001596	**Salivary Transcriptomic Profiling Reveals TGF-β and IL-17 Pathways as Key Drivers of Immune Dysregulation in FPIES** Julián Montoto-Louzao (Spain)
17:06	000652	**Characterizing a human monoclonal IgE antibody binding to walnut alpha-hairpinin allergens** Gage Leighton (United States of America)
17:13	000932	**Measurement of specific IgE antibodies to the N-terminal fragment of vicilins improves the diagnosis of almond allergy** Nobuyuki Maruyama (Japan)
17:20	000714	**Characterization on genome-wide profile of H3K4me2 histone methylation in mouse skin suffering from peanut allergic sensitization** Mengzhen Hao (Spain)
17:27	001275	**MY006: A Trispecific Antibody Blocking Four Allergenic Epitopes For the Treatment of Peanut Allergy** Natascha Wuillemin (Switzerland)
17:34	001512	**Structural analysis of IgE epitopes on major peanut allergens Ara h 2 and Ara h 6** Sandhya Bangaru (United States of America)

17:41 000887 **A ten years trend in sensitization to respiratory and food allergens in Cali, Colombia**
Johanna Amparo Ramirez Villamizar (Colombia)

17:48 000368 **A multicenter study on the sensitization of six common food allergens in patients with respiratory allergic diseases in China**
Baoqing Sun (China)

17:55 000631 **Diagnosis and Management of LTP allergy: results of a survey addressed to Italian Allergists**
Serena Traversi (Italy)

18:02 100303 **Diverse allergen-specific CD4+ T cell immune responses and gut microbial association prevail in IgE and Non-IgE mediated pediatric cow milk allergy**
Tracy Augustine (Qatar)

16:45 - 18:15 IH4 - Artificial intelligence in allergy and health: from analytics to patient interaction
(Innovation Hub, Innovation Hub)

*Chairs: **Paul V. Williams (United States of America), Bernardo Sousa-Pinto (Portugal)***

16:45 **Potential of AI for biostatistical analyses**
Michal Ordak (Poland)

17:15 **Artificial Intelligence-Supported development of health guideline questions**
Amelia Licari (Italy)

17:45 **Chatbots in allergy care: enhancing practice through ai conversations**
Ebru Damadoğlu (Türkiye)

16:45 - 18:15 ISW 8 - Interpreting clinical and laboratory signs of mastocytosis
(Meeting Academy M1, Interactive Workshop)

*Chairs: **Mariana Castells (United States of America), Theo Gülen (Sweden)***

16:45 **Skin lesions: recognition and further management**
Karin Hartmann (Switzerland)

17:15 **Elevated tryptase: diagnostic significance**
David González-de-Olano (Spain)

17:45 **Testing for KITD816V mutation in peripheral blood: does the technique matter**
Sigurd Broesby-Olsen (Denmark)

16:45 - 18:15 NAIS Jeopardy Quiz Challenge
(Forth, NAIS Session)

*Chair: **M. Kacar (Ljubljana, Slovenia)***

16:45 - 18:15 OAS11 - Clinical and immunological aspects in allergen immunotherapy
(Carron 1, Oral Abstract Sessions)

Chairs: ***Mattia Giovannini (Italy), Carmen Riggioni-Viquez (Canada)***

16:45 000114
Clinical remission of allergic rhinoconjunctivitis with a 300IR 5-grass pollen sublingual immunotherapy tablet
Randolf Brehler (Germany)

16:57 000172
Effectiveness of House Dust Mite Subcutaneous Immunotherapy on Co-existing Allergen Symptoms in Polysensitized Patients with Allergic Rhinitis: A Multicenter Retrospective Analysis
Zhouxian Pan (China)

17:09 000599
Immunological Effects of Repeated Subcutaneous Administration of Vitamin D3 in Birch Pollen Allergic and Healthy Individuals
Noémi Anna Nagy (Netherlands)

17:21 000743
The efficacy analysis and immunological changes after Alternaria alternata immunotherapy
Juan Liu (China)

17:33 001098
Increased Inhibitory Surface Marker PD-1 Expression in CD4+T Cells and Th2+T Cells in Allergen-specific Immunotherapy
Liu Yun (China)

17:45 001359
Allergen-specific IgE-blocking antibodies in the course of allergen immunotherapy
Katarína Repiská (Austria)

17:57 001369
Proof-of-concept study for the monitoring of AIT-efficacy by detecting sIgE-changes by allergen-macroarray
César Galván-Calle (Peru)

16:45 - 18:15 OAS12 - New trends in atopic dermatitis
(Carron 2, Oral Abstract Sessions)

Chairs: ***Torsten Zuberbier (Germany), Anders Funch (Denmark)***

16:45 000539
National trendNational trends and disparities in complementary food diversity for infants with atopic dermatitis: A 12-year cross-sectional cohort study of births
Man Yong Han (Korea, Republic of)

16:57 000993
Treatment of severe atopic dermatitis in pediatric patients with Dupilumab and effects of therapy on nasal and skin microbiota: preliminary experimental evidence
Cristiana Indolfi (Italy)

17:09 001559
Atopic Dermatitis in Early Childhood: Linking Disease Severity, Food Sensitization, Biomarkers, and Airway Dysfunction
Zeynep Gulec Koksal (Türkiye)

17:21 001105
Atopic dermatitis patients with IL-22 response by House dust mite-activated circulating CLA+ memory T cells display a distinct molecular signature in lesional skin
Luis F Santamaria-Babi (Spain)

17:33 001535
Evaluation of sleep quality, social-emotional development and parental stress levels of children with atopic dermatitis
Deniz Yılmaz (Türkiye)

17:45 001633
Therapeutic effectiveness and safety of cannabinoids in the treatment of atopic dermatitis: a systematic review
Maria Fernanda Moreno (Colombia)

17:57 001239
Nationwide Big Data Analysis of Atopic Dermatitis Treatments in Japan: Real-World Findings on the Impact of Dupilumab
Chiaki Takahashi (Japan)

16:45 - 18:15 SY17 - Non-allergic comorbidities in allergic patients
(Lomond Auditorium, Symposium)

Chairs: ***Marie-Charlotte Brüggen (Switzerland), Audrey Dunn Galvin (Ireland)***

16:45 **Trends and considerations regarding comorbid conditions in patients with atopic dermatitis**
Peter Schmid-Grendelmeier (Switzerland)

17:15 **Mental health conditions related to allergic disease**
Joshua Lawson (Canada)

17:45 **Approaches to the management of patients with airway diseases and comorbid non-allergic conditions**
Mario Cazzola (Italy)

16:45 - 18:15 SY18 - Th2 immune responses and clinical outcomes
(Hall 1, Symposium)

Chairs: ***Sophia Karagiannis (United Kingdom), Francesco Cinetto (Italy)***

16:45 **Type 2 innate lymphoid cells in cancer immunity.**
Nicolas Jacquelot (Canada)

17:15 **Association between immunodeficiency, atopy and malignancy in IgE-deficient patients**
Denisa Ferastraoaru (United States of America)

17:45 **Tregs and IgE responses at the interphase between allergy, autoimmunity and cancer**
Oscar Palomares (Spain)

16:45 - 18:15 YIR-YIR1
(EAACI Global Stage, Year in Review)

Chairs: ***Ozlem Goksel (Türkiye), Désirée Larenas-Linnemann (Mexico)***

16:45 **Allergen immunotherapy for airway allergy**
Domingo Barber (Spain)

17:15 **Oral immunotherapya for food allergy**
Philippe Eigenmann (Switzerland)

17:45 **Biologicals for skin allergy**
Maria Bova (Italy)

16:45 - 18:30 SY16 - Healthier planet, healthier people: the recipe for a sustainable future
(Clyde Auditorium, Symposium)

Chairs: ***Monika Raulf (Germany), Wojciech Feleszko (Poland)***

16:45 **Prescribing natural food for immune and mental health**
Emilia Vassilopoulou (Greece)

17:15 **Inequalities on environmental exposures and allergic diseases and asthma**
Allison J. Burbank (United States of America)

17:45 **Global environmental changes, conflicts and migration, and related respiratory health impacts**
Jouni Jaakkola (Finland)

18:15 **From Patient to Planet: Building a Healthier Future Together**
Angel Sanchez (Spain)

07:45 - 08:30 MTE9 - Management of the reactions to inodiated contrast media
(Carron 1, Meet the Expert)

*Chair: **Anca-Mirela Chiriac (France)***

07:45 **Management of the reactions to inodiated contrast media**

07:45 - 08:30 MTE10 - Mast cell activation test and food allergy
(Carron 2, Meet the Expert)

*Chair: **Alexander Eggel (Switzerland)***

07:45 **Mast cell activation test and food allergy**

07:45 - 08:30 MTE11 - Improve statistics to analyse your data
(Dochart 1, Meet the Expert)

*Chair: **Michal Ordak (Poland)***

07:45 **Improve statistics to analyse your data**

07:45 - 08:30 MTE12 - Recent advances in natural killer cells and innate lymphoid cells
(Dochart 2, Meet the Expert)

07:45 **Recent advances in natural killer cells and innate lymphoid cells**
Günnur Deniz (Türkiye)

09:00 - 10:00 SSS 6 - EAACI & KAAACI Joint Symposium : New horizons toward controlling allergy and allergens
(Boisdale, Sister Society Symposium)

*Chairs: **An-Soo Jang (Korea, Republic of), Patrizia Bonadonna (Italy)***

09:00 **Pet and laboratory animal allergy in Korea**
Lee Sang Min (Korea, Republic of)

09:20 **Unraveling the origins of pediatric allergy: Insights from Korean cohort studies for allergy control**
Hyo-Bin Kim (Korea, Republic of)

09:40 **Trends of drug allergy in Asia**
Philip Li (Hong Kong)

09:00 - 10:30 FT15 - The Heterogenicity of asthma
(Dochart 2, Flash Talks)

Chairs: ***Zeynep ÇElebi Sözener (Türkiye), Javier Dominguez-Ortega (Spain)***

09:00 000843
Evaluation of sinonasal involvement in patients with asthma and chronic obstructive pulmonary disease
Nilay Orak Akbay (Türkiye)

09:07 001426
Clinical Effectiveness of Tezepelumab on Upper and Lower Airway Symptoms in Patients with Asthma and Co-morbid Nasal Polyposis
Jessica Gates (United Kingdom)

09:14 000740
Dupilumab alleviates the abnormal differentiation of club cells induced by IL-13 in chronic rhinosinusitis with nasal polyps
Zhi-Qun Huang (China)

09:21 001060
Alterations in cell-cell contacts are relevant for bradykinin-mediated endothelial barrier disruption
Raphael Möhrle (Germany)

09:28 001251
The effect of brief and sustained hypoxic conditions on immunological properties of Human Lung Microvascular Endothelium
Jolanta Kalinowska (Poland)

09:35 000440
CD62L blockade may affect the activity of the eosinophil
Daniel Rodríguez-González (Spain)

09:42 000820
Association between Blood Eosinophil Counts, Nasal Cytology, and Serum Inflammatory Biomarkers in Patients with Severe Asthma. The BRISA STUDY
Gabriela Leon-Zambrana (Spain)

09:49 000997
Long-term Qipian® administration prevents airway inflammation in ovalbumin-induced mouse asthma via restoring Th1/Th2 balance and modulating gut microbiota
Huiying Wang (China)

09:56 000109
Elevated Fucosylation and the Role of Fut1 in Asthma: A Key Contributor to Abnormal Glycosylation in Airway Epithelial Cells
Chuangli Hao (China)

10:03 001012
Challenges for transitional care for adolescents and young adults with asthma - from the healthcare professionals' perspectives
Maria Ödling (Sweden)

10:10 000348
Multicohort Analysis Profiles the Blood-Based Transcriptome Features of Adult and Childhood Asthma
Fengming Zhao (China)

09:00 - 10:30 FT14 - Allied health and primary care
(Dochart 1, Flash Talks)

Chairs: ***Emilia Vassilopoulou (Greece), Dermot Ryan (United Kingdom)***

09:00 001361
Pattern of insect venom hypersesitivities: Is there a difference between Eastern and Western Europe?
Kateryna Gashynova (Ukraine)

09:07 001374
China's First Three-Dimensional Indoor Dust Mite Allergen Distribution Map: A Cross- Sectional Study of Dust Mite-Allergic Patients in Guangzhou
He Zhang (China)

09:14 001688
Study on the Reliability and Validity of Psychological Assessment Scales for Children with Allergic Rhinitis and Analysis of Influencing Factors
Xiang Gao (China)

09:21 000644 **Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On- demand Treatment Claims in the US**
Daniel Soteres (United States of America)

09:28 001483 **Anaphylaxis management: an evaluation on physicians' expertise of a healthcare unit**
Adriana Grilo Mendes (Portugal)

09:35 000998 **The diagnostic value of peripheral blood cell parameters, fractional exhaled nitric oxide, serum total IgE and lung function in eosinophilic asthma**
Liu Yun (China)

09:42 001126 **From Itch to Emergency: Eczema Herpeticum Threat in Atopic Dermatitis Patients**
Gül ÜNLÜ KILAVUZ (Türkiye)

09:49 000971 **Prevalence and risk factors of systemic allergic reactions to bee venom among Slovenian beekeepers: implications for public health and clinical practice**
Tanja Carli (Slovenia)

09:56 100525 **Comprehensive Allergy Education program for primary care professionals EAACI Task Force, following the publication of General Practitioners and Primary Care Paediatricians EAACI Position papers**
Dermot Ryan (United Kingdom)

09:00 - 10:30 IH5 - Telemedicine
(Innovation Hub, Innovation Hub)

*Chairs: **Stephanie Dramburg (Germany), Gavriela Feketea (Greece)***

09:00 **Asthma management in the digital age**
Sharon R. Chinthrajah (United States of America)

09:30 **Current applicability of telemedicine to allergic diseases**
Tomás Chivato (Spain)

10:00 **The future of telemedicine after COVID-19 pandemic**
Mário Morais-Almeida (Portugal)

09:00 - 10:30 IWS9 - How to manage asthma patients in the clinic
(Meeting Academy M1, Interactive Workshop)

*Chairs: **Ruby Pawankar (Japan), Jasper Kappen (Netherlands)***

09:00 **Benefits and pitfalls of high dose ICS in asthma**
Christer Janson (Sweden)

09:30 **Finding the right asthma patient for LAMA therapy**
Santiago Quirce (Spain)

10:00 **Potential of biologicals usage in moderate asthma**
Stefano Del Giacco (Italy)

09:00 - 10:30 IWS10 - Management of hypersensitivity to chemotherapy
(Forth, Interactive Workshop)

Chairs: ***Ricardo Madrigal-Burgaleta (United Kingdom), Mona Al-Ahmad (Kuwait)***

09:00 **Risk evaluation in hypersensitivity to chemotherapy**
Mauro Pagani (Italy)

09:30 **Platinum drug hypersensitivity reactions - diagnosis and management with desensitization**
Sevim Bavbek (Türkiye)

10:00 **Beyond the intravenous route for drug desensitization to chemotherapeutic agents and monoclonal antibodies: Intramuscular, subcutaneous, and intraperitoneal protocols**
Mariana Castells (United States of America)

09:00 - 10:30 JMA 5 - JM-NAS Symposium : Early life exposure and allergy development
(EAACI Global Stage, JMA)

Chairs: ***Polina Pyatilova (Germany), Ozge Can Bostan (Türkiye)***

09:00 **Food allergies and infant feeding practices**
Idit Lachover-Roth (Israel)

09:30 **The effect of early exposure to pet animals on allergy and asthma development**
Angela Klain (Italy)

10:00 **Allergen characteristics in human milk**
Maria Kostara (Greece)

09:00 - 10:30 OAS14 - Natural history and treatment of food allergy
(Carron 2, Oral Abstract Sessions)

Chair: ***Enza D'Auria (Italy)***

09:00 000302 **Decreased frequency and severity of oral immunotherapy induced gastrointestinal eosinophilic reactions following revisions in treatment protocol**
Naama Epstein-Rigbi (Israel)

09:12 001320 **Oral immunotherapy to hazelnut in children: a single-center retrospective study in an Italian cohort**
Simona Barni (Italy)

09:24 100272 **National Insights into EHR Allergy Documentation: Standards and Practices Revealed through FOI Requests**
Melvin Lee Qiyu (United Kingdom)

09:36 001529 **Food allergies and quality of life in children and their families: a multicenter study**
Cristina Ferrigno (Italy)

09:48 000365 **Infant feeding and allergy prevention guidelines reduce IgE-mediated egg and peanut allergies prevalence – a cohort comparison study**
Debra Palmer (Australia)

10:00 000219 **Natural History Of Sesame Allergy In Pediatric Patients: Insight From A Retrospective Analysis**
Alp Kazancioglu (Türkiye)

10:12 001152 **High degree of sustained unresponsiveness and safety after three years of slow up-dose peanut oral immunotherapy in toddlers - results from the SmaChO study (Small Children Oral Immunotherapy)**
Susanna Klevebro (Sweden)

09:00 - 10:30 OAS13 - Diagnosis and management of Eosinophilic Esophagitis
(Carron 1, Oral Abstract Sessions)

Chairs: ***George Konstantinou (Greece), Willem Van De Veen (Switzerland)***

09:00 000344
Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis
Lisa Beck (United States of America)

09:12 000176
Disrupted mucosal vascular barrier in adult patients with eosinophilic esophagitis
Carlo Maria Rossi (Italy)

09:24 000403
Dupilumab Is Efficacious in Children Aged 1–11 Years Weighing ≥15 kg With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study
Antonella Cianferoni (United States of America)

09:36 001173
Dupilumab decreases the number of days with dysphagia in adult and adolescent patients with eosinophilic esophagitis: post hoc analysis of LIBERTY EoE TREET study
Francesca Racca (Italy)

09:48 000541
Cross-Sectional Real-World Survey of Adult Patients with Eosinophilic Oesophagitis: Symptom Burden and Adaptive Behaviours
Mirna Chehade (United States of America)

10:00 000691
Outcomes of food reintroduction and identification of food triggers in paediatric eosinophilic gastritis
Wenyin Loh (Singapore)

10:12 000685
Reference values of Eosinophilic Derived-Neurotoxin in blood of adults: reasons to use EDTA plasma
Douwe de Boer (Netherlands)

09:00 - 10:30 SY20 - Present and future of allergen immunotherapy
(Lomond Auditorium, Symposium)

Chairs: ***Mubeccel Akdis (Switzerland), Oliver Pfaar (Germany)***

09:00 **Real-world allergen immunotherapy effectiveness in allergic asthma**
Benedikt Fritzsching (Germany)

09:30 **Sustained and Long-term effect of allergen immunotherapy in local respiratory allergy**
Carmen Milagros Rondon (Spain)

10:00 **Novel allergen immunotherapy strategies**
Janice A Layhadi (United Kingdom)

09:00 - 10:30 SY21 - Very early nutrition and allergy outcomes
(Hall 1, Symposium)

Chairs: ***Rosan Meyer (France), Berber Vlieg-Boerstra (Netherlands)***

09:00 **The role of the maternal diet during pregnancy and allergy prevention**
Carina Venter (United States of America)

09:30 **The importance of colostrum in allergy prevention**
Valérie Verhasselt (Australia)

10:00 **Update on early life nutrition guidelines and allergy prevention**
Graham Roberts (United Kingdom)

09:00 - 10:30 TSY5 - The role of mucus in asthma and CRS severity
(Alsh, Thematic Symposium)

Chairs: ***Korneliusz Golebski (Netherlands), Markus Ollert (Luxembourg)***

09:00 **Mucus in practice**
Parameswaran Nair (Canada)

09:30 **Immunology of mucus**
Adam Chaker (Germany)

10:00 **Mucus plugs and T2 biology**
Helena Aegerter (Belgium)

09:00 - 10:45 SY19 - Atopic dermatitis; the other side of the mirror
(Clyde Auditorium, Symposium)

Chairs: ***Jan Gutermuth (Belgium), Helen Brough (United Kingdom)***

09:00 **Feeding the epithelial barrier: the impact of diet on skin barrier function**
Andrea Reboldi (United States of America)

09:30 **The impact of food allergens on atopic dermatitis**
Mark Boguniewicz (United States of America)

10:00 **Impact of aero allergens and microbes on atopic dermatitis**
Luis F Santamaria-Babi (Spain)

10:30 **Atopic Dermatitis in the Mirror: Seeing Beyond the Symptoms**
Tina Mesaric (Slovenia)

11:00 - 12:30 PL7 - New horizons in the management of severe atopic dermatitis
(Clyde Auditorium, Plenary Lectures)

Chairs: ***Annick Barbaud (France), Marie-Charlotte Brüggen (Switzerland)***

11:00 **Biomarkers for Atopic Dermatitis: Towards Personalized Treatment**
Lisa Beck (United States of America)

11:30 **Biologicals for Atopic Dermatitis: Current Efficacy and Future Directions**
Marjolein De Bruin-Weller (Netherlands)

12:00 **JAK Inhibitors for Atopic Dermatitis: A New Frontier in Treatment**
Jan Gutermuth (Belgium)

11:00 - 12:30 PL8 - One Health: Addressing Environmental Challenges in Allergy and Immunology
(Lomond Auditorium, Plenary Lectures)

Chairs: ***Oliver Pfaar (Germany), Isabella Annesi-Maesano (France)***

11:00 **Biodiversity Loss and Allergic Diseases: Connecting Ecosystem Health with Human Immunity**
Kari Nadeau (United States of America)

11:30 **Climate Change and Its Impact on Allergic Diseases: A Global Perspective**
Claudia Traidl-Hoffmann (Germany)

12:00 **Environmental Pollutants and Allergic Diseases: what the evidence says**
Elaine Fuertes (United Kingdom)

11:00 - 12:30 PL9 - Highlights of EAACI Task Forces: Bridging Innovation and Clinical Practice
(Hall 1, Plenary Lectures)

*Chairs: **Arantza Vega Castro (Spain), Sophia Tsabouri (Greece)***

11:00 **PRACTALL on Artificial Intelligence: Revolutionizing Allergy Research and Care**
Mohamed Shamji (United Kingdom)

11:30 **Immunopharmacology in Allergy: New Horizons**
Cristiana Stellato (Italy)

12:00 **AllergoOncology: Connecting Allergology and Cancer Research**
Sophia Karagiannis (United Kingdom)

12:45 - 13:00 Georgia - NAIS: Georgian Association of Allergology and Clinical Immunology (GAACI)
(EAACI Global Stage, NAIS Session)

12:45 **Developing Allergology and Immunology in Georgia: Past, Present and Future**

12:45 - 13:45 L-FT08 - Dermatology
(Dochart 1, Flash Talks)

*Chairs: **Peter Schmid-Grendelmeier (Switzerland), Maria Bova (Italy)***

12:45 100087 **LP-003 Significantly Decreases CSU Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial**
Heng Liu (China)

12:52 100143 **Burden of illness in adult patients with hereditary angioedema due to C1 inhibitor deficiency**
Teresa Caballero (Spain)

12:59 100203 **CD8+ Skin-Resident Memory T Cells Require TCR Signaling for their Persistence in a Mouse Model of Allergic Contact Dermatitis**
Anders Funch (Denmark)

13:06 100270 **Poorly controlled chronic spontaneous urticaria is associated with significant clinical, humanistic, and economic burden**
Pavel Kolkhir (Germany)

13:13 100281 **Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from a Phase 1b/2a Study**
Martin Metz (Germany)

13:20 100290 **Rupatadine treatment improves disease control in patients with chronic spontaneous urticaria – results from the CURE registry**
Pavel Kolkhir (Germany)

13:27 100338 **Treatment with Omalizumab in chronic spontaneous urticaria: experience in a tertiary hospital**
Dinara Korshunova (Spain)

13:34 100575 **Cellular and Molecular Immunoprofiling of Lupus Panniculitis: Elucidating the Roles of Cytotoxic and skin homing T Cells, B Cells, and Complement Activation**
Mohammadmilad Ameri (Switzerland)

12:45 - 13:45 L-FT09 - Anaphylaxis
(Dochart 2, Flash Talks)

*Chairs: **Tomás Chivato (Spain), Philip Li (Hong Kong)***

12:45 100149 **Preventing Future Deaths from anaphylaxis: A review of regulation 28 reports over 11 years**
Vibha Sharma (United Kingdom)

12:52 100168 **Are large local reactions a risk factor for subsequent systemic sting reactions?**
Eva Schadelbauer (Austria)

12:59 100210 **Threshold doses and severity of peach allergy linked to lipid transfer protein sensitisation**
Rosialzira Natasha Vera-Berrios (Spain)

13:06 100248 **Probabilistic risk assessment of anaphylactic reaction to peanut traces in peanut allergic subjects**
Antoine Deschildre (France)

13:13 100428 **Pharmacokinetics and pharmacodynamics of nasal epinephrine powder under normal and allergic rhinitis conditions**
Anne Ellis (Canada)

13:20 100451 **Parental perspectives on nasal adrenaline spray for the acute management of anaphylaxis: an international survey**
Marta Vazquez-Ortiz (United Kingdom)

13:27 100453 **Challenges and Well-Being in Children with IgE-Mediated Food Allergy**
Aysegul Ertugrul (Türkiye)

13:34 100460 **Characteristics of Anaphylaxis in Children Referred to an Allergy Clinic in Sri Lanka: A Descriptive Study**
Inoka Sepali Aberathna (Sri Lanka)

13:41 100523 **Is Skin Testing Necessary in Mild Immediate-Type Penicillin Reactions in Children?**
Gulay Irem Parlak Ozel (Türkiye)

12:45 - 13:45 L-OAS09 - Food Allergy
(Carron 1, Oral Abstract Sessions)

*Chairs: **Montserrat Fernandez Rivas (Spain), Natalia Isabel Perez Sanchez (Spain)***

12:45 100014 **Random Forest for predicting successful reintroduction of milk using dietary advancement therapy: A proof-of-concept analysis from the COWS cohort**
Caoimhe Cronin (Ireland)

12:57 100407 **In vitro sensitisation assay for safety assessment of alternative proteins**
Federica Orsenigo (United Kingdom)

13:09 100427 **Global Access to Psychological Services for Food Allergy: Phase Two survey on Quality of Life and Experiences of Mental Health Services for Food Allergy Related Psychological Distress**
Rebecca Knibb (United Kingdom)

13:21 100495 **Are milk ladders created equal? A biochemical analysis of milk ladder foods**
Samantha Blamires (United Kingdom)

13:33 100633 **Is there any allergen in eco-friendly materials made of plant proteins?**
Pascale Couratier (France)

12:45 - 13:45 L-OAS10 - Drug Allergy
(Carron 2, Oral Abstract Sessions)

Chairs: ***Francesca Mori (Italy), Gabriele Cortellini (Italy)***

12:45 100121 **Interoperable Digital Allergy or Adverse Reaction Passport: A Novel Approach to ADR Prevention and Management**
Mingyu Kang (Korea, Republic of)

12:57 100251 **Feasibility of a dedicated preoperative antibiotic allergy delabelling clinic in paediatrics**
Sheena Coyne (Ireland)

13:09 100340 **Dissecting the plasma proteome of DRESS amongst HIV/TB coinfected patients from South Africa**
Jonny Peter (South Africa)

13:21 100362 **Specific single-cell multi-omic signatures define HLA-class I-restricted co-trimoxazole- induced SJS/TEN in persons living with and without HIV**
Andrew Gibson (Australia)

13:33 100578 **Evaluation of PEN-FAST for Cephalosporin and Non-Beta-Lactam Allergy Assessment**
Deniz Göcebe (Germany)

12:45 - 13:45 PiS01 - A booster for our (interconnected) future
(Innovation Hub, Pitch Session)

Chairs: ***Fabio S. Ryser (Switzerland), Ebru Damadoğlu (Türkiye)***

12:45 000950 **Advancing Nasal Polyp Pathology with AI: A Study on 2D to 3D Microscopic Visualization**
Xin Luo (China)

12:52 001462 **Artificial Intelligence Driven Approaches to Endotype Patients with Recurrent Angioedema**
Ilkim Deniz Toprak (Türkiye)

12:59 000490 **Open source release of the Allergen Chip national French database of clinical and multiplex IgE data**
Julien Goret (France)

13:06 100320 **Enhancing Indoor Air Quality by Novel Airborne Pollutant Removal with NanoJet Platform Technology**
Yankang Tian (United Kingdom)

13:13 100323 **The Impact of Nanoparticles on Peripheral Blood Mononuclear Cells and Erythrocytes: A Holotomographic and Bioenergetic Analysis**
Magdalena Zemelka-Wiącek (Poland)

13:20 100559 **Accuracy and Utility of Generative AI in Urticaria Management: A Comparative Study of DeepSeek-R1 and ChatGPT-4.0**
Zhao Wang (China)

12:45 - 13:45 TPS - Poster Session
(Poster Area, Poster Walk)

12:45 - 13:45 SSS 11 - EAACI & GA2CI Joint Symposium : Clinical Frontiers in Allergy and Immunology: A Gulf Region Perspective

(Meeting Academy M1, Sister Society Symposium)

12:45 **The Clinical Relevance of Desert Ecosystem Allergens: Challenges and Insights**
Maryam Ali Al-Nesf (Qatar)

13:05 **Redefining Asthma Outcomes: Is Remission the New Goal?**
Adeeb Bulkhi (Saudi Arabia)

13:25 **Chronic Urticaria: Trends, Challenges, and Therapeutic Advances**
Iman Nasr (Oman)

12:45 - 13:45 SSS 10 - EAACI & ASBAI Joint Symposium : Current overview of the investigation and treatment of immunoallergic diseases in Brazil

(Lomond Auditorium, Sister Society Symposium)

Chairs: ***Fátima Fernandes (Brazil), Herberto José Chong-Neto (Brazil)***

12:45 **Neonatal Screening for Inborn Errors of Immunity**

13:05 **Brazilian Registry of Hereditary Angioedema**
Eli Mansour (Brazil)

13:25 **Anaphylaxis and mast cell activation diseases**
Pedro Giavina-Bianchi (Brazil)

12:45 - 13:45 SSS 7 - EAACI & APAAACI Joint Symposium : Recent Developments in Environmental Issues, Allergic Diseases, and Vaccination in Asia Pacific

(Hall 1, Sister Society Symposium)

12:45 **Exploring the Impact of Climate Change, Microbiome, and Pollution on Allergic Diseases and Health; Intersections with AI**
Ruby Pawankar (Japan)

13:05 **Chronic inflammatory skin diseases and primary atopic disorders**
Amir Abdul Latiff (Malaysia)

13:25 **Integrating Vaccination Innovation for Respiratory Disease Outbreak preparedness**
Iris Rengganis (Indonesia)

12:45 - 13:45 TPS70 - Eosinophilic esophagitis

(Poster Zone, Thematic Poster Session)

Chairs: ***Arzu Bakirtas (Türkiye), George Konstantinou (Greece)***

D3.399 **Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis**
Zhirong Du (China)

D3.402 **Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis**
Serena Coppola (Italy)

D3.403 **Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study**
Antonella Cianferoni (United States of America)

D3.404 **Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent**
Alfred Doyle (United States of America)

D3.406 **Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients**
Ana Bernardino (Portugal)

D3.407 **Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece**
Irene Modestou (Greece)

D3.409 **Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment**
Lisa Nuyttens (Belgium)

D3.410 **A concurrence of eosinophilic esophagitis and eosinophilic gastritis in a patient with hypereosinophillia**
Adhora Mir (Canada)

12:45 - 13:45 TPS59 - Food allergy 04

(Poster Zone, Thematic Poster Session)

Chairs: ***Riccardo Asero (Italy), Mahir Serbes (Türkiye)***

D3.207 **Exercise-Induced Anaphylaxis: A Case Study on Pea Consumption and Allergenic Protein Profiling**
Maria Soledad Zamarro Parra (Spain)

D3.208 **Alpha-L-Fucosidase and Other Allergens in Cardamom-Induced Allergy: A Case Study**
Ana Luísa Pinhal (Portugal)

D3.209 **Cross-Reactivity Between Birch Pollen and Hazelnut: A Case Study on PR-10 Allergens**
María José Martínez (Spain)

D3.210 **Profiling Allergens in Saffron and Achiote: A Case Study on Spice-Induced Anaphylaxis**
Cristina Guerra Auyanet (Spain)

D3.211 **Alpha-Actinin and Hemocyanin as Major Allergens in Crustacean Allergy: A Case Study**
Vanesa Garcia-Paz (Spain)

D3.213 **Anaphylaxis to Sumac in a Patient with Cashew and Pistachio Allergy: Cross-Reactivity Among Anacardiaceae Species**
Joseph Cuthbert (United Kingdom)

D3.214 **Flexible and Safe Oral Immunotherapy (OIT) Regimen Using Home Boiled Nut Broths (HBNB)**
Patarin Jaovisidha (Thailand)

D3.215 **An unusual cause of frequent episodes of severe nausea with near-fainting**
Frank Schultheiss (Australia)

D3.216 **Audit of Peanut Allergy Patients Eligible for Oral Immunotherapy (OIT) in a Paediatric Cohort at Galway University Hospital (2020-2023)**
chiedza chimbare (Ireland)

D3.217 **Lentils anaphylaxis: BAT to the rescue!**
Benoit Sterling (France)

D3.218 **The prevalence of sensitization to major food allergens among children with seasonal allergy symptoms, skin allergy and/or complaints of allergic reactions upon consuming certain food products**
Leyla Namazova-Baranova (Moscow)

D3.219 **Selective Octopus Allergy: A Unique Case Report**
Luisa Iglesias Pena (Spain)

D3.220 **Insect – Seafood Cross-Reactivity: A Combined Skin and Molecular Diagnostic Approach**
Marta Pérez Montoya (Spain)

D3.222 **Contact urticaria to raw potato possible due to cross-reactivity with birch pollen**
Madalina Coman-Stanemir (Romania)

12:45 - 13:45 TPS60 - Food allergy 05

(Poster Zone, Thematic Poster Session)

Chairs: ***Thuy-My Le (Netherlands), Heimo Breiteneder (Austria)***

D3.223 **Investigating Allergens in Mandarin Seeds: A Case Study on Food-Induced Anaphylaxis**
Fernando Pineda de la Losa (Spain)

D3.224 **Barley Flour as a Major Allergen in Gluten-Induced Food Allergy**
Tania Galán Díez (Spain)

D3.225 **Cysteine Protease Fic c 2 in Fig-Induced Allergy: A Case Study on Cross-Reactivity**
María José Martínez (Spain)

D3.226 **Unveiling Allergenic Variability in Peach: A Case Study of Profilin Sensitization and Cross- Reactivity**
Tania Galán Díez (Spain)

D3.227 **Millet as a Rare Allergenic Source: A Case Study of Systemic Allergic Reactions**
Tania Galán Díez (Spain)

D3.228 **Distinguishing True Fish Roe Allergy from Contamination: A Case of Anaphylaxis Linked to Anisakis simplex**
María José Martínez (Spain)

D3.229 **Profiling Allergens in Onion and Garlic Shoots: A Case Study on Severe Food Allergy**
Laura Rodríguez Calderón (Spain)

D3.230 **Thaumatin-like Protein (TLP) as a Common Allergen in Banana, Kiwi, Grape, and Avocado Allergy: A Case Study**
Tania Galán Díez (Spain)

D3.231 **“All-You-Can-Eat”: Omalizumab as a Curative Treatment for Severe Food Allergies - A Case Report**
Inon Sarig (Israel)

D3.232 **Hidden allergy: Anaphylaxis despite negative initial tests**
Sarah Dager García (Spain)

D3.233 **DEFASE assessment for severity of wheat allergy in Chinese children**
Ting Fan Leung (Hong Kong)

D3.234 **Personalized Selection of Milk Formulas for Children with Cow’s Milk Allergy and Histamine Intolerance: Intersection of Innovative Allergy Management and Sustainability**
Nigora Magbulova (Uzbekistan)

D3.235 **A Combined SLIT and OIT Approach for Desensitization in LTP Syndrome: A Promising Strategy**
Tania Davila Teran (Spain)

D3.237 **Legumes Sensitization in Tree nut- vs. Peanut-Allergic Children: What Makes the Difference?**
Isabela Assugeni (Luxembourg)

12:45 - 13:45 TPS65 - Immune deficiencies and autoimmunity 03
(Poster Zone, Thematic Poster Session)

Chair: ***Hideaki Morita (Japan)***

D3.317 **Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus**
Richard Borrelli (Italy)

D3.318 **Difficult diagnosis of rare XMEN primary immunodeficiency syndrome**
Jana Emlerová (Czech Republic)

D3.319 **Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency**
Andrea Zanichelli (Italy)

D3.322 **Acquired chronic granulomatous disease secondary to myelodysplastic disorder**
Aviv Talmon (Israel)

D3.324 **Mastoiditis as complication of Hyper IgM syndrome**
Ariadna Palafox Olvera (Mexico)

D3.325 **Gene Testing in a Cohort of Patients with Hypogammaglobulinaemia: Experience from a Singaporean Centre for Adults**
Shang Ming Samuel Lee (Singapore)

D3.326 **A rare coexistence: Card9 deficiency and IgG4-related disease in a pediatric patient**
Muhammet Kaya (Türkiye)

D3.327 **Use of C1 Inhibitor Subcutaneously in the United Kingdom**
Ky Lyn Tan (United Kingdom)

D3.328 **Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia**
Sladjana Andrejevic (Serbia)

D3.329 **5.5 Years of Long-Term Efficacy of Oral Berotralstat-LTP in Hereditary Angioedema Patients**
Tamar Kinaciyan (Austria)

D3.331 **Changes in the attacks's frequency during Lanadelumab treatment in patients with hereditary angioedema from Romania**
Noemi-Anna Bara (Romania)

D3.332 **Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults**
Seda Altiner (Türkiye)

12:45 - 13:45 TPS72 - Insect venom hypersensitivities
(Poster Zone, Thematic Poster Session)

Chairs: ***Gunter Sturm (Austria), Polina Pyatilova (Germany)***

D3.423 **Cross-Reactivity Among Hymenoptera Venoms: A Case Study on Apis, Vespula, and Polistes Allergens**
Fernando Pineda de la Losa (Spain)

D3.424 **Long-term efficacy and re-sting outcomes following venom immunotherapy discontinuation: A 978-patient analysis**
Lidija Bojanić (Slovenia)

D3.425 **Anaphylactic reaction to carpenter bee**
Gabriele Cortellini (Italy)

D3.426 **The Frequency of Previous Large Local Reactions in a Group of 158 Patients with a History of Systemic Reaction after Insect Sting**
Martina Vachová (Czech Republic)

D3.427 **Current practices in diagnosis and treatment of Hymenoptera venom allergy (HVA) in Poland**
Ewa Cichocka-Jarosz (Poland)

D3.428 **CAP-Inhibition use to diagnose genuine double sensitization to vespoid venoms: description of a spanish cohort**
Javier Pereira-Gonzalez (Spain)

12:45 - 13:45 TPS71 - Mastocytosis and mast cells

(Poster Zone, Thematic Poster Session)

*Chairs: **Theo Gülen (Sweden), Mariana Castells (United States of America)***

D3.411 **Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases**
Nina Serwas (United States of America)

D3.412 **MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin**
Emily Brown (United States of America)

D3.413 **Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity**
Frank Siebenhaar (Germany)

D3.414 **The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis**
Cem Akin (United States of America)

D3.415 **Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes**
Fotios Koliofotis (Greece)

D3.416 **Hereditary Alpha-Tryptasemia: A Case Series**
Fatma Esra Gunaydin (United Kingdom)

D3.417 **“Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study”**
Alejandra Jover Walsh (Spain)

D3.418 **Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists**
Zhao Wang (China)

D3.419 **Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data**
Jan Romantowski (Poland)

D3.420 **IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas**
Kinga Fabiańczyk (Poland)

D3.422 **Evaluating Elevated Baseline Mast Cell Tryptase: Insights from an Adult Allergy Service**
Intisar Abdelhakam (United Kingdom)

12:45 - 13:45 TPS73 - Artificial Intelligence + Epithelial cell biology
(Poster Zone, Thematic Poster Session)

Chair: ***Joana Vitte (France)***

D3.429 **Performance Analysis of Five Large Language Models, Including GPTo1-Preview, On an Allergy and Clinical Immunology Exam**
Ozge Can Bostan (Türkiye)

D3.430 **Artificial intelligence Chatbots Can Influence the Decision-Making and Behavior of Patients with Allergies: Results of a Multicenter Evaluation Study**
Artemii Bogomolov (Ukraine)

D3.431 **Can Artificial Intelligence-Based Large Language Models Provide Accurate and Reliable Information to Asthma Patients? A Comparative Analysis with Expert Insights**
Ozge Can Bostan (Türkiye)

D3.432 **Anti-inflammatory properties of IPA on epithelial barrier sites**
Yagiz Pat (Switzerland)

D3.433 **Transcriptome kinetics of esophageal epithelial cells in response to interleukin 13**
Mirelle Kleuskens (Netherlands)

D3.434 **Inverted Air-liquid Interface: Advanced Coculture of Esophageal Epithelium and Mast Cells**
Thea Marie Bek (Netherlands)

12:45 - 13:45 TPS68 - Biomarkers
(Poster Zone, Thematic Poster Session)

Chair: ***Blanca Cárdaba (Spain)***

D3.369 **Childhood exhaled nitric oxide levels predict new-onset allergic rhinitis in adolescence and young adulthood**
Chin-Hung Wang (Taiwan)

D3.370 **Inverse Association between Mitochondrial DNA Copy Number and Atopic Dermatitis in Schoolchildren**
Tzu-Han Su (Taiwan)

D3.371 **Impact of sensitization to main allergen molecules during childhood on adult asthma, atopic dermatitis, rhinitis and food allergy in the BAMSE cohort**
Marit Westman (Sweden)

D3.372 **SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps**
Yong Seok Jo (Korea, Republic of)

D3.373 **Hives and hidden codes: detection of miRNA in chronic spontaneous urticaria patients - pilot study**
Lāsma Lapiņa (Latvia)

D3.374 **Assessment of leukotriene E4 as a long term marker of inflammation between regular maintenance (36 weeks therapy) versus as-needed intranasal corticosteroid use in pediatric allergic rhinitis**
Yong Mean Park (Korea, Republic of)

D3.375 **The impact of strontium exposure on allergic rhinitis development via IRE1-mediated protein expression: ECHO-COCOA study**
Hyo-Bin Kim (Korea, Republic of)

D3.376 **The severity of the dyspnea and symptom components of COPD determines the disease course**
Lawrence DuBuske (United States of America)

D3.377 **Eosinophil-derived neurotoxin measured in nasal mucosal lining fluid (Nasosorption) is a promising type 2 biomarker in allergic rhinitis**
Robert Movérare (Sweden)

D3.378 **Long Covid in epithelial barrier type2 disease: an Italian experience**
Cristiano Caruso (Italy)

D3.379 **Allergen sensitization as a One Health approach: computational IgE clustering in a large cohort of dogs to resolve exposure profiles across Europe**
Theresa-Maria Boehm (Luxembourg)

D3.380 **IL-8 levels in saliva following cigarette smoke extract exposure may serve as a biomarker for predicting COPD development**
Lawrence DuBuske (United States of America)

D3.382 **Evaluation of Serum Arginase-1 Levels in Chronic Urticaria**
Seda Altiner (Türkiye)

D3.383 **Prediction of walnut allergy in sensitized children with atopic diseases**
Franziska Sattler (Germany)

D3.384 **Prevalence of sensitization to panallergens and IgΓ4 profiles against specific foods in patients with eosinophilic esophagitis of allergic phenotype**
Joan Domenech Witek (Spain)

D3.385 **Patterns of molecular allergen sensitization throughout childhood and related allergic diseases: insights from the PARIS birth cohort**
Fanny Rancière (France)

D3.386 **A novel machine learning based gene expression signature for Atopic dermatitis**
Debajyoti Ghosh (United States of America)

D3.387 **The association of early-life urban chemical exposures and cytokines in Thai infants: evidence from a pilot birth cohort study**
Ratchaneewan Sinitkul (Thailand)

D3.388 **Exome Sequencing Provides Critical Insights into Genetic Causes of Food Allergy**
Cynthia Haddad (United States of America)

12:45 - 13:45 TPS75 - Prevention

(Poster Zone, Thematic Poster Session)

Chairs: ***Gonçalo Silva (Portugal), Ekaterina Khaleva (United Kingdom)***

D3.436 **Advancing Equity in Food Allergy Prevention – Insights and Takeaways from CFAAR's Summit for Advancing Equity in Food Allergy**
Michael Yang (United States of America)

D3.437 **An EAACI Task Force Initiative for Visualizing Historical Pollen and Spore Calendars in Europe**
Jose Oteros (Spain)

D3.438 **Advances in Automated Pollen Monitoring in Mediterranean Regions: New Developments from the SYLVA Project in Córdoba (Spain)**
Jose Oteros (Spain)

D3.439 **On-demand treatment of hereditary angioedema attacks: Assessing self-treatment, outcomes and barriers to early intervention**
Nuno Piedade (Portugal)

12:45 - 13:45 TPS58 - Allergen immunotherapy 05
(Poster Zone, Thematic Poster Session)

Chairs: ***Martha Jimenez Freites (Spain), Anna Bobcakova (Slovakia)***

D3.164 **Safety and Efficacy of VIT against Wasp Venom in Patients Older than 60 Years**
Andrzej Bożek (Poland)

D3.165 **Consistent long term benefit of allergen immunotherapy in patients with allergic rhinitis**
Plamena Novakova (Bulgaria)

D3.166 **The mental health of adolescent patients with cat allergy improves with rapid dosing of depigmented cat allergoids**
Angelika Sager (Germany)

D3.167 **Allergoids: Characterising Identity Pre- and Post- Modification Using Compendial and Novel Methods**
Chris Farrier-Ledden (United Kingdom)

D3.169 **Advantage of IgG reactivity testing for the analytical quantification of allergoids**
Amy Hargreaves (United Kingdom)

D3.170 **Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor**
Yara Ruiz García (Spain)

D3.172 **Allergen-specific immunotherapy in patients with allergic rhinitis**
Olga Kolesnikova (Ukraine)

D3.173 **Nationwide pivotal registry study on house dust mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)**
Rongfei Zhu (China)

D3.174 **Comparative analysis of extracts from Cupressus arizonica and Juniperus ashei pollens**
Raquel Moya (Spain)

D3.175 **Tumor Necrosis Factor Receptor 2 (TNFR2) is crucial for the efficacy of Allergen-Specific Immunotherapy in a Pre-clinical Murine Model**
Murilo Luiz Bazon (Luxembourg)

D3.176 **The value of TNF and IL1RN genes in predicting the clinical efficacy of SCIT in children with asthma**
Xiang Gao (China)

D3.177 **Potency of Dermatophagoides spp SLIT tablet compared to US standardized mite in ID testing**
Désirée Larenas-Linnemann (Mexico)

12:45 - 13:45 TPS51 - Allergy diagnosis 10
(Poster Zone, Thematic Poster Session)

Chairs: ***Maria Kostara (Greece), Annette Kuehn (Luxembourg)***

D3.02 **Benefits of non-invasive methods in the diagnosis of occupational asthma: example of asthma due to ammonium persulphate in a hairdresser**
Vera van Kampen (Germany)

D3.03 **Trend analysis of the occurrence of allergic diseases in Polish children over the past 30 years**
Grzegorz Brozek (Poland)

D3.05 **Predictive Value of Bronchodilator Reversibility and FeNO in Assessing Positive Outcomes of Bronchial Provocation Tests in Asthma Patients**
Liu Yun (China)

D3.06 **The Role of Inflammatory Parameters in Predicting Allergy in Childhood Asthma**
Halil Alkaya (Türkiye)

D3.07 **Allergic Asthma in Children: The Hidden Role of Cockroaches**
Angela Klain (Italy)

D3.08 **Cross-disciplinary working in adult food allergy: experience from the UK**
Hannah Hunter (United Kingdom)

D3.10 **Systemic characteristic of 15-LOX and 5-LOX oxo-metabolites in older patients with aspirin exacerbated respiratory disease**
Piotr Szatkowski (Poland)

D3.11 **Bird-Egg Syndrome and Beyond: Exploring Allergies to Egg Yolk and Seeds from Bird Feed Components**
Ana Vitória Soares (Portugal)

D3.12 **A case of Pneumothorax as first manifestation of asthma**
Angela Klain (Italy)

D3.13 **Real-life experience with tezepelumab in severe allergic asthma**
Angel Jose Albarracin Contreras (Spain)

D3.14 **Validation of an environmental exposure chamber for the diagnosis of olive tree pollen allergy**
Elena Ramirez-Mateo (Spain)

D3.15 **Mislabeling of Anaphylaxis in the Emergency Department: A Retrospective Study at King Abdulaziz University Hospital, Jeddah**
Amer Khojah (Saudi Arabia)

D3.16 **Recommendations to travelers with pollen allergy, main pollens identified in aerobiological stations from Perú and Spain**
Oscar Calderón (Peru)

12:45 - 13:45 TPS52 - Allergy diagnosis 11

(Poster Zone, Thematic Poster Session)

Chair: ***Leyla Pur Ozyigit (United Kingdom)***

D3.17 **Systemic Histaminergic Findings in Children with Chronic Urticaria**
Neslihan Gücüyener Özkan (Türkiye)

D3.18 **Allergy to Isobornyl Acrylate (IBOA) present in Sensors and Insulin Infusion Systems in Pediatric Population**
Viviana Mendoza (Spain)

D3.19 **Evaluation of allergens in Atopic Dermatitis in children between 6 months and 18years**
Muntajibuddin Ahmed (India)

D3.20 **Searching for an Alternative Contrast Agent in a Patient Allergic to Multiple Nonionic Iodinated Contrast Media**
Aitana Alberdi (Spain)

D3.22 **Fixed Drug Eruption in a Patient with Vitiligo: localized patch testing as a diagnostic tool**
Nuzhat Abdurrachid (Portugal)

D3.23 **Descriptive and Comparative Analysis of Clinical and Endoscopic Characteristics and Treatment Response in Adult Patients with Eosinophilic Esophagitis (EoE): a preliminary experience of an Italian centre**
Eleonora Piano (Italy)

D3.24 **From angioedema to Kimura disease: Diagnostic challenge**
Sona Harutyunyan (Armenia)

D3.26 **Anaphylaxis associated with biosimilar Tocilizumab: in vitro and in vivo diagnosis**
Maria Victoria Espejo Garcia (Spain)

D3.27 **Chlorhexidine as a Hidden Everyday Allergen**
maria victoria sousa pérez (Spain)

D3.28 **Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria**
Abhishek De (India)

D3.29 **Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients**
Lauren Loop (United States of America)

D3.30 **Fixed drug eruption: exploring diagnostic considerations and triggers in a cohort study**
Maria-Lucia Apostol (Romania)

D3.31 **Successful Management of Primary Cold Urticaria in Medical Practitioners: A Small Case Series**
Alexandra Chera (Romania)

D3.33 **Severe Eosinophilic Esophagitis: the Key Role of Biologics in Disease Management**
Catarina Guedes (Portugal)

12:45 - 13:45 TPS53 - Allergy diagnosis 12

(Poster Zone, Thematic Poster Session)

Chair: ***Teresa Alfaya Arias (Spain)***

D3.34 **Cephalosporine drug provocation in a population of children with confirmed serum sickness- like reaction to amoxicillin**
Victor Paradis (Canada)

D3.35 **Severe atopic dermatitis poorly controlled, or something else?**
Natalia Martos Bianqui (Spain)

D3.36 **Contact allergy to sodium metabisulfite in Singapore: A single-center retrospective study of patch test data from 2004 to 2021**
Shi Yu Derek Lim (Singapore)

D3.37 **Beware of the Rare: AGEP**
Irena Stancheva (Bulgaria)

D3.38 **Clinico-demographic study of foot dermatitis and role of patch testing**
Mona Sharma (India)

D3.39 **Autoimmune Progesterone Dermatitis Case Report**
Merve Taş (Türkiye)

D3.42 **Symmetrical drug-related intertriginous and flexural exanthema related to symptomatic slow- acting drug for osteoarthritis (SYSADOA) – a case report**
Elena Petkova (Bulgaria)

D3.43 **PsAllergy – combination of psoriasis and allergic pathology in paediatric patients**
Leyla Namazova-Baranova (Moscow)

D3.44 **The Role of Medical History and Diagnostic Testing in Identifying Post-Surgical Allergic Reactions**
Vania Livia Cantafio Duo' (Italy)

D3.45 **Perioperative Immediate Hypersensitivity Reactions: First Chilean Cohort Study 2020-2024 Clinical Hospital University of Chile**
Mackarena Beltrán Avello (Chile)

D3.46 **Prevalence of Sleep-Disordered Breathing and Its Impact on Quality of Life in Children with Allergic Diseases in Makkah, Saudi Arabia**
Amer Khojah (Saudi Arabia)

12:45 - 13:45 TPS54 - Allergy diagnosis 13

(Poster Zone, Thematic Poster Session)

Chairs: ***Nuria Contreras (Spain), Willem Van De Veen (Switzerland)***

D3.47 **Implementing Penicillin Delabelling in an Inpatient setting**
Usmaan Ahmed (United Kingdom)

D3.48 **The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital**
Cristina Higuera Benítez (Spain)

D3.49 **Clinical significance and safety of provocation test for drug allergy diagnosis in outpatient unit: A real world observational study**
Huiying Wang (China)

D3.50 **Penicillin-allergic labelled patients with a PEN-FAST score of 0 could safely be de-labelled by non-allergists**
Nina Frelih (Slovenia)

D3.51 **Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists**
Xin Rong Lim (Singapore)

D3.53 **A retrospective audit of NSAID hypersensitivity in children and young people in a tertiary paediatric allergy centre**
Monisah Ahmed (United Kingdom)

D3.54 **Hypersensitivity reactions during therapy with platinum compounds and taxanes – who can benefit from consulting an allergist?**
Olga Plackowska (Poland)

D3.55 **Synthetic folic acid allergy**
Vyanka Redenbaugh (United Kingdom)

D3.56 **Relevant Aspects in the Investigation of Hypersensitivity Reactions to Non-Beta-Lactam Antibiotics**
Maria Eduarda Trocoli Zanetti (Brazil)

D3.57 **Isoniazid-Induced Lupus in a Filipino Female: A Case Report**
Alhana Ayaon (Philippines)

D3.58 **Drug-Induced Enterocolitis Syndrome (DIES) Associated to Amoxicillin and Amoxicillin- Clavulanic Acid: A Growing Concern at a Tertiary Hospital**
Carolina Macedo (Portugal)

D3.59 **Insights from Drug Provocation Testing in Quinolone Allergy**
Anna Ventosa (Spain)

D3.60 **Iodinated Contrast Media During Acute DRESS: A Hidden Risk for Future Drug Hypersensitivity?**
Irene Rosmaninho (Portugal)

D3.63 **5 Year Follow Up: Unveiling True Beta-Lactam Immediate Hypersensitivity in the University of Chile Clinical Hospital**
Valeria Cortés Bórquez (Chile)

D3.62 **Beta-Lactam Hypersensitivity: 5-year characterization of patients evaluated at the University of Chile Clinical Hospital**
Daniela Cereceda Molina (Chile)

D3.64 **Allergic diseases in children with autism spectrum disorders**
Leyla Namazova-Baranova (Moscow)

D3.65 **Risk factors and molecular profiles of sensitization in infants with atopy in early ontogenesis**
Leyla Namazova-Baranova (Moscow)

12:45 - 13:45 TPS69 - Allied health and primary care
(Poster Zone, Thematic Poster Session)

Chairs: ***Pedro Alves (Portugal), Farah Hannachi (Luxembourg)***

D3.389 **Deep Learning-Based Real-Time Identification of Wheezing in Lung Sounds: Applications in Disease Prediction and Early Intervention**
Sungchul Seo (Korea, Republic of)

D3.390 **Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)**
Emel Aygören-Pürsün (Germany)

D3.391 **Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)**
William Lumry (United States of America)

D3.392 **What information and education is crucial for people with food allergies?**
Nam Sze Cheng (Hong Kong)

D3.393 **Daily life with a peanut allergy, as a young adult- an interview study**
Susanne Lundin (Sweden)

D3.394 **Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy**
Mauro Cancian (Italy)

D3.395 **Evaluation for suspected penicillin allergy - the patient perspective**
Agnes Csuth (Sweden)

D3.396 **Evidence summary of indoor environmental controls in dust mite allergic patients**
He Zhang (China)

D3.397 **China's Hypoallergenic Home Visit Program: A Standardized Process for Environmental Control Based on a Mobile Application**
He Zhang (China)

D3.398 **Food provision experience of inpatients with adverse food reactions in the acute hospital setting**
Kate Grimshaw (United Kingdom)

12:45 - 13:45 TPS63 - Anaphylaxis 04
(Poster Zone, Thematic Poster Session)

Chairs: ***Vanesa Esteban (Spain), Deniz İlgün Gürel (Türkiye)***

D3.265 **Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report**
Helena Garcia Vila (Spain)

D3.268 **Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production**
Aidan Maloney (United States of America)

D3.269 **Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings**
Gizem Koken (Türkiye)

D3.270 **A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system**
Andrea Escolar-Peña (Spain)

D3.272 **Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients**
Büşra Koçali (Türkiye)

D3.273 **Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria**
Rosalind Capelin-Jones (United Kingdom)

D3.274 **Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria**
Büşra Koçali (Türkiye)

D3.275 **Anaphylaxis caused by polyhexanide**
Begoña Astrain (Spain)

D3.276 **Acalabrutinib as premedication in platinum agents desensitization protocols: a case series supporting its role in enhancing tolerance with a repeatible efficacity**
Ileana Maria Ghiordanescu (France)

D3.277 **Features of severe anaphylaxis in children, data from the Moscow Pediatric Register**
Aliya Barmenova (Kazakhstan)

12:45 - 13:45 TPS55 - Asthma 06

(Poster Zone, Thematic Poster Session)

Chairs: ***Oliver Price (United Kingdom), José Antonio Cañas (Spain)***

D3.96 **A Case of Herpes Zoster Following the First Dose of Benralizumab**
Kurtulus Aksu (Türkiye)

D3.97 **Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis with Nasal Polyps and Asthma: Efficacy and Prognostic Factors**
Xiaomei Yang (China)

D3.99 **Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics**
Ruperto González Pérez (Spain)

D3.100 **Risk Factors and Biomarkers for COVID-19 and Allergic Diseases**
I-Jen Wang (Taiwan)

D3.102 **PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience**
Solange Oliveira Rodrigues Valle (Brazil)

D3.103 **Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease**
Adam Stępień (Poland)

D3.104 **A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study**
Valentina Marzio (Italy)

D3.105 **Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report**
Ágnes Kiricsi (Hungary)

D3.106 **Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry**
Enrico Heffler (Italy)

D3.107 **Investigating the Role of IL17 rs763780 Gene Polymorphism Associated with Asthma among Population of West Bengal, India**
Saibal Moitra (India)

D3.108 **PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5- Targeted Therapies in Severe Asthma**
Ignacio Davila (Spain)

D3.109 **Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis**
Ava de Brugerolle (France)

D3.110 **Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs**
Sarah Bounetta Belmokhtar (France)

D3.111 **Lymphocyte profile and asthma control during the treatment with benralizumab in real life**
Justina Sematonyte (Lithuania)

D3.112 **Role of nasal cytology in patients with bronchial asthma**
Emanuele Cataldo (Italy)

D3.113 **In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab**
Ashish Kalra (United States of America)

12:45 - 13:45 TPS56 - Asthma 07

(Poster Zone, Thematic Poster Session)

Chairs: ***Paraskevi Xepapadaki (Greece), Susanne Vijverberg (Netherlands)***

D3.114 **Does severe asthma exist in preschool children?**
Francisco de Asís Palazón Rico (Spain)

D3.115 **Outcome and complications of COVID-19 among children with asthma in South Korea: a national incident cohort study**
Hwan Soo Kim (Korea, Republic of)

D3.116 **Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis**
Andreas Hoheisel (Germany)

D3.117 **Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice**
Mang Yu (United States of America)

D3.118 **Antibiotic Cocktail-Induced Gut Microbiota Dysbiosis Modulates Gut and Airway Immunity, Attenuating Allergic Airway Inflammation**
Choi Doo Young (Korea, Republic of)

D3.119 **Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype**
Masanori Ikeda (Japan)

D3.122 **Management Challenges in Pediatric Asthma with Long QT Syndrome**
Amelia Licari (Italy)

D3.123 **Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study**
Tamara Hernandez Hernandez (Mexico)

D3.124 **Severe asthma associated with hereditary angioedema type 1 and other pathologies**
Dánae Andreu Costa (Spain)

D3.125 **"Save the World-SynAir-G": Evaluation of Internal Reliability of an Innovative Application for Student Health Data Collection**
Maria Kritikou (Greece)

D3.126 **Occupational exposure, sensitisation and respiratory symptoms in shrimp processing plants**
Fikirte Debebe Zegeye (Norway)

D3.127 **A cost effective, self-sustaining, and effective way of improving asthma understanding in undergraduate students**
William Tan (United Kingdom)

D3.128 **THE BACK COVER OF ASTHMA: Retrospective case-report of a 21-year-old woman**
Luis Ruben Resano Redin (Spain)

D3.129 **Descriptive Analysis of Health-Related Physical Activity Patterns Among Korean Adolescents Diagnosed with Asthma**
Dong In Suh (Korea, Republic of)

D3.130 **Selective IgA Deficiency in the Pediatric Population: A Gateway to Allergies and Autoimmunity**
Rocio del Pilar Garcia Brito (Spain)

D3.131 **Predictors of Asthma Development Following Rhinovirus Infection in Preschool Children**
Peter Kunc (Slovakia)

12:45 - 13:45 TPS57 - Asthma 08

(Poster Zone, Thematic Poster Session)

Chair: ***Hille Suojalehto (Finland)***

D3.133 **Association between Asthma and Risk of Respiratory Syncytial Virus-Acute Respiratory Infection in Adults 50 Years or Older Before and After the Covid 19-Pandemic in a Midwest Region of the U.S**
Chung-Il Wi (United States of America)

D3.134 **Evaluation of the level of asthma control in the pulmonology-phtisiology department of the Ignace Deen University Hospital**
Ibrahima Thierno Diallo (Guinea)

D3.135 **Nasal and respiratory symptoms, functional features, and sensitization to platinum salts in platinum catalysts manufacturing workers**
Dragan Mijakoski (North Macedonia)

D3.136 **Worse asthma control in patients with asthma and respiratory allergies in the CAPTURE study: Rationale for developing the RespiratoryAllergyOptimiser**
Dermot Ryan (United Kingdom)

D3.137 **Effectiveness of Dupilumab in improving Quality of Life in patients with “steroid-resistant” asthma and severe atopic dermatitis**
Bashir Omarjee (Réunion)

D3.138 **Asthma remission in EGPA patients: applicability and concordance of the main international guidelines**
Giulia Costanzo (Italy)

D3.139 **Asthma Comorbidities - do they add more cost, A 3-year follow-up study in Réunion Island**
Bashir Omarjee (Réunion)

D3.140 **Xiaoqinglong Decoction Combined with Yupingfeng Powder Alleviates Allergic Rhinitis Complicated with Asthma by Inhibiting B Lymphocyte Activation via JAK2/STAT1/MHC-II signaling pathway**
Ruizhi Wang (China)

D3.142 **Differential Impact of Heat-not-Burn Tobacco Products and Conventional Cigarettes on Pulmonary Cells and Immune Response**
Dilara Karaguzel (Türkiye)

D3.143 **Seasonal Patterns of Airborne Pollen in Ecuador: Influence of Wet and Dry Seasons on Allergenic Taxa Concentrations**
Ivan Cherrez-Ojeda (Ecuador)

D3.144 **Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Mexico City: The Role of Industrial and Traffic Emissions**
Victor Gonzalez-Uribe (Mexico)

D3.146 **Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers**
Ana Filipa Vassalo (Portugal)

12:45 - 13:45 TPS66 - Basic immunology 03

(Poster Zone, Thematic Poster Session)

Chairs: ***Christoph Bergmann (Germany), Nida Öztop (Türkiye)***

D3.333 **Unveiling the Role of PGD2/CRTH2 Signaling in Antigen-Specific IgE Production**
Takahisa Murata (Japan)

D3.334 **Characterization of novel nickel specific cd4+ regulatory T cells from a nickel sensitized joint implant failure patient**
Karin Pacheco (United States of America)

D3.335 **The role of activated leukocyte cell-adhesion molecule in hyperoxia induced acute lung injury**
Jooyeon cho (Korea, Republic of)

D3.336 **CC variant of the -634G/C polymorphism of the VEGF gene is associated with higher HDL levels in patients with type 1 diabetes mellitus**
Lawrence DuBuske (United States of America)

D3.337 **The -634G/C polymorphism of the VEGF gene affects BPI concentration in patients with type 1 diabetes mellitus**
Lawrence DuBuske (United States of America)

D3.338 **The sCD14 level in patients with type 1 diabetes mellitus may be related to the -786T/C polymorphism of the NOS3 gene**
Lawrence DuBuske (United States of America)

D3.339 **Assessment of the immune status of systemic sclerosis patients by flow cytometry**
Lawrence DuBuske (United States of America)

D3.340 **Protocol for autofluorescence-driven isolation of human peripheral blood eosinophils**
Ulrike Raap (Germany)

D3.342 **Involvement of periostin-dependent and -independent pathways in the formation of skin inflammation and itch in a mouse model of atopic dermatitis**
Yukako Tanaka (Japan)

12:45 - 13:45 TPS67 - Biologicals 03
(Poster Zone, Thematic Poster Session)

Chair: ***Friederike Bärhold (Germany)***

D3.358 **The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings**
Cathryn Mcdougall (South Africa)

D3.359 **Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment**
Àlvar Piracés Buitrago (Spain)

D3.362 **Use and safety of canakinumab during pregnancy**
Branislav Šlenker (Slovakia)

D3.363 **Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis**
Marta Lemieszek (Poland)

D3.364 **Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema**
Marta Planas Vinós (Spain)

D3.365 **The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis**
James Hooi (Hong Kong)

D3.366 **Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria**
Anca Gheorghiu (Romania)

D3.367 **Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed- methods study**
Nathalia Vanegas (Colombia)

D3.368 **Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year**
Ana Nin Valencia (Spain)

12:45 - 13:45 TPS64 - Dermatology 04
(Poster Zone, Thematic Poster Session)

Chair: ***Mauro Cancian (Italy)***

D3.290 **Manifestations of allergic skin lesions in the early childhood and adult population: Epidemiological manifestations of diseases**
Lasha Tchelidze (Georgia)

D3.291 **Hereditary angioedema with normal C1Inh and PLG mutation treated with tranexamic acid : Beware of the risk of thrombosis**
Laurence Bouillet (France)

D3.292 **“Evaluating Inflammatory Markers in Chronic Spontaneous Urticaria: Impact of Omalizumab Treatment”**
Corina Ureche (Romania)

D3.293 **Acrodermatitis chronica atrophicans in the field of scleroderma**
Zuzana Humlova (Czech Republic)

D3.294 **Serum Lactate Dehydrogenase levels distinguish atopic dermatitis patients with a predominant production of IL-13, IL-5 and IL-9 in response to house dust mite allergen and increased prevalence of allergic comorbidities**
Irene García-Jiménez (Spain)

D3.295 **Mental health support for atopic dermatitis patients in the Republic of Kazakhstan**
Zhanat Ispayeva (Kazakhstan)

D3.296 **Urticaria activity, quality of life and disease control in chronic spontaneous urticaria patients in Kazakhstan**
Lawrence DuBuske (United States of America)

D3.298 **Monomorphic maculo-papular late age onset cutaneous mastocytosis**
Lawrence DuBuske (United States of America)

D3.299 **Cholinergic urticaria treated with dupilumab**
María Sola Fernández (Spain)

D3.302 **Elevated Kocuria rhizophila contributing to repair of skin barrier function in patients with atopic dermatitis**
Chaewon Lee (Korea, Republic of)

D3.303 **Contact Dermatitis and Rhinoconjunctivitis due to Palisander Wood Exposure in a Cabinetmaker**
Ana Melissa Yanes Bonilla (Spain)

D3.304 **Monitoring skin inflammation in atopic dermatitis by non-invasive sampling through skin tape stripping for multiplex protein analysis is complementary to serum biomarkers**
Edward Knol (Netherlands)

12:45 - 13:45 TPS61 - Drug allergy 04

(Poster Zone, Thematic Poster Session)

Chair: ***Marina Labella Alvarez (Spain)***

D3.239 **Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpesvirus-7 (HHV-7)**
Sook Yin Loh (United Kingdom)

D3.242 **Desensitization to ampicillin fixed drug eruption. Spotting the solution to fix the heart**
Patricia Quijada-Morales (Spain)

D3.243 **Successful subcutaneous desensitization protocols for Canakinumab, Trastuzumab, and Triptorelin: a case series report**
Johanna Amparo Ramirez Villamizar (Colombia)

D3.244 **Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection**
Raisa Millan (Philippines)

D3.245 **Positive HLA-B*13:01 Allele in a Patient with Clinical Diagnosis of Drug Induced Eosinophilia with Systemic Symptoms (DRESS)**
Narissara Suratannon (Thailand)

D3.246 **Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) induced by enoxaparin: a case report and allergology work up**
Rita Sá Teixeira (Portugal)

D3.247 **A case report of multiple drug hypersensitivity triggered by DRESS to beta-lactamase inhibitors**
Megan McCullagh (United Kingdom)

D3.248 **Anaphylactic shock after indocyanine green intracervical administration**
Marina Ruiz De Galarreta (Spain)

D3.249 **Delayed-Type Drug Allergy Combined with Adverse Drug Reactions**
Sofiya Dzhikova (Bulgaria)

D3.250 **Macrolide Hypersensitivity: Exploring the Value of Skin and Provocation Tests in a Portuguese Case Series**
Nuno Piedade (Portugal)

D3.251 **Selective Facial Angioedema Induced by Propionic Acids: A Clinical Study of NSAID Idiosyncratic Reactions (Type 3a)**
Sofía Gómez De La Cruz Pérez (Spain)

12:45 - 13:45 TPS62 - Drug allergy 05
(Poster Zone, Thematic Poster Session)

*Chair: **Tugba Kiratli Yolcu (Türkiye), Cecilia Frecha (Spain)***

D3.252 **Azithromycin and Mycoplasma pneumonia: an unusual Stevens-Johnson syndrome case**
Pauls Bērziņš (Latvia)

D3.256 **Is an Early-Type Hypersensitivity Reaction Possible with Both Peroral and Parenteral Anticoagulant Drugs? A Successful 2-Day Peroral Desensitization Protocol to Rivaroxaban**
Ceyda Tunakan Dalgıc (Türkiye)

D3.257 **Two cases of propofol anaphylaxis revealed by provocation test**
Sophie Vandenberghe (Switzerland)

D3.258 **Probable drug- induced Enterocolitis Syndrome (DIES) caused by Amoxicillin**
Jose Alessandro Bastidas Parlanti (Spain)

D3.259 **KOLLIPHOR : An excipient to be futher explored**
Leyla Barakat (France)

D3.260 **Bempedoic acid allergy in a patient with hypercholesterolemia**
Vyanka Redenbaugh (United Kingdom)

D3.262 **Bempedoic acid allergy in a statin-intolerant patient with hypercholesterolemia**
Vyanka Redenbaugh (United Kingdom)

D3.263 **Rare case of anaphylaxis to lidocaine in skin testing during perioperative anaphylaxis investigation**
Albertina Capelo (Brazil)

D3.264 **Pioneering study evaluating the Basophil Activation Test (BAT), PENFAST and skin sensitization to penicillin in patients with gestational syphilis**
Albertina Capelo (Brazil)

12:45 - 13:45 L-TPS17 - Allergen immunotherapy 07
(Poster Zone, Thematic Poster Session)

*Chairs: **Deniz Eyice Karabacak (Türkiye), Cherie Zachary (United States of America)***

D3.178 **Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies**
Danilo Di Bona (Italy)

D3.179 **Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience**
Eric Fromentin (France)

D3.180 **Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme**
Cor Stengs (Netherlands)

D3.182 **Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden**
Randolf Brehler (Germany)

D3.183 **Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real- World Evidence from Spain and Italy**
Raphaëlle Bazire (Spain)

D3.184 **Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study**
Axel Nöding (Germany)

D3.185 **The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting**
Oliver Pfaar (Germany)

D3.186 **A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase**
Jose Carlos Hernandez Walias (Spain)

D3.187 **Adverse reactions to sublingual immunotherapy with carbamylated allergoids of different sources in clinical studies**
Enrico Compalati (Italy)

D3.188 **Comparison of Completion Rates and Factors Influencing Discontinuation in Paediatric Allergen Immunotherapy: A Five-Year Single-Center Experience**
Elvira Efstathiou (United Kingdom)

D3.189 **Adverse reactions to subcutaneous immunotherapy for mite in children and adolescents in a tertiary care center**
Heloísa Gouveia Machado (Brazil)

D3.190 **Follow up cases of subcutaneous allergen Immunotherapy in respiratory allergic diseases continuing for 10-30years "A Real life experience of 14 cases"**
Sonam Spalgais (India)

D3.191 **Case report: Acute systemic reactions to sublingual immunotherapy for tree pollen**
Marta Navratil (Croatia)

12:45 - 13:45 L-TPS18 - Allergen immunotherapy 08

(Poster Zone, Thematic Poster Session)

Chairs: ***Ozge Can Bostan (Türkiye), Yagiz Pat (Türkiye)***

D3.193 **Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study**
Dominika Ochab-Krupnik (Poland)

D3.194 **Renewal's analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study**
Julien Cottet (France)

D3.195 **Reasons for declining venom immunotherapy and its burden on patients' daily lives**
Tomás Freitas (Portugal)

D3.196 **Efficacy of sublingual immunotherapy in children with allergic rhinitis**
Gintarė Galdikaitė (Lithuania)

D3.197 **When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus**
Carlota Dias (Portugal)

D3.198 **Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy**
Matteo Cavara (Italy)

D3.202 **Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania**
Ieva Jankunaite (Lithuania)

D3.203 **Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts**
Abid Hussain (Denmark)

D3.204 **Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment**
Gjustina Loloci (Albania)

12:45 - 13:45 L-TPS16 - Asthma 11
(Poster Zone, Thematic Poster Session)

Chairs: ***Alina Gherasim (France), Janice A Layhadi (United Kingdom)***

D3.147 **The inhaled PDE4 inhibitor tanimilast shows a broad anti-inflammatory effect in two mouse models of asthma induced by house dust mite**
Anna Rita Pisano (Italy)

D3.148 **Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab**
Robert Greig (United Kingdom)

D3.149 **Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting**
Robert Greig (United Kingdom)

D3.150 **Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33**
Irene Paggi (Italy)

D3.151 **Prevalence and clinical characteristics of adult asthma patients with different phenotype across GINA step 1 to 5 asthma**
Wang Chun Kwok (Hong Kong)

D3.152 **Phenotype and treatment response of allergic patients with severe asthma: a real-world experience from Argentina**
Carla Ritchie (Argentina)

D3.153 **ETB receptor signaling regulates allergic airway inflammation and hyperreactivity**
Christoph Tabeling (Germany)

D3.154 **Safety of allergen immunotherapy in patients with severe asthma. A real-world, multicentre, observational retrospective study**
Eloina Gonzalez Mancebo (Spain)

D3.155 **IL-1 signaling pathway molecules as key markers in childhood severe asthma**
Wenping Wei (China)

D3.156 **Self-reported asthma symptoms and asthma medication usage in patients with possible asthma: A MASK-air® real-world study**
Tuuli Thomander (Portugal)

D3.157 **A study of the detailed patterns of wheeze presence and absence from infancy through to adolescence**
Darije Custovic (United Kingdom)

D3.158 **Clinical and functional profile of children with asthma in a tertiary referral hospital**
Soraya Regina Abu Jamra (Brazil)

D3.159 **Investigation of Huai Qi Huang Granules' Impact and Mechanism on Asthmatic Mice's Antiviral Capability**
Yan Bai (China)

D3.162 **The Effects of Phthalate Exposure on Asthma via Microbiota Changes**
I-Jen Wang (Taiwan)

D3.163 **Mast cell activation test and airway hyperresponsiveness in cat allergy: investigating the link to cat allergen induced asthma**
Clare Murray (United Kingdom)

12:45 - 13:45 L-TPS14 - Allergy diagnosis 16
(Poster Zone, Thematic Poster Session)

Chairs: ***Aray Batyrbaeva (Kazakhstan), Sejal Saglani (United Kingdom)***

D3.66 **National Survey on Perioperative Hypersensitivity Reactions: Clinical and Epidemiological Insights from Spanish Hospitals**
Jose Julio Laguna Martinez (Spain)

D3.67 **Desensitization to Pertuzumab in a Patient with a Mixed Hipersensitivity Reaction**
Ana Raquel Pinto (Portugal)

D3.68 **Pattern of house dust mite and food allergen sensitization in atopic dermatitis patients in Malaysia: Are they important allergens in atopic dermatitis?**
Noormalin Abdullah (Malaysia)

D3.69 **Tissue-Specific Allergen Distribution in Blue Swimmer Crab (Portunus pelagicus): Implications for Shellfish Allergy Diagnostics**
Sahel Heidari (Australia)

D3.70 **Multiple Food Protein-Induced Enteropathy Syndrome: The Role of Skin Patch Testing in Guiding Effective Decision-Making**
Florencia Baillieau (Argentina)

D3.71 **Anaphylaxis Induced by Macrogol: A Case Report**
Maria Jose Calvo Delgado (Spain)

D3.72 **Utility of Basophil Activation Testing in Drug and Peanut Allergy: Concordance with Clinical Outcomes**
Emine Nebati (United Kingdom)

D3.73 **Review of skin testing for delay hypersensitivity drug reactions, possible covariates involved in the results**
Julia Rodriguez De Guzman (Spain)

D3.74 **Algorithmic methods for quantifying spontaneous activation in basophil activation tests: toward scalable data analysis**
Adrian Leathers (Switzerland)

D3.75 **May the presence of eczema alter IgE cut-offs to diagnose egg allergy?**
Davide Caimmi (France)

D3.76 **Allergy to pitaya and granadilla: a common allergen?**
Kristhell Alvarez (Spain)

D3.77 **Hypersensitivity Reactions to Iodinated Contrast Media: A Single-Center Experience**
Soad Haj Yahia (Israel)

D3.78 **A rare case of scombroid syndrome with hypotension and biphasic course**
Christian Paolo Ratti (Italy)

D3.79 **Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata**
Clara Padró (Spain)

D3.82 **Could Lipid Transfer Protein Induced Anaphylaxis Be a Surprising Outcome of Sleeve Gastrectomy?**
Seda Altiner (Türkiye)

12:45 - 13:45 L-TPS15 - Allergy diagnosis 17
(Poster Zone, Thematic Poster Session)

Chair: ***Duygu Yazici (Switzerland)***

D3.84 **Delayed hypersensitivity to hydroxychloroquine with positive patch test**
Andrea Alejandra Fernández Bolívar (Spain)

D3.85 **Evaluation of a new Multiplex Allergen Test Kit for the simultaneous detection of allergen specific IgE**
Hye Jung Lee (Korea, Republic of)

D3.86 **Cholinergic Urticaria and Provocation Testing: Are We Missing the Mark?**
Carlota Dias (Portugal)

D3.87 **Assessing the agreement between skin prick test and specific-IgE for ten common food allergens in infants**
Kayla Parker (Australia)

D3.88 **5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification**
Joana Guimarães (Portugal)

D3.89 **Unexpected Culprit: The Role of Acrylates in Recurrent Anaphylaxis and Antibiotic Hypersensitivity**
Magdalena Adamczewska (Poland)

D3.90 **A long-term freezing protocol to help democratize a streamlined approach to the basophil activation test**
Marie-Elise Castaing-Lasvignottes (France)

D3.91 **Safety of Skin Prick Tests: more than 30 years of spontaneous data from real practice**
Franco Frati (Italy)

D3.92 **Sensitization pattern and diagnostic value of 6 almond components in The Netherlands and Portugal**
Emily Kallen (Netherlands)

D3.93 **An exotic anaphylaxis in the mediterranean: due to a clinical case**
María Jesús Giménez Revilla (Spain)

D3.94 **An exotic anaphylaxis in the mediterranean: due to a clinical case**
María Jesús Giménez Revilla (Spain)

D3.95 **Chronic Scrotal Edema in a Patient with Hereditary Angioedema: A Diagnostic Challenge**
Karina Gojny (Poland)

12:45 - 13:45 L-TPS19 - Anaphylaxis 06
(Poster Zone, Thematic Poster Session)

Chairs: ***Mark Kacar (Slovenia), Sergio Fernandez-Bravo (Spain)***

D3.278 **Cold urticaria: a case report**
Valentina Marmora (Italy)

D3.279 **Biomarkers in anaphylaxis**
Urška Bidovec-Stojković (Slovenia)

D3.282 **Anaphylaxis to Gadoteric Acid: A Case Report**
Verónica Vatnani Moolchandani (Spain)

D3.283 **Taming the Unpredictable: Omalizumab's Role in Idiopathic anaphylaxis and chronic spontaneous urticaria**
Sara Flores Regalo (Portugal)

D3.284 **Update of the Brazilian Anaphylaxis Registry**
Dirceu Solé (Brazil)

D3.285 **Improving Emergency Department Management of Adult Anaphylaxis: A Quality Improvement Initiative**
Leyla Pur Ozyigit (United Kingdom)

D3.286 **Rapid Symptom Resolution in Oral Allergy Syndrome Following Anaphylm Administration: A Phase 2 Study Update**
Matthew Greenhawt (United States of America)

D3.287 **Adverse reactions and complications of Allergic Skin Test (SPT) in North Indian population**
Raj Kumar (India)

D3.288 **Asthma and Anaphylaxis Induced by Milk with NSAID as a Cofactor in Adult Patient Sensitized to Dairy Proteins Due to Environmental Exposure in a Dairy Farm**
Alvaro Moreno Ancillo (Spain)

D3.289 **Pharmacokinetics of adrenaline administered via the ZiBiPen: First human trial findings**
Michael Levin (South Africa)

12:45 - 13:45 L-TPS20 - Dermatology 05

(Poster Zone, Thematic Poster Session)

*Chair: **Laurence Bouillet (France)***

D3.305 **Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety**
Abrar Al-Ahmadi (Canada)

D3.307 **Experience with Systemic Emergent Therapies for Moderate-to-Severe Atopic Dermatitis: Insights from an Allergy and Clinical Immunology Department**
Ana Luísa Pinhal (Portugal)

D3.308 **Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort**
Paola Triggianese (Italy)

D3.309 **Challenges in HAE therapy in children**
Antonia Scherer (Germany)

D3.310 **Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis**
Sara Isik (Germany)

D3.311 **Screening for Hereditary Angioedema in Pediatric Patients with Autoinflammatory Diseases and Chronic Abdominal Pain**
Zülfikar Akelma (Türkiye)

D3.312 **Lymphatic supplementation improves atopic dermatitis in dogs**
Franziska Roth-Walter (Austria)

D3.313 **Chronic Spontaneous Urticaria and its relationship with Allergies to Aerogenic Fungi: dermographism, skin hyperreactivity, and chemical patterns of inflammation**
Maria Alul (Argentina)

D3.314 **Sensitization Profile in Patch Tests with the Portuguese Baseline Series in the Algarve**
Maria Lages (Portugal)

D3.315 **Airborne allergic contact dermatitis to dry shampoo**
Michael Haeberle (Germany)

D3.316 **Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia**
Vesna Karanikolic (Serbia)

12:45 - 13:45 L-TPS21 - Basic immunology 04
(Poster Zone, Thematic Poster Session)

Chair: ***Todor Popov (Bulgaria)***

D3.344 **Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis**
Galiya Tussupbekova (Kazakhstan)

D3.345 **Blood Dendritic Cell Antigen 3-Positive Dendritic Cells Attenuate Th2 Responses in Allergic Rhinitis and Chronic Rhinosinusitis**
Sang Chul Park (Korea, Republic of)

D3.346 **Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke**
Lawrence DuBuske (United States of America)

D3.347 **AllergoOncology: a systematic review of the impact of glycosylation on IgE antibody structure function and mechanisms of disease**
Alex McCraw (United Kingdom)

D3.348 **A Case of 19p13.3 Microdeletion**
Lala Guliyev (Türkiye)

D3.349 **Evaluation of natural killer cells in female infertility**
Brigita Semekliene (Lithuania)

D3.350 **Monocytic myeloid-derived suppressor cells (M-MDSCs) increase the expression of TIGIT on γδ T cells**
Michał Zarobkiewicz (Poland)

D3.351 **Characterization of peanut roasting-enhanced Ara h 2 - Ara h 1 complexes**
Jaap Akkerdaas (Netherlands)

D3.352 **Pathophysiology of autoallergy in atopic dermatitis (PAAD): A Prospective Study**
Hafsa Belasri (Belgium)

D3.353 **An EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology**
Elena Izquierdo (Spain)

D3.354 **Selective IgE deficiency in children: its role in autoimmunity**
Konstantinos Miliordos (Greece)

D3.355 **Decoupling of total IgE and peripheral blood eosinophilia in pancreatic ductal adenocarcinoma: preliminary study**
Alicja Majos (Poland)

D3.356 **Unconventional T cells in leukocyte adhesion deficiency I (LAD-I)**
Izabela Morawska-Michalska (Poland)

13:00 - 13:15 Poland - NAIS: Polish Society of Allergology PTA
(EAACI Global Stage, NAIS Session)

13:00 **"Allergy Care at a Crossroads: Challenges in Specialist Training and Immunotherapy in Poland"**
Karina Gojny (Poland)

13:15 - 13:30 Turkey - NAIS: Society of Pediatric Allergy Immunology and Asthma (CAIAD)
(EAACI Global Stage, NAIS Session)

13:15 **Current trends and characteristics of pediatric anaphylaxis cases in Türkiye**
Esra Yucel (Türkiye)

14:00 - 14:45 P & C 5 - Should we be concerned when starting allergen immunotherapy in patients with controlled HIV infection or autoimmune diseases?

(EAACI Global Stage, Pro Con)

*Chair: **Ingrid Terreehorst (Netherlands)***

14:00 **PRO**
Enrico Heffler (Italy)

14:23 **CON**
Constantinos Pitsios (Cyprus)

14:00 - 15:00 ET 3 - EAACI Enlightening Talks - 3

(Innovation Hub, EAACI Enlightening Talk)

14:00 **From Vision to Legacy: The Story of EAACI and Its Impact on Allergy and Immunology**
Sergio Bonini (Italy)

14:30 **Transforming Allergy and Respiratory Care: Insights from a Lifetime of Research and Innovation**
Jean Bousquet (France)

14:00 - 15:30 FT17 - Predictive value of allergy test

(Dochart 2, Flash Talks)

*Chairs: **Graham Roberts (United Kingdom), Mattia Giovannini (Italy)***

14:00 001322 **Multi-omics analysis of a prebiotic intervention with pectin in lipid transfer proteins (LTPs) allergic patients**
Andrea Macías-Camero (Spain)

14:07 000466 **Dupilumab treatment leads to clinically meaningful improvements in a range of symptoms and quality of life in patients with eosinophilic esophagitis: Post hoc analysis of LIBERTY EoE TREET**
Francesca Racca (Italy)

14:14 000584 **Hypersensitivity reactions to platinum salts and taxanes: determination of mediator release and relation with endotypes involved and reaction severity**
Adriana Ariza (Spain)

14:21 001610 **Starting with Low-Dose Sesame Food Challenges for Oral Immunotherapy**
Adi Ovadia (Israel)

14:28 000756 **Tolerance to alternative fish species in fish-allergic patients: a systematic review**
Lucía Parrado-Gil (Spain)

14:35 000426 **Does dietary supplementation with prebiotics in pregnancy have an effect on child allergy outcomes at 3 years of age? The SYMBA-3-study**
Kristina Rueter (Australia)

14:42 000462 **Profiling of Exhaled Volatile Organic Compounds in different phenotypes of allergic rhinitis**
Trinidad Ilda Gaitan Nievas (Spain)

14:49 000260 **Hypersensitivity to Proton Pump Inhibitors: Are Agents Determined by Provocation Tests in the Clinic Safe in Real Life?**
Ceyda Tunakan Dalgıc (Türkiye)

14:56 001502 **Enhanced Sensitivity of Amoxicillin-Specific IgE Detection in ImmunoCAP and RAST via IgG Removal**
Adriana Ariza (Spain)

15:03 000668	**The Utility of Predicting Outcomes by Considering Intake Amount and Antigen-Specific IgE Levels in Oral Food Challenge Tests** Kyohei Takahashi (Japan)
15:10 000850	**Fish Allergy: Beyond Parvalbumins** Gabriela Acuña Vila (Spain)
15:17 001200	**Skin prick tests with Der p 1, Der p 2 and Der p 23: are they useful?** Pedro Samuel Figueiredo (Portugal)
15:24 100119	**The future of house dust mite allergy diagnostics: can molecules replace extracts?** Laura Dziki (Poland)

14:00 - 15:30 FT16 - Immunodeficiencies and autoimmunity

(Dochart 1, Flash Talks)

Chairs: ***Sophia Karagiannis (United Kingdom), Elif Karakoç Aydiner (Türkiye)***

14:00 000076	**Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study** Anna Valerieva (Bulgaria)
14:07 000075	**Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants With Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study** Markus Magerl (Germany)
14:14 000636	**Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study** Isabelle Boccon-Gibod (France)
14:21 001055	**Substantial and Sustained Reductions in Physician-Reported Attack Rates With Lanadelumab in Patients With Hereditary Angioedema: Final Data From the ENABLE Study** Inmaculada Martinez Saguer (Germany)
14:28 000068	**CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks** William Lumry (United States of America)
14:35 001327	**Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P** Mauro Cancian (Italy)
14:42 000436	**Latent Tuberculosis in Inborn Errors of Immunity: Role of Tuberculin Skin Testing** Pelin Korkmaz (Türkiye)
14:49 000849	**Evaluation of Sleep and Quality of Life in Patients Receiving Immunoglobulin Replacement Therapy for Inborn Errors of Immunity** Ceren Üstün (Türkiye)
14:56 001020	**Cutaneous Manifestations in Inborn Errors of Immunity: A Retrospective Analysis of Prevalence, Phenotypes, and Treatment Outcomes** Zeynep Meric (Türkiye)
15:03 001433	**Kabuki syndrome: unmasking the clinical and immunological profile in pediatric patients** Patricia Quijada-Morales (Spain)

08:30 - 10:00 JMA 6 - JM Sister Societies Symposium
(Boisdale, JMA)

Chairs: ***Jitesh Chauhan (United Kingdom), Mark Kacar (Slovenia)***

14:00 **The importance of translational science in the respiratory field**

14:30 **New strategies in the treatment of severe asthma**
Jordon Jaggers (United States of America)

15:00 **Biologics and rhinosinusitis with and without nasal polyps**
Luo Zhang (China)

14:00 - 15:30 OAS15 - Outcomes in chronic rhinosinusitis and type 2 inflammation
(Carron 1, Oral Abstract Sessions)

Chairs: ***Almudena Testera-Montes (Spain), Michele Schiappoli (Italy)***

14:00 001300 **Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: Findings from the European CRS Outcome Registry (CHRINOSOR)**
Carlo Cavaliere (Italy)

14:12 000620 **Distribution of Baseline Type 2 Inflammation Characteristics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Biologic Clinical Trials: A Comparative Assessment**
Marjolein Cornet (Netherlands)

14:24 001331 **Real-Life Effectiveness of Monoclonal Antibody Therapy in Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study**
Philippe Gevaert (Belgium)

14:36 001243 **Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health- associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis**
Fabio S. Ryser (Switzerland)

14:48 001702 **Association between olfactory function, nasal polyp score, nasal obstruction and quality of life in CRSwNP patients treated with dupilumab**
Helga Kraxner (Hungary)

15:00 000973 **Construction of prediction model for olfactory dysfunction improvement in patient with chronic rhinosinusitis after endoscopic sinus surgery**
Linlu Wang (China)

15:12 001011 **Emerging Biologic Use May Reduce the Need for Corticosteroid Treatment and Surgery for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in France, Germany, Italy, Spain and the UK**
Waseem Ahmed (United Kingdom)

14:00 - 15:30 OAS16 - Efficacy and safety of allergen immunotherapy in clinical practice
(Carron 2, Oral Abstract Sessions)

Chairs: ***Domingo Barber (Spain), Umit Murat Sahiner (Türkiye)***

14:00 000065 **Steroid sparing effect of 300IR house dust mite sublingual immunotherapy tablet in mite allergic rhinitis patients with concomitant asthma**
Oliver Pfaar (Germany)

14:12 000157 **The Sting Challenge Test: a key tool for monitoring the effectiveness of venom immunotherapy**
Maria de los Angeles Gonzalez-Labrador (Spain)

14:24 000592	**Experience with ALUTARD SQ Immunotherapy in Patients Allergic to Hymenoptera Venom** Andrea Moran Garrido (Spain)
14:36 000848	**Safety of Hymenoptera Venom Immunotherapy in Patients with Oncological and Autoimmune Diseases: A Clinical Case Series** Andrea Moran Garrido (Spain)
14:48 000900	**Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients with Diverse Sensitization Patterns: A Multicenter Study** Rongfei Zhu (China)
15:00 001435	**Oral Immunotherapy for Fish Allergic Children** Agnes Sze Yin Leung (China)
15:12 001447	**Prescription rates and adherence to bee- and vespid- immunotherapy in Austria – a population-based study** Stefan Woehrl (Austria)

14:00 - 15:30 SY22 - Crosstalk between lung structural cells and immune cells in airway inflammation and remodeling

(Clyde Auditorium, Symposium)

Chairs: ***Günnur Deniz (Türkiye), Ismail Ogulur (Switzerland)***

14:00	**The role of airway epithelium in innate immune responses** Urszula Radzikowska (Switzerland)
14:30	**The role of epithelial basal cells in modulating extracellular matrix in the airways** Clare M Lloyd (United Kingdom)
15:00	**The role of T cell regulation and airway remodelling in asthma** Korneliusz Golebski (Netherlands)

14:00 - 15:30 SY23 - Breakthroughs Biologicals in allergic diseases

(Lomond Auditorium, Symposium)

Chairs: ***Thomas Eiwegger (Austria), Ibon Eguiluz (Spain)***

14:00	**Anti-IgE in the management of food allergy: pros and cons** Stefania Arasi (Italy)
14:30	**Anti-IL-5 biologicals and eosinophils: a step forward in precision medicine** Alessandra Vultaggio (Italy)
15:00	**Hypersensitivity to biologicals** Ricardo Madrigal-Burgaleta (United Kingdom)

14:00 - 15:30 TSY6 - Molecular mapping of asthma: Decoding airway remodelling for targeted interventions

(Hall 1, Thematic Symposium)

Chairs: ***Ludger Klimek (Germany), Ian Adcock (United Kingdom)***

14:00 **How oxidative stress shapes the architecture of asthmatic remodeling**
Cagatay Karaaslan (Türkiye)

14:30 **Single cell sequencing to unravel asthma inflammation and remodeling**
Nicole Boucheron (Austria)

15:00 **Biologics and airway remodeling in asthma**
Marcin Moniuszko (Poland)

14:15 - 15:15 GBD2 - Ground breaking discoveries 2

(Meeting Academy M1, Ground Breaking Discoveries)

Chairs: ***Elizabeth Phillips (United States of America), Riccardo Castagnoli (Italy)***

14:15 **Potential of JAKi for toxic epidermal necrolysis**
Thierry Nordmann (Germany)

14:35 **Systemic and skin T cell subsets in SCAR**
Ana Maria Copaescu (Canada)

14:55 **Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease.**
Hideaki Morita (Japan)

12:15 - 15:15 SSS 8 - EAACI & WAO Joint Symposium - Improved approaches in food allergy

(Forth, Sister Society Symposium)

Chairs: ***Mário Morais-Almeida (Portugal), Maria Jose Torres (Spain)***

14:15 **Efficacy and safety of biologics in children for food allergy**
Gary Wong (China)

14:35 **What are the new strategies in the management of food allergy?**
Motohiro Ebisawa (Japan)

14:55 **Clinical remission in food allergy: How close are we?**
Alessandro Fiocchi (Italy)

14:00 - 14:45 P & C 6 - Sting challenge test

(EAACI Global Stage, Pro Con)

Chair: ***Elisa Boni (Italy)***

15:00 **PRO**
Arantza Vega Castro (Spain)

15:23 **CON**
Beatrice Maria Bilò (Italy)

15:45 - 17:15 FT19 - New insights on allergen immunotherapy
(Dochart 2, Flash Talks)

*Chairs: **Dario Antolin-Amerigo (Spain), Enrico Heffler (Italy)***

15:45 000886 **Utility of basophil activation test (BAT) in evaluation of efficacy of venom immunotherapy determined by sting challenge: A systematic review**
Shweta Mhatre (Australia)

15:52 001363 **Changing Allergen Immunotherapy Practice Profiles in Mexico**
Désirée Larenas-Linnemann (Mexico)

15:59 000465 **Efficacy Study on Intratonsillar Immunotherapy for Patients with Allergic Rhinitis Induced by House Dust Mites (Tonsil-AIT)**
Zhi-Qun Huang (China)

16:06 000362 **Effectivity and serological correlation analysis in patients undergoing their first year of mixed subcutaneous immunotherapy for dust mites and cat**
Àlvar Piracés Buitrago (Spain)

16:13 001191 **Safety Data for House Dust Mite and Pollen Subcutaneous Allergen Immunotherapy in Children: Systemic Reactions and Risk Factors**
Figen Celebi Celik (Türkiye)

16:20 001666 **Cluster immunotherapy for bee venom in delayed levo-tyrosine formulation with short protocol**
Gabriele Cortellini (Italy)

16:27 000119 **A new immunotoxin design against allergy, based on a single chain variable fragment (scFv) targeted against FcεRI and the ribotoxin α-sarcin**
Javier Narbona Corral (Spain)

16:34 000873 **Identification of the optimal immunotherapy via CAP Inhibition in Vespa velutina anaphylaxis patients**
Sofia Carreras-Kàtcheff (Spain)

16:41 000165 **Protein and allergen content variability of peanut-containing products used in oral immunotherapy for peanut allergy**
Thierry Batard (France)

16:48 100527 **Combined biological and immunotherapy approach in patients with severe allergic asthma**
Sofía Gómez De La Cruz Pérez (Spain)

15:45 - 17:15 FT18 - Mechanisms in asthma: understanding the disease
(Dochart 1, Flash Talks)

*Chairs: **Ozge Can Bostan (Türkiye), Christer Janson (Sweden)***

15:45 001024 **The distinctive apoptosis pathways of late-phase allergic asthma in bronchial immune cells**
Nicole van der Burg (Sweden)

15:52 000814 **The modulation of ICAM-1 and ICAM-3 is mediated by alarmins in severe eosinophilic asthma**
laura bergantini (Italy)

15:59 001238 **Airway hyperresponsiveness to mannitol in relation to inspiratory and expiratory resistance in subjects with asthma, COPD and healthy smokers**
Ellen Tufvesson (Sweden)

16:06 000782 **The Correlation Between Two Different Reversibility Criteria (GINA and ATS/ERS) Used in Asthma Diagnosis and the Relationship Between the Concordance of These Criteria and Phenotypic Features**
Zeynep ÇElebi Sözener (Türkiye)

16:13	000142	**Lung function and exacerbations by different type 2 inflammation criteria in a general asthma population** Selin Ercan (Sweden)
16:20	000598	**Dietary fructo-oligosaccharides induced suppression of type 2 inflammation coincides with changes in the fecal microbiome and and systemic short chain fatty acids levels in a mouse model for house-dust-mite allergy** Roos Verstegen (Netherlands)
16:27	001031	**Early gut microbiota in association to IgE-mediated asthma in young adults** Ulrika Hellberg (Sweden)
16:34	000460	**Dual role of MAPK13 in epithelial barrier integrity and mucus production in asthma** Lucía Cremades-Jimeno (Spain)
16:41	001719	**Genetic associations with asthma in the kazakh population** Zhanat Ispayeva (Kazakhstan)
16:48	000448	**To study intra-breath variability in oscillometric parameters with level of asthma control among children from North India** Neeraj Gupta (India)
16:55	001106	**Asthma increases short-time sickness absence and presenteeism in young adults** Sandra Ekström (Sweden)

15:45 - 17:15 IWS11 - Food Allergy Management

(Meeting Academy M1, Interactive Workshop)

*Chairs: **Isabel Skypala (United Kingdom), Emilia Vassilopoulou (Greece)***

15:45	**Food allergy: Management of complications** Inger Kull (Sweden)
16:15	**Heating, cooking, and mixing food allergens: Effects on allergic reactions and dietary advice modification** Ines Padua (Portugal)
16:45	**Psychosocial aspects of food allergies and food elimination** Audrey Dunn Galvin (Ireland)

15:45 - 17:15 IWS12 - Environmental impact of asthma treatment: prioritizing patient outcomes and reducing environmental burden

(Boisdale, Interactive Workshop)

*Chairs: **Allison J. Burbank (United States of America), Jouni Jaakkola (Finland)***

15:45	**Environmental impact of asthma treatment** Sayantani Sindher (United States of America)
16:15	**Greener practice and patients' outcomes in asthma** Ashley Woodcock (United Kingdom)
16:45	**The future: novel approaches to improve human and planetary health** André Moreira (Portugal)

15:45 - 17:15 L-OAS-CT3 - Clinical Studies on Airways Diseases
(Innovation Hub, Oral Abstract Session on Clinical Trials)

Chairs: ***Gianni Marone (Italy), Javier Dominguez-Ortega (Spain)***

15:45 100176 **Real-World Effectiveness of Dupilumab vs. Other Biologics in Achieving Clinical Remission as Assessed by a Composite Measure of Selected Asthma Outcomes in Patients with Severe Asthma: EU ADVANTAGE**
Giorgio W Canonica (Italy)

15:57 100178 **Dupilumab Reduces the Rate of Severe Exacerbations and Improves Lung Function in Children With Moderate-to-Severe Type 2 Asthma, Irrespective of Early Increases in Blood Eosinophil Counts**
Clare Murray (United Kingdom)

16:09 100239 **Dupilumab Improves Small Airway Dysfunction in Patients With Moderate-to-Severe Asthma: The Phase 4 VESTIGE Study**
Brian Lipworth (United Kingdom)

16:21 100366 **Efficacy and safety of dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): Results from a prospective, head-to-head phase 4 trial**
Eugenio De Corso (Italy)

16:33 001702 **Mepolizumab provides sustained clinical benefits in patients with severe asthma regardless of age of asthma onset: Real-world data from the REALITI-A study at 2 years**
Santiago Quirce (Spain)

15:45 - 17:15 OAS17 - Allergy diagnosis using in-vitro assays
(Carron 1, Oral Abstract Sessions)

Chairs: ***Alma Villasenor Solis (Spain), Alexandra Santos (United Kingdom)***

15:45 001573 **Expanding the Differential Diagnosis of Blood-culture-negative Endocarditis: A Case Report of Delayed-type Hypersensitivity to Bioprosthetic Valve**
Aviv Talmon (Israel)

15:57 001573 **Use of dendrimeric nanostructures in mast cell activation test for evaluating IgE-mediated allergy**
Carlos Aranda Clemente (Spain)

16:09 001573 **Dual intracellular staining of CD154(CD40L) and cytokines at single cell level: a novel aid to document immediate hypersensitivity to rocuronium**
Jessy Elst (Belgium)

16:21 001573 **The Hoxb8 mast cell activation test shows favorable performance in assay development studies for multiple food allergies**
Alexander Eggel (Switzerland)

16:33 001573 **Basophil Activation by Digested Peanut Protein Enhances the Prediction of Clinical Reactivity and Delayed Responses in Peanut Allergy**
Noémi Anna Nagy (Luxembourg)

16:45 001043 **Relationships and Diagnostic Accuracy of Storage Protein Sensitizations in Microarray Analysis**
Canan Caka (Türkiye)

16:57 001053 **Sensitization profiles of individual allergic patients in Portugal**
Cristina Cacheiro-Llaguno (Spain)

15:45 - 17:15 OAS18 - Immunodeficiencies and autoimmunity
(Carron 1, Oral Abstract Sessions)

Chairs: ***Francesco Cinetto (Italy), Ayca Kiykim (Türkiye)***

15:45 000506 **Long-Term Durability of CRISPR-Based Gene Editing of KLKB1 From Phase 1 of a Phase 1/2 Trial of Patients With Hereditary Angioedema**
Hilary Longhurst (New Zealand)

15:57 000044 **Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone**
Laurence Bouillet (France)

16:09 000792 **Psychological Burden on Parents of Children with Primary Immunodeficiency After Hematopoietic Stem Cell Transplantation: A Focus on Anxiety, Depression, and Caregiver Stress**
Sezin Aydemir (Türkiye)

16:21 001611 **AllergoOncology: Application of the basophil activation test (BAT) in pre-clinical testing and the first-in-class clinical trial of anti-cancer IgE immunotherapy**
Jitesh Chauhan (United Kingdom)

16:33 001412 **Challenges in Managing Adult Patients with Inborn Errors of Immunity: Key Takeaways from a Difficult Case Series in a Real Life**
Semra Demir (Türkiye)

16:45 001613 **Characteristics of IgE Deficiency in Patients with an Associated Immunodeficiency - Lessons Learned from USIDNET Registry**
Ashley Jakubowicz (United States of America)

15:45 - 17:15 SY25 - Breathing Easier: Cutting-Edge Advances in Paediatric Asthma Management
(Lomond Auditorium, Symposium)

Chairs: ***Özge Soyer (Türkiye), Adnan Custovic (United Kingdom)***

15:45 **Asthma beginnings: Unraveling the early triggers**
Nikos Papadopoulos (Greece)

16:15 **Little lungs, big challenges: The latest on preschool wheeze**
Wojciech Feleszko (Poland)

16:45 **Battling the beast: New frontiers in biologics for severe pediatric**
Sejal Saglani (United Kingdom)

15:45 - 17:15 SY26 - Epithelial cell biology and barrier regeneration
(Hall 1, Symposium)

Chairs: ***Urszula Radzikowska (Switzerland), Korneliusz Golebski (Netherlands)***

15:45 **Key pathways in restoring epithelial barrier integrity**
Cezmi Akdis (Switzerland)

16:15 **Human organoids: Advancing disease modeling and barrier regeneration for personalized medicine**
Kai Kretzschmar (Germany)

16:45 **Modeling asthmatic epithelial reprogramming via IL-13–induced differentiation in airway spheroids**
Yagiz Pat (Switzerland)

15:45 - 17:15 SY24 - A practical approach to chronic urticaria
(Clyde Auditorium, Symposium)

*Chairs: **Allen Kaplan (United States of America), Maria Bova (Italy)***

15:45 **Differential diagnosis of urticarial lesions: how to differentiate, tips and tricks**
Hanna Bonnekoh (Germany)

16:15 **Diagnosis of inducible urticaria with the recommended tools**
Sabine Altrichter (Austria)

16:45 **Biomarkers in chronic spontaneous urticaria**
Riccardo Asero (Italy)

16:00 - 17:00 SSS 9 - EAACI & IPCRG Joint Symposium : Rhinitis Right Care: how to gain interest, confidence and competence in good quality primary care
(Forth, Sister Society Symposium)

*Chair: **Ema Paulino (Portugal)***

16:00 **Allergic rhinitis: what are the problems we are trying to solve in primary care and what are the "Right Care" messages?**
Dermot Ryan (United Kingdom)

16:20 **Is there a role for a social movement approach. Lessons from Asthma Right Care**
Garry McDonald (United Kingdom)

16:40 **Teaching and learning needs for primary care**
Jaime Correia de Sousa (Portugal)

17:30 - 17:45 Highlight Session
(Alsh, SponsoredSessions) *Organisateur: CSL Behring*

17:30 **The Evolving Landscape of Hereditary Angioedema Treatment: Targeting FXIIa and Beyond**
Asli Akkor (Türkiye)

17:30 - 19:00 FT20 - Practical advances in food allergy and management
(Dochart 1, Flash Talks)

*Chairs: **Nandinee Patel (United Kingdom), Jonathan Hourihane (Ireland)***

17:30 000634 **Nuts Allergy in Children: A Single-Center Retrospective Analysis of Prick-to-Prick Test Results, Clinical Course, and Tolerance Status**
Damla Baysal Bakır (Türkiye)

17:37 001553 **Long term impact of formula choice in children with cow milk protein allergy: 6-year follow-up of the Atopic March Cohort Study**
Rita Nocerino (Italy)

17:44 001527 **Induction of oral specific tolerance to cow´s milk proteins before 12 months of age - is it worth it?**
Marta Isabel Dias (Portugal)

17:51 001574 **Impact of IgE and non-IgE-mediated cow's milk protein allergy on infection frequency**
Gaye Kocatepe (Türkiye)

17:58 000102	**Protein-Enriched Dairy Products as Triggers of Allergic Reactions: A Case Study** Maria Jose Castillo (Spain)
18:05 001464	**A Comparative Evaluation of In Vivo and In Vitro Diagnostic Test Performance for Sesame Allergy in the Pediatric Population** Maria De filippo (Italy)
18:12 001031	**Impact of Causative Foods on Quality of Life in Parents and Children with Food Allergies in Japan** Chisato Jimbo (Japan)
18:19 000262	**Advanced glycation end-products in formulas for the dietary management of cow's milk protein allergy** Serena Coppola (Italy)
18:26 001507	**A Growing Cause Of Food Allergies In Children: Sesame** Deniz Yılmaz (Türkiye)
18:33 001299	**Phase 2 Study to Evaluate the Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic Tool for Non–IgE-Mediated Cow's Milk Allergy in Children (APTITUDE)** Roberto Berni Canani (Italy)
18:40 100618	**DUPEOETALY: A Real-World Study on the Long-Term Effectiveness of Dupilumab in Eosinophilic Esophagitis** Alessandra Vultaggio (Italy)

17:30 - 19:00 FT21 - Allergic rhinitis: updates on epidemiology, diagnostics, and novel therapy

(Dochart 2, Flash Talks)

*Chairs: **Almudena Testera-Montes (Spain), Philippe Gevaert (Belgium)***

17:30 000649	**Allergic rhinitis: Incidence and remission from childhood to adulthood in a Swedish cohort** Styliana Vasileiadou (Sweden)
17:37 000786	**Has climate change already impacted the epidemiology of allergic sensitisation in the UK and how might it affect clinical allergy?** Graham Roberts (United Kingdom)
17:44 000284	**Association Between Allergic Rhinitis and Nasal Septum Deviation in Children: Results from the ARHINASD Study** Laura Carucci (Italy)
17:51 000572	**Validation of a Skin Prick Automated Test (SPAT) cutoff value in birch pollen and house dust mite clinically allergic patients** Sven Seys (Belgium)
17:58 001220	**Can the Dermatophagoides Pteronyssinus Molecular Allergen Sensitization Profile, assessed with a Skin Prick Test, Be Useful in Evaluating Clinically Relevant House Dust Mite Allergy?** Ana Vitória Soares (Portugal)
18:05 000467	**Corneal topography parameters among children with systemic allergic diseases or allergic conjunctivitis: a cross-sectional observational study** Neeraj Gupta (India)
18:12 001595	**Using an Environmental Exposure Chamber (EEC) to Conduct Allergy Trials Mitigates Trial Disruptions and Provides Consistent Drug Testing Outcomes after the Trial is Resumed** Anne Marie Salapatek (Canada)
18:19 001677	**Operational performance of the Nasal Provocation Test in determining the frequency of allergy to Blomia tropicalis in sensitized patients at an allergy center: A 5-year follow-up** Johans Rojas (Colombia)

18:26 001326	**MY010: An Anti-Allergen Multispecific for the Treatment of Multiple Tree Pollen Allergies** Natascha Wuillemin (Switzerland)
18:33 001391	**Onset of Action (OOA) and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray (AZNS) on Allergy Symptoms in an Environmental Exposure Chamber (EEC) Compared to Placebo (PL) and Mometasone Furoate/ Olopatadine Hydrochloride NS (MFONS)** Anne Marie Salapatek (Canada)

17:30 - 19:00 IWS14 - Updates on contact dermatitis and patch testing

(Meeting Academy M1, Interactive Workshop)

Chairs: ***Mar Guilarte (Spain), Charlotte Mortz (Denmark)***

17:30	**Recommendations for a standard series of contactants for patch testing** Jose Luis Garcia-Abujeta (Spain)
18:00	**Contact Dermatitis to essential or vegetable oils: green but not safe** Annick Barbaud (France)
18:30	**Immune mechanisms behind local skin reactions to contact allergen** Anders Funch (Denmark)

17:30 - 19:00 JMA 7 - JM Case report

(Boisdale, JMA)

Chairs: ***Ekaterina Khaleva (United Kingdom), Jitesh Chauhan (United Kingdom)***

17:30 000879	**Redefining STAT5B N642H Gain of function Mutation: Unique Phenotypic Features and First Successful Mepolizumab Treatment in a Pediatric Case** Areej Alkahtani (Saudi Arabia)
17:38 000867	**Paediatric case of butylscopolamine anaphylaxis** Miguel Abad Cobo (Spain)
17:46 000503	**Paediatric case of Drug Induced Enterocolitis Syndrome (DIES) due to amoxicillin** Miguel Abad Cobo (Spain)
17:54 000561	**STAT1 GoF: Navigating from Adulthood to Motherhood** Fatema-Zahra El Rhermoul (United Kingdom)
18:02 001206	**Anaphylaxis triggered by flower pollen supplement: identification of the allergen involved** Alejandro de la Torre Carrión (Spain)
18:10 001453	**Overcoming DRESS Syndrome with HLH and Organ Failure: The Potential Role of Benralizumab** Irene Rosmaninho (Portugal)
18:18 001281	**When Immunotherapy Strikes Twice: IgE Hypersensitivity and HES as Dual Adverse Effects of Pembrolizumab** Mihaela Ruxandra Vintila (Romania)
18:26 100295	**When Antihistamines Trigger Allergies: A Case of Hydroxyzine Allergy** Ana Cristina Coelho (Portugal)
18:34 100464	**Recurrent Pneumonia During Grape Harvest: A Rare Case of Hypersensitivity Pneumonitis** María Noriega Herrera (Spain)
18:42 100524	**Fixed Drug Eruption induced by acetylsalicylic acid – a successful desensitization in delayed- type drug hypersensitivity** Rita Sá Teixeira (Portugal)

17:30 - 19:00 OAS20 - Allergen specific diagnostic testing
(Carron 2, Oral Abstract Sessions)

*Chairs: **Paolo Matricardi (Germany), Riccardo Asero (Italy)***

17:30 000518
Molecular Profiling of Banana Allergens: Insights from Clinical Cases
Ana Maria Puentes Ortiz (Spain)

17:42 001233
Malate Dehydrogenase as a King Crab-Specific Allergen: Differentiation between King Crab and True Crab Allergies
Christine Yee Yan Wai (Hong Kong)

17:54 001248
Wheat endoglucanase – a novel food allergen
Eva-Maria Rick (Germany)

18:06 001605
Specific IgE to the Cross Reactive Carbohydrate Determinant MUXF3 explains high prevalence and close correlation between IgE to peanut, wheat, sesame, oak, and tree allergens in a cohort of 248 schoolchildren in Honduras
Charlene Dunaway Altamirano (United States of America)

18:18 000213
Prevalence and characteristics of local allergic rhinitis to American cockroach in chronic rhinitis
Sira Nanthapisal (Thailand)

18:30 001690
Impact of hazelnut roasting methods on the diagnostic value of prick tests for hazelnut food allergy
Anays Piotin (France)

18:42 100349
Diagnostic Comparison of Basophil Activation Test and Specific IgE to Venom Components in Hymenoptera-Allergic Patients with Low or Negative Venom-Specific IgE
Luka Dejanović (Slovenia)

17:30 - 19:00 OAS219 - Treatment response in severe asthma: from rehabilitation to biologic
(Carron 1, Oral Abstract Sessions)

*Chairs: **Dilşad Mungan (Türkiye), Jasper Kappen (Netherlands)***

17:30 001232
Sustained reduction in Severe Asthma Exacerbations and Hospitalisations in the 12 months after Alpine Altitude Climate Treatment
Fleur Louise Meulmeester (Netherlands)

17:42 001116
Registry on Severe Asthma with and without biological treatment in Spain: Results of a 2 year follow-up of AlergoDATA
Dario Antolin-Amerigo (Spain)

17:54 000482
Baseline Predictors of Multicomponent Clinical Remission Following Dupilumab Treatment in Patients With Moderate-to-Severe Asthma
Giorgio W Canonica (Italy)

18:06 000497
Benralizumab reduces annual cumulative OCS dose while improving asthma control and quality of life in severe eosinophilic asthma: Real-World Evidence from the AURORA study
Aleksandra Kucharczyk (Poland)

18:18 001107
Assessing the Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
Mena Soliman (United States of America)

18:30 000606
Twice-Yearly Depemokimab Efficacy is Sustained Across Seasons in Patients with Asthma: Analyses of Pooled Phase III SWIFT-1/2 Studies
David Jackson (United Kingdom)

18:42 001348
Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years
Giorgio W Canonica (Italy)

17:30 - 19:00 SY27 - Diagnostic Challenges in Patients with Inborn Errors of Immunity with Different Manifestations of Immune Dysregulation

(Clyde Auditorium, Symposium)

Chairs: ***Ayca Kiykim (Türkiye), Marketa Bloomfield (Czech Republic)***

17:30 **Inborn errors of immunity with atopic manifestations**
Riccardo Castagnoli (Italy)

18:00 **Inborn errors of immunity with autoimmune and autoinflammatory manifestations**
Mahir Serbes (Türkiye)

18:30 **Inborn errors of immunity with lymphoproliferative disorders**
Francesco Cinetto (Italy)

17:30 - 19:00 SY28 - Eosinophilic esophagitis: Exploring local responses, immune mechanisms, and clinical diversity

(Lomond Auditorium, Symposium)

Chairs: ***Arzu Bakirtas (Türkiye), Constantinos Pitsios (Cyprus)***

17:30 **Local inflammatory responses in EoE**
Frank Redegeld (Netherlands)

18:00 **Antigen-specific immune responses in EoE**
Willem Van De Veen (Switzerland)

18:30 **Update on eosinophilic esophagitis variants**
Thomas Greuter (Switzerland)

17:30 - 19:00 TSY7 - Epithelial dynamics and barrier function

(Hall 1, Thematic Symposium)

Chair: ***Cezmi Akdis (Switzerland)***

17:30 **Epithelial-microbiome-immune cell interactions**
David Moyes (United Kingdom)

18:00 **Employing organoids for modelling of respiratory diseases**
Ivonne Vazquez Armendariz (Germany)

18:30 **Mechanisms of gut barrier dysfunction: Epithelial damage and mucosal responses to environmental and dietary substances**
Ismail Ogulur (Switzerland)

17:30 - 19:00 YIR-YIR2

(Forth, Year in Review)

Chairs: ***Ozlem Goksel (Türkiye), Désirée Larenas-Linnemann (Mexico)***

17:30 **Impact of viral infection on allergic diseases**
Jurgen Schwarze (United Kingdom)

18:00 **Endogene receptors modulating immune response**
Alba Angelina (Spain)

18:30 **TL1A as a novel biomarker for allergic conditions in the gut and the airways**
Gianni Marone (Italy)

09:00 - 10:30 PL10 - Precision Medicine in Airway Diseases: Biomarkers and Phenotyping
(Clyde Auditorium, Plenary Lectures)

Chairs: ***Stefano Del Giacco (Italy), Maria Escribese (Spain)***

09:00 **Biomarkers for Chronic Rhinitis and Rhinosinusitis: Towards Tailored Therapies**
Adam Chaker (Germany)

09:30 **Biomarkers for Asthma: Stratifying Patients for Optimal Treatmen**
Salman Siddiqui (United Kingdom)

10:00 **Phenotyping Occupational Rhinitis and Asthma: Towards Better Management**
Jolanta Walusiak-Skorupa (Poland)

09:00 - 10:30 PL11 - Biologicals in Allergy and Asthma: Where Are We?
(Lomond Auditorium, Plenary Lectures)

Chairs: ***André Moreira (Portugal), Cezmi Akdis (Switzerland)***

09:00 **Head-to-Head Comparison of Biologics in Asthma: What Have We Learned?**
Brian Lipworth (United Kingdom)

09:30 **Biologics in Eosinophilic Esophagitis: Current and Future Perspectives**
Alexander Straumann (Switzerland)

10:00 **Type 2 Responses and the Future of Food Allergy Treatment: A Biological Perspective**
Cecilia Berin (United States of America)

10:45 - 12:15 FT22 - Chronic rhinosinusitis: from bedside to bench
(Dochart 1, Flash Talks)

Chairs: ***Jan Hagemann (Germany), Ibon Eguiluz (Spain)***

10:45 001368 **The Clinical Characteristics and Inflammatory Endotypes of Chronic Rhinosinusitis with Nasal Polyps in Southern China: A Multi-Center, Cross Section study**
Zhaofeng Xu (China)

10:52 000929 **Clinical and Treatment Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps by Treating Physician Specialty: Results from an EU Chart Review Study**
Martin Wagenmann (Germany)

10:59 001682 **Effectiveness of Dupilumab in Severe CRSwNP: A Brazilian Study**
Maria Eduarda Trocoli Zanetti (Brazil)

11:06 001018 **Endotype in nasal inflammatory diseases using minimally invasive sampling techniques**
Pauline Janssen (Belgium)

11:13 001309 **A comparative analysis of pediatric and adult endotypes of chronic rhinosinusitis**
Gwanghui Ryu (Korea, Republic of)

11:20 000277 **Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps**
Xin Feng (China)

11:27 100500 **Hippo-YAP inhibits the autophagic degradation of Cyclin D1 in chronic rhinosinusitis with nasal polyps**
Mingrui Pan (China)

11:34 000728	**Site-specific proteomics reveals key molecular features underlying the transition to nasal polyps** Yi-Sook Kim (Korea, Republic of)
11:41 000769	**A Regulatory Risk haplotype in HLA-DQ region regulates antigen presentation of monocyte in Type 2 inflammation in chronic rhinosinusitis with nasal polyps** Jingyun Li (China)

10:45 - 12:15 FT23 - News in hereditary angioedema management

(Dochart 2, Flash Talks)

*Chairs: **Asli Akkor (Türkiye), Davide Firinu (Italy)***

10:45 001252	**Hereditary Angioedema with Normal C1 Inhibitor: Novel Genetic Mutations and Insights from a Large Genomic Cohort Study** Xiaoqun Luo (China)
10:52 001286	**Initial description of a patient with a new plasminogen mutation who exhibits symptoms consistent with hereditary angioedema** Andreas Treccosti (Germany)
10:59 001431	**Elucidating the pathogenesis of hereditary angioedema through advanced genetic sequencing and single-cell sequencing analyses** Ruizhi Wang (China)
11:06 000618	**Correlation Between Subjective and Objective Disease Control in Hereditary Angioedema: Association Between the Angioedema Control Test and Attack Rate** Danny M. Cohn (Netherlands)
11:13 001309	**Burnout and Stress in Angioedema Care: Insights from a Multicenter Observational Study MENPHYS** Ivan Cherrez-Ojeda (Ecuador)
11:20 001057	**The Effect of Surgical and Interventional Procedures on Attack Frequency in Hereditary Angioedema Patients** Emine Nihal Mete Gokmen (Türkiye)
11:27 001030	**Innovation to collect data for a national registry of patients with hereditary angioedema: the first phase of establishing the dynamic HARPE registry** Alexis Bocquet (France)
11:34 000325	**Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States** Alexis Bocquet (France)
11:41 000498	**Attack-free probability modeling of garadacimab long-term prophylaxis for hereditary angioedema** Philip Li (Hong Kong)
11:48 000597	**Safety assessment of garadacimab in clinical studies involving patients with hereditary angioedema, idiopathic pulmonary fibrosis, and COVID-19** Harsha Shetty (United States of America)
11:55 001144	**Clinical characteristics and unmet treatment need in patients with hereditary angioedema treated with long-term prophylaxis: A real-world survey** Mar Guilarte (Spain)

10:45 - 12:15 ISW 15 - Methodology of Allergen challenges for airway allergy
(Forth, Interactive Workshop)

Chairs: ***Jolanta Walusiak-Skorupa (Poland), Adam Chaker (Germany)***

10:45 **Conjunctival allergen challenge**
Diana Silva (Portugal)

11:15 **Nasal allergen challenge**
Almudena Testera-Montes (Spain)

11:45 **Chamber challenge**
Alina Gherasim (France)

10:45 - 12:15 ISW 16 - Time to redefine healthy eating?
(Boisdale, Interactive Workshop)

Chairs: ***Ismail Ogulur (Switzerland), Emilia Vassilopoulou (Greece)***

10:45 **Ultraprocessed foods and allergy outcomes**
Roberto Berni Canani (Italy)

11:15 **Practical aspects of Phthalates, microplastics so much more than the nutrients we eat**
Pete Smith (Australia)

11:45 **Obesity and Allergy**
Zeynep ÇElebi Sözener (Türkiye)

10:45 - 12:15 OAS22 - Clinical Management
(Carron 2, Oral Abstract Sessions)

Chairs: ***Peter Kopac (Slovenia), Jose Julio Laguna Martinez (Spain)***

10:45 000268 **Evaluation of Direct Oral Provocation Test Results in Mild Cutaneous Reactions to Cephalosporins in Children**
Fatma Kuzucu (Türkiye)

10:57 001547 **Assessing Hypersensitivity to Iodinated Contrast Media: Insights from Skin Testing and Drug Challenges**
Pedro Alves (Portugal)

11:09 001262 **Shedding Light on the Controversy: Are Drug Challenges with Iodinated Contrast Media Useful?**
Ana Vitória Soares (Portugal)

11:21 000177 **Treatment of insulin allergy by intranasal Fc-fused preproinsulin**
Widad NEFIDA (France)

11:33 001440 **Misdiagnosed Drug Hypersensitivity: A 15-Year Investigation into the Rare Occurrence of True Lidocaine Allergies**
Marina Ikić Matijašević (Croatia)

11:45 001140 **Clinical and Epidemiological insights into generalized bullous fixed drug eruption (GBFDE) in African TB HIV endemic settings: A comparison with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)**
Helen Hoenck (South Africa)

10:45 - 12:15 OAS21 - Update on major food allergies
(Carron 1, Oral Abstract Sessions)

Chairs: ***Isabel Skypala (United Kingdom), Thuy-My Le (Netherlands)***

10:45 000430 **Exploring Fish Parvalbumins through Allergen Names, Gene Identities, and IgE Reactivities**
Johannes Martinus Dijkstra (Japan)

10:57 000434 **Walnut and cashew nut allergies have been on the rise in Japan over the past decade**
Chizuko Sugizaki (Japan)

11:09 001103 **Health-Related Quality of Life in Children and Adults with Peanut and Tree Nut Allergies Data from the TINA Study**
Veronika Höfer (Germany)

11:21 000827 **Lupine allergy in children: relevance of sensitization and severity of reaction**
Tania Adam (France)

11:33 000593 **Augmentation factors enhance gliadin absorption in Wheat Allergy Dependent on Augmentation Factors (WALDA) and in healthy controls**
Valentina Faihs (Germany)

11:45 001401 **Assessing the effects of baking on the measurement of multiple specific food allergens in an incurred biscuit matrices using a multiplex immunoassay**
Maria Oliver (United Kingdom)

11:57 000610 **Impact of Cooking Methods on Egg Allergenicity: Clinical Insights and Protein Profiling**
Jose Alessandro Bastidas Parlanti (Spain)

10:45 - 12:15 SY31 - Early life Immuno modulation
(Hall 1, Symposium)

Chairs: ***Carina Venter (United States of America), Mattia Giovannini (Italy)***

10:45 **Sublingual allergen immunotherapy in children with AR**
Motohiro Ebisawa (Japan)

11:15 **Probiotics for airway allergy**
Jiu-Yao Wang (Taiwan)

11:45 **Tolerance induction through oral immunotherapy**
Pablo Rodríguez del Río (Spain)

10:45 - 12:15 SY37 - Biomarkers for asthma and allergic diseases
(Alsh, Symposium)

Chairs: ***Brian Lipworth (United Kingdom), Alexandra Santos (United Kingdom)***

10:45 **Eosinophil granule proteins as a biomarker for managing asthma**
Ruby Pawankar (Japan)

11:15 **Peanut-specific IgG subclasses as biomarkers of peanut allergy**
Carolyn Baloh (United States of America)

11:45 **Periostin and osteopontin to predict astma in preschool children**
Umit Murat Sahiner (Türkiye)

10:45 - 12:15 SY30 - Rare cases in paediatric allergy clinical practice
(Lomond Auditorium, Symposium)

*Chairs: **Teresa Caballero (Spain), Vito Sabato (Belgium)***

10:45 **Hereditary Angioedema**
Mauro Cancian (Italy)

11:15 **Masto cytosis and hereditary alphatryptasemia**
Karin Hartmann (Switzerland)

11:45 **Hyper IgE Syndromes**
Ayca Kiykim (Türkiye)

10:45 - 12:15 SY32 - Periocular and ocular surface disorders: Beyond What Meets the Eye
(Meeting Academy M1, Symposium)

*Chair: **Jose Luis Garcia-Abujeta (Spain)***

10:45 **Vernal and Atopic Keratoconjunctivitis: disease spectrum or different entities?**
Vibha Sharma (United Kingdom)

11:15 **Allergic contact dermatitis and the ocular surface**
Charlotte Mortz (Denmark)

11:45 **Advances in Immunomodulation for Ocular Allergy and ocular surface disorders**
Virginia Calder (United Kingdom)

10:45 - 12:15 SY29 - War related exposures and asthma development
(Clyde Auditorium, Symposium)

*Chaisr: **Sharon R. Chinthrajah (United States of America), Hasan Bayram (Türkiye)***

10:45 **The epidemiological consequences of the war on asthma incidence**
Joao Rufo (Portugal)

11:15 **Ravaging land, mind and lungs: asthma is associated with PTSD in individuals exposed warzones**
Joshua Lawson (Canada)

11:45 **Natural disasters and the Impact on Air quality**
Isabella Annesi-Maesano (France)

12:30 - 14:00 FT25 - Pre-clinical modeling of allergic and asthmatic diseases
(Dochart 2, Flash Talks)

*Chairs: **Helena Aegerter (Belgium), Domingo Barber (Spain)***

12:30 **GRPR/ERK and NPRA/ERK Signaling Pathways Play a Critical Role in Spinal Transmission of Chronic Itch**
000534 Xueting Liu (China)

12:37 **Spinal GRPR and NPRA contribute to chronic itch in a murine model of allergic contact dermatitis**
000533 Xueting Liu (China)

12:44 **Interleukin-17A Promotes the Neurite Outgrowth and Sensitization of Trigeminal Neuron in Vitro**
001305 Fan Ye (China)

12:51 001256	**Assessing the role of specific IgA in prophylactic sublingual immunotherapy for peanut allergy: A Brown Norway rat study** Katrine Bøgh (Denmark)
12:58 001125	**Sublingual immunotherapy with peanut protein extract has an effect in Brown Norway rats sensitised via the skin** Juan Manuel Puerta-Pertínez (Denmark)
13:05 000837	**Increase in airway resistance and respiratory bronchial reactivity is accompanied by cellular and antibody Type 2 immune response in a mouse model of asthma induced by Der p 23 allergen** Leonardo Puerta (Colombia)
13:12 000662	**Understanding the pathophysiology of hereditary angioedema (HAE) using a personalized expanded potential stem cell (EPSC) platform** Jane Wong (Hong Kong)
13:19 001280	**Smaller-sized micro- and nano-plastics with diverse chemical structures severely compromise epithelial barrier integrity and cause extensive cell damage** Sena Ardicli (Switzerland)
13:26 000498	**Commonly used food emulsifiers disrupt the epithelial barrier and cause a pro-inflammatory response and cell death** Duygu Yazici (Switzerland)
13:33 100353	**Role of the RNA-binding protein AU-rich-element factor-1 (AUF-1) in human airway epithelial senescence and inflammatory response** Alessia N. Calabrese (Italy)
13:40 100562	**Single-cell RNA sequencing reveals distinct gene expression profiles specific to bullous pemphigoid, differentiating it from atopic dermatitis and psoriasis vulgaris** Yale Liu (China)

12:30 - 14:00 FT24 - Aerobiology and Climate change: something is blowing in the wind

(Dochart 1, Flash Talks)

*Chairs: **Stefanie Gilles (Germany), Carmen Galan (Spain)***

12:30 000722	**Climate change leads to stronger and longer airborne pollen seasons, or more complex ones? Evidence from a multi-decadal pollen time-series in Thessaloniki, Greece** Athanasios Damialis (Greece)
12:37 001567	**Allergen Nomenclature - Allergens newly identified in 2024 through the lens of planetary health** Joana Vitte (France)
12:44 000208	**Impact of air pollutants, influenza infection on asthma exacerbation** Jae-Hyuk Jang (Korea, Republic of)
12:51 001037	**Association of anthropogenic heat with asthma and related symptoms among children in China: a novel index reflecting climate change** Fengwen Shan (China)
12:58 001501	**The Impact of Environmental Soil Nitrogen Pollution on Birch Pollen Allergy: Insights from a Multi-Year Study across Europe** Paulien Verscheure (Belgium)
13:05 001542	**Impact of Saharan dust on emergency department admissions for respiratory diseases in a tertiary hospital in the centre of Portugal** Margarida Alves (Portugal)

13:12 001056 **Holographic sensing reveals sub-daily patterns of wet deposition and refines temporal resolution of grass pollen aerobiology**
Janet Davies (Australia)

13:19 001002 **Automated pollen sensing by holography in the Southern Hemisphere: insights and future directions**
Janet Davies (Australia)

13:26 000712 **Enhanced Symptom Assessment Accuracy: Allergen Exposure Chambers vs. Nasal Allergen Challenges for Timothy Grass Pollen-Induced Allergic Rhinitis**
Anna Kosowska (Poland)

13:33 001405 **Adherence to the Planetary Health Diet and Asthma Risk in Children: Evidence from a Birth Cohort**
Mónica Rodrigues (Portugal)

12:30 - 14:00 ISW 18 - Innovations in angioedema diagnosis
(Forth, Interactive Workshop)

*Chairs: **Mauro Cancian (Italy), Allen Kaplan (United States of America)***

12:30 **How to differentiate histaminergic from bradykinergic angioedema**
Davide Firinu (Italy)

13:00 **Classification of patients with hereditary angioedema**
Asli Akkor (Türkiye)

13:30 **How to identify acquired angioedema with low C1-inhibitor**
Mar Guilarte (Spain)

12:30 - 14:00 ISW 19 - Food Allergy in Clinical Practice
(Boisdale, Interactive Workshop)

*Chairs: **Ines Padua (Portugal), Alla Nakonechna (United Kingdom)***

12:30 **How to prevent allergic reactions during commercial flights?**
Nandinee Patel (United Kingdom)

13:00 **FPIES - how to distinguish it from IBS in adults**
Sonsoles Infante (Spain)

13:30 **Presenting features of food allergy in adults**
Barbara Ballmer-Weber (Switzerland)

12:30 - 14:00 OAS24 - Clinical aspects of chronic urticaria
(Carron 2, Oral Abstract Sessions)

*Chairs: **Emek Kocaturk Goncu (Türkiye), Torsten Zuberbier (Germany)***

12:30 000741 **Knowledge, attitudes and practice patterns in chronic spontaneous urticaria management among Italian General Practitioners: Baseline data from the BRIDGE implementation science study**
Riccardo Asero (Italy)

12:42 001407 **Evaluation of Real-World Mental Health and Sleep Outcomes Over Time in US Patients With Chronic Spontaneous Urticaria**
Tara Raftery (Ireland)

12:54 001190	**Comorbidities including infections and atopic conditions in CSU patients compared to healthy controls: results from the first, large, multinational case control study -RIFA-CU** Emek Kocaturk Goncu (Türkiye)
13:06 001004	**Clinical Characteristics, Diagnosis, And Treatment Outcomes In Chronic Cold Urticaria: Insights From A 15-Year Study** Ana Cristina Coelho (Portugal)
13:18 000934	**The Urticaria Voices study: Experiences and unmet needs of patients with chronic inducible urticaria (CIndU)** Tonya Winders (Austria)
13:30 001367	**Demographic and Laboratory Differences Between Chronic Spontaneous and Chronic Inducible Urticaria: Insights from a Lisbon UCARE** Gonçalo Martins (Portugal)
13:42 000958	**Impact of chronic inducible urticaria (CIndU) on patients' health-related quality of life: Results from Urticaria Voices study** Tonya Winders (Austria)

12:30 - 14:00 OAS23 - Predicting pediatric asthma and airway disease

(Carron 1, Oral Abstract Sessions)

*Chairs: **Wojciech Feleszko (Poland), Thulja Trikamjee (South Africa)***

12:30 000107	**Preliminary analysis of microbiome and metabolomics characteristics of upper respiratory tract in school-age children with bronchial asthma** Lina Xu (China)
12:42 001438	**Development of AsthmaSense: A Web-Based Predictive Tool for Childhood Asthma Risk Assessment** Francisca Mendes (Portugal)
12:54 001577	**An explainable machine learning approach on early predictors of persistent childhood asthma and allergic rhinitis** Frederikke Skov (Denmark)
13:06 001097	**Duration of Asthma-like Episodes in Early Life Varies by Specific Viral and Bacterial Triggers** Julie Kyvsgaard (Denmark)
13:18 000391	**Evaluation of Impaired Lung Function in Children with Allergic Shiners Using the Impulse Oscillometry Method** Nur Torer (Türkiye)
13:30 000400	**Breaking the Silence of Small Airway Dysfunction in Stable Pediatric Asthma: The Powerful Combination of Impulse Oscillometry and Blood Eosinophilia** Sibel Gurbuz (Türkiye)
13:42 001222	**Predicting Asthma in Preschool Children: The Role of Eosinophil Blood Counts During Acute Wheezing Episodes** Aleksander Adamiec (Poland)

12:30 - 14:00 SY35 - Updates in the clinical management of allergen immunotherapy
(Hall 1, Symposium)

Chairs: ***Carmen Milagros Rondon (Spain), Enrico Heffler (Italy)***

12:30 **Allergen immunotherapy and biologicals: when and how**
Andrzej Bożek (Poland)

13:00 **Allergen immunotherapy in childhood: setting up the therapeutic goals**
Mattia Giovannini (Italy)

13:30 **Effect of allergen immunotherapy on quality of life**
Umit Murat Sahiner (Türkiye)

12:30 - 14:00 SY33 - Drug allergy during childhood
(Clyde Auditorium, Symposium)

Chairs: ***Özge Soyer (Türkiye), Ana Maria Copaescu (Canada)***

12:30 **Diagnostic work-up for allergy to betalactam antibiotics**
Jean-Christoph Caubet (Switzerland)

13:00 **NSAID hypersensitivity phenotypes**
Francesca Mori (Italy)

13:30 **Perioperative anaphylaxis**
Lene Heise Garvey (Denmark)

12:30 - 14:00 TSY8 - Allergenic risk of novel foods
(Alsh, Thematic Symposium)

Chairs: ***Mahir Serbes (Türkiye), Isabel Skypala (United Kingdom)***

12:30 **Vegan diets from an allergy point of view**
Uta Jappe (Germany)

13:00 **Allergenic potential of pasta and meat products made from legumes**
Beatriz Cabanillas (Spain)

13:30 **New edible insects as possible sources of cross-reactivity**
Kitty Verhoeckx (Netherlands)

12:30 - 14:15 SY36 - Communication with allergic patients in primary care
(Meeting Academy M1, Symposium)

Chairs: ***Dilşad Mungan (Türkiye), Audrey Dunn Galvin (Ireland)***

12:30 **Smart Healthcare in Allergic Diseases: AI application**
I-Jen Wang (Taiwan)

13:00 **Medical jargon: Words mean different things to patients and health care providers**
Dermot Ryan (United Kingdom)

13:30 **Misconceptions about allergies**
Cevdet Ozdemir (Türkiye)

14:00 **Patient support organisations, providing communication beyond the clinic door**
Amena Warner (United Kingdom)

12:30 - 14:15 SY34 - Focus on exercise and asthma management
(Lomond Auditorium, Symposium)

Chairs: ***Stefano Del Giacco (Italy), Ozge Can Bostan (Türkiye)***

12:30 **Diagnosis of exercise-induced asthma**
André Moreira (Portugal)

13:00 **Exercise recommendations and practical considerations for asthma management**
Oliver Price (United Kingdom)

13:30 **Environmental considerations for the exercising asthmatic**
Valerie Bougault (France)

14:00 **Prevention, environment and care: An integrated approach to better living with asthma**
Cristina Jacomelli (Italy)

14:15 - 14:45 Closing Ceremony
(Clyde Auditorium, Ceremony)

National Society Village

The National Allergy Society Village is open throughout the entire Congress and features the virtual booths of our NAS from all over Europe. At each booth you will be able to visualise brochures, watch videos, consult important national resources and much more. You will also have the chance to interact with respective members of the NAS through an e-mail form. We encourage you to visit this area to learn more about your country's very own society dedicated to allergy, asthma, and immunology, or explore developments in the field from other countries.



Albania
Albanian Society of Allergy, Asthma and Clinical Immunology (ASAACI)



Armenia
Armenian Association of Allergologists and Immunologists (AAAI)



Armenia
Armenian Association of Molecular Immunology and Allergology (AAMIA)



Austria
Austrian Society for Allergology and Immunology (ÖGAI)



Azerbaijan
Azerbaijani Society for Allergy Immunology and Immunorehabilitation



Belgium
Belgian Society for Allergy and Clinical Immunology (BelSACI)



Belgium
Association Belge de Formation Continue en Allergologie (ABEFORCAL)



Bulgaria
Bulgarian Society of Allergology



Croatia
Croatian Society for Allergology and Clinical Immunology



Cyprus
Cyprus Society of Allergology and Immunology



Czech Republic
Czech Society for Allergy and Clinical Immunology



Denmark
Danish Society of Allergology



Estonia
Estonian Society for Immunology and Allergology



Finland
Finnish Paediatric Allergy Society



France
Association Nationale de Formation Continue en Allergologie (ANAFORCAL)



France
French Society of Allergology and Clinical Immunology



Georgia
Georgian Association of Allergology and Clinical Immunology (GAACI)



Germany
German Society of Allergology (AEDA)



Germany
German Society for Allergology and Clinical Immunology (DGAKI)



Germany
Society for Pediatric Allergology and Environmental Medicine (GPA)



Greece
Greek Paediatric Allergy Society (GPAS)



Greece
Hellenic Society of Allergy and Clinical Immunology



Hungary
Hungarian Society of Allergologyand Clinical Immunology (MAKIT)



Iceland
Icelandic Society of Allergology and Clinical Immunology



Ireland
Irish Association of Allergy and Immunology (IAAI)



Israel
Israel Association of Allergy and Clinical Immunology



Italy
Associazione Italiana Pneumologi Ospedalieri (AIPO)



Italy
Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO)

National Society Village

Italy
Italian Society of Allergology and Clinical Immunology (SIAAIC)

Italy
Italian Society of Pediatric Allergy and Immunology (SIAIP)

Italy
Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA)

Kazakhstan
Kazakhstan Association of Allergology and Clinical Immunology (KAACI)

Kosovo
Kosovo Immunology Asthma and Allergy Association (KIAAA)

Latvia
Latvian Association of Allergists

Netherlands
Dutch Society of Allergology

Lithuania
Lithuanian Society of Allergology and Clinical Immunology

Luxembourg
Societe Luxembourgeoise d'Allergologie et d'Immunologie

North Macedonia
North Macedonia Paediatric Respiratory Society (PEDIARES)

North Macedonia
North Macedonian Society of Allergy and Clinical Immunology

North Macedonia
Society of Pulmonologists of the Republic of Macedonia (SPRM)

Norway
Norwegian Society of Allergology and Immunopathology

Poland
Polish Society of Allergology (PTA)

Portugal
Portuguese Society of Allergology and Clinical Immunology (SPAIC)

Portugal
Sociedade Portuguesa de Alergologia Pediátrica (SPAP)

Romania
Romanian Society of Allergology and Clinical Immunology (RSACI)

Romania
Romanian Society of Pneumology

Serbia
Serbian Association for Allergology and Clinical Immunology

Slovakia
Slovakian Society of Allergology and Clinical Immunology

Slovenia
Slovenian Association of Allergology and Immunology

Spain
Spanish Pediatric Society of Clinical Immunology, Allergy and Asthma (SEICAP)

Spain
Spanish Society of Allergology Clinical Immunology (SEAIC)

Sweden
Swedish Association for Allergology

Switzerland
Swiss Society of Allergology and Immunology

Turkey
Society of Pediatric Allergy Immunology and Asthma (CAIAD)

Turkey
Turkish National Society of Allergy and Clinical Immunology


Turkey
Turkish Thoracic Society

Ukraine
Ukrainian Society of Specialists for Immunology, Allergology and Immunorehabilitation

United Kingdom
British Society for Allergy and Clinical Immunology (BSACI)

Sponsorship and Exhibition

This section contains information that is promotional in nature, distinct from the scientific / educational elements of the EAACI Congress 2025.



This programme has been printed on June 12, 2025.
For the up-to-date Industry programme please check the EAACI Congress Mobile Application



Discover an HAE treatment option approved for a range of patients at booth B10

Join us for our symposium at EAACI on 13 June 2025 from 12 PM–1 PM

This symposium is initiated, organized, and funded by Takeda. Takeda products will be discussed.
EAACI=European Academy of Allergy and Clinical Immunology; HAE=hereditary angioedema.

Copyright © 2025 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
C-ANPROM/INT/TAK/0019 | C-ANPROM/GB/TAK/0044 | April 2025

Founder Sponsors

EAACI and the Local Organising Committee gratefully acknowledge the support of the 2025 Founder Sponsors.

Platinum Founder Sponsors

ALK
AstraZeneca
Allergy Therapeutics
CSL Behring
Biotherapies for Life™
NOVARTIS
sanofi | REGENERON
STALLERGENES GREER™

Gold Founder Sponsors

dbv technologies
GSK
hal allergy
Takeda

Silver Founder Sponsors

allergopharma
biocryst
blueprint MEDICINES
CELLTRION
Pharming
LETIPharma since 1919

Please CLICK HERE to view the full list of the EAACI Founder Sponsors.

At the Intersection of Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma

FACULTY



Brian Lipworth (Chair)
MD
United Kingdom



Zuzana Diamant
MD, PhD
Netherlands



Philippe Gevaert
MD, PhD
Belgium

In the UK, ADVENT is an education program for healthcare professionals organised and funded by Sanofi and Regeneron.

Products are discussed within this program.

Prescribing Information is available by scanning the QR code.

EAACI 2025 Symposium

13 June 2025 / 12:00-13:00 BST / Scottish Event Campus / Alsh Room

LEARNING OBJECTIVES

- Discuss the impact of co-existing type 2 inflammatory diseases on patient burden and management approaches
- Understand the common type 2 pathophysiological mechanisms underlying severe asthma and CRSwNP and the compounded burden of co-existing type 2 inflammatory diseases
- Highlight efficacy data in patients with severe/uncontrolled CRSwNP and co-existing asthma from biologic studies

AGENDA

Welcome and Introductions
Brian Lipworth (Chair)

Compounded Burden of Co-existing Type 2 Airway Diseases
Brian Lipworth (Chair)

Spotlight on Type 2 Inflammation in the Upper and Lower Airways
Zuzana Diamant

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
Philippe Gevaert

Panel Discussion and Audience Q&A
All Faculty

UK Prescribing Information is available at the following link: https://pro.campus.sanofi/dam/jcr:426d3c80-f750-4b27-a639-7d4c33fdecd7/Dupixent-(CRSwNP)-PI-UK.pdf

ADVERSE EVENTS SHOULD BE REPORTED.

In the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com.

In Ireland: Visit www.hpra.ie or email: medsafety@hpra.ie
Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to IEPharmacovigilance@sanofi.com

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2502400 - 1.0 - 06/2025

Friday 13 June 2025

12:00 - 12:15 SAT - CSL Behring: Garadacimab for HAE long-term prophylaxis: first real world experiences from Germany

(Innovation Hub, Product Theatre)

12:00 **Long-term integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis**
Mar Guilarte (Spain)

12:00 - 13:00 SAT1- 1 - ALK - The arrival of nasal adrenaline – an innovation in the treatment of anaphylaxis

(Lomond Auditorium, 2- Lomond, Sponsored Sessions)

*Chairs: **M. Worm (Berlin, Germany), A. Anagnostou (Houston, United States of America)***

12:00 **Introduction**
A. Anagnostou (Houston, United States of America)

12:03 **Unmet needs and limitations of anaphylaxis management – patient perspectives**
A. Ellis (Kingston, Canada)

12:18 **Clinical pharmacology of nasal adrenaline under various conditions**
G. du Toit (London, United Kingdom)

12:33 **Evidence of nasal adrenaline for the management of anaphylaxis in clinical practice**
M. Greenhawt (Aurora, United States of America)

12:48 **Panel discussion and conclusions**
M. Worm (Berlin, Germany)

12:00 - 13:00 SAT1-2 - AstraZeneca - Epithelial health: uniting the airway to transform patient care towards clinical remission

(Hall 1, 3- Hall 1, Sponsored Sessions)

*Chair: **C. Porsbjerg (Copenhagen, Denmark)***

12:00 **Welcome and introduction**
C. Porsbjerg (Copenhagen, Denmark)

12:05 **The role of the epithelium in the lower airway**
C. Porsbjerg (Copenhagen, Denmark)

12:15 **The role of the epithelium in the lower airway**
D. Antolin-Amerigo (Madrid, Spain)

12:30 **The implications of epithelial activation across the upper and lower airway**
E. De Corso (Rome, Italy)

12:45 **Panel discussion and audience Q&A**
C. Porsbjerg (Copenhagen, Denmark)

12:57 **Meeting close**
C. Porsbjerg (Copenhagen, Denmark)



Join us for the ALK-sponsored **EAACI 2025 symposia**

The arrival of nasal adrenaline – an innovation in the treatment of anaphylaxis

When
Friday 13 June, 12:00–13:00

Where
Lomond Auditorium

Co-chairs: Aikaterini Anagnostou & Margitta Worm

- *Unmet needs and limitations of anaphylaxis management – patient perspectives*
  Anne K Ellis
- *Clinical pharmacology of nasal adrenaline under various conditions*
  George Du Toit
- *Evidence of nasal adrenaline for the management of anaphylaxis in clinical practice*
  Matthew Greenhawt

The evolution of immunotherapy in children – from respiratory to peanut allergy

When
Saturday 14 June, 12:00–13:00

Where
Lomond Auditorium

Chair: Graham Roberts

- *Improving outcomes in children with respiratory allergy – the broadening evidence of SLIT-tablets*
  Oliver Pfaar
- *SLIT-tablets in clinical practice – identifying and managing children with respiratory allergy*
  Ann-Marie Schoos
- *SLIT for food allergy in children – current and future aspects*
  Edwin Kim

GL-NPR-2500005 | Date of Prep: April 2025

Friday 13 June 2025

12:00 - 13:00 SAT1-3 - Takeda - Advancing HAE management: the impact of modern long-term prophylaxis

(Forth, 5- Forth, Sponsored Sessions)

Chairs: ***S. Savić (Leeds, United Kingdom), S. Savić (Leeds, United Kingdom)***

Objectives:

- *Explore the continued potential of long-term prophylaxis (LTP) for the management of hereditary angioedema (HAE) based on long-term effectiveness and safety data*
- *Highlight the patient experience of using LTP through quality of life (QoL) improvements*
- *Facilitate scientific exchange and clinical experience sharing*

12:00 **Welcome and introductions**
S. Savić (Leeds, United Kingdom)

12:03 **Assessing the long-term effectiveness and safety of LTP in HAE**
T. Buttgereit (Berlin, Germany)

12:23 **Patient-centered approaches to help improve outcomes and QoL in HAE**
A. Zanichelli (Milan, Italy)

12:38 **A family's perspective on navigating the challenges of HAE**
S. Savić (Leeds, United Kingdom), T. Buttgereit (Berlin, Germany), A. Zanichelli (Milan, Italy)

12:58 **Meeting close**
S. Savić (Leeds, United Kingdom)

12:00 - 13:00 SAT1-4 - LETI Pharma - Milestones Achieved and the Road Ahead

(Boisdale, 6- Boisdale, Sponsored Sessions)

Chair: ***J. Bartra (Barcelona, Spain)***

12:00 **Introduction**
J. Bartra (Barcelona, Spain)

12:05 **Foundations of our journey**
R. Mösges (Cologne, Germany)

12:20 **At the Crossroads: Where today shapes de future**
S. Cimbollek (Seville, Spain)

12:35 **The road ahead: Focus on innovation**
J. Carnes (Madrid, Spain)

12:50 **Q&A**
J. Bartra (Barcelona, Spain), R. Mösges (Cologne, Germany), S. Cimbollek (Seville, Spain), J. Carnes (Madrid, Spain)

NOVARTIS | Reimagining Medicine



Novartis-organized and funded medical symposium at EAACI 2025

Chronic Spontaneous Urticaria (CSU): The patient experience

SEC, Glasgow, Scotland

Saturday 14 June 2025
13:45–14:45 BST

Meeting Academy M1, Scottish Event Campus

Join **Tonya Winders** (patient advocate) with Professors **Sinisa Savic** and **Martin Metz** as they explore how to cultivate improved outcomes in the management of CSU

This non-promotional medical symposium has been organised and funded by Novartis Pharma AG, CH-4056 Basel, Switzerland and is intended for an audience of healthcare professionals only within the context of the EAACI congress 2025, Glasgow.

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

UK | FA-11396146 | April 2025
Copyright © 2025 Novartis Pharma AG

Friday 13 June 2025

12:00 - 13:00 SAT1-5 - Sanofi Regeneron - At the Intersection of Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma

(Alsh, Sponsored Sessions)

Chair: ***B. Lipworth (Dundee, United Kingdom)***

Objectives:

- *Explore the continued potential of long-term prophylaxis (LTP) for the management of hereditary angioedema (HAE) based on long-term effectiveness and safety data*
- *Highlight the patient experience of using LTP through quality of life (QoL) improvements*
- *Facilitate scientific exchange and clinical experience sharing*

12:00 **Welcome and Introductions**
B. Lipworth (Dundee, United Kingdom)

12:05 **Compounded Burden of Co-existing Type 2 Airway Diseases**
B. Lipworth (Dundee, United Kingdom)

12:20 **Spotlight on Type 2 Inflammation in the Upper and Lower Airways**
Z. Diamant (Leuven, Netherlands)

12:30 **CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma**
P. Gevaert (Gent, Belgium)

12:50 **Panel Discussion and Audience Q&A**
B. Lipworth (Dundee, United Kingdom), Z. Diamant (Leuven, Netherlands), P. Gevaert (Gent, Belgium)

12:20 - 12:35 CSL Behring: Garadacimab for HAE long-term prophylaxis: first real world experiences from Germany

(Innovation Hub, Product Theatre)

12:20 **CSL Behring: Garadacimab for HAE long-term prophylaxis: first real world experiences from Germany**
R. Lochbaum (Ulm, Germany), M. Guilarte (Barcelona, Spain)

13:30 - 14:30 SAT1-6 - Stallergenes Greer - Breath of change: redefining respiratory allergy care with remission in sight

(Meeting Academy M1, 4- Academy M1, Sponsored Sessions)

Chair: ***A. Custovic (London, United Kingdom)***

13:30 **Introduction**
A. Custovic (London, United Kingdom)

13:35 **Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift**
G. Lezmi (Paris)

13:50 **From symptom control to disease remission: a new vision for allergic asthma**
O. Pfaar (Marburg, Germany)

14:05 **Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis**
R. Brehler (Münster, Germany)

14:20 **Questions & Answers**
A. Custovic (London, United Kingdom)

JOIN OUR COMPANY SPONSORED SYMPOSIUM



SAVE THE DATE

FROM STINGS TO SNEEZES: BUSY BEES & MIGHTY MITES

Saturday, 14 June 2025, 13:45 -14:45 hrs, room Alsh

Chair
Stephen Durham, United Kingdom

Speakers
Andrzej Bożek, Poland
Battling the Invisible: Understanding House Dust Mite Allergies

Gunter Sturm, Austria
The Sting of Danger: Exploring Venom Allergies

EAACI 2025 GLASGOW

Solutions for Allergologists

HAL Allergy B.V. | J.H. Oortweg 15 | 2333 CH Leiden | The Netherlands | www.hal-allergy.com

hal allergy

Friday 13 June 2025

00:00 - 00:00 SAT1-7 - Pharming - A new era in APDS management: Advances in tackling PI3Kδ hyperactivity

(Alsh, 7- Alsh, Sponsored Sessions)

*Chair: **S. Savić (Leeds, United Kingdom)***

Objectives:

Activated PI3 kinase delta syndrome (APDS) is a rare, unpredictable and life-limiting disease that can progress rapidly at any point and is caused by hyperactivity of the PI3K delta pathway. During this session, we will discuss the challenges in diagnosing APDS, explore current unmet treatment needs and introduce Joenja® • (leniolisib), the first and only disease-specific therapy licenced for APDS. Discussions will include insights into real-world clinical experience with Joenja as well as an overview of efficacy and safety data.

• Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events and product complaints should also be reported to Pharming by emailing safety@pharming.com.

This meeting has been sponsored and fully funded by Pharming. For Joenja (leniolisib) prescribing information for the UK, please visit https://www.pharming.com/HCPPrescribingInformationUK.pdf.

LEN-UK-2025-0092 | April 2025

13:30 **Welcome**
S. Savić (Leeds, United Kingdom)

13:35 **Understanding APDS: a progressive and life-limiting inborn-error of immunity**
K. Sacco (London, United Kingdom)

13:45 **Current unmet treatment needs in APDS**
K. Sacco (London, United Kingdom)

13:50 **Introducing Joenja: Clinical experience with the first and only licensed disease-specific therapy for APDS**
S. Savić (Leeds, United Kingdom)

14:00 **Joenja efficacy and safety data**
M. Bloomfield (Prague, Czech Republic)

14:20 **Q&A session**
S. Savić (Leeds, United Kingdom)

15:00 - 16:00 SAT1-8 - Menarini - The hidden burden of allergic rhinitis: From symptoms to solutions for a better quality of life

(Boisdale, 6- Boisdale, Sponsored Sessions)

*Chairs: **S. Del Giacco (Cagliari, Italy), S. Del Giacco (Cagliari, Italy)***

15:00 **Introduction**
S. Del Giacco (Cagliari, Italy)

15:05 **Burden of Disease: Uncovering the Unexpected**
L. Klimek (Wiesbaden, Germany)

15:20 **Rhinitis Control in a Real-World setting**
P. Gevaert (Gent, Belgium)

15:35 **Clinical Insights into Mometasone furoate/Olopatadine Combination Therapy**
S. Del Giacco (Cagliari, Italy)

15:50 **Questions & Answers**
S. Del Giacco (Cagliari, Italy)

13 June 2025
12:00–13:00 BST

Symposium
sponsored by
AstraZeneca

Hall 1

EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIUM IN SEVERE ASTHMA AND BEYOND

European Academy of Allergy and Clinical Immunology (EAACI) International Congress 2025
Hosted in Glasgow, UK

Epithelial health: uniting the airway to transform patient care towards clinical remission



Celeste Porsbjerg
Bispebjerg Hospital,
Copenhagen, Denmark



Darío Antolín-Amérigo
Hospital Universitario Ramón y
Cajal, Madrid, Spain



Eugenio De Corso
Agostino Gemelli University
Policlinic, Rome, Italy

Agenda

Celeste Porsbjerg	Welcome and introductions
Celeste Porsbjerg	Restoring epithelial health: a step towards clinical remission
Darío Antolín-Amérigo	The role of the epithelium in the lower airway
Eugenio De Corso	The implications of epithelial activation across the upper and lower airway
All	Panel discussion and audience Q&A
Celeste Porsbjerg	Meeting Close

Click here to explore EpiCentral for further information on the central role of the epithelium

Veeva ID: Z4-75023; date of preparation: June 2025.
This non-promotional symposium is organised and funded by AstraZeneca.
The information displayed during the meeting is exclusively for healthcare professionals.
© 2025 AstraZeneca. All Rights Reserved. EpiCentral is sponsored by AstraZeneca.

AMGEN AstraZeneca

Friday 13 June 2025

15:00 - 16:00 SAT1-8 - Menarini - The hidden burden of allergic rhinitis: From symptoms to solutions for a better quality of life

(Boisdale, 6- Boisdale, Sponsored Sessions)

Chairs: ***S. Del Giacco (Cagliari, Italy), S. Del Giacco (Cagliari, Italy)***

15:00 **Introduction**
S. Del Giacco (Cagliari, Italy)

15:05 **Burden of Disease: Uncovering the Unexpected**
L. Klimek (Wiesbaden, Germany)

15:20 **Rhinitis Control in a Real-World setting**
P. Gevaert (Gent, Belgium)

15:35 **Clinical Insights into Mometasone furoate/Olopatadine Combination Therapy**
S. Del Giacco (Cagliari, Italy)

15:50 **Questions & Answers**
S. Del Giacco (Cagliari, Italy)

15:00 - 16:00 SAT1-9 - Biocryst - NAVIGATING-TO-NORMALITY: Targeting normalisation of life in Hereditary Angioedema (HAE) for better patient outcomes

(Alsh, 7- Alsh, Sponsored Sessions)

Chairs: ***P. Yong (Frimley, United Kingdom), M. Cancian (Padova, Italy)***

Objectives:
Targeting normalisation of life in HAE for better patient outcomes through:
- *Exploring the definitions of treatment goals*
- *Practical advice on how to implement guidelines*
- *Expert-led clinical case discussions*

15:00 **Welcome, introductions and objectives**
P. Yong (Frimley, United Kingdom), M. Cancian (Padova, Italy)

15:05 **How a 'treat-to-target' approach to HAE management can support optimised patient outcomes**
T. Buttgereit (Berlin, Germany)

15:20 **Implementing treat-to-target in practice: Debating real-world patient cases**
M. Guilarte (Barcelona, Spain), A. Bocquet (Grenoble)

15:50 **Summary and Q&A**
M. Cancian (Padova, Italy)

Allergy Therapeutics

Bencard Allergie

Subcutaneous allergen immunotherapy

WE WILL ROCK YOU

ROCKIN' ALL OVER THE ALLERGY WORLD!

EAACI 2025 GLASGOW



Friday
13th June
4.30 - 5.30pm
BST
Room: Alsh

Symposium introduction:

MORE THAN WORDS,

Our commitment to patients

Chair: Dr. Montserrat Alvaro

Reaching

THE FINAL COUNTDOWN

to state-of-the-art evidence

Prof. Lawrence DuBuske

WIND OF CHANGE

in the peanut allergy treatment paradigm

Dr. Wayne Shreffler M.D, PhD

IM/GEN/E/2025/017

Friday 13 June 2025

16:30 - 17:30 SAT1-10 - Medscape - Hereditary Angioedema Headlines: Early Intervention Stratergies for Managing Attacks and Improving Patient Outcomes

(Boisdale, 6- Boisdale, Sponsored Sessions)

*Chair: **D. Jones (Layton, United States of America)***

Objectives:
Upon completion of this activity, participants will:
Have increased knowledge regarding the
• Importance of early intervention to reduce the burden and severity of HAE attack
• Key factors that delay timely utilization of on-demand therapies for HAE
• Key data for on-demand therapies for HAE
Demonstrate greater confidence in their ability to
• Empower patients to recognize early symptoms of an HAE attack

16:30 **Introduction and Welcome**

16:35 **Behind the HAE Attack: Uncovering the Real Burden of HAE**
D. Jones (Layton, United States of America), A. Burnette (Washington DC, United States of America), H. Longhurst (Auckland, New Zealand)

16:40 **In Depth: The Importance of Early Intervention for HAE Attack**
D. Jones (Layton, United States of America), A. Burnette (Washington DC, United States of America), H. Longhurst (Auckland, New Zealand)

16:50 **Barriers and Breakdowns With On-Demand Therapies**
D. Jones (Layton, United States of America), A. Burnette (Washington DC, United States of America), H. Longhurst (Auckland, New Zealand)

17:00 **Breaking News: Innovation in HAE On-Demand Therapies**
D. Jones (Layton, United States of America), A. Burnette (Washington DC, United States of America), H. Longhurst (Auckland, New Zealand)

17:10 **The Power of Early Intervention and Patient Partnerships in HAE**
D. Jones (Layton, United States of America), A. Burnette (Washington DC, United States of America), H. Longhurst (Auckland, New Zealand)

17:20 **Q&A and Closing Remarks**

16:30 - 17:30 SAT1-11 - Allergy Therapeutics - Subcutaneous allergen immunotherapy - we will rock you

(Alsh, 7- Alsh, Sponsored Sessions)

*Chair: **M. Alvaro Lozano (Barcelona, Spain)***

16:30 **Symposium introduction: More than words, Our commitment to patients**
M. Alvaro Lozano (Barcelona, Spain)

16:40 **Reaching the final countdown to state-of-the-art evidence**
L. DuBuske (Gardner, United States of America)

17:00 **Wind of change in the peanut allergy paradigm**
W. G. Shreffler (Boston, United States of America)

17:20 **Q&A**

Milestones achieved and the road ahead

FRIDAY 13TH June 2025, 12:00-1:00 PM · BOISDALE

Chairperson: Dr. Joan Bartra: Hospital Clinic Barcelona, Spain

Foundations of our journey
Prof. Ralph Mösges.
ClinCompetence, Cologne GmbH, Germany

At the Crossroads: Where today shapes the future
Dr. Stefan Cimbollek.
Hospital U. Virgen del Rocío, Sevilla, Spain

The road ahead: Focus on innovation
Dr. Jerónimo Carnés.
R&D Director, LETI Pharma, Madrid, Spain

Company Sponsored Symposia

Friday 13 June 2025

18:00 - 18:30 MSAT1-2 - GSK - Persistent Cough, Persistent Questions: A Clinical Approach to Identifying Refractory Chronic Cough
(Alsh, 7- Alsh, Sponsored Sessions)

*Chair: **P. Hellings (Leuven, Belgium)***

Objectives:
The objectives of this GSK organised and funded Symposium are to:
• Raise awareness of RCC as a distinct disease associated with neuronal hypersensitivity
• Raise awareness of and demonstrate the allergist's clinical evaluation of patients presenting with chronic cough throughout their diagnostic journey
For Healthcare Professionals or Other Relevant Decision Makers only
[NX-GBL-CML-AGND-250003] ¦ Date of preparation: May 2025

18:00 **Introduction and welcome**
P. Hellings (Leuven, Belgium)

18:03 **Defining RCC and the pathway to diagnosis**
L. Klimek (Wiesbaden, Germany)

18:08 **Clinical work-up in practice**
P. Hellings (Leuven, Belgium), L. Klimek (Wiesbaden, Germany)

18:23 **Summary**
P. Hellings (Leuven, Belgium)

18:25 **Q&A and close**
L. Klimek (Wiesbaden, Germany), P. Hellings (Leuven, Belgium)

Saturday 14 June 2025

09:00 - 10:00 SAT2-1 - Celldex - Shining a Light on Mast Cells in Chronic Spontaneous Urticaria
(Boisdale, 6- Boisdale, Sponsored Sessions)

Chair: ***M. Metz (Berlin, Germany)***

09:00 **CSU: Disease Overview**
M. Ferrer (Pamplona, Spain)

09:25 **CSU: Mechanism of Disease**
M. Metz (Berlin, Germany)

09:40 **CSU: Treatment Options - Emerging Therapies**
A. M. Giménez-Arnau (Barcelona, Spain)

12:00 - 12:15 The Eye-Opening Truth About Allergy Treatment
(Innovation Hub, Product Theatre)

12:00 **The Eye-Opening Truth About Allergy Treatment**
M. Recto (Mani, Philippines), R. Mösges (Cologne, Germany)

12:00 - 13:00 SAT2-2 - ALK - The evolution of immunotherapy in children - from respiratory to peanut allergy
(Lomond Auditorium, 2- Lomond, Sponsored Sessions)

Chair: ***G. Roberts (Southampton, United Kingdom)***


12:00 **Introduction**
G. Roberts (Southampton, United Kingdom)

12:03 **Improving outcomes in children with respiratory allergy - the broadening evidence of SLIT-tablets**
O. Pfaar (Marburg, Germany)

12:18 **SLIT-tablets in clinical practice - identifying and managing children with respiratory allergy**
A.-M.M. Schoos (Copenhagen, Denmark)

12:48 **Panel discussion and conclusions**
G. Roberts (Southampton, United Kingdom)

Breathing as one:
The expanded role of IL-5 inhibition in CRSwNP and Asthma



Sunday, 15th June | 12:45-13:45 BST |
Scottish Event Campus | Session Room: Forth

Join our esteemed experts at our Industry Lunchtime Symposium.



Dr Santiago Quirce
(Chair), Spain



Özlem Ceylan
Türkiye



Prof. Petros Bakakos
Greece



Dr Pascal Werminghaus
Germany

Objectives:

- Uncover the disease burden and experiences in managing CRSwNP through the patient's voice
- Strive for ambitious treatment goals with emerging IL-5 science in CRSwNP and SA
- Highlight the power of unified airway care in optimising CRSwNP and SA treatment outcomes

Agenda:

Living with CRSwNP: Navigating challenges in the care pathway	Özlem Ceylan
Transforming unified airway care with emerging science	Dr Santiago Quirce
Breathing as one: Integrating upper and lower airways	Prof. Petros Bakakos and Dr Pascal Werminghaus

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on +44 800 221 441.

CRSwNP, chronic rhinosinusitis with nasal polyps; IL-5, interleukin-5, SA, Severe Asthma.
This promotional symposium is organised and funded by GSK. GSK sponsored studies and products being discussed. Full prescribing information is available at the meeting, or at the GSK booth.

GSK

PM-GBL-MPL-BROC-250001 | May 2025

Saturday 14 June 2025

12:00 - 13:00 SAT2-3 - CSL Behring - Changing the flow: Shifting HAE treatment toward normalization of patients' lives

(Meeting Academy M1, 4- Academy M1, Sponsored Sessions)

Chair: ***M. A. Riedl (San Diego, California, United States of America)***

12:00 **Introduction**
M. A. Riedl (La Jolla, United States of America)

12:05 **Navigating troubled waters: Barriers to the improvement of QoL for patients with HAE**
M. A. Riedl (La Jolla, United States of America), A. Dorr (London, United Kingdom)

12:25 **Charting a course: Supporting each patient with their unique HAE management journey**
M. Cancian (Padova, Italy)

12:35 **Shifting the current: Exploring the pathophysiology of HAE and novel therapeutic targets**
M. Magerl (Berlin, Germany)

12:50 **Q&A - Session**
M. A. Riedl (San Diego, California, United States of America), A. Dorr (London, United Kingdom), M. Cancian (Padova, Italy), M. Magerl (Berlin, Germany)

12:00 - 13:00 SAT2-4 - GSK - Is disease modification possible in severe asthma?

(Forth, 5- Forth, Sponsored Sessions)

Chair: ***L. Heaney (Belfast, United Kingdom)***

Objectives:

To summarise clinical remission as an achievable treatment goal for patients with severe asthma and to outline the evidence for greater benefit with earlier biologic intervention, with a view on future management approaches

- *To inform on the biology and consequences of mucus plugging in asthma and discuss how it drives pathological processes and disease progression*
- *To highlight airway remodelling as a key contributor to disease progression in severe asthma, and the opportunities for intervention*

12:00 **Welcome and general introduction**
L. Heaney (Belfast, United Kingdom)

12:05 **Clinical remission: achieving disease control in severe asthma**
L. Heaney (Belfast, United Kingdom)

12:20 **Mucus plugging and airway obstruction in severe asthma**
M. Mukherjee (Hamilton, Canada)

12:35 **Airway remodelling and its relevance to disease progression in severe asthma**
H. Rupani (Southampton, United Kingdom)

12:50 **Q&A and concluding remarks**
L. Heaney (Belfast, United Kingdom)

Advancing towards an AIT Breakthrough



Saturday, 14 June 2025
15:30 – 16:30 Hall Alsh

Chairs

Prof.
Mohamed Shamji
United Kingdom



Dr.
Stephanie Dramburg
Germany



Speakers

Step 1:
Diagnosis
Olga Luengo
Spain



Step 2:
Therapy Decision
Prof. Marek Jutel
Poland



Step 3:
Adherence
Prof. Christian Vogelberg
Germany



Join this Allergopharma-sponsored symposium and visit us at our booth!

allergopharma

Company Sponsored Symposia

Saturday 14 June 2025

12:00 - 13:00 SAT2-5 - DBV Technologies - Peanut Allergy: Recent Research Highlights
(Boisdale, 6- Boisdale, Sponsored Sessions)

Objectives:
To highlight to burden of food allergies in Europe from the points of view of clinicians and patients
To update the audience on the latest scientific data with epicuteneous immunotherapy for food allergies

12:00 **Introduction**
G. Lack (London, United Kingdom)

12:10 **The Allergist - Food Allergic Patient Clinical Relationship**
S. Tsabouri (Ioannina, Greece), O. Ceylan (Istanbul, Türkiye)

12:30 **Epicutaneous Immunotherapy: New Data and Insights**
K. Blümchen (Frankfurt, Germany)

12:50 **Conclusion**
A. Santos (London, United Kingdom)

Saturday 14 June 2025

12:00 - 13:00 SAT2-5 - DBV Technologies - Peanut Allergy: Recent Research Highlights
(Boisdale, 6- Boisdale, Sponsored Sessions)

Objectives:
To highlight to burden of food allergies in Europe from the points of view of clinicians and patients
To update the audience on the latest scientific data with epicuteneous immunotherapy for food allergies

12:00 **Introduction**
G. Lack (London, United Kingdom)

12:10 **The Allergist - Food Allergic Patient Clinical Relationship**
S. Tsabouri (Ioannina, Greece), O. Ceylan (Istanbul, Türkiye)

12:30 **Epicutaneous Immunotherapy: New Data and Insights**
K. Blümchen (Frankfurt, Germany)

12:50 **Conclusion**
A. Santos (London, United Kingdom)

12:00 - 13:00 SAT2-6 - Blueprint - Unmasking Indolent Systemic Mastocytosis: Strategies for Accurate Diagnosis & Comprehensive Care to Improve Patient Outcomes
(Alsh, 7- Alsh, Sponsored Sessions)

Chair: ***P. Bonadonna (Verona, Italy)***

12:00 **Welcome & Introductions**
P. Bonadonna (Verona, Italy)

12:02 **Diagnostic Challenges in ISM**
P. Bonadonna (Verona, Italy)

12:10 **Understanding the Disease Burden**
J. Hobart (London, United Kingdom)

12:20 **The Multidisciplinary Team (MDT) Care Approach**
D. González-de-Olano (Madrid, Spain)

12:35 **Optimizing Treatment Decisions and Patient Outcomes**
F. Siebenhaar (Berlin, Germany)

12:50 **Q&A**

12:20 - 12:35 Beyond the Pill: A 360° Approach to Allergic Relief
(Innovation Hub, Product Theatre)

12:20 **Beyond the Pill: A 360° Approach to Allergic Relief**
M. Recto (Mani, Philippines), R. Mösges (Cologne, Germany)



Join us for our company-sponsored mini-symposium at **EAACI 2025**

Myth busting in peanut allergy: separating fact from fiction

Speakers



Dr Aikaterini Anagnostou
Texas Children's Hospital and Baylor College of Medicine,
Houston, United States of America



Dr Pablo Rodríguez del Río
Hospital Infantil Universitario Niño Jesus,
Madrid, Spain

14th June 2025 | 14:30–15:00

Room Boisdale (Ground floor of the SEC Centre, adjacent to the Lomond Auditorium)

You can also join us virtually at the EAACI Hybrid Congress

EAACI 2025 GLASGOW

STALLERGENES GREER

2025_021EN01_April 2025

Saturday 14 June 2025

13:45 - 14:45 SAT2-7 - Novartis - Chronic spontaneous urticaria (CSU): The Patient Experience

(Meeting Academy M1, 4- Academy M1, Sponsored Sessions)

Chair: ***T. Winders (Vienna, Austria)***

13:45 **Welcome and introductions**
T. Winders (Vienna, Austria)

13:50 **Sowing the seeds of understanding: The patient perspective on living with CSU**
T. Winders (Vienna, Austria)

14:00 **Unearthing the roots of CSU pathophysiology**
S. Savić (Leeds, United Kingdom)

14:15 **Branching out: Expanding our approach to diagnosis and care in CSU**
M. Metz (Berlin, Germany)

14:35 **Panel discussion and Q&A**
T. Winders (Vienna, Austria), S. Savić (Leeds, United Kingdom), M. Metz (Berlin, Germany)

13:45 - 14:45 SAT2-8 - HAL Allergy - From stings to sneezes: busy bees and mighty mites

(Alsh, 7- Alsh, Sponsored Sessions)

Chair: ***S. R. Durham (London, United Kingdom)***

13:45 **Battling the Invisible: Understanding House Dust Mite Allergies**
A. Bożek (Katowice, Poland)

14:15 **The Sting of Danger: Exploring Venom Allergies**
G. Sturm (Graz, Austria)

14:30 - 15:00 MSAT2-1 - Stallergenes Greer - Myth Busting in Peanut Allergy: Separating Fact from Fiction

(Boisdale, 6- Boisdale, Sponsored Sessions)

Chairs: ***P. Rodríguez del Río (Madrid, Spain), A. Anagnostou (Houston, United States of America)***

14:30 **Myth Busting in Peanut Allergy: Separating Fact from Fiction**
A. Anagnostou (Houston, United States of America)

14:45 **Myth Busting in Peanut Allergy: Separating Fact from Fiction**
P. Rodríguez del Río (Madrid, Spain)

CSL Behring

A CSL Behring-sponsored symposium

Changing the flow:
Shifting HAE treatment toward normalization of patients' lives



Saturday June 14, 2025 | 12:00–13:00 BST

Meeting Academy M1, the Scottish Event Campus (SEC), Glasgow, Scotland

We are pleased to invite you to this innovative and interactive promotional symposium, organized and funded by CSL Behring for healthcare professionals only. In the first session, our faculty will be joined by two guest speakers to discuss the challenges patients with HAE face in achieving complete disease control and normalization of their lives. We will also explore individualized patient management approaches and reflect on recent developments in the HAE treatment landscape. We look forward to welcoming you to what promises to be an exciting, immersive, and impactful meeting.

Faculty



Marc A Riedl (Chair)
University of California San Diego, San Diego, CA, USA



Anthony Dorr
Barts Health NHS Trust, London, UK



Mauro Cancian
University Hospital of Padua, Padua, Italy



Markus Magerl
Charité - Medical University of Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology, Berlin, Germany

Agenda

Time (BST)	Session title	Speaker(s)
	Lunch available (11:40–12:00)	
12:00–12:05	Introduction	Marc A Riedl (Chair)
12:05–12:25	Navigating troubled waters: Barriers to the improvement of QoL for patients with HAE	Marc A Riedl (Chair), Anthony Dorr, and two guest speakers
12:25–12:35	Charting a course: Supporting each patient with their unique HAE management journey	Mauro Cancian
12:35–12:50	Shifting the current: Exploring the pathophysiology of HAE and novel therapeutic targets	Markus Magerl
12:50–13:00	Q&A session	Marc A Riedl (Chair), Anthony Dorr, Mauro Cancian, and Markus Magerl

Meet us at the CSL Behring booth at EAACI, located at C20 in Hall 4 of the exhibition area, from June 13–15, 2025

This promotional symposium, for healthcare professionals only, is initiated, organized, and funded by CSL Behring.
Prescribing information for CSL Behring products mentioned will be available at the symposium.

EAACI, European Academy of Allergy and Clinical Immunology; HAE, hereditary angioedema; QoL, quality of life.

GBR-GDM-0043 | April 2025

Saturday 14 June 2025

15:30 - 16:30 SAT2-10 - Allergopharma - Advancing towards an AIT Breakthrough
(Alsh, 7- Alsh, Sponsored Sessions)

Chairs: ***M. Shamji (London, United Kingdom), S. Dramburg (Berlin, Germany)***

15:30 **Step 1: Diagnosis**
O. Luengo (Barcelona, Spain)

15:45 **Step 2: Therapy Decision**
M. Jutel (Wrocław, Poland)

16:00 **Step 3: Adherence**
C. Vogelberg (Dresden, Germany)

15:30 - 16:30 SAT2-9 - Thermo Fisher Scientific - Utility of allergen specific IgE testing in daily routine: why, who, when and how?
(Boisdale, 6- Boisdale, Sponsored Sessions)

Chair: ***A. Santos (London, United Kingdom)***
Moderator: ***R. Movérare (Uppsala, Sweden)***

15:30 **Welcome & Introduction**
A. Santos (London, United Kingdom)

15:33 **Importance of quantitative and qualitative aspects of IgE testing**
R. van Ree (Amsterdam, Netherlands)

15:51 **New insights from the HealthNuts study: follow up over time and novel diagnostics**
R. Peters (Parkville, Australia)

16:09 **Highlights on the use of singleplex and multiplex platforms in clinical practice**
A. Santos (London, United Kingdom)

16:12 **Interactive discussion**
A. Santos (London, United Kingdom), R. van Ree (Amsterdam, Netherlands), R. Peters (Parkville, Australia)

16:27 **Summary & Closure**
A. Santos (London, United Kingdom)

Learn more about peanut allergy

Join our symposium!

Saturday 14 June - 12.00 to 13.00
Room Boisdale



Peanut Allergy: Recent Research Highlights

Co-chairs:
Gideon Lack
Alexandra Santos

Introduction
Gideon Lack

The Allergist – Food Allergic Patient Clinical Relationship
Ozlem Ceylan
Sophia Tsabouri

Epicutaneous Immunotherapy: New Data and Insights
Katharina Blümchen

Conclusion
Alexandra Santos

2025-MLR-019

Epicutaneous immunotherapy is under clinical investigation and has not yet been approved by any health or regulatory authority

Saturday 14 June 2025

17:15 - 18:15 SAT2-11 - Siemens Healthineers - Unlocking Molecular Diagnostics: From Basics to Clinical Impact

(Boisdale, 6- Boisdale, Sponsored Sessions)

Chairs: ***C. Hilger (Esch-sur-Alzette, Luxembourg), S. Blank (Munich, Germany)***

17:15 **Introduction to component-resolved diagnostics in allergy**
C. Hilger (Esch-sur-Alzette, Luxembourg)

17:35 **Peanut components in practice - diagnosing peanut allergy**
L. Klimek (Wiesbaden, Germany)

17:55 **Disentangling respiratory allergies by molecular IgE testing**
S. Dramburg (Berlin, Germany)

17:15 - 18:15 SAT2-12 - KalVista - Closing Gaps in HAE Management: Understanding what control means for your HAE patients

(Alsh, 7- Alsh, Sponsored Sessions)

Chair: ***D. Jones (Layton, United States of America)***

Objectives:
- *Treatment burden and HAE control*
- *Benefits of treating attacks early*
- *Evolving our discussion with patients*

17:15 **Closing Gaps in HAE Management: Presentation and Panel Discussion**
D. Jones (Layton, United States of America), T. Buttgereit (Berlin, Germany), S. Savić (Leeds, United Kingdom), S. Betschel (Toronto, Canada)

Navigating –TO–Normality

Targeting normalisation of life in Hereditary Angioedema (HAE) for better patient outcomes

Alsh room, Friday 13 June, 3–4pm

Co-Chairs



Prof. Mauro Cancian



Dr Patrick Yong

Speakers



Dr Thomas Buttgereit



Dr Alexis Bocquet



Dr Mar Guilarte



Targeting normalisation of life in HAE for better patient outcomes through:

- Exploring the definition of treatment goals
- Practical advice on how to implement guidelines
- Expert-led clinical case discussions

This promotional symposium is organised and funded by BioCryst® Pharmaceuticals, intended for healthcare professionals only.
Date of preparation: April 2025 | EU.ORL.00060

bio cryst

Company Sponsored Symposia

Sunday 15 June 2025

12:45 - 13:45 SAT3-1 - GSK - Breathing as one: The expanded role of IL-5 inhibition in CRSwNP & Asthma
(Forth, 5- Forth, Sponsored Sessions)

*Chair: **S. Quirce (Madrid, Spain)***

Objectives:

- *Uncover the disease burden and experiences in managing chronic rhinosinusitis with nasal polyps (CRSwNP) through the patient's voice*
- *Strive for ambitious treatment goals with emerging IL-5 science in CRSwNP and Severe Asthma (SA)*
- *Highlight the power of unified airway care in optimising CRSwNP and SA treatment outcomes*

12:45 **Welcome and Introductions**
S. Quirce (Madrid, Spain)

12:50 **Living with CRSwNP: Navigating challenges in the care pathway**
O. Ceylan (Istanbul, Türkiye)

13:05 **Transforming unified airway care with emerging science**
S. Quirce (Madrid, Spain)

13:20 **Breathing as one: Integrating upper and lower airways**
P. Bakakos (Athens, Greece), P. Werminghaus (Dusseldorf, Germany)

13:35 **Panel discussion and closing remarks**
S. Quirce (Madrid, Spain), P. Bakakos (Athens, Greece), P. Werminghaus (Dusseldorf, Germany)

Sunday 15 June 2025

12:45 - 13:45 SAT3-2 - Otsuka Pharmaceutical - Did I hear you right? How to ensure bi-directional HCP-patient communication

(Boisdale, 6- Boisdale, Sponsored Sessions)

Chair: ***S. Kiani (London, United Kingdom)***

Objectives:

- *Explore and provide a psychological readout of patient and HCP expectations that can undermine bi-directional communication*
- *Share practical guidance on how to act on the expectations to improve HCP-patient communication*
- *Discuss the therapeutic benefits of improved HCP-patient communication based on objective real-world evidence*

12:45 **Introduction and housekeeping**
S. Kiani (London, United Kingdom)

12:50 **Communication expectations: Patient's perspective**
A. Metcalfe (Bridgwater, United Kingdom)

13:00 **Audience Q&A**
S. Kiani (London, United Kingdom), A. Metcalfe (Bridgwater, United Kingdom), D. M. Cohn (Amsterdam, Netherlands), M. Campbell (London, United Kingdom)

13:05 **Communication expectations: HCP's perspective**
D. M. Cohn (Amsterdam, Netherlands)

13:15 **Audience Q&A**
S. Kiani (London, United Kingdom), A. Metcalfe (Bridgwater, United Kingdom), D. M. Cohn (Amsterdam, Netherlands), M. Campbell (London, United Kingdom)

13:20 **The 'Therapeutic Alliance' between HCPs and patients: Practical guidance on how to establish bi-directional communication**
M. Campbell (London, United Kingdom)

13:35 **Audience Q&A**
S. Kiani (London, United Kingdom), A. Metcalfe (Bridgwater, United Kingdom), D. M. Cohn (Amsterdam, Netherlands), M. Campbell (London, United Kingdom)

13:40 **Meeting close**
S. Kiani (London, United Kingdom)

12:45 - 13:45 SAT3-3 - Celltrion - Getting to Know Omalizumab Biosimilar in Allergic Diseases

(Alsh, 7- Alsh, Sponsored Sessions)

Chairs: ***S. Saini (Baltimore, United States of America), S. Saini (Baltimore, United States of America)***

Objectives:

- *Understand the process of biosimilar medicine development and regulatory approval*
- *Review the treatment algorithm for patients with chronic spontaneous urticaria (CSU) and Phase 3 trial data of omalizumab biosimilar conducted in patients with CSU*
- *Explore how omalizumab biosimilar can fit within the treatment landscape of severe asthma*

12:45 **Introduction**
S. Saini (Baltimore, United States of America)

12:50 **Demystifying Biosimilars: Foundations and Future**
J. Gonçalves (Lisboa, Portugal)



Navigating Indolent Systemic Mastocytosis

A quest for effective multidisciplinary collaboration to improve patient outcomes

Saturday 14 June
12:00–13:00 (BST)

Alsh room, SEC & the EAACI Hybrid Congress Digital Platform

Faculty: Patrizia Bonadonna, Jessica Hobart, David González-de-Olano, Frank Siebenhaar

The path forward needs many perspectives – will yours be among them?

Join us at this **Blueprint Medicines-sponsored symposium** to learn more

BST, British Summer Time.

Blueprint Medicines and the associated logo are trademarks of Blueprint Medicines Corporation.
© 2025 Blueprint Medicines Corporation.

UKBP-PRAVA-25.006 | May 2025

Company Sponsored Symposia

Sunday 15 June 2025

13:05 **Changes in Treatment Landscape of Urticaria : Clinical Data of Omalizumab Biosimilar**
S. Saini (Baltimore, United States of America)

13:20 **Future Treatment Landscape with Omalizumab Biosimilar in Asthma**
S. Del Giacco (Cagliari, Italy)


13:35 **Panel Discussion / Q&A**
S. Saini (Baltimore, United States of America), J. Gonçalves (Lisboa, Portugal), S. Del Giacco (Cagliari, Italy)

14:15 - 14:45 **MSAT 3-1 - Chiesi - Single Inhaler Triple Therapy: looking into the Achievable Outcomes**
(Alsh, 7- Alsh, Sponsored Sessions)

Chair: ***S. Del Giacco (Cagliari, Italy)***

14:15 **Single Inhaler Triple Therapy: looking into the Achievable Outcomes"**
G. W. Canonica (Rozzano, Italy)

Exhibition Floor Plan




List of Exhibitors & Sponsors

COMPANY NAME	ONSITE BOOTH
A2M	E62
AAAAI	B63
ALK	C01 & C10
AllergoEye	B01
Allergopharma	E20
Allergy Therapeutics	H10
AstraZeneca	C10
Astria Therapeutics	A52
Beckman Coulter	F04
Bedfont Scientific	F03
BioCryst	B30
Blueprint Medicines	G20
BÜHLMANN Labs	G60
Celldex	B50
Celltrion	F30
Cliantha Research	F62
Cogent Biosciences	G43
CSL Behring	C20
DBV Technologies	H20
Diater	A32
Dr. Fooke-Achterrath Laboratorien	F02
EUROIMMUN	F60
Faes Farma	E53
GSK	F20
HAL Allergy	B20
Hippo DX	A01
Hycor Biomedical	E60
Inbio	A50
Inmunotek	A20

COMPANY NAME	ONSITE BOOTH
Innova Nanojet Technologies	H40
KalVista Pharmaceuticals	B03
Karger Publishers	B62
LETI Pharma	C30
Lofarma	E50
MacroArray Diagnostics	C60
Med Learning Group	A25
Menarini	C50
NeilMed Pharmaceuticals	A51
Nexkin Medical	B02
Novartis	G10
Noucor	H30
Otsuka Pharmaceuticals	B42
Pharming	C40
Pharvaris	G01
Probelte Pharma	H46
Protia	G44
Reacta Healthcare	G02
Red Maple Trials	C02
Royal College of Physicians - IQAS & QPIDS	B61
Sanofi Regeneron	A10
Scibase	E52
Stallergenes Greer	F10
Swisens	F63
Takeda	B10
Tamakona	E63
Thermo Fisher Scientific	F40
WAO	B64
Wisepress Publishers	G61

NAIS Village Floor Plan



List of NAS

BOOTH NAME	BOOTH NUMBER
Algerian Society of Allergology and Clinical Immunology	N 1
Austrian Society of Allergology and Immunology	N 2
Azerbaijan Society of Allergology, Immunology and Immunorehabilitation	N 3
French Society of Allergology and Clinical Immunology (SFA)	N 4
Society of Allergology and Immunology (CIS)	N 5
Georgian Association of Allergology and Clinical Immunology (GAACI)	N 6
Armenian Association of Allergologists and Immunologists (AAAI)	N 7
Greek Pediatric Allergy Society (GPAS)	N 8
Hungarian Society of Allergology and Clinical Immunology (MAKIT)	N 9
Italian Society of Pediatric Allergy and Immunology (SIAIP)	N 10
Italian Association Of Hospital And Territorial Allergists And Immunologists (AAIITO)	N 11
Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)	N 12
Kazakhstan Association of Allergology and Clinical Immunology (KAACI)	N 13

BOOTH NAME	BOOTH NUMBER
Polish Society of Allergology (PTA)	N 14
Romanian Society of Allergology and Clinical Immunology (RSACI)	N 15
Serbian Association of Allergology and Clinical Immunology	N 16
Sociedad inmunología clínica y alergia Pediátrica (SEICAP)	N 17
Society of Pediatric Allergy Immunology and Asthma (CAIAD)	N 18
Turkish National Society of Allergy and Clinical Immunology (TNSACI)	N 19
Turkish Thoracic Society	N 20
British Society for Allergy & Clinical Immunology (BSACI)	N 21
POC	N 22
Gulf Academy of Allergy and Clinical Immunology	N 23
APAAACI | United Arab Emirates	N 24
Czech Society of Allergology and Clinical Immunology (CSAKI)	N 25
Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI)	N 26

A2M (www.a2m.care)

A young French company created in 2020 specializes in the development of medical devices dedicated to allergy testing. Its main purpose is to support the medical profession as closely as possible to its practice, by providing reliable, functional and ergonomic equipment. A2M aims to become the preferred partner of doctors in their practice.

ALK (www.alk.net)

With 100 years of experience, ALK continuously apply our scientific knowledge and offers a comprehensive range of allergy products and services to help people take control of their allergy and life. ALK has worked with the allergy community and conducted large clinical trials with 23,000 patients demonstrating consistent efficacy and safety of sublingual immunotherapy (SLIT) tablets for respiratory allergies (including house dust mite and pollen from grass, tree, ragweed and Japanese cedar). More than half of ALK's SLIT-tablets is already available to children and adolescents, and we have completed further paediatric clinical trials to ensure evidence-based SLIT-tablets become available.

AllergoEye GmbH & Co. KG (www.allergoeye.com)

AllergoEye GmbH & Co. KG is a medtech company based in Dresden, combining cutting-edge artificial intelligence with clinical and diagnostic expertise. With a multidisciplinary team of AI engineers, clinicians, and researchers, we create innovative solutions designed for use in clinical trials, specialist practices, and everyday care. Our CE-certified platform AllergoEye uses the conjunctival provocation test (CPT) to redefine how allergen immunotherapy is measured, monitored, and understood. The system ensures speed, precision, and standardization in allergy diagnostics. We seek collaboration with leaders in pharma and medtech—to deliver the future of diagnostic precision today!

Allergopharma GmbH & Co. KG (allergopharma.dermapharm.com)

Allergopharma is a German company with a global network. For over 50 years, we have collaborated with physicians and scientists to develop high-quality allergy treatments – from diagnostics to allergen immunotherapy (AIT). We were the first to publish data on major, mid-tier, and minor allergens in AIT products for house dust mite-, grass-, tree-, and mugwort-allergic patients. With our expertise and scientific excellence, we provide physicians with treatment options that help allergy sufferers live a full life. Step by step, we are moving closer to realising our vision: curing allergies.

Allergy Therapeutics (www.allergytherapeutics.com)

Allergy Therapeutics is a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Driving convenience; our short-course treatments make life easier. Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. Our operations deliver growth and transforms the way we think about immunology.

American Academy of Allergy, Asthma & Immunology (www.aaaai.org)

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the most prominent membership organization of more than 7,000 allergists /immunologists (in the United States, Canada and 72 other countries) and patients' trusted resource for allergies, asthma and immune deficiency disorders. This membership includes allergist / immunologists, other medical specialists, allied health and related healthcare professionals-all with a special interest in the research and treatment of allergic and immunologic diseases.

AstraZeneca PLC (www.astrazeneca.com)

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit http://www.astrazeneca.com/">astrazeneca.com and follow the Company on https://twitter.com/AstraZeneca @AstraZeneca

Getting to Know


Omalizumab Biosimilar in Allergic Diseases

AGENDA	
Topic	Speaker
Demystifying Biosimilars: Foundations and Future	Prof. João Gonçalves (Portugal)
Changes in Treatment Landscape of Urticaria: Clinical Data of Omalizumab Biosimilar	Prof. Sarbjit Saini (United States)
Future Treatment Landscape with Omalizumab Biosimilar in Asthma	Prof. Stefano Del Giacco (Italy)

Alsh (Ground Floor)

12:45-13:45

Sunday 15th June, 2025



Omlyclo® (omalizumab) is licensed in the UK, however, will only be available upon patent expiry that is anticipated later this year.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Celltrion Healthcare by emailing ukadverseevents@celltrionhc.com or calling + 44 (0) 1753 983500

Click the URL below for **Omlyclo® (omalizumab)** prescribing information
https://omlyclo-omalizumab-pi.tiiny.co

A Leading Global Biosimilar Company

CELLTRION

UK--25-00078
© Celltrion, Inc. 2025
HCOML-00 AD-0525/25EAACI-02
May 2025

Industry Profiles

Astria Therapeutics (astriatx.com)

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com

Beckman Coulter UK Ltd (www.biocryst.com)

Beckman Coulter Life Sciences is dedicated to developing and providing advanced technologies and equipment for research and discovery to explore new treatment methods. Our products are implemented in all major areas of Life Sciences to simplify and automate existing processes in the lab For more information please visit http://www.beckman.com

Bedfont Scientific Ltd (www.bedfont.com)

For 15 years, the NObreath® FeNO device has supported asthma diagnosis and management. It offers quick, easy testing to help distinguish allergic from non-allergic asthma. NObreath® features anti-microbial tech for infection control and includes free patient software, FeNOchart™. For over 35 years, the Gastrolyzer® range has aided detection of GI disorders via hydrogen and methane breath testing. Gastro+™ is portable; GastroCH4ECK® offers remote breath testing. Includes free software, GastroCHART™. Visit Bedfont® at stand FO3 to learn more!

BioCryst Ireland Limited (www.biocryst.com)

BioCryst is a biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases. BioCryst discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. With expertise in drug discovery, clinical development, and regulatory affairs, we are advancing clinical programs and new compounds from our own discovery engine.

Blueprint Medicines (www.blueprintmedicines.com)

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines in two core focus areas: allergy/inflammation and oncology/hematology.

Bühlmann Laboratories AG (www.buhlmannlabs.ch)

BÜHLMANN is a fully independent, globally active Swiss based company offering Cellular Allergen Stimulation Tests since 1995. CAST are based on in-vitro activation of basophiles with specific allergen determined in flow cytometry by cell surface marker CD63 and CD203c, or secreted leukotrienes via ELISA. They provide functional results and significantly improve detection of drug, venom and food allergies.BÜHLMANN, the only company offering more than 140 standardized allergens for BAT tests, is focused on the continuous development of new allergens to extend this exclusive panel.

Celldex Therapeutics (www.celldex.com)

Celldex Therapeutics is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic and autoimmune and other devastating diseases.

Celltrion, Inc. (www.celltrion.com/en-us)

We are a fully integrated biopharmaceutical company committed to delivering innovative and affordable medications to improve patients' access to advanced therapies. Our end-to-end capabilities ensure efficiency, quality, and innovation at every stage, bringing life-changing therapies to patients. With a legacy in the biosimilar sector, and now as a leader in antibody discovery and development, we strive to add value to biologics to address unmet medical needs.

Chiesi Farmaceutici (www.chiesi.com/en)

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

Cliantha Research (www.cliantha.com)

Full-service CRO in Early (FIH/POC/MOA) and Late Phase trials, specializing in allergy. Our integrated services allow efficiency and customization to meet clients' requirements. Our clinics' excellent regulatory track record and large, diverse, participant databases, support trials applicable worldwide. As experts in allergen challenges, both direct instillation and the naturalistic type in our Environmental Exposure Chambers (qualified for perennial/seasonal allergens), we apply 25+ years of experience to plan programs for drug therapies/devices throughout their development lifecycle.

Cogent Biosciences (www.cogentbio.com)

Cogent Biosciences is a biotech company focused on developing precision therapies for genetically defined diseases. The lead program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

CSL Behring (www.cslbehring.de/en-us)

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

DBV Technologies (www.dbv-technologies.com)

DBV is a biotechnology company committed to helping children with food allergies live safely. We are developing Viaskin®, a non-invasive patch technology based on epicutaneous immunotherapy, that re-educates the immune system through the skin. Our goal is to offer families a safe, effective, and accessible treatment option to help protect them from accidental exposure reactions.*Epicutaneous immunotherapy and Viaskin are under clinical investigation and have not yet been approved by any health or regulatory authority.

Diater (www.diater.com/es)

Diater is an international biotechnology company based in Spain, focused on the development and manufacturing of immunotherapy treatments and diagnosis for allergic patients worldwide. Established in 1999, we work with top quality raw materials, through our partner Allergen Servilab, to deliver the highest quality personalized treatments and diagnostic solutions. We are pioneers in molecular immunotherapy and betalactamic allergy diagnosis and we are committed to delivering innovation and immunoprecision to patients worldwide.

Dr. Fooke-Achterrath Laboratorien GmbH (www.fooke-labs.de)

Dr. Fooke Laboratories offer innovative high-quality assays for allergy and autoimmune diagnostics. Dedicated to fulfilling our customers needs, we use state of the art technologies for the development of flexible and reliable routine applications.

Euroimmun Medizinische Labordiagnostika AG (www.euroimmun.de)

EUROIMMUN is an international provider of medical laboratory products with an extensive portfolio for allergy diagnostics. The company's EUROLINE system encompasses more than 500 different allergens and allergen components and provides reliable screening assays for the efficient determination of specific IgE antibodies. A comprehensive spectrum of indication-oriented and country-specific profiles is available, as well as component-resolved profiles (defined partial allergy diagnostics, DPA-Dx) for in-depth characterisation of allergy triggers. Specialised instruments and software provide efficient automation of analyses. EUROIMMUN's allergy range complements its products for autoimmune, infection and molecular genetic diagnostics.

Faes Farma (www.faesfarma.pt)

FAES FARMA is a leading Spanish pharmaceutical company with international projection, with more than 1.600 employees, between its headquarters in Madrid, R& D&I center in Bilbao and its subsidiary companies abroad.Bilastine, is the latest novelty. A new 2nd generation, non-sedating antihistamine, for children and adults, present in more than 100 countries, to relieve the symptoms of allergic rhinoconjunctivitis and to treat itchy skin rashes (wheals or urticaria). FAES FARMA continuous investigation plan will bring news in a near future!

Medscape EDUCATION

CPD

NEWS REPORT

Hereditary Angioedema Headlines

Early Intervention Strategies for Managing Attacks and Improving Patient Outcomes

FRIDAY, 13 JUNE 2025 | 16:30 – 17:30 BST

SCOTTISH EVENT CAMPUS, EXHIBITION WAY
G3 8YW, GLASGOW | **ROOM:** BOISDALE

HYBRID

MODERATOR



Douglas Jones, MD
Medical Director
Rocky Mountain Allergy, Asthma, and Immunology
Layton, Utah, United States

FACULTY



Autumn F. Burnette, MD, FACAAI
Assistant Professor
Division of Allergy and Immunology
Howard University
Washington, DC, United States



Hilary J. Longhurst, MA, FRACP, PhD, FRCPath
Honorary Associate Professor
Department of Medicine
University of Auckland
Senior Medical Officer
Department of Immunology
Auckland City Hospital
Auckland, New Zealand

HOST



Alok S. Patel, MD
Physician
Medical Journalist
Stanford Medicine
Palo Alto, California, United States

AGENDA

16:30
Welcome and Introduction
Alok S. Patel, MD

16:35
Behind the HAE Attack: Uncovering the Real Burden of HAE
Douglas Jones, MD
Autumn F. Burnette, MD
Hilary J. Longhurst, MA, FRACP, PhD, FRCPath

16:40
In Depth: The Importance of Early Intervention for HAE Attack
Douglas Jones, MD
Autumn F. Burnette, MD
Hilary J. Longhurst, MA, FRACP, PhD, FRCPath

16:50
Barriers and Breakdowns With On-Demand Therapies
Douglas Jones, MD
Autumn F. Burnette, MD
Hilary J. Longhurst, MA, FRACP, PhD, FRCPath

17:00
Breaking News: Innovation in HAE On-Demand Therapies
Douglas Jones, MD
Autumn F. Burnette, MD
Hilary J. Longhurst, MA, FRACP, PhD, FRCPath

17:10
The Power of Early Intervention and Patient Partnerships in HAE
Douglas Jones, MD
Autumn F. Burnette, MD
Hilary J. Longhurst, MA, FRACP, PhD, FRCPath

17:20
Q&A and Closing Remarks
Alok S. Patel, MD

Learn More!

For more information visit:
www.medscape.org/symposium/hae-intervention-strategies

Supported by an independent educational grant from KalVista.

Produced by Medscape LIVE!

GSK (www.gsk.com/en-gb)

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We are proud to be joining experts from around the world to discuss our science, create opportunities to connect with peers and deliver compelling content at this year's EAACI congress. Please visit us at our booth, attend our industry symposia to learn more about GSK in Allergy & Immunology.

HAL Allergy (www.hal-allergy.com)

HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy strives to provide the best possible medical products and scientific output. HAL Allergy is located in the Bio Science Park in Leiden, The Netherlands.

Hippo Dx (www.hippo-dx.com)

Hippo DX is a MedTech start-up introducing a state-of-the-art medical device, S.P.A.T. (Skin Prick Automated Test) for automated allergy testing and diagnosis. Developed by physicians, designed for patients, S.P.A.T. combines evidence-based medicine and pioneering technology.The S.P.A.T. device executes 12 equal pricks simultaneously in 10 seconds. It images the pricked spots 15 minutes after pricking, enabling physicians to make a diagnosis based on digital, standardized results. Automating Skin Prick Tests account for a decrease in result variability in a cost-efficient way. More info: www.hippo-dx.com.

Hycor Biomedical (www.HYCORbiomedical.com)

HYCOR is a global manufacturer and marketer of in vitro diagnostics products in allergy diagnostics. NOVEOS System requires only 4-µL sample size per test, reduces QNS errors, resampling and patient trauma. Our advanced micro-particle technology is designed to limit interference from: Biotin, IgG / IgG4, and Solid-phase related cross-reactive carbohydrate determinant (CCD). It has high sensitivity and an excellent low-end precision for up to 13 hours of true walk-away capability. Pinpoint your true allergy triggers with NOVEOS.

InBio (inbio.com)

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that's exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialized needs. Broad product catalog - *new standardised reagents for BAT/MAT assays. Deep scientific background and ongoing commitment to well-documented subject-matter expertise. Direct contact with our scientific team. Flexible, collaborative relationships.

Inmunotek (www.inmunotek.com)

Inmunotek, established in 1992, is a Spanish pharmaceutical company specializing in the research, development, manufacturing, and distribution of innovative products in allergy and immunology for both human and veterinary medicine. With a commitment to enhancing patient well-being and supporting healthcare professionals, Inmunotek has embarked on a robust international expansion journey. Presently, the company operates through subsidiaries and exclusive distributors in over 50 countries across five continents.

Innova Nanojet Technologies Ltd (www.innova-nanojet.co.uk)

Discover AirSancta CDa by Innova NanoJet at EAACI 2025. The world's first water-based, filterless, chemical-free air treatment system. Engineered for allergy, asthma, and COPD sufferers, CDa purifies, humidifies, cools, and protects indoor air with nano-scale water droplets, removing >99% of airborne allergens and pathogens. Visit us to experience safe, filter-free respiratory innovation. Breathe better. Live healthier.

Jasper Therapeutics (www.jaspertherapeutics.com)

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast cell-driven diseases such as chronic urticaria and asthma. To date, briquilimab has a demonstrated efficacy and safety profile in over 145 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD.

KalVista Pharmaceuticals Inc (www.kalvista.com)

KalVista was founded in 2011 as a small molecule drug development company with less than 20 employees who brought deep expertise in the plasma kallikrein pathway. For more than a decade, KalVista has been focused on bringing scientific advances to address the unmet needs of the HAE community. Today, we have 270 employees worldwide who share this mission.

LETI Pharma (www.leti.com/en)

LETIPharma is an independent and family-owned biopharmaceutical research company.In its different areas of expertise, it seeks to contribute products to society that add value to health care. Its headquarters are in Barcelona and its industrial plant and allergy research laboratory are in Tres Cantos (Madrid). It has subsidiaries in Germany (Ismaning and Witten) and Portugal (Oporto). LETIPharma operates with exclusive distributors in several countries in Europe, Latin America and Africa.

Lofarma Spa (www.lofarma.it)

Lofarma S.p.A. researches, produces and markets specific immunotherapy tablets, drops and injections (AIT) to treat allergic respiratory diseases. For almost 80 years, Lofarma has been committed to significantly improve the health and quality of life of individuals with allergies. Lofarma's manufacturing site works under GMP guidelines and undergoes routine inspections by Health Authorities. Production excellence is a prerequisite for ensuring quality in Lofarma's own processes. The Company, based in Milan, operates globally through its affiliates in Portugal and Spain, as well as distributors in Albania, Austria, Germany, Greece, Hungary, Mexico, Mongolia, South Korea, Turkey, Ukraine and United Kingdom.

Macro Array Diagnostics (www.macroarraydx.com)

With MADx you experience the revolution in allergy diagnostics! You achieve higher specificity thanks to molecular allergens, you cover all relevant allergens with just one analysis run and all our systems are digitally connected - 24/7. Since the company's foundation in 2016, we have been producing reliable, affordable allergy tests for allergy centres, diagnostic laboratories, doctors' offices and hospitals. To evaluate patient blood samples reliably and quickly, we produce and distribute proprietary MADx processing systems. For the analysis and interpretation of the results, we offer in-house software solutions to our business customers.

Med Learning Group (medlearninggroup.com)

Visit our CONQUER T2 Immersive Learning Experience to explore several assets to help you better understand T2 inflammation. You will be able to practice engaging with interactive patient holograms and make real-time treatment decisions, participate in an interactive augmented reality experience on T2 inflammation, and view virtual reality animations on AD, CRSwNP, COPD, EoE, & asthma. You will also have the opportunity to create your own clinical practice poster with your name and practice! Explore https://conquer-t2.com to stay ahead of the latest content, screening, access educational resources, and become an ambassador.

Menarini Group (www.menarini.com/en-us)

The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,603 million in consolidated turnover and more than 17,000 employees. With 9 centres for Research & Development, Menarini's products are present in the most important treatment areas. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, located in Italy and abroad, which produce over 609 million packets of product a year and distribute them to five continents. www.menarini.com

NeilMed Pharmaceuticals Ltd (www.neilmed.com)

The NeilMed brand of products help alleviate common nasal and sinus symptoms in a simple, safe, effective and affordable way. The company supplies millions of products to end users through various trade channels. Our headquarters & manufacturing facility is based in Santa Rosa, California, USA. In addition to our USA headquarters, we also supply and have offices in multiple countries worldwide.

Nexkin Medical (nexkinmedical.com)

Nexkin helps physicians better understand, diagnose, treat and follow up on allergies. Therefore, we have developed Nexkin DSPT and Nexkin ID, the first CE-marked medical devices and data platform for the digitalization of allergy offices and the main allergy tests: skin prick tests and intradermal tests.

Noucor (www.noucor.com)

Noucor, based in Barcelona, is a Spanish pharmaceutical company whose business is focused on R+D, licensing, manufacturing and the supply of pharmaceutical products. The company has extensive knowledge and experience offering quality products and solutions in the health ecosystem. Noucor has a 100% industrial focus, with a fine chemical plant dedicated to the development and production of active pharmaceutical ingredients, a pharmaceutical plant manufacturing solid and semi solid forms and a plant exclusively focused on food supplements. Noucor has a presence in over 100 markets, Japan, Canada and the EU being key markets for our company.

Novartis Pharma AG (www.novartis.com)

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Find out more at https://www.novartis.com

Otsuka Pharmaceutical Europe Limited (www.otsuka-europe.com)

At Otsuka Europe we all share the same values and are dedicated to a common purpose. Otsuka-people creating new products for better health worldwide. Every day across Europe, Otsuka-people channel their passion and commitment into aiming to improve the health of our patients. We aim to help people with diseases that range from those affecting millions to those that affect relatively few.UK-based Otsuka Pharmaceutical Europe Ltd. (OPEL) oversees our businesses in Europe working in close collaboration with our European affiliates and global colleagues. www.otsuka-europe.com

Pharming Group N.V. (www.pharming.com)

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

Pharvaris GmbH (www.pharvaris.com)

Building on our deep-seated roots in HAE, Pharvaris has developed novel oral therapies to compete with the ultimate HAE cascade event and prevent bradykinin from engaging with the B2-receptor. We aspire to offer people living with HAE, regardless of subtype, more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. For more information, visit our website https://pharvaris.com

Probelte Pharma S.L.U. (www.probeltepharma.es/en)

Probelte Pharma is a spanish biopharmaceutical laboratory specialized in the research, development, manufacture and commercialization of allergen immunotherapy vaccines and individualized autovaccines for human use since 1995. In Probelte Pharma, we care about people, and that is why we look for solutions to satisfy the needs of the population. We have a state-of-the-art factory, inaugurated in 2006, which allows us to manufacture our vaccines adapting to the needs of patients and clients in an agile and flexible way, maintaining the highest quality standards in our production without depending on an external company. Our commitment is to continue growing and increasing our production both nationally and internationally.

Protia Inc. (www.protia.co.kr)

PROTIA Inc. aims to contribute to human health and well-being through finding new protein targets for disease prediction, early diagnosis, and development of new medicines. Based on our dedication for identification of bio-markers needed in early diagnosis of incurable diseases with and our advanced technology in "protein analysis" we have successfully developed unique in vitro diagnosis merchandise such as allergy diagnosis kits, immunity monitoring kits and next-generation pregnancy diagnosis kits, and are currently developing early cancer diagnosis kits.

Reacta Healthcare (www.reactahealthcare.com)

Reacta Healthcare, established in 2013, operates from a pharmaceutical manufacturing facility in Deeside, North Wales. It is licenced to manufacture challenge meals for use in clinical trials. These challenge meals are currently used to diagnose and monitor food allergy in numerous worldwide therapeutic trials. Patents for the challenge meals have been granted in a number of countries. Reacta Healthcare is developing its in-house analytical capability and has plans in place for expansion into niche areas of food allergen development and manufacture. This will include all aspects from sourcing through to manufacture of end product.

Red Maple Trials Inc. (www.redmapletrials.com)

Red Maple Trials provides a unique combination of novel testing facilities and specialty services in allergy, asthma and immunology clinical research. Our skillful team brings years of experience in designing, performing, and managing clinical trials, and our advanced allergen exposure chambers provide exciting opportunities for innovative clinical research.

Royal College of Physicians- IQAS & QPIDS (www.iqas.org.uk)

Improving Quality in Allergy Services (IQAS) and Quality in primary immunodeficiency services (QPIDS) are accreditation programmes designed to support allergy and immunodeficiency services to improve quality of care and provide assurance to patients, referrers and commissioners about the service provided. Led by the Royal College of Physicians, the programmes evaluate the service against a set of standards developed with multi-professional input.

S. Karger AG (www.karger.com)

Karger Publishers is a worldwide publisher of scientific and medical content based in Basel, Switzerland. It is independent and family-led in the fourth generation by Chairwoman and Publisher Gabriella Karger. Karger has been continuously evolving, keeping pace with the current developments and shifts in research and publishing. The publishing house is dedicated to serving the information needs of the scientific community, clinicians and patients with publications of high-quality content and services in health sciences. A comprehensive range of topics covered by leading scientists characterizes the portfolio in Immunology and Allergy.

Sanofi Regeneron (www.sanofi.com)

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patient's needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biological medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

SciBase AB (www.scibase.com)

SciBase is a medical technology company that has developed a unique point of care platform for the non-invasive detection of skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assist researcher, dermatologists and others. SciBase's products include Nevisense and Nevisense Go and the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment.

Siemens Healthineers (www.siemens-healthineers.com)

At Siemens Healthineers, our mission is to enable healthcare providers to increase their value by equipping them with our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine as well as digital health and enterprise services. Our portfolio is at the center of clinical decision making across the

Stallergenes Greer (www.stallergenesgreer.com)

Stallergenes Greer is a fully integrated global biopharmaceutical company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. We are committed to furthering precision medicine and personalised AIT treatments to improve life for people with allergies. Our extensive product portfolio, covering all drug delivery modes, and personalised treatment solutions provide unparalleled patient care which meets the needs of both individual patient profiles and the medical community.

Swisens AG (www.swisens.ch)

The earth and our living space is in a state of change and so is the microcosmos of particles in the air that surrounds us. We make these changes visible. We contribute to a better knowledge and understanding of the air we breathe, the food we eat and the aerosol microcosm with all its facets. Together with our customers we improve the health and quality of life for people, plants and animals around the world.

Takeda (www.takeda.com)

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.

Tamakona Inc. (www.tamakona.com)

We are dedicated to transforming the lives of children with food allergies and their families. Our mission is to provide scientifically-backed solutions for easier and more effective allergy management. Our flagship product, Tamakona, is a heated whole egg powder used for oral food challenges (OFCs) in medical facilities, enabling simpler and more accurate tests. Tamakona is also useful for oral immunotherapy (OIT), allowing safe and convenient home treatment by reducing daily preparation burdens. Join us in creating a world where food allergies no longer limit happiness and well-being.

Thermo Fisher Scientific (www.thermofisher.com/phadia)

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Our complete blood test systems support the clinical diagnosis of allergy, asthma and autoimmune diseases. With 1,800 employees worldwide, we are a global leader in in-vitro allergy diagnostics a European leader in autoimmunity diagnostics. The allergy and autoimmunity product lines operate on a common automated instrument platform, which supports both productivity and cost efficiencies in clinical laboratories around the world.

Wisepress Ltd (www.wisepress.com)

Wisepress.com, Europe's leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @ WisepressBooks.

World Allergy Organization (WAO) (www.worldallergy.org)

World Allergy Organization (WAO) is an international umbrella organization consisting of 115 regional and national allergology and clinical immunology societies. By collaborating with the member societies, WAO provides educational programs, symposia, and lectureships in nearly 100 countries around the globe. Founded in 1951, WAO organizes major congresses, sponsors scientific symposia in developing areas, and jointly sponsors postgraduate programs during professional, non-allergy association congresses. The WAO mission is to be a global resource and advocate for the specialty, advancing awareness and excellence in clinical care through education, research, and training. World Allergy Organization Journal: global, online, open access, 2023 IF: 3.9.

EAACI
EUROPEAN academy OF ALLERGY AND CLINICAL IMMUNOLOGY

U.E.M.S.

Join us for the EAACI/UEMS KNOWLEDGE EXAM

20 October 2025



Apply by 8 July 2025, 23:59 CET

17th EAACI/UEMS

EAACI
EUROPEAN academy of allergy
AND CLINICAL IMMUNOLOGY

EAACI 2025 GLASGOW

EAACI Congress 2025



www.eaaci.org

#eaaci2025